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I. MEDICINAL CHEMISTRY 
1. HISTORY OF MEDICINAL CHEMISTRY: FROM HERBALISM TO DRUG DESIGN. 
I.1.1 Era of herbalism  
Human health is a primary concern to mankind. As such, throughout history and around the world 
man has been actively searching among available natural resources to increase chances of survival 
and has discovered by trial and error, an arsenal of roots, berries , barks and leaves that could be 
used to mitigate symptoms of illness.  
Perhaps as early as 4,000 BC1,2 in India, Ayurveda medicine has used numerous herbs such 
as turmeric roots, as evidenced by Sanskrit writings like the Rig Veda. In old Iraq by 3,000 BC in 
Mesopotamia, the Sumerians left clay tablets with hundreds of medicinal plants such as opium and 
myrrh3. By 2,000 BC, Chinese started prescribing herbal medicines4 and seeds, likely used for 
herbalism, have also been found in archaeological sites of the Bronze Age5. By 1550 BC, Egyptian 
texts (papyrus) are of particular interest due to the language 
translation that join texts from this region 6. The translated 
papyrus consist of lists of diseases, their treatments and has 
information on more than 850 plant medicines, 
including  juniper, cannabis, garlic,  castor , aloe, bean7,8. For 
instance, depicted in figure I.1, the Ebers Papyrus contains a 
prescription for Cannabis sativa (marijuana) applied topically 
for inflammation.                                                                             Figure I.1: The Ebers Papyrus 
Published around 400 BC, the Hippocratic Corpus book is a combination of around 60 early 
Ancient Greek medical works strongly related with the physician Hippocrates and his teachings, 
describing popular and predominant treatments of the early ancient Greek period9. Galen, a Greek 
physician practicing in Rome, was obviously productive in his attempt to write down his 
knowledge about medicine and notes for the follow up of the patients, resulting in many texts 
regarding herbs and their properties10. During the Middle Ages (400-1500), there were three major 
sources of information. Firstly, the Canon of Medicine from the Arabian school is known for the 
discovery of infectious diseases, the study of physiology and sexually transmitted diseases. The 
Canon includes a description of some 760 medicinal plants and the medicine that could be derived 
from them11. Secondly, Anglo-Saxon Leechcraft series consists of three books (known as Bald’s 
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Leechbook I, II and III), presenting a collection of treatment organized by ailment. The books are 
a collation of both Mediterranean and English medical practice12. Thirdly, Salerno was a famous 
school in Italy, concentrating on health and medicine. A student of the school was Constantine, 
credited with getting Arab medicine to Europe12. 
I.1.2 Introduction of modern medical science at the molecular level  
From this overview, we can therefore say that the history of medicine is closely tied with the 
history of herbalism from prehistoric times up to the introduction of the germ theory of diseases 
(Italian entomologist: Agostino Bassi between 1808 and 181313) and the birth of organic synthesis 
(Wöhler, 1828). In contrast, the medicinal chemistry from the 19th century onward is based on 
evidence assembly using scientific methods, and as a result synthetic drugs have largely substituted 
herbal treatments in epochal health care. In the nineteenth century, with the development of organic 
chemistry and chemical analysis the door towards the isolation and characterization of numerous 
active plant principles was opened. Soon, chemists tried to manipulate these compounds 
chemically to improve their activity and to reduce their side effects. Examples of compounds 
isolated from nature and synthesized include: Urea (described in 1727 by Herman Boerhaave14, 
anf first artificially organic compound ever synthesized in 1828 by Wöhler), and Morphine I.1 
(isolation by Friedrich Sertürner15, 16 in 1805 - synthetic analogue Heroin I.2 was first synthesized 
in 1874 by C.R. Alder Wright).Furthermore, Quinine I.3 is used to prevent and treat malaria and 
babesiosis18, 19 (isolation in 1820 by Pierre Joseph and Joseph Caventou - first total synthesis in 
1943 by RB Woodward and WE Von Doering17). Salicin I.4 is the active extract of willow bark, 
was isolated and named by the German chemist Johann Buchner in 182820, and is often used to 
treat pain, fever and inflammation21 (isolation 1828 - synthetic analogue aspirin 1853). 
Acetylsalicylic acid (Aspirin I.5) was first synthesized by Frederic Gerhardt in 1853. The 
discovery of Penicillin I.6 in 1928 by Fleming was a great landmark in the history of drug 
research22. His research was completed up by Florey and Chain in 1938 who could eventually 
industrialize the process of fermenting and extracting penicillin23. For their work on penicillin they 
were rewarded the Nobel Prize in Medicine in 1945. The first orally active semisynthetic 
steroidal estrogen is 17α-ethynylestradiol I.7 (isolation in 1929 by Adolf Butenandt and Edward 
Doisy - semi synthesized in 1938 by Herloff Inhoffen and Walter Hohlweg), and was used for 
diseases such as amenorrhea, breast cancer, hypogonadism, menopausal disorders, postpartum 
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breast engorgement, and prostatic cancer. This synthetic derivative is 15-25% more active than the 
natural estradiol when administrated orally25. The isolation and determination of estrogen 
structure24 accelerated the hormonal drug research.  
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Figure I.2: Examples of identified compounds isolated from natural sources and synthesized 
derivatives thereof. 
As a cytotoxic quinoline alkaloid isolated from the “Happy tree”, Camptothecin (CPT) I.8 
(isolation in 1966 by M. E. Wall and M. C. Wani- synthesized 1992) inhibits the DNA enzyme 
topoisomerase. Because of low solubility and high reverse drug reactions, synthetic and medicinal 
chemists have developed numerous syntheses for Camptothecin26, 27 and its derivatives. 
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Topotecan I.9 and Irinotecan I.1029 are two CPT analogues which have been approved and used 
in cancer chemotherapy28 today. Paclitaxel I.11 is used to treat ovarian, breast, lung, pancreatic 
and other cancers (isolation in 1967 by M. E. Wall and M. C. Wani30, 31 - synthesized in 1994 by 
Robert Holten32, 33), marketed in 1989 by Bristol-Myers Squibb as taxol®. 
I.1.3 Advancements towards rational drug design 
Predominantly referred to as rational drug design is the contrived process of finding new 
medications based on the knowledge of biological targets34. The drug is most commonly a small 
organic molecule that stimulate or inhibits the function of a biomolecule such as protein, which in 
turn results in a therapeutic benefit to the patient. There are two major types of drug design35: 
ligand-based or structure-based. 
I.1.3.1 Ligand-based  
Based on knowledge of other molecules (ligands) able to bind to the biological target of interest, 
a pharmacophore model can be established that includes the necessary structural characteristics in 
order to bind to the target36. In addition a quantitative structure activity relationship (QSAR), in 
which a correlation between calculated properties of molecules and their experimentally 
determined biological activity, may be derived37. 
I.1.3.2 Structure-based  
Based on information of the three-dimensional structure of the biological target obtained through 
methods such as NMR spectroscopy  or X-ray crystallography38. Computational medicinal 
chemists can identify potential new drug candidates by evaluating the binding affinity to the 
biological target39 in silico. The first unequivocal example of the application of structure-
based drug design leading to an approved drug is the carbonic anhydrase inhibitor dorzolamide 
I.12, (figure I.3) which was approved in 199540.  
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Figure I.3: Structure of dorzolamide I.12. 
 
I.2. PRIVILEGED STRUCTURES 
I.2.1 Definition and characterization 
The retrospective analysis of the chemical structures of the many drugs used in medicine led 
medicinal chemists to identify molecular motifs that are more frequently associated with high 
biological activity than other structures. Such molecular motifs were coined privileged structures 
by Evans et al., 41 to represent substructures that confer activity to two or more different receptors.  
Though he was originally referring to the benzodiazepine nucleus I.13(41, 42), which is thought to 
be privileged because of its ability to structurally mimic beta peptide turns43, work over the past 
several decades has revealed that there are additional such scaffolds. Although still unclear why, 
such structures appear to have the intrinsic property of binding with biochemical receptors44.  
Among the most popular privileged structures, historical representatives are arylethylamines 
(including tryptamines I.14), diphenylmethane derivatives I.15, tricyclic psychotropics I.16 and 
sulfonamides I.14. Dihydropyridines I.1845, biphenyl I.19 and pyridazines I.2044 are other 
examples of such recurring motifs as privileged structure such as benzopyrans I.21, isoxazoles 
I.22, and monosaccharides I.23 46 (figure I.4). 
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Figure I.3: Some examples of privileged structures. 
 
Based on the chemical diversity of privileged structures and their intrinsic binding properties, in 
addition to favorable physiochemical properties and 3D-shape, it was expected that their use as 
scaffolds in combinatorial libraries would lead to the discovery of multiple active molecules for a 
variety of therapeutic targets. Combinatorial libraries based on the 1,4-benzodiazepin-2-one 
privileged structure were first synthesized by Ellman et al.47. From a 1680 member library, 3 
compounds were identified by affinity for three different receptors. Nicolaou and co-workers, used 
the naturally occurring benzopyran scaffold for finding highly active agonists for the farnesoid X 
receptor48 and Schultz and Legraverend used the purine scaffold49. 
Besides the use of already known privileged structures for finding new biological activity, there is 
also interest in the identification of new privileged structures. As a consequence more 
computational techniques are deployed via a slightly more reasoned approach50. Studies have 
shown that a remarkable proportion of privileged substructures suitable for combinatorial 
applications meets the following structural features: 1) the central motif is a bicyclic or tricyclic 
basic skeleton, as it provides a degree of molecular rigidity upon binding, resulting in less entropy 
loss than to "open-chain structures,"; 2) the molecular weight should be low enough to permit the 
introduction of the necessary extra substituents without causing violation of Lipinski’s Rule of 
five51 (i.e. MWscaffold <300 Da); 3) there is a relatively simple synthetic access to the basic 
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skeleton, preferentially via automatable methods; 4) there should be a possibility to introduce a 
wide variety of substituents through different attachment points to explore the peripheral space. 
 
I.2.2 Benzodiazepines as a privileged structure and inspiration for new skeletons 
The classic example among the so-called privileged structures is the 1,4-benzodiazepine skeleton, 
where the first benzodiazepines (Librium® I.24, Valium® I.2552, figure I.5) were found to have 
significant activity in the central nervous system. The success of the structural privileged 1,4-
benzodiazepine skeleton induced a rush of syntheses of new-closely related bioisosteric analogues. 
For instance, the rearrangement or substitution of the atoms in the diazepine moiety led to all kinds 
of new pharmaceutically interesting compounds (figure I.5). Moving one or both of the nitrogen 
atoms, for example, led to biologically active 1,5- and 2,3-benzodiazepines (I.26 and I.27)53,54, 
while the further introduction of heteroatoms led to 1,3,4-benzotriazepines55 for example (I.28). 
Several of the derived classes of structures (for example, 1,5-benzodiazepines I.26 and 1,4-
benzodiazepine-2,5-diones I.29)56 have a broad range of diverse biological activity and may be 
nowadays themselves considered to be privileged structures. 
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Figure I.5: Small structural changes in the classical 1,4-benzodiazepine skeleton give rise to new 
classes of biologically active compounds. 
 
In addition to the above changes in the benzodiazepine skeleton by atomic substitutions, 
potentially interesting analogues may also be discovered by modification of the ring size of the 
skeleton, e.g. by adding one more carbon atom to have eight-membered ring analogs, the so-called 
benzodiazocines which are the subject of this PhD-thesis. More data about the synthesis and 
biological activity of known derivatives of different skeletons of benzodiazocines can be found in 
chapter III. 
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II. COMBINATORIAL CHEMISTRY 
1. DEFINITION&PRINCIPLES 
The introduction of a new pharmaceutical is a lengthy and expensive undertaking. Methods which 
promise to shorten the time or the cost are eagerly applied, as has been the case with combinatorial 
chemistry. Combinatorial chemistry is a collection of methods that allow the simultaneous 
chemical synthesis of large numbers of compounds using a variety of starting materials, instead of 
doing reactions in a stepwise, time-consuming manner (figure II.1). The resulting combinatorial 
library can contain all of the possible chemical structures that can be produced by combining 
different building blocks (figure II.2. e.g. n x m compounds of type A-B from n building blocks 
A and m building blocks B) 
              
A1                      +                          B1                                                               A1B1
A1                      +                          B2                                                               A1B2
A1                      +                          B3                                                               A1B3  
Figure II.1 Conventional synthesis. 
A1                           B1                                              A1B1       A2B1              An-1B1      AnB1
A2                           B2                                              A1B2       A2B2              An-1B2      AnB2
An-1                        Bm-1                                           A1B3       A2Bm-1           An-1Bm-1  AnBm-1
An                           Bm                                             A1B1      A2Bm              An-1Bm  AnBm
+
Figure II.2 Combinatorial Synthesis.  
Libraries can be constructed in solution or on solid supports and the choice between these 
techniques is often a matter of personal preference, and the task at hand.  
2. HISTORY OF COMBINATORIAL CHEMISTRY  
Combinatorial chemistry grew out of peptide chemistry and the path leading to the present state of 
combinatorial chemistry essentially started with the solid phase synthetic experiments on peptides 
by Bruce Merrifield in 19631,2. After coupling the first amino acid covalently onto an insoluble 
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polymer resin, the peptide was elongated while remaining attached to the solid support: In contrast 
to classical solution synthesis of peptides, problems due to solubility/aggregation issues were 
completely eliminated.  
Because of the essentially iterative reactions and its susceptibility to automation, a dramatic 
increase of product output was achievable in a given amount of time. Moreover, by the use of 
reagents in excess and the ease of removing these reagents and byproducts from the resin-bound 
intermediates by simple washing ensured quick and high yielding access to final peptide products. 
At first this extremely useful technology was employed in a parallel fashion.  
It was Furka in 1988 who first realized that the methodology could lead to simultaneous synthesis 
of large collections of peptides and conceived of the split-mix method or (“Split-pool” method) 3, 
the procedure being depicted in figure II.3.  The synthesis is executed by repetition of the following 
three simple operations that form a cycle: 1. Dividing the solid support into equal portions; 2. 
Coupling each portion individually with only one of the different amino acids; 3. Mixing and 
homogenizing the portions. By repeating this cycle several times using sets of selected amino 
acids, large libraries can be obtained; however each bead has just one unique product attached to 
it, leading to a so called “ one bead-one compound” library.  
After carrying out the synthesis of the resin-bound peptide library, all peptides can be cleaved from 
the support to yield the mixture of free peptides in solution, also called soluble peptide libraries. 
In such collections millions of peptides may be present and identifying a bioactive peptide among 
them seems like finding a needle in a hay stack. Nevertheless, appropriate strategies have been 
developed to address the problem, such as deconvolution strategies or tag-based library synthesis; 
however they can be lengthy and time consuming. 
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A1 A2 Ai
A1
A2
Ai
A1
A2
Ai A1
A2
Ai A1
A2
Ai
A1B1 A1B2 A1Bi
A2B1 A2B2 A2Bi
AiB1 AiB2 AiBi
A1 A2 Ai
B1 B2 Bi
A1B1
A2B1
AiB1 A1B2
A2B2
AiB2 A1B1
A2Bi
AiBi
 
Figure II.3 “Split-pool” method. 
Another common strategy to build up a combinatorial library is parallel synthesis. This term was 
introduced by Lam 4. In this method, the reactions are performed in spatially separated reaction 
vessels throughout the whole synthesis (figure II.4). In comparison with "split-pool" methods, 
parallel synthesis is less reaction efficient and therefore the generated libraries are usually smaller, 
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but each vessel now contains its own unique compound ("one vessel - one compound" principle). 
Another advantage is that parallel synthesis can be performed both in solution and on solid phase. 
          
A1B1C1 A1B1C2 A1B2C1 A1B2C2 A3B1C1 A3B1C2 A3B2C1 A3B2C2
A2B1C1 A2B1C2 A2B2C1 A2B2C2 A4B1C1 A4B1C2 A4B2C1 A4B2C2
A1-4
A1A1 A1 A1 A3 A3 A3 A3
A2 A2 A2 A2 A4 A4 A4 A4
A1B1 A1B1 A1B2 A1B2 A3B1 A3B1 A3B2 A3B2
A2B1 A2B1 A2B2 A2B2 A4B1 A4B1 A4B2 A4B2
B1-2
C1-2
Figure II.4 Parallel synthesis 
Geysen introduced the first automated solid phase procedures and tools for peptide synthesis 
(Multipin apparatus), making the whole process technically simpler in 1984 and produced large 
scale compound collections of peptides using a pin shaped solid support5 (figure II.5). Houghton 
introduced “tea bag” methodologies in 1985 in which porous bags of resins were suspended in 
solutions of reagents6 (figure II.6). 
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Figure II.5 The multipin apparatus5 
 
Figure II.6 The tea bag method6 
3. SOLID-PHASE SYNTHESIS AS A TOOL FOR COMBINATORIAL CHEMISTRY  
Solid phase synthesis is that branch of organic chemistry in which compounds are synthesized 
while they are covalently anchored to a polymeric carrier. It is highly advantageous for multistep 
iterative processes and notable for the comparative ease of purification by simple filtration which 
allows to drive reactions to completion by the use of excess reagents. Throughout the previous 
decade, solid phase organic synthesis (SPOS) has dominated combinatorial chemistry, and many 
novel methods have been developed as a result. Initially developed by Merrifield in the sixties for 
the synthesis of peptides7, it was later applied to other oligomers such as oligonucleotides8 and 
peptides9 and more recently introduced in the synthesis of non-oligomeric small molecules10, 11, 12. 
An advantage for the use in the combinatorial chemistry is the possibility to automate these solid 
phase syntheses. Automated systems with computer-controlled mechanical robots can routinely 
add the desired reagents and solvents accurately, subsequently let the reaction run at the desired 
temperature after which the resins are automatically filtered and washed13. 
Pin 
Solution 
a 
b 
reaction vessels with bags Tea-bag 
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To perform an efficient solid-phase synthesis two elements have to be chosen rationally, the solid 
support matrix and the linker which connects the substrate and the solid-support via a connection 
point (figure II.7). A spacer, which creates a defined distance between the solid support and the 
linker to avoid sterical hindrance, can also be incorporated, but will not be discussed further as this 
element can be comprised in the linker. 
                                            
X
Linker Moiety
Support
    Linker 
Attachment
Substrate
 
Figure II.7 Schematic representation of a solid-phase structure. 
3.1. Solid Support 
Since Merrifield introduced solid-phase peptide synthesis [SPPS], by using a chloromethylated 
polystyrene resin (lightly cross-linked with divinylbenzene, so called Merrifield resin II.1, figure 
II.8), the use of polymers to facilitate synthesis and product purification has become widespread 
and the resin itself underwent an evolution14. There are different types of solid supports, based on 
alternative polymeric networks. By far the most common polymer matrix is based on polystyrene 
which is crosslinked with p-divinylbenzene 1%. The individual resin beads have a size of around 
75-150 μm and have a good mechanical stability, high loading capacity and are chemically inert 
under various reaction conditions while being relatively inexpensive. 
They display good swelling properties in organic solvents such as THF, dichloromethane and 
DMF, but swell badly in water, methanol and hexane15. Another particular advantage is the ease 
of modifying the aromatic backbone with a variety of functional groups, which allows the chemist 
to attach diverse linkers onto the resin. These functional groups are not only present on the surface 
of the polymer particle, but are evenly distributed throughout the whole bead16. When the resin is 
nicely swollen in an appropriate solvent, the polymer backbone induces no steric hindrance at the 
reactive sites of the resin as illustrated by Sarin et al., who synthesized peptides up to 60 residues 
on solid phase without loss of efficiency compared to a similar solution phase protocol17. 
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Better swelling in protic polar solvents is possible with the use of so-called TentaGel resin18. The 
better compatibility of the resin with such solvents is a result of the grafting of more polar 
polyethylene glycol arms on a central polystyrene matrix. However, disadvantages of this type of 
resin, are the inevitable lower loading capacity and the more expensive purchase.  
Cl
Cl
II.1    "Merrifield" resin
O
O
O
OH
O
HO
II.2    "TentaGel" resin n=4
HN
O
NH
O
NMe2
O
N
H
O
NH2
HN
O
NMe2
OO
NMe2
II.3 "Sheppard" resin
 
Figure II.8 Polymer backbones of classic solid phase resins 
 
So-called Sheppard resin19 is built up from a polyacrylamide matrix and was developed 
specifically for peptide synthesis, as the high amide content allows better interaction with the 
growing peptide and thus preventing self-aggregation and thus lower reactivity of the resin-bound 
peptide. In addition to these more popular polymeric matrices, many (and are) alternative 
polymeric supports with interesting properties have been developed, but they are less routinely 
used by other groups, potentially because of their expensive purchase price or because they are not 
(yet) commercially available. 
 In this PhD work the popular polystyrene matrix-based solid carriers was chosen.  
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3.2. The Linker 
The linker is often described as a bifunctional protecting group and requires careful consideration 
in view of the intended synthetic transformations to be applied on the solid phase. On one hand it 
is bound to the polymer matrix via a permanent covalent bond while on the other hand a temporary 
covalent anchoring element is used to attach the first building block to the solid support. The linker 
should fulfill a number of criteria: (i) stable against a planned set of conditions; (ii) immobilization 
of organic molecule should be readily achieved in high yield and (iii) synthesized molecules on 
polymer supports should be cleaved under mild conditions that do not degrade the products.  
Linkers are categorized according to the method of cleavage from the resin20, and can be further 
sub-classified based on the liberated functional group of the product after cleavage (i.e. carboxylic 
acid, carboxamide, alcohol, amine and ketone linkers). The most commonly applied conditions for 
cleavage are acidic conditions and these are usually based on the formation of a resin-bound benzyl 
cation during cleavage. According to the relative stability of the latter, the cleavage conditions can 
range from strongly (HF, TFMSA) to mildly acidic (0.1% TFA). 
The original Merrifield resin II.1, bearing no stabilizing substituents, needed to be treated with HF 
to cleave off the desired peptide. 4-Alkyloxybenzyl linker (Wang resin II.4) allows the use of a 
concentrated TFA solution to cleave off the desired product21. With additional 
methoxysubstituents on one22 (SASRIN resin II.5) or both23 (HAL resin II.6) of the ortho-
positions of the benzylic moiety, even dilute TFA solutions can be used to induce cleavage. 
Another strategy to stabilize the cation consisted of the introduction of one or two (substituted) 
phenyl groups on the benzylic positions, resulting respectively in benzhydryl24 (Rink resin II.7) or 
trityl25 type resins (trityl resin II.8 or 2-chlorotrityl II.9). Both linkers allow cleavage of the desired 
products in dilute TFA solutions. More details about linkers, their applications and cleavage 
conditions will not be discussed further in this work due to the broad scope of this topic, but are 
extensively reviewed in the literature26. Many alternative linker systems are designed and for a 
comprehensive overview it is better to refer to the literature20. 
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Cl O
O
H2N
MeO
OMe
R1
R2
OH
Cl
R
II.1: Merrifield
II.4; Wang, R1=H, R2=H
II.5; SASRIN, R1=OMe, R2=H
II.6; HAL, R1=OMe, R2=OMe
II.7; Rink
II.8; trityl, R=H
II.9; 2-chlorotrityl, R=Cl
 
Figure II.9 Resins with a varying stability towards acids  
4. ANALYSIS OF SOLID PHASE INTERMEDIATES 
Monitoring techniques used in solution chemistry (e.g. TLC) are not possible to apply on solid 
phase syntheses due to the physical nature of the resin beads. Although the resin-bound 
intermediates can in principle be cleaved from the resin and thus submitted to the conventional 
analytical techniques, it is important to understand that this does not allow "real time reaction 
monitoring" as the resin-cleavage already takes some time. Moreover, it has to be kept in mind 
that this is a destructive analytical approach, as cleaved intermediates can no longer be recovered 
for further use in the solid phase synthesis sequence. Therefore, new techniques were developed 
or adapted from existing techniques. 
4.1. On-bead analysis methods 
On-bead analysis using classical NMR27 techniques has limitations, due to insoluble character of 
the polymer matrix which leads to broad proton signals in 1H NMR-spectroscopy. This so-called 
"Gel-phase NMR" technique is quasi only feasible on resin matrices containing more flexible 
chains (TentaGel instead of polystyrene resins)28. A more advanced methodology is HR-MAS 
NMR (High Resolution-Magic Angle Spinning NMR), where the sample is rotated at a 
predetermined angle (54.7°, the "magic" angle) with respect to the applied magnetic field, giving 
better resolution 29. However, such MAS probes are expensive, which makes this technique less in 
general use. 
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On-resin reaction monitoring via FT-IR30 techniques is also possible, but requires the appearance 
or disappearance of a characteristic absorption band in the spectrum related to the transformation 
of a functional group. In addition, band overlap with functional groups present on the solid support 
could also hinder an accurate monitoring of the reaction. 
The use of color tests31 allows a fast and cheap alternative consuming only tiny amounts of resin-
bound product. The use of colorimetric functional group tests, wherein aliquots of resin are mixed 
with stock solution of coloring agents and changes in solution/resin color are used to indicate the 
presence or absence of functional groups on the resin. Most color tests have been developed for 
the determination of free amine groups32, but there are also color tests designed for other functional 
groups such as alcohols33, thiols34, aldehydes35 and carboxylic acids36. A short overview of the 
tests applied during this research is depicted in figure II.10. 
O
O
Cl
Cl
Cl
Cl
primary or secondary 
amine O
O
Cl
Cl
Cl
N
SO3H
NO2O2N
NO2
primary amine
HN
NO2O2N
NO2
Chloranil test
TNBS test
II.10 II.11
II.12 II.13
NHR
NH2
R
acetaldehyde
[via initial enamine formation]
 
Figure II.10 Color tests for solid-supported amines as applied during this research 
4.2. UV quantification of resin cleavable chromophore groups – the Fmoc test   
The use of cleavable resin bonded chromophore groups makes more quantitative data available. 
UV spectrophotometric determination of the concentration of the respective cleaved chromophore 
can be correlated to the absolute amount of resin-bound product.  
A more frequently used method for quantitative measurements of coupling efficiencies is Fmoc 
UV-quantification. This method, developed by Sheppard37, is therefore only applicable when using 
an Fmoc-based synthetic strategy. It is based upon the formation of the chromophore 
dibenzofulvene-piperidine adduct II.18 after base-induced elimination of the Fmoc-protecting 
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group with piperidine (figure II.11). However, because of inconveniences concerning the ordering 
of piperidine and the toxicity problems related, we have used 4-methylpiperidine as suggested by 
Hachmann as a suitable replacement38. 
 
O
H
N O
O
R O
H
II.14
H
N
CO2
"E1cb"
H
N
N
II.15
II.16
max,1=300nmMe
Me
Me
Figure II.11 Fmoc-deprotection mechanism and 4-methylpiperidine-dibenzofulvene adduct 
formation. 
 
By measuring the absorption at 300 nm39 (𝜆max,1, figure II.12), the concentration of this adduct can 
be determined using the Lambert-Beer equation: A = ε.l.c  (in which A = absorption, ε = molar 
extinction coefficient, l = path length, c = molar concentration).  
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Figure II.12 UV spectrum of a solution containing the dibenzofulvene-(4-methylpiperidine) 
adduct 
Practically, the UV absorbance of the adduct is measured at 300 nm, while the extinction 
coefficient of the 4-methylpiperidine-dibenzofulvene adduct was determined using a calibration 
line by treating different concentration of Fmoc-alanine. 
For the two spectrophotometers used during the work, values of 8.3585 M-1cm40 and 8.4137 M-
1cm-1 were found respectively, for concentrations between 0 and 0.16 mM.  
There have been several other useful chromophores reported in solid phase synthesis. Amines 
protected with the Bsmoc-41 or o-NBS group42 can be used in an analogous manner. Using DMT-
Cl43 or NPIT44, leads to a resin-bound (dimethoxy)trityl group, which can be quantified as 
dimethoxytritylkation after acid treatment. As an example of another functional group, aldehydes 
can be determined in an analogous manner after derivatization using dansylhydrazine45 or the 
fluorenylmethyl ester of 4-hydrazinobenzoic acid46. 
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III LITERATURE REVIEW ON BENZODIAZOCINE DERIVATIVES 
 
III.1 INTRODUCTION 
Benzene-annelated medium ring diaza-compounds are an important class of heterocyclic 
structures, occurring in a wide range of biologically active products1-3. There is a sound basis for 
their appeal in pharmacological research; they offer restricted conformational flexibility, allowing 
higher intrinsic binding capacity because of favorable entropic reasons while their moderate size 
allows the introduction of diverse side chains to obtain compounds complying to Lipinski’s rule 
of five4. As such they possess properties of so-called privileged structures, as evidenced by the 
pharmacologically successful 1,4-benzodiazepine archetype (see chapter I) 5, 6. 
The term ‘medium ring’ by origin is applied to alicyclic compounds having a ring size in the range 
of 7-117, although more commonly designated to 7-9 membered cycles. By far the most reported 
medium-ring derivatives are seven-membered systems, as evidenced by naturally occurring 
carbacycles (for example Frondosin B III.18 isolated from the sponge Dysidea frondosa, and 
Laserpitine III.29 which has been isolated from underground parts of Laserpitium latifolium 
(Apiaceae) species and synthetical azepines and derivatives such as benzodiazepines (for example 
Diazepam III.310 which is used in treatment of anxiety).  
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Figure III.1 Examples of naturally occurring 7-membered carbacycles and synthesized 
benzodiazepines. 
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Much less data is available on the homologous eight-membered ring structures, although examples 
are known with interesting biological activity. For example, benzodiazocines have been shown to 
display diverse activities by acting as central nervous system depressant (III.4)11, muscle relaxant 
(III.5) and (III.6)12,13, RNA polymerase inhibitor (III.7)14, Ca2+-sensitizer (III.8) 15, inhibitor of 
leukemia cells (III.9)16 and  activator for PKCε (III.10)
17. Additionally, some members of the 
benzodiazocine system have found application as homologues of benzodiazepine drugs (III.11)18 
(figure III.1) and as reversal agents in multidrug resistance.19,20.  
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Figure III.1. Examples of biologically active benzodiazocines. 
The dibenzodiazocine skeleton has gained considerable interest as a challenging target and 
pharmacologically interesting compounds have been identified, such as the 17-β-hydroxysteroid 
dehydrogenase type 3 inhibitor (III.12)21 and the cholesterol-lowering III.1322. 
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In recent years, material chemists have explored the electrochemical properties of 
diaryldibenzo[b,f][1,5]diazocines (III.14) which were found to be useful as a basis for molecular 
machines and artificial muscles23,24. Moreover, a bridged variant of dibenzo[b,f][1,5]diazocine, 
“Troger’s base” (III.15) has a chiral aromatic cleft structure with a unique ability to host guests 
and as a result, derivatives can act as a molecular receptor (figure III.2)25,26. 
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Figure III.2 Examples of interesting dibenzodiazocines.  
 
However, medium sized heterocycles, (especially eight- or higher membered rings) are difficult to 
prepare due to enthalpic and entropic reasons and potential trans-annular interactions27. In 
continuation of our interest in developing expeditious routes to various medium-sized heterocyclic 
molecules, our laboratory is interested in establishing a convenient synthetic route to diverse 1,5-
benzodiazocine-2,6-diones III.16 (figure III.3) for potential pharmaceutical applications. 
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Figure III.3 Target molecules: 1,5-benzodiazocine-2,6-diones  III.16. 
As any recent overview on benzodiazocines is lacking in the literature28, in this chapter 
representing syntheses of the different possible skeletons of benzodiazocines (1,2-; 1,3-; 1,4-; 1,5-
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; 1,6-; 2,3-; 2,4-; 2,5-; 3,4-) and available data regarding their biological activity are reviewed, with 
particular comprehensive focus on reported cases of our target skeleton (1,5-benzodiazocine-2,6-
dione III.16).  
 
III.2 1,2-BENZODIAZOCINES 
1,2-Benzodiazocines are a class of azobenzenes which are the most frequently used photochromic 
switches in chemistry29 and they are mainly presented as dibenzo[1,2]-diazocines. Merino et. al30 
reported the synthesis of 3,3`-amino-substituted III.19 and 3,3`-acetamide-substituted diazocine 
derivatives III.20; starting from commercially available 1,2-bis(4-aminophenyl)ethane III.17, a 
nitration reaction gives 1,2-bis(2-nitro-4-aminophenyl)ethane III.18, for which intramolecular 
reductive coupling of the nitro groups give azo compound III.19. The acetamide derivative III.20 
is formed by treatment of 3,3`-diamino-2,2`-ethylene-bridged azobenzene (3,3`-diamino-EBAB) 
III.19 with acetic anhydride (figure III.4). 
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Figure III.4 Synthesis of 3,3`-diamino-EBAB III.19 and its acetamide derivative III.20. 
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III.3 1,3-BENZODIAZOCINES  
The first compounds of this series have been synthesized31,32 by Kempter through reduction of 3-
(2-nitrophenyl)propionaldehyde oxime derivatives (III.21) to afford (III.22) which undergo 
cyclocondensation with formaldehyde, phosgene or carbon disulfide to give a variety of 1,3-
benzodiazocines III.23 (figure III.5). A preference for the α-adreno-receptors was observed with 
moderate seven fold α2/α1 selectivity33.  
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Figure III.5 The first synthesized 1,3-benzodiazocines in 1978 by Kempter.  
 
The 1,3-benzodiazocine scaffold was patented in 198634. The cyclization step involves 
condensation of the α,ω-ureido-aniline III.24 with carbon disulfide in hot ethanol affording the 
thioureas III.25 (figure III.6). 
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Figure III.6 Synthesis of thioxobenzo[d][1,3]diazocine-3(4H)-carboxamide derivatives. 
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III.4 1,4-BENZODIAZOCINES  
III.4.1 1,4-Benzodiazocine-2,5-diones via ring expansion (Muchowski) 
The first publication on the 1,4-benzodiazocine skeleton describes a three step synthesis of 
unsubstituted 1,4-benzodiazocine-2,5-dione III.3035. Acetylation of sodioisatin III.26 with 
azidoacetyl chloride produced azido compound III.27, which was catalytically hydrogenated in 
one step to the aminoacetyloxindole III.28. Extraction of an aqueous bicarbonate solution of III.28 
with DCM gave the parent 1,4-benzodiazocine III.30 via ring expansion (figure III.7). 
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Figure III.7 Synthesis of the parent 1,4-diazocine-2,5-dione (III.30) by Muchowski. 
III.4.2 1,4-Benzodiazocine-2-ones via lactamization 
Another synthetic route developed by Muchowski involved the synthesis of 1,4-benzodiazocines 
III.35 via the corresponding 1,4-benzodiazocin-2-ones III.34. Alkylation of secondary amine 
III.31 with ethyl bromoacetate III.32 was followed by 3 steps to obtain α,ω-aminocarboxylic acid 
III.33. Cyclization using DCC in pyridine or acetonitrile gave the lactams III.3436, which could 
be further reduced to the diamine III.35 (Figure III.8). 
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Figure III.8 Synthesis of 4-substituted 1,4-benzodiazocin-2-ones (III.34) and reduced analogues 
(III.35).  
Tumor-promoting teleocidins induce growth inhibition, cell adhesion and differentiation to 
monocytes of human promyelocytic leukemia cells (HL-60). These teleocidins such as III.36, 
consist of a nine-membered indole-fused heterocycle and are known to exist in an equilibrium 
between two conformational states (the twist form and sofa form) in solution37. The simplified 
structure Indolactam V (III.37) serves as a reference compound, although it has a lower activity 
than teleocidine B-4. BenzolactamV8 (BL-V8-310) III.9, in which the indole ring of  indolactam 
III.37 is replaced with a benzene ring, was synthesized in an attempt to reproduce the active 
conformation of teleocidins. The resulting 8-membered lactam III.9 was found to be more active 
than indolactam-V III.37, which was attributed to mimicking the teleocidine twist conformation 
in solution. The twist-restricted benzolactam-V8-310 (III.9) caused growth inhibition and 
differentiation of HL-60 cells at a concentration of 10 nM which is one order weaker than that of 
teleocidin B-4 but 30 times stronger than that of indolactam-V16, 38, 39. 
Furthermore, it has been suggested that not only the 5-(S)-configuration of benzolactam-V8 III.9 
40 (or the 9-(S)-configuration of indolactam-V III.37), but also the lactam hydrogen atom, play an 
important role for the biological activity (figure III.9) 41. 
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Figure III.9 The structures of Teleocidine B-4 III.36, indolactam-V III.37 and the analogue 
Benzolactam-V8-310 III.9.   
In view of this, Endo and coworkers did a lot of synthetic efforts to synthesize benzolactams-V8 
with a variety of substituents42,43. The general strategy consisted of the synthesis of N-Boc-
protected α,ω-aminocarboxylic acids which (exemplified by III.41, figure III.10) could be 
cyclized after succinimidyl ester activation to obtain the 1,4-benzodiazocin-3-one skeleton of 
benzolactam-V8 derivatives 16, 38, 42, 44, 45, 46. As an example, the synthesis towards diastereomeric 
III.9 and III.42 (figure III.1045) starts from the reaction of 4-bromomethyl-3-nitrobenzaldehyde 
III.38 with diethyl acetamidomalonate III.39, followed by Wittig reaction giving III.40 which 
was transformed to the strategic N-Boc aminocarboxylic acid III.41. Condensation with N-
hydroxysuccinimide using DCC gave the activated esters (96%) which was subjected to Boc 
removal using CF3COOH and cyclization (carried out under dilute conditions) giving III.9 (48 %) 
and the epimers III.42(43 %). 
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Figure III.10 Illustration of the synthesis of the Benzolactams-V8 ring system according to Endo 
and coworkers45. 
Ma Dawei and coworkers 47, 48 were able to develop an alternative synthetic route for the synthesis 
of benzolactam-V8 with overall yield 17.7%. The aldehyde III.44, prepared from  2-iodobenzoic 
acid III.43, was condensed with methyl-2-nitroacetate under the action of TiCl4 and NMM to 
furnish olefin III.45. A Pd/C-catalyzed hydrogenation yielded crude amino acid III.46, which was 
cyclized under the action of DPPA to afford a mixture of diastereoisomers III.47 and III.48. 
Finally, LiBH4 reduction of III.48 afforded benzolactam-V8 III.49 (figure III.11).  
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Figure III.11 Synthetic route towards benzolactam-V8 described by Ma Dawei. 
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III.5 1,5-BENZODIAZOCINES 
III.5.1 Comprehensive literature review 1,5-benzodiazocine-2,6-diones 
Our proposed 1.5-benzodiazocine-2,6-diones are only very limitedly described in the literature. 
The following paragraphs will give a comprehensive overview of reported derivatives and their 
synthesis. 
III.5.1.1 Synthesis of Auret, Grundon and McMaster (1968) 
Starting from the epoxide-ester III.51 (formed from a Darzen reaction between benzaldehyde and 
chloroacetanilide III.50), followed by N-methylation and treatment with an excess of methyl 
amine, benzodiazocinedione III.53 could be obtained (figure III.12)49. Reaction with tosyl 
chloride followed by elimination led to compound III.55.  
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Figure III.12 Synthesis of Auret, Grundon and McMaster  
III.5.1.2 Synthesis of Gatta and Landi-Vittory (1970) 
Gatta described a synthetic route for compounds III.60 (R = phenyl or benzyl), via cyclization of 
the open-chain precursors III.59 under the action of ethyl chloroformate (figure III.13)50. The 
open-chain precursors themselves were prepared from the nitro derivatives III.57, obtained from 
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the reaction of 2-nitrobenzoyl chloride with the ethyl ester of N-benzyl or N-phenyl-β-alanine 
(III.56)51. Note that in case of direct catalytic hydrogenation of the nitroester III.57 no ring-closed 
product III.60 is observed (these are conditions which are known to readily give the corresponding 
seven membered 1,4-benzodiazepine-2,5-diones). Compounds III.60 can undergo a methylation 
reaction at N1 position with methyl iodide after deprotonation with sodium methoxide leading to 
the analogs III.61. 
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Scheme III.13 Synthesis of 1,5-benzodiazocine-2,6-diones by Gatta and Landi-Vittory.  
An alternative approach via cyclization of intermediate β-chloropropionyl anthranilamide III.62 
did not furnish the desired lactam, as elimination reaction was observed (III.65) in the presence of 
sodium hydride or trimethylamine, whereas treatment with sodium methoxide gives rise to methyl 
ethers III.63 and III.64 (figure III.14). 
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NH
Cl
NHR
O
O
III.62
R = Ph, Bn
X
NaOMe
NaH or Et3N
NH
NHR
O
O
III.63
Ph: 54%
Bn: 53%
OMe
+
N
N OMe
R
O
III.64
Ph: 25%
Bn: 28%
NH
NHR
O
O
III.65
NaH Et3N
Ph
Bn
72%
78%
81%
82%
Figure III.14 Attempted cyclization of chlorobenzamides III.62. 
We suggest that the presence of a secondary amide function is responsible for this observed 
behavior, as it is known that secondary amides are generally exclusively present as their Z- (trans) 
isomer which is geometrically unfavorable for cyclization (figure III.15).  
                     
NH
Cl
NHR
O
O
Z-III.62
(trans)
X
H
N
NH
O
O
Cl
R
E-III.62
(cis)
 
Figure III.15 Internal secondary "trans" - isomer as a possible cause for the failure of the ring 
closure of III.62. 
 
III.5.1.3 Synthesis of Möhrle, Rohn and Westle (1998) 
After a more recent study of the oxidation behavior of γ-carbolines, Möhrle reported that treatment 
of mebhydrolin (III.66, R = Bn, figure III.16) with sodium periodate afforded a number of 
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different products, including benzodiazocinedion III.68.52 This procedure was also applied to N-
Me and N-Ph analogues. 
 
N
H
N
Me
H
H
COO
O
N
N
Me
R
N
N
O
O Me
R
NaIO4
R = H
NaIO4
R = Me, Ph, Bn
Me: 15%
Ph: 18%
Bn: 18%
III.67 III.68III.66
Figure III.16 Access to 1.5-benzodiazocine-2,6-diones via oxidation of γ-carbolines. 
 
The reaction mechanism of this transformation hypothesized by the authors is depicted in figure 
III.1753. In a first step, the indole ring of III.66 can be readily oxidized at the C2-C3 bond to give 
the benzazonine skeleton III.69 54, 55. The present α-amino ketone functionality is not stable and 
reacts under oxidative conditions further via the iminium ion III.70, which is trapped with water 
to give the hemiaminal III.71. This is in equilibrium with the open form III.72 which can give the 
alternative eight-membered hemi-aminal III.7356. Hydroxide elimination and hydration of the 
aldehyde function give rise to the iminium salt III.75 which can undergo a further periodate 
oxidation to the final 1,5-benzodiazocine-2,6-dione III.68.  
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Me
III.69
NaIO4 N
N
O
O
R
Me
III.70
H2O N
N
O
O
R
MeOH
III.71
N
O
O
R
Me
III.72
HN
O
N
N
HO
O
R
Me
O
NaIO4
R = H
OH
N
O
O
R
Me
III.67
HN
III.73
N
N
O
O
Me
Me
III.68
N
N
O
R
Me
O
III.74
N
N
R
Me
O
H2O
OH
HO
I
O
O
O
O
NaIO4
III.76
N
N
O
Me
O
R
OI
O
O
O
III.75
OH
-IO3
-
-HCOOH
R = Me, 
Ph, Bn
R=H, Me, Ph, Bn
 
Figure III.17 Proposed mechanism for the periodate oxidation of γ-carbolines to 1,5-
benzodiazocine-2,6-diones III.68. 
It is important to note that if III.66 concerns a NH-substituted indole nucleus (R = H), the 
corresponding benzodiazocinedione is not formed, but rather the open derivative III.67, probably 
via the displayed alternative route.  
                      
O
E-III.72
O
N
H
NHMe
O
Z-III.72
O
N
H
NHMe
X
(trans) ( cis)
O
O
 
Figure III.18 Internal secondary "trans" - amide in III.72 (R=H) as a possible cause for not 
forming hemiaminal III.73 (R=H).  
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Again, we may suggest that this is a consequence of the presence of an internal secondary amide 
function having the trans geometry, so that ring contraction on the stage of III.72 (on the way to 
III.73) cannot occur, and alternative periodate oxidation to the carboxylic acid III.67 takes place 
(figure III.18).                        
III.5.1.4 Synthesis of Karp and colleagues (1998)  
Synthesis of a single 1,5-benzodiazocine-2,6-dione III.81 was reported by Karp and coworkers57. 
Reaction between the methyl ester of N-tert-butyl β-alanine III.77 and 5-chloro-2-nitrobenzoyl 
chloride, followed by hydrogenation provided amino-ester III.79 which underwent hydrolysis 
followed by cyclization using DCC to give the desired 1,5-benzodiazocinedione III.81 (figure 
III.19), which was tested for herbicidal activity, but was found to be inactive. 
 
H
N OMe
O
NO2
Cl
Cl
O
Et3N, THF
N OMe
O
NO2
Cl
O
III.77 III.78
H2, Pd/C
EtOAC
N OMe
O
NH2
Cl
O
III.79
NaOH
H2O/THF
N OH
O
NH2
Cl
O
III.80
DCC
CH3CNN
HN
O
O
Cl
III.81
 
Figure III.19 Synthesis of Karp via cyclization of α,ω-aminocarboxylic acid III.80. 
III.5.2 1,5-benzodiazocine-2-one via imine formation 
Derieg described the synthesis of 8-chloro-3,4-dihydro-1-methyl-6-phenyl-1,5-benzodiazocine-2-
one III.11 (the direct ring homologue of diazepam) via cyclization of the open-chain precursors 
III.84 under reflux in toluene (figure III.20)18.The open-chain precursor is prepared from 
treatment of carboxybenzyl-β-alanine III.82 with PCl5 leading to the acid chloride which was 
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treated with 5-chloro-2-methylamino benzophenone to give III.83. The acid hydrolysis of III.83 
provides the amine III.84.    
HO
O
NHCbz
1) Ether, 0°C, PCl5, 1.5 h
2) 5-chloro-2-methylamino 
benzophenone, CHCl3, r.t. 
3) water, 3N NaOH, 3N HCl
Cl
N NHCbz
O
O
HBr (31%), CH3COOH,2 h, r.t
Cl
N
CH3
NH2
O
O
Toluene, reflux o.n.
23.4%
N
N
O
III.11
III.82
III.83
III.84
Cl
NH4OH
 
Figure III.20 Synthesis of 1,5-benzodiazocine-2-one III.11. 
 
III.6 1,6-BENZODIAZOCINES 
III.6.1 Via Intramolecular nucleophilic substitution (Stetter) 
The first report on the 1,6-benzodiazocine58 skeleton described the condensation of o-phenylene 
diamine sulfonamide III.85 with dibromobutane III.86 to produce N,N-ditosyl-1,6-
benzodiazocine III.87, which was treated with H2SO4 to liberate the amino groups to afford the 
parent 1,6-benzodiazocine III.88 (figure III.21). 
NH
NH
Ts
Ts
+ Br(CH2)4Br
Na-BuOH
N
N
Ts
Ts
N
H
HN
III.85 III.86 III.87 III.88
35%
H2SO4
70%
 
Figure III.21 Synthesis of 1,2,3,4,5,6-hexahydro[b][1,4]diazocine III.88.  
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III.6.2 Via Schmidt rearrangement (Kawamoto) 
An attempt to enlarge the benzazepinone ring in III.89 by one nitrogen atom using the Schmidt 
reaction unexpectedly afforded benzimidazole derivative III.94 as the major component, along 
with a small amount of the eight-membered lactams III.92 and III.93 via intermediates III.90, 
III.91, figure III.2259. 
  
H
N
O
N
H
N
C+
N
H
HN
O
N
N
III.92
III.89
III.90
III.94
majorminor
CCl3COOH
NaN3
C N
H
N
(42%)
III.91
H2O +
N
H
HN
III.93
minor
+
O
  
Figure III.22 Attempted synthesis of eight-membered lactam III.92 using the Schmidt 
rearrangement. 
III.6.3 Via Lactamization (Elguero). 
The strategy of Elguero and coworkers60 involves a base-catalyzed condensation of o-
phenylenediamines III.95 and diethyl succinates III.96 to obtain a series of five 1,6-
benzodiazocine-2,5-dione derivatives (III.97 - III.101)  (figure III.23). Interestingly, the presence 
of an internal secondary amine does not prevent the successful cyclization to the eight-membered 
ring system. 
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N
N
R1
R2
O
O
R3
III.97  R1=R2=R3=H, 40%
III.98  R1=R2=CH3, R3=H, 10% 
III.99  R1=CH3, R3=R2=H, 10%
III.100  R1=R2=H, R3=CH3, 45%
III.101 R1=R2=R3=CH3, 35%
NH
NH
R1
R2
+
O
O
O
O
R3
NaH, THF
III.96III.95
Figure III.23 Synthesis of a series of 1,6-benzodiazocine-2,5-dione derivatives via condensation 
of o-phenylenediamines and succinates. 
III.6.4 Via intramolecular N-acylation (Yang et al.). 
Coupling of N-phosphoamino acid III.103 with 2-bromoaniline III.102 in pyridine using 2 equiv 
of diphenyl phosphite (DPP)gave amide III.104 which was cyclized via a Cu-catalyzed reaction 
to give 1,6-benzodiazocine-2-ones  III.105. Deprotection of in acidic medium led to compound 
III.92 (figure III.24).61 
DIPP:
NH2
Br
III.103
+
DPP, Py
65-95%
Br
H
N
O
III.104
5 mol % CuI
10 mol % proline
N
H
N
O
DIPP
acid
N
H
H
N
O
III.105
III.92
III.102
2 eq K2CO3
toluene, 110 °C
72 h, 68%
HOOC
HN
DIPP NH
DIPP
O
P OO
DIPP-: diisopropylphosphoryl
Figure III.24 Synthesis of 3,4,5,6-tetrahydrobenzo[b][1,4]diazocin-2(1H)-one III.92, via Cu-
catalyzed intramolecular N-arylation (DIPP= diisopropylphosphoryl) 
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Compared to N-protected intermediate III.104, the corresponding intermediate containing a free 
primary amino group product failed to cyclize by the same conditions. The authors hypothesize 
that introduction of phosphoryl at the N-terminus could conformationally restrain the acyclic 
precursor, which could be favorable for intramolecular reaction. According to the authors, a 
simplified mechanistic view for the formation of cyclic products III.105 from the open forms 
III.104 is summarized in figure III.25. 
Br
H
N
O
III.104
NH
DIPP
N
H
N
O
DIPP
CuL
or
or
N
H
N
O
Cu
L
DIPP
N
H
O
O
Cu
III.106
N
HN
O
DIPP
III.105 III.109 III.110
= CuL
Br
H
N
O
III.107
NH
DIPP
CuL
Br
H
N
O
III.108
NH
DIPP
LCu
 
Figure III.25 Possible copper-catalyzed cyclization mechanism61.   
 
The copper catalyst III.106 resulting from the reaction of cuprous ion with proline salt could 
undergo coordination with the two nitrogen atoms of the amide and the DIPP-NH leading to the 
complex III.107, which places both bromine and DIPP-NH in the appropiate orientation for 
formation of III.109. Alternatively the coordination of copper catalyst III.106 with the phenyl ring 
and nitrogen of the DIPP-NH could afford the Л-complex III.108, which can also undergo the 
intramolecular N-arylation providing the desired nitrogen heterocycle III.110. Decomplexation of 
copper catalyst system in III.109 or III.110 yields the target product III.105. 
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III.6.5 Via reductive ring expansion (Shvidenko et al.) 
The reduction of benzimidazole derivative III.94 in toluene using a six-fold excess of DIBAL-H 
led to the formation of a mixture of 1,6-benzodiazocine III.88 and o-phenylenediamine derivative 
III.111 (figure III.26)62. 
                                  
N N
DIBAL-H
NHHN N
NH2
+
III.94 III.88 III.111
35% 43%
 
Figure III.26 Synthesis of 1,2,3,4,5,6-hexahydrobenzo[b][1,4]diazocine by Shvidenko. 
The formation of compounds III.88 can be easily rationalized by the reduction mechanism of 
amidines with DIBAL-H which includes a sequential electrophilic attack of DIBAL-H at the two 
nitrogen atoms ((figure III.27). path 1). At the same time the reductive cleavage of the C-N bond 
resulting in intermediates III.112 may be implemented by a double attack at the same nitrogen 
atom to form aluminum imides III.114 to afford the compound III.111 ((figure III.27). path 2), 
which are usually less energetically favorable compared to intermediates III.11362. 
N N
III.94
DIBAL-H
NN
III.112
Al(i-Bu)2
Path
 1
Path 2
N
Ni-Bu2Al
Al(i-Bu)2
N
N(Ali-Bu2)2
III.113
III.114
III.88
III.111
H
" H  "
1
2
DIBA
l-H
DIBAl-H
Al
CH3
CH3
CH3
H3C
H
DIBAL-H:
" H  "
Figure III.27 Assumed mechanistic paths for the DIBAL-H reduction of III.94. 
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III.6.6 Via ring-closing metathesis (Taher, Van Otterlo) 
A set of 1,6-benzodiazocines was synthesized by ring-closing metathesis63,64 from the 
corresponding bis-allyl o-phenylenediamine precursors using Grubbs second generation catalyst. 
(figure III.28). Ru-catalyzed isomerization was shown to give isomeric products III.119 and 
III.119`. 
N N
CH3
H3C
Ru
Ph
Cl
Cl
PCy3
NH
NH
R
R
Br
NaH or K2CO3
III.117a R: Boc : 66%
III.117b R: Bz :  81%
III.117c R: Ts :  92%
III.117d R: Ac :  92%
+
N
N
R
R
Grubbs second 
generation catalyst
N
N
R
R
III.118a R: Boc: 49%
III.118b R: Bz :  97%
III.118c R: Ts :  92%
III.118d R: Ac :  80%
N
N
R
R
N
N
R
R
and/or
[RuClH(CO)(PPh3)3]
III.116
III.119a R: Boc
III.119b R: Bz 
III.119c R: Ts
III.119d R: Ac
III.117 III.118
III.119 III.119`
Grubbs Catalyst, 2nd Generation
III.115
H3C
CH3
H3C
CH3
Figure III.28 Synthesis of a series of 1,6-benzodiazocines using Grubbs second generation RCM 
catalyst. 
 
III.6.7 Via thermal ring expansion (Shue) 
According to Shue and Fowler, N,N-dimethylbenzo-1,6-dihydro-1,6-diazocine III.12365 was 
synthesized through the thermal ring opening of cyclobutene III.122. Gas phase thermolysis at 
285 °C produces the benzodiazocine III.123 as the only detectable product. Irradiation of 
diazocine III.123 results in the reversal formation of cyclobutene III.122 (figure III.29). 
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NH
Me
NH
Me
+
Cl
Cl N
N
Me
Me
N
N
Me
Me
n-BuLi
-78 C
III.120 III.121 III.122 III.123

h
 
Figure III.29 Synthesis of 1,6-benzodiazocine III.123 via gas phase thermolysis of III.122. 
 
III.7 2,3-BENZODIAZOCINES  
III.7.1 Via cycloaddition (Dennis) 
The only known literature example66 describes the reaction of betaine III.124 with 
phenylacetylene III.125 in refluxing xylene to give two isomeric products. Besides the normally 
expected cycloadduct III.126 the 2,3-benzodiazocine III.127 was isolated. (figure III.30).  
N+
N
O-
Ph
N
N O
Ph
Ph
III.124 III.126
N
N
PhO
Ph
III.127
++
III.125
Xylene, reflux
75%10%
majorminor
Figure III.30 Synthesis of the 2,3-benzodiazocine III.127. 
 
From the authors point of view the diazocine III.127 was obtained from the normal cycloadduct 
III.126 via electrocyclic ring opening reaction as illustrated in (figure III.31). 
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N
N O
Ph
Ph
N
N O
Ph
Ph
III.126
N
N
PhO
Ph
III.127
III.128
 
Figure III.31 Proposed mechanism for the formation of 2,3-benzodiazocine III.127. 
 
 
III.8 2,4-BENZODIAZOCINES 
III.8.1 Via intramolecular aminal formation  
Starting from 4-isoquinolinecarboxylic acid III.129, Kametani and coworkers67 synthesized 
bridged 2,4-benzodiazocines III.133 and III.134 via consecutive amide formation, catalytic 
hydrogenation of the heteoaryl moiety and LiAlH4 reduction to bisamine III.132, which was 
subjected to aminal formation using appropriate aldehydes to give the cyclized targets III.133 and 
III.134 (figure III.32).  
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N
COOH
III.129
N
CONHCH2C6H5
NH
CH2NHCH2C6H5
NH
CONHCH2C6H5
N
N
III.133
III.130 III.131
III.132
PhCH2NH2
POCl3, 88%
H2, PtO2
LiAlH4, 84%
CH2O, benzene
N
N
C6H5
80%
III.134
Reflux, 81%
PhCHO,
MeOH,
66%
 
 Figure III.32 Synthesis of bridged 2,4-benzodiazocines. 
 
III.9 2,5-BENZODIAZOCINES 
III.9.1 Via nucleophilic substitution   
Reaction of 1,2-bis-bromomethyl-3,4,5,6-tetrachloro-benzene III.135 with 2-
dimethylaminoethylamine III.136 afforded the quaternary ammonium salt 2,2-dimethyl-
1,2,3,4,5,6-hexahydro-7,8,9,10-tetrachloro-2,5-benzodiazocinium bromide68 (III.137) (figure 
III.33). 
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Cl
Cl
Cl
Cl
Br
Br +
H2N
N
Me
Me
N
H
N
Cl
Cl
Cl
Cl
Me
Me
Br-
III.135 III.136 III.137
 
Figure III.33 Synthesis of  2,5-benzodiazocine III.137. 
 
Similarly, Sawanish and coworkers reported the synthesis of compound III.14069 through 
condensation of III.139 and α,α′-dibromo-o-xylene III.138 in basic medium (figure III.34). The 
compound was shown to suppress the efflux of vinblastine from P388/ADR cells and increased its 
intracellular accumulation, while it barely increased the vinblastine accumulation in sensitive cells 
(P388/S).  
                        
Br
Br
+
NH
HN
Ts
Ts
Na, n-BuOH
N
N
Ts
Ts
III.138 III.139 III.140
 
Figure III.34 2,5-benzodiazocine synthesized by Sawanish and coworkers. 
 
The copper catalyzed reaction of bis acetate III.141 with N,N-diphenylethane-1,2-diamine III.142 
using Ph-PyBOX as a ligand afforded compound III.14370 in 68% yield as a mixture of two 
diastereoisomers (meso-isomer/DL-isomer = 8/1), the minor DL-isomer was obtained with 66% ee. 
(figure III.35).  
Part 1: Introduction  
 
53 
 
OAc
OAc +
PhHN
NHPh N
N
Ph
Ph
5 mol%, CuOTf.1/2C6H6
10mol% Ph-PyBOX
68% yield (meso/dl=8/1), 66% ee
III.141 III.142 III.143
Ph-PyBOX
2.4 equiv  i-Pr2NEt
MeOH, r.t., 20 h
N
N
OO
N
Ph Ph
Figure III.35 Synthesis of benzodiazocine III.143. 
 
III.9.2 Via Ugi/carbonylative lactonization sequence  
Various amines III.144, ortho-iodobenzaldehydes III.145, isocyanides III.146 and Boc-
aminoacids III.147 were reacted in an Ugi 4-component reaction and the products purified via 
sequential treatment with PS-trisamine and MPCO3 resins to afford pure Ugi products III.148 
(figure III.36) in respectable yields (70 - 88%) as mixtures of diastereomers71, where applicable.  
 
R1 NH2 +
I O
H
R3
HN COOH
Boc
R2 NC
+
+
MeOH
I
N
O
NH
O
R3 NHBoc
R1
R2 NH
N
O
O
R3
R1
HN
O
R2
1. 4N HCl
2. Mo(CO)6,
Pd(OAc)2III.144
III.145
III.146
III.147
III.148 III.149
(70-88%) (33-77%)
Ugi MCR
Figure III.36 Library of 2,5-benzodiazocines via the Ugi- carbonylative lactamization sequence. 
 
Deprotection of the Ugi MCR products with 4N HCl was followed by a carbonylation/ 
intramolecular amidation reaction, delivering the intended sturucturally diverse 2,5-
benzodiazocine-3,6-dione III.149 library in a moderate yields (33-77 %) (figure III.36). 
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N
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O
III.150 III.151
O
O
 
Figure III.37 Examples of compounds synthesized by Vasudevan and coworkers. 
 
III.10 3,4-BENZODIAZOCINES 
 
III.10.1 Via hydrazone formation 
Dicarboxylic acid III.152 was converted to diketones III.153 which were cyclized using hydrazine 
hydrobromide to afford 3,4-benzodiazocines III.154 and III.155 (figure III.38)72. 
1. SOCl2
2. Ar-H, AlCl3
COOH
COOH R
R
O
O
N
N
R
R
NH2NH2.HBr
III.153 III.154 R= phenyl
III.155 R= 2,4-xylyl
III.152
 
Figure III.38 The 3,4 benzodiazocines synthesized by Norman. 
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IV. AIM AND STRATEGY 
IV.1 GENERAL AIM 
As part of our ongoing research on medium ring heterocycles as potential new privileged 
structures, our interest in this project is in synthesizing 1,5-benzodiazocine-2,6-dione derivatives 
which have only been limitedly studied to date, although they can be considered as 
pharmaceutically interesting, as they are closely related to the benzodiazepine privileged structure 
(chapter I).  
The aim of this research project is to synthesize libraries of structurally diverse compounds on the 
basis of a 1,5-benzodiazocine-2,6-dione skeleton, on which up to ten substitutable attachment 
points are in principle available (IV.1, figure IV.1). For reasons of clarity throughout this 
dissertation a simplified general representation (IV.2) is used where epimeric side chain R2a and 
R2b are represented by a general substituent R2. Similarly R3a and R3b are represented by R3 while 
R5a-R5d are represented by R5. Starting from commercially available and/or easy to synthesize 
building blocks the purpose will be to build up the eight-membered (bis)lactam ring using a solid-
phase synthesis approach which would allow the introduction of side chain diversity during the 
synthesis. In this way, ideally a general synthesis methodology could be applied to the parallel 
construction of a combinatorial collection of 1,5-benzodiazocine-2,6-dione derivatives. 
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Figure IV.1 Representative structure for the 1,5-benzodiazocine-2,6-dione skeleton 
IV.2 SYNTHESIS STRATEGIES  
A. General retro synthesis 
The most obvious strategic disconnections in the intended 1,5-benzodiazocine-2,6-dione skeleton 
can be made at both lactam functionalities, (figure IV.2). The resulting 
synthons IV.3 and IV.4 can then be related to two possible basic building blocks: anthranilic acid 
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derivatives IV.5 and β-amino acids IV.6. In principle, sets of these building blocks are readily 
available, either via commercial sources or established synthetic methodology. 
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Figure IV.2 Retrosynthetic scheme towards 1,5-benzodiazocine-2,6-dione derivatives; anthranilic 
acids and β-amino acids as the necessary key building blocks 
Our combinatorial approach is based on the use of a solid phase synthesis sequence. As such, an 
appropriate anchor point has to be chosen for the synthesis route on the solid support. In the solid 
phase synthesis of (hetero) cyclic systems where a ring closure is the key step of the synthesis, two 
approaches can be distinguished. In the first approach, the ring closure is accompanied with 
simultaneous cleavage of the final product from the solid support, and the resin can thus be 
considered as a leaving group ("cyclization/release strategy ", route A, figure IV.3). In the 
alternative strategy, cyclization led to a ring closure product that is still resin bonded ("on-resin 
cyclization", route B, figure IV.3). Both approaches have intrinsic advantages and disadvantages 
which are briefly outlined in the following paragraph.  
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Figure IV.3 Two possible solid phase synthesis approaches: route A through simultaneous ring 
closure and resin cleavage; Route B where ring closure leads to resin-bound product IV.9 in which 
an additional cleavage step is necessary.  
B. Cyclization/release vs. on-resin cyclization  
The cyclization/release strategy is part of the so-called traceless linker methods, in which there is 
no residual functional group (trace) left on the product after cleavage1. An advantage of this 
strategy is that only ring-closed products are expected to be selectively cleaved from the resin, 
resulting in a crude product with a relatively higher degree of purity. A disadvantage is that all on-
resin scaffold decoration needs to happen before ring closure. Most literature examples of this 
strategy make use of a nitrogen atom as the nucleophile and an ester or amide moiety as solid 
phase anchor functionality, resulting in the formation of five-2, six-3 or seven-membered lactams4. 
The success of this approach not only depends on the nucleophilicity and electrophilicity of both 
the reaction partners, but also on steric factors.  
On the other hand, in the on-resin cyclization strategy, the ring closed products remain anchored 
onto the solid support. The main advantages of this approach are the possibility to derivatize the 
cyclized product further on-resin and to activate both reaction partners involved during the ring 
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closure (in contrast to the above-mentioned cyclization/release approach). Main disadvantages are 
the loss of one diversity position (the anchoring point) and the usually lower purity of the final 
products compared to the cyclization-release approach, because cleavage is not selective for the 
ring-closed products. Based on the above-mentioned advantages and on previous successful results 
in our laboratory5, we decided in this research work to use the cyclization release strategy.  
Applied to our target compounds, this leads to a general retrosynthetic scheme as depicted in figure 
IV.4. The 1,5-benzodiazocine-2,6-dione IV.2 could be obtained by cyclization through the ester 
bond resin-bound dipeptide precursors IV.11 which could be built up in turn from the coupling of 
anthranilic acid with resin-bound β-amino acid derivatives IV.12, (route A) or by changing the 
sequence of the building blocks (route B); both indicated routes (A and B) could essentially lead 
to the same benzodiazocinedion. However, prior research in our laboratory5 has shown that the 
amide formation between the amine group of anthranilic acid and the carboxylic group of β-amino 
acid (route B) provides low yields, probably because of the low nucleophilicity of that amine group 
as it can be considered to be a vinylogous amide.   
 
N
N
O
O
R1
R5
R2
R3
R4
NH
N
R4
O
R1
R3
R4
O
O
R5
route A route B
O
O N
R1
O
R2
R3
NH
R4
R5
amide formation amide formation
NH
R4
R3
R4
O
O
O
O NH
R1
R5
OH
esterfication esterfication
lactam 
formation
lactam 
formation
IV.2IV.11 IV.14
IV.12 IV.15IV.13
A
B
Figure IV.4 Retro synthetic approaches for a cyclization/release strategy. 
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C. Cyclization/release strategy: Previous work in our laboratory 
C.1 The effect of secondary or tertiary amide bond [N-5 substitution]  
Wang resin and HMBA-AMPS resin were used in a solid phase synthesis sequence in our 
laboratory to synthesize IV.19, through the resin-bound precursor IV.18. Cyclization was tested 
under many conditions using acid, base or nucleophilic catalysis, but all attempts failed to afford 
the cyclized IV.19. 
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O NH2
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or 
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N
H
O
OH
HMBA-AMPS resin
IV.17
IV.18 IV.19
O
OH
Wang resin
IV.16
5
Figure IV.5 Previous attempts to cyclize secondary amide resin-bound precursor IV.18 to IV.19. 
 
These negative results are thought to arise from the presence of the internal secondary amide. In 
order to obtain appropriate cyclization, the reactive centers should be able to approach each other, 
meaning that the amine function has to approach the ester group to carry out the desired acyl 
substitution. However, the internal secondary amide function affects the flexibility of the 
molecule; as a result of the partial double bond character of the C-N bond (IV.22), there are two 
possible isomers, cis (E-)isomer and trans (Z-)isomer as shown in figure IV.6. 
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Figure IV.6 E- and Z- isomers of the amide. 
The population of these conformations and their isomerization kinetics have been studied 
extensively6. Unless for very simple examples, in case of secondary amides, the amide bond is 
predominantly present in the trans- conformation (e.g the ratio of cis / trans is already 0/100 for 
the simple combination of a methyl and ethyl group as R and R`). The isomerization rate appears 
to be very slow, even at a higher temperature, as a result of the high activation energy for rotation 
about the C-N bond. On the contrary, for tertiary amides having similar R` and R`` groups, 
approximate equimolar mixtures of cis and trans- forms are present7. Moreover, the activation 
energy required to carry out a rotation around the C-N bond is lower than in secondary amides 
because of the higher energy level of the tertiary amide rotamers compared to the energetically 
more stable trans-secondary amide rotamer due to sterical effects of R/R`/R``, while the 
corresponding transition states have a comparable energy8. This issue of amide conformational 
restriction has been reported to limit cyclization feasibility in medium-sized rings. As an example, 
the group of Van Maarseveen9, found that the seven-membered IV.27, (figure IV.7) can be formed 
from tertiary amide IV.28 as opposed to IV.26 which is attributed to the presence of the trans- 
conformation of secondary amide in IV.25 on the peptide bond of the precursor.  
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Figure IV.7 Example of the influence of a secondary or tertiary amide bond on the formation of 
homodiketopiperazines IV.26 and IV.27. 
Applied to our strategy (figure IV.8), to achieve a successful ring closure, in IV.29 an internal 
tertiary amide needs to be present; allowing the necessary cis-conformation, since the alternative 
trans-conformation causes a particularly unfavorable dimensional arrangement of the 
corresponding reaction partners. 
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Figure IV.8 Cis-/trans- isomerization in tertiary amides IV.29 and their impact on cyclization. 
C.2 Effect of α-H atoms in position C-3: 
Based on the above, a solid phase synthesis was applied in our laboratory in order to obtain N5-
benzylated model compound IV.34 through the resin-bound precursor IV.30. Cyclization using 
acids, lewis acids, bases or nucleophiles were tested and failed to afford the cyclized IV.34. A 
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minute amount (5%) of the intended benzodiazocinedion could be observed when treating resin-
bound precursor IV.30 with t-BuOK (strong base), in addition to a major elimination product 
(95%) IV.31, while the use of NaOiPr or NaOMe could not alleviate the elimination problem and 
additionally gave transesterification products. The observation of a small amount of cyclized 
product seems to result from the deprotonation of the anthranilamine moiety, leading to a more 
nucleophilic species. Unfortunately the presence of acidic α-hydrogen prevents the use of these 
conditions for successful library construction.  
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Figure IV.9 Formation of by-product IV.31: elimination under strongly basic conditions. 
 
Therefore a solution-phase cyclization was investigated, in which TFA-cleavage of IV.30 was 
followed by cyclization of IV.33 with the aid of DIC or polystyrene-bound DCC to afford VI.34. 
Based on this methodology, a simple small library was achieved5 (SPS yields: 15-91% and 
cyclization yields: 27-90%). The main problem of this cyclization seems to be the formation of N-
acyl urea side products arising from O→N acyl urea rearrangement after carbodiimide activation. 
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Scheme IV.1 Library prepared by solution-phase cyclization using DCC resin. 
 
The successful use of KOtBu-mediated cyclization was demonstrated for resin-bound precursors 
IV.37 (which do not contain acidic α-protons) leading to a small library of 3,3-dimethyl-1,5-
benzodiazocine-2,6-diones IV.38 (yields: 4-58% with crude purity 60-98%)5. 
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Scheme IV.2 Cyclization of resin bound precursor in KOtBu in THF to form IV.38. 
 
IV.3 SPECIFIC AIMS OF THIS WORK 
As already mentioned, this project forms the continuation of the above previous work at our 
laboratory. The specific aims of this PhD can be summarized as follows (figure IV.10): 
GOAL 1: In a first part, the synthesis of model compound IV.34 will be repeated, and the synthesis 
will be optimized where possible. Especially, the cyclization step will be further investigated. Until 
now, only carbodiimide-based activation was explored in this reaction, leading to less than optimal 
yields because of unwanted O→N acyl migration side reactions.  
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GOAL 2: From the resulting optimal conditions, further libraries of structurally diverse 1,5-
benzodiazocine-2,6-diones will be constructed using the solution-based cyclization approach; 
diversity at the 3- and 4-positions will be examined. To this end, anthranilic acid building blocks 
IV.42 will be used on one hand; on the other hand skeletal diversity at 3- and 4- position will arise 
from β2- and β3-amino acid building blocks, respectively. 
GOAL 3: Lastly, we wish to extend the cyclization/release methodology using strong base-induced 
cyclization to more complexly-substituted derivatives IV.41 from appropriate β2,2- amino acids 
GOAL 4: As the required β-amino acids are generally not commercially available, an in-house 
synthesis will be necessary.  
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Figure IV.10 Goals of this PhD-research project. The chosen target compounds are shown and 
their respective basic building blocks. 
In the next chapters, a solid phase synthesis route of model compound IV.34 will be discussed 
intensively, followed by building blocks synthesis and solid phase synthetic route for each 
representative target compound IV.39, IV.40 and IV.41. 
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V SOLID PHASE SYNTHESIS OF A MODEL 1,5-BENZODIAZOCINE-2,6-DIONE 
As this work is the continuation of previous work performed at our laboratory1, the earlier 
developed solid phase methodology forms the base of the current project. In this chapter the 
synthetic approach is demonstrated for a model compound 5-benzyl-3,4-dihydro-1,5-
benzodiazocine-2(1H),6(5H)-dione and further optimization efforts are explored where necessary.   
 
V.1 SELECTION OF THE SOLID SUPPORT 
Wang resin II.4 as a hydroxyl substituted polystyrene resin is chosen for current synthesis as it is 
available at low cost in a variety of loadings. It allows to cleave off the intermediates after each 
reaction step in concentrated trifluoroacetic acid solution (TFA). For simplification in this thesis 
the annotation V.1 is further used. 
                           
O
PS
OH
II.4
OH
V.1
                                  
Figure V.1: Structure of Wang resin II.4 and a simplified representation V.1 (PS=polystyrene). 
 
V.2 COUPLING OF FMOC-β-AMINO ACID ON WANG RESIN AND FMOC REMOVAL 
Coupling of Fmoc-β-alanine on Wang resin was done using classical (Steglich) conditions; 
preactivation of the carboxylic acid with diisopropylcarbodiimide (DIC) is followed by ester 
formation in the presence of a catalytic amount of DMAP2, (scheme V.1, step 1). No reaction is 
observed with the use of other "classical" (amide bond forming) coupling reagents (DIC / HOBt, 
HBTU, PyBrOP)1. Any unreacted remaining alcohol moities are protected via "capping" with an 
acetyl group by treatment with an excess of acetic anhydride, (scheme V.1, step 2). At this stage, 
the loading was determined via UV Fmoc-quantitation (see chapter II). The yield of the final 
product will be calculated from this value. Typical loading is around 0.6 mmolg-1. 
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OH O
O
NHFmoc
 2) Ac2O/DIPEA/CH2Cl2 
     (1/1/3), r.t, 2 x 1h.
V.1 V.2
1) a) 2 eq Fmoc--alanine, 2 eq DIC, 20 min, CH2Cl2, 0°C.
OH
O
O
NHFmoc
OAc
V.3
b) 0.2 eq DMAP, CH2Cl2, r.t,  24h.
     
Scheme V.1: Coupling of Fmoc-β-alanine to Wang resin.   
Fmoc removal with 4-methylpiperidine in DMF delivered the resin V.4, (scheme V.2) with a free 
primary amine functional group, which allows further attachment with the next building blocks.  
O
O
NHFmoc O
O
NH2
20% 4-methylpiperidine in DMF, 
2 x 20 min, rt
V.3 V.4
Scheme V.2: Fmoc removal using a solution of 20% 4-methylpiperidine in DMF. 
 
V.3 MITSUNOBU-FUKUYAMA ALKYLATION SEQUENCE  
In this proposed synthesis, diversity is introduced to the N-5 position via alkylation. In the 
literature, the difficulty of mono-alkylation of primary amines is a long recognized problem which 
was also observed by us in solid-phase syntheses (e.g. N-overalkylation using reductive alkylation 
with aldehydes). To overcome this issue of overalkylation, a stepwise so-called Mitsunobu-
Fukuyama alkylation has been developed. The reaction sequence consists of three main steps; 1) 
amine protection with nosyl chloride, 2) alkylation with alcohol and 3) thiol-mediated deprotection 
of the alkylated product. The utility of this methodology is a result of the presence of an acidic 
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sulfonamide proton (prerequisite for Mitsunobu reaction) and secondly, the simple removal of the 
carefully selected sulfonamide by a nucleophilic aromatic substitution reaction 3,4.  
V.3.1 Step 1: Protection with nosyl group: 
Treating the resin-bound amino acid V.4 with excess 2-nitrobenzenesulfonyl chloride (conc: 0.2 
M in CH2Cl2) in the presence of collidine provides cleanly the resin-bound protected amino acid 
V.5, as evidenced by negative (=colorless) TNBS test for amines and by LCMS analysis of the 
crude product obtained by cleaving an aliquot of resin with TFA.                             
O
O
NH2 O
O
N
H
S
NO2OO
V.4 V.5
CH2Cl2, r.t, 2x1h.
NO2
SO2Cl
5eq
N
, 10 eq
Scheme V.3 Protection of the resin-bound amino acid with o-nosyl group. 
V.3.2 Step 2: Mitsunobu Reaction  
At this stage, the actual Mitsunobu alkylation of the sulfonamide can take place using benzyl 
alcohol through a bimolecular nucleophilic substitution (SN2) reaction after activation with 
triphenyl phosphine and diisopropylazodicarboxylate5, scheme V.4.  
O
O
N
S
H
OO NO2
O
O
N
S
Bn
OO NO210 eq BnOH, 5 eq Ph3P, 5 eq DIAD,
V.5 V.6
DCE, rt, 3 x 2 h
Scheme V.4 Mitsunobu alkylation of V.5 with benzyl alcohol.  
Complete alkylation is achieved after triple treatment for 2 h, as monitored by LCMS analysis of 
TFA-cleaved intermediate. 
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VI.3.3 Step 3: Removal of nosyl group                     
Removal of the 2-nitrobenzenesulfonyl is accomplished by reaction with 2-mercaptoethanol in 
presence of the base DBU. The reaction proceeds via a nucleophilic aromatic substitution in which 
the electron deficient aromatic ring undergoes a nucleophilic attack of the thiolate anion and the 
thus formed Meisenheimer complex (V.8, scheme V.6) after elimination affords the desired mono-
alkylated secondary amine V.7.  
O
O
N
S
NO2OO
O
O
NH
BnBn
HS
OH
5 eq , 2.5 eq DBU, DMF,
V.6 V.7
r.t, 2 x 30 min
Scheme V.5 Removal of the nosyl group by 2-mercaptoethanol and DBU. 
O
O
N
S
NO2OO
O
O
NH
BnBn
V.6
V.7
O
O
N
S
OO
Bn
S NO2
OH
Meisenheimer
complex
+ SO2
NO2
S
HO
V.8
+
V.9
S
OH
Scheme V.6 Mechanism for the deprotection of sulfonamide V.6.  
 
V.4 COUPLING OF FMOC-ANTHRANILIC ACID DERIVATIVES 
In the literature, there are several problems observed around the coupling of secondary amines to 
carboxylic acids6. Even though these secondary amines may be expected to display a higher 
nucleophilicity than their primary counterparts, it appears that the steric hindrance has an important 
influence during amide coupling reactions. Many conditions using a range of coupling reagents 
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and additives have been previously tested in our laboratory for this transformation. It turned out 
that only activation of the carboxylic acid as anhydride could afford the desired resin-bound amide 
in good yields, in agreement with literature reports. Thus, the reaction of 10 eq N-Fmoc-anthranilic 
acid with 5 eq diisopropylcarbodiimide (DIC) yields the symmetrical anhydride V.11, which is 
then allowed to react with resin-bound secondary amine V.7. A full conversion was observed after 
24 hours treatment (concentration anhydride: 0.2 M). 
NHFmoc
OH
O
NHFmoc
N
O
O
O
Preactivation Step
BnHN
O
O
V.10
O
OFmocHN O NHFmoc
a) 10 eq V.10 , 5 eq DIC, CH2Cl2/DMF 9/1, 20 min, r.t, 0 C. b) r.t, 24h.
a) b)
Coupling Step
V.12
V.11
V.7 (1 eq)
Scheme V.7 Coupling of a secondary amine with an anthranilic acid in two steps; preactivation 
to symmetrical acid anhydride then coupling to primary resin-bound amine.  
The use of halogenated solvents is necessary for successful reaction, which has been hypothesized 
to occur via intermolecular hydrogen bonding during the nucleophilic addition step (figure V.2)7. 
The use of a polar solvent would increase competitive solvent hydrogen bonding, thereby slowing 
down the reaction considerably. Because of the poor solubility of Fmoc protected anthranilic acid 
derivatives and their symmetrical anhydride in halogenated solvents, the reaction is typically 
performed in CH2Cl2/DMF 9/1. 
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N
R'
R H
"R
O
O
O
R"
CH2Cl2
V.13
V.14
N
H
O
O
R
R'
O
"R
R"
N
H
O
O
R
R'
O
"R
R"
"R
O
N
R'
R
+ "R
O
OH
V.15 V.16
V.17 V.18  
Figure V.2: Hypothesized reaction mechanism between a secondary amine and a symmetrical 
acid anhydride in halogenated solvent. 
 
V.5 FMOC REMOVAL AND CLEAVAGE FROM RESIN 
Before we could perform the cyclization reaction, the amine had to be deprotected (scheme V.8). 
This Fmoc removal was achieved by shaking the resin V.12 in a solution of 20% 4-
methylpiperidine in DMF for 20 min. The reaction is repeated once to afford V.19.  
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NHFmoc
N
O
O
O
V.12
NH2
N
O
O
O
V.19
20 % 4-methylpiperidine in DMF,
TFA/H2O 95/5, 
1 h
NH2
N
O
HO
O
V.20
2x 20 min
(88% from V.3)
Scheme V.8 Fmoc removal using a solution of 20% 4-methylpiperidine in DMF and cleavage from 
Wang resin in a mixture of TFA/H2O 95/5. 
Cleavage from the resin is done by treatment of the resin with a mixture of TFA/H2O 95/5 for 1 h 
to obtain the ring closing precursor V.20 in solution (scheme V.8). Purification of the crude 
material (crude purity: 95%, 214 nm) by column chromatography gave the pure dipeptide with an 
isolated overall yield of 88% (calculated from V.3). 
 
V.6 CYCLIZATION IN SOLUTION 
An overview of attempted cyclization conditions is displayed in scheme V.9 and table V.1. 
Reactions were typically performed on small scale and monitored by LCMS. Promising conditions 
were then repeated on larger scale, for which isolated yields are reported. 
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HO
O
N
O NH2
N
H
N
O
O
V.20 IV.34
a) coupling reagents (V.28-V.36) and
solvent (see table V.1), shaking 1 hour, r.t.
Scheme V.9 Cyclization step using different conditions. 
Table V.1: Results for cyclization reaction with coupling reagents V.28-V.36. 
Exp reagent (a) Eq Solvent results(b) Purity(c) 
18 ClCOOEt 
Et3N 
1.1 
1.2 
Dioxane Product  
(48% isolated yield) 
 
2 ClCOOMe 
DIPEA 
2 
4 
Dioxane Product + starting material  
84%+1% 
85% 
3 ClCOOMe 
DIPEA 
2 
4 
DCM/DMF 
95/5 
Product  
94% (75% isolated yield) 
94% 
41 DCC resin  
1.9 mmol/g 
2 DCM Product + cyclic dimer 
89%+2%           
89% 
5 DIC 
DIPEA 
2 
4 
DCM/DMF 
95/5 
Product + N-acylurea  
35% +58% 
35% 
6 DIC 
HOBt 
2 
2 
DCM/DMF 
95/5 
Starting material + product + 
N-acylurea  
1% +53% +13%  
54% 
7  
 
DIPEA 
HBTU  
2 
2 
DMF Product + HOBT 
74% + 15% 
74% 
8 Pivaloyl chloride 
DIPEA 
2 
4 
DCM/DMF 
95/5 
Starting material + product + 
N-Pivaloyl side product  
1% + 34% + 20% 
35% 
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9 BOP 
DIPEA 
2 
4 
DMF Starting material + product + 
mixture 
2% + 68% 
70% 
10 PyBrop 
DIPEA 
2 
4 
DMF Starting material + product + 
mixture 
1% + 56% 
57% 
11 TFFH 
DIPEA 
2 
4 
DMF Starting material + product + 
O-acylurea (mixture) 
4% + 46% 
50% 
(a) The concentration of the coupling reagent is 0.01M (b) Relative ratio determined from the peak 
areas in the HPLC chromatogram at 214 nm of the corresponding compounds unless specified 
otherwise; (c) Total HPLC purity of starting material and end product in the crude mixture (214 
nm).  
The cyclization of V.20 to IV.34 was literally described by Gatta8 (scheme V.10) using ethyl 
chloroformate to activate the carboxylic acid, giving the desired product with a reported yield of 
63%. However, in our hands we achieved lower yields (48%). Upon using DIPEA as an alternative 
base (table V.1, experiment 2) and changing solvent to DCM/DMF 95/5 (table V.1, experiment 3) 
LCMS analysis of crude reaction mixture showed increasing amounts of product (85%/94%; 
relative purity determined via LCMS at 214 nm). Repeating the experiment (experiment 3) led to 
an isolated yield of 75%. 
HO
O
N
O NH2
O O
O
N
O NH2
N
H
N
O
O
V.20 IV.34
O1.1 eq ethyl chloroformate, 
1.2 eq Et3N, 1,4-dioxane, 
r.t, 1 h
V.21
 48%
(63% according to Gatta)
Scheme V.10 Ring closure of V.20 according to reported Gatta8 conditions.  
A more successful ring closure was achieved at our laboratory1 through the resin-bound 
dicyclohexylcarbodiimide (DCC) coupling reagent (scheme V.11), giving a clean reaction 
mixture, leading to the purified compound in 75% yield. According to LCMS-analysis, the crude 
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product was contaminated with a low amount of cyclic dimer V.23 (figure V.3). The loss of the 
remaining (25%) material was attributed to the occurrence of an O→N acyl migration of the DCC-
resin-activated carboxylic acid. This O→N acyl migration was confirmed by treatment of V.20 
with DIC, giving the N-acylurea derivative V.27 (scheme V.12, table V.1, experiment 5).  
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Figure V.3: LC-MS spectrum reported by a DAD detector at 214 nm after the cyclization reaction. 
HO
O
N
O NH2
V.20
N C N +
V.36 V.22
HN
N
O
O
IV.34
NH
O
HN
+
V.24
filtered75%
+
V.23
cyclic dimer
ring closure
2 eq
 2h, r.t.
N
NH
N
HN
O
O
O
O
16
CH2Cl2
NH
O
O
N
N
H
O
H2N
activation
Scheme V.11: Cyclization of V.20 using resin-bound DCC. 
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NH
O
O
N
O NH2
N
V.22
O N acyl migration N
H
O
N
O
N
O NH2
V.25
resin-bound by-product
Side reaction:
N
H
O
N
O
N
O NH2
V.27
H2N
O
O
N
O NH2
N
V.26
O N acyl migration
using PS-DCC
using DIC:
V.20
V.20
PS-DCC
DIC
Scheme V.12 By-products formed using DCC resin or DIC as a coupling agent due to O→N acyl 
migration 
 
In an attempt to optimize the yields of compound IV.34, further conditions have been tested for 
cyclization, using a variety of coupling reagents and additives (structures, see figure V.4). 
Where treatment of V.20 with DIC affords 35% (relative purity determined via LCMS at 214 nm) 
of the 1,5-benzodiazocine in addition to 58% of N-acyl urea V.26 (experiment 5), the amount of 
the latter could be decreased by adding the additive HOBT (experiment 6). Using HBTU as the 
coupling agent, 74% of product can be obtained. However, performing the reaction in DMF is not 
desirable due to difficulty of removing it from reaction (experiment 7). Using pivaloyl chloride 
(experiment 8), with 4 eq of DIPEA, led to a lower percentage of cyclized product besides 20% of 
the product resulting from N-pivaloylation. 
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NCN
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N
N
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OH
PyBrOP
N
N
N
O P
N
N
N
N
F
N
PF6
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Pivaloyl Chloride
N
N
H
N
O
P N
N
N
Br
PF6
DIC HOBT
BOP TFFH
IIDQ-PS DCC-PS
V.28 V.29 V.30 V.31
V.32 V.33 V.34
V.35 V.36
N
N
H3C
CH3
CH3
CH3
HBTU
PF6
O
PF6
Figure V.4: Structures of the used coupling reagents and additives. 
The use of BOP reagent in presence of DIPEA affords the product in moderate purity. PyBrOP in 
presence of DIPEA affords lower percentage of product in addition to mixture of compounds (56% 
purity). The use of TFFH to activate the carboxylic acid as acid fluoride affords lower percentage 
of product and traces of the open form in addition to unexplained mixture of compounds (purity 
50%). 
Based on these experiments, both the use of carbodiimide or ClCOOMe-based activation of V.20 
seems to deliver the best cyclization results. Although also effective, the HBTU method is not 
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preferred considering the use of DMF and the equimolar formation of HOBt, which has to be 
removed using chromatography. 
Although the isolated yield of both DCC resin and ClCOOMe is 75%, the work up of DCC resin 
is easier than ClCOOMe, as the higher temperature required to remove DMF used in the latter 
could lead to decomposition of cyclized product. The formation of 2 % of 16-membered ring next 
to 8-membered ring occurs during the cyclization with DCC resin, while no observation of such 
16-membered ring using ClCOOMe.   
Syntheses based on solid carrier-bound reagents are gaining more popularity in comparison with 
pure solid-phase synthesis strategy, especially since the benefits of solution phase chemistry 
remain available (easy reaction monitoring, intermediate purification; if necessary) surmounted by 
a simple finishing procedure (in the ideal case: filtering off the solid phase reagents and / or 
scavengers, extraction of the product and evaporation of the volatiles).  
The overall yield of the model 1,5-benzodiazocine-2,6-dione IV.34 calculated from resin-bound 
N-Fmoc-β-Alanine V.3 is 67% (8 steps). This yield is encouraging to undertake the synthesis of 
libraries of 3- and 4-substituted analogous. Our effort in this respect are discussed in the following 
chapters. 
 
 
 
 
 
 
 
 
 
 
Part 2: Results and discussion 
 
83 
 
References  
1 Caroen J., Ontwikkeling van een vastefasesynthesestrategie voor 1,2,3,4,5,6-hexahydro-1,5-
benzodiazocine-2,6-dionen voor toepassing in combinatorische bibliotheken, (Development of a solid-
phase synthesis strategy for 1,2,3,4,5,6-hexahydro-1,5-benzodiazocine-2,6-diones for application in 
combinatorial libraries) 2012. PhD dissertation, UGent. 
2 a) Mergler, M.; Tanner, R.; Gostelli, J.; Grogg, P. Tetrahedron Lett. 1988, 29, 4005-4008; b) Pedroso, E.; 
Grandas, A.; Saralegui, M. A.; Giralt, E.; Granier, C.; Shots of Reed J. "Convergent solid phase peptide 
synthesis. I. Synthesis of protected segments. 
3 Lin, X.; Dorr, H.; Nuss, J. M. Tetrahedron Lett. 2000, 41, 3309-3313. 
4 Kan, T.; Fukuyama, T. Chem. Commun. 2004, 4, 353-359. 
5 Swamy, K. C. K.; Kumar, N. N. B.; Balaraman, E.; Kumar, K. V. P. P. Chem. Rev. 2009, 109(6), 2551-
2651.   
6 Humphrey, J. M.; Chamberlin, A. R. Chem. Rev. 1997, 97 (6), 2243. 
7 Fu, Y.; Hammarström, L. G.; Miller, T. J.; Fronczek, F. R.; McLaughlin, M. L.; Hammer, R. P. J. Org. 
Chem. 2001, 66 (21), 7118-7124 
8 Gatta, F.; LandiVittory, R. Farmaco, Ed. Sci. 1970, 25, 991-998 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Part 2: Results and discussion 
 
84 
 
VI SYNTHESIS OF 3-SUBSTITUTED-1,5-BENZODIAZOCINE-2,6-DIONES  
 
VI.1 RETROSYNTHESIS  
In this chapter we would like to discuss the synthesis of 3-substituted-1,5-benzodiazocine-2,6-
dione derivatives. After a retrosynthetic analysis, the synthesis of necessary building blocks is 
described after which the application of these to the construction of a library is treated. 
As been described in chapter IV, ring-closure is planned through lactam formation from precursor 
VI.2, in which a second amide bond can be disconnected, affording two general building blocks: 
the anthranilic acids VI.4 and the resin-bound β-amino acids VI.3. A series of (unprotected) 
anthranilic acids is commercially available while the resin-bound β-amino acids VI.3 can be 
synthesized from β-amino acid building blocks VI.5 and alcohols R2OH.  
N
H
N
O
O
NO
O O NH2
NHO
O
NHFmocHO
O
OH
R2
R2
R2
R1
R1 R1
R1
lactam
formation
+
NHFmoc
HOOC
amide bond 
formation
-amino acid 
coupling and N-
alkylation (R2OH)
+
VI.1 VI.2 VI.3
VI.4
VI.5VI.6
R3
R3
R3
anthranilic acids
-amino acid
Figure VI.1: Retrosynthesis for target benzodiazocinedione VI.1. 
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VI.2 BUILDING BLOCK SYNTHESES  
VI.2.1 Synthesis of N-Fmoc-anthranilic acid building blocks 
VI.2.1.1 Direct protection 
For the intended solid-phase synthesis route, the use of N-protected anthranilic acid building 
blocks is necessary. We opted for the 9-fluorenylmethoxycarbonyl (Fmoc) protecting group, as it 
is well established in solid-phase synthesis literature. 
Although N-Fmoc-anthranilic acid is commercially available, it is too expensive when needing 
greater amounts. The protection step, however, is very simple: by using equivalent amounts of 
anthranilic acid and 9-fluorenylmethyl-N-succinimidyl carbonate (Fmoc-OSu) in an aqueous basic 
environment, large scale synthesis is possible (scheme VI.1). These reaction conditions were 
successfully applied for the synthesis of aryl-substituted analogues (VI.7-VI.11) which are useful 
building blocks for library synthesis; yields are provided in table VI.1. 
 
  
COOH
NH2
COOH
NHFmoc
ii) 1 eq NaHCO3, 1 eq Fmoc-OSu, 
    THF/H2O 2/1, r.t, o.n
MeO
NHFmoc
COOHBr
NHFmoc
COOH
NHFmoc
COOH
F
Me
NHFmoc
COOH
NHFmoc
COOH
Fmoc-2-aminobenzoic acid2-aminobenzoic acid
VI.9VI.8
VI.10 VI.11
VI.7
1
2
3
4
5
6
i) 1 eq NaOH, H2O, r.t, 5 min
R
R
 
Scheme VI.1 Synthesis of N-Fmoc-2-aminobenzoic acid derivatives.  
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Table VI.1: Yields of the prepared anthranilic acid derivatives.  
Entry Compound R Yield %a 
1 
2 
3 
4 
5 
VI.7 
VI.8 
VI.9 
VI.10 
VI.11 
H 
5-Br 
5-OMe 
5-Me 
6-F 
85 
83 
63 
60 
57 
a Yields are calculated after recrystallization . 
To increase diversity, we also envisaged the use of 5-phenyl anthranilic acid, which would contain 
a biphenyl moiety, a well-known privileged substructure. However, since the compound is not 
commercially available, we tried different synthetic routes to prepare it, which is discussed in the 
following paragraphs. 
VI.2.1.2 Attempts to the synthesis of 5-phenyl anthranilic acid 
VI.2.1.2.1 Via Baeyer-Villiger oxidation of 5-phenyl isatine: 
A- Starting from 4-amino biphenyl: 
Inspired by the known conversion of anilines to their isatin derivatives and the subsequent 
oxidation/hydrolysis to the anthranilic acid derivatives, we initially started from 4-amino biphenyl 
VI.12. Although the reaction with chloral hydrate in presence of excess hydroxylamine 
hydrochloride yielded the oxime VI.13 in moderate yield1, treatment of VI.13 in strong acidic 
medium, as is commonly used for isatin derivatives synthesis, surprisingly did not afford 5-phenyl 
isatine (scheme VI.21). Instead, starting material remained as major product in addition to a 
mixture of compounds. 
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Chloral hydrate, NH2OH.HCl
Na2SO4, Conc. HCl, H2O, 80C
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H
N
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O
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Villiger Oxidation
Ph
NH2
COOH
VI.15
VI.12 VI.13 VI.14
Ph
NHFmoc
COOH
VI.16
76%
2) hydrolysis
OH
Scheme VI.2 Initially tried synthetic route through the formation of anilide VI.13. 
B- Starting from 5-iodoisatine:  
According to a one pot procedure by Rault2, Suzuki cross-coupling reaction of 5-iodoisatine VI.17 
with phenylboronic acid under palladium catalysis, followed by oxidative cleavage with H2O2, 
would afford 5-phenyl anthranilic acid VI.15 in 62%. However, application of these conditions 
only allowed us to isolate the expected product in 15% yield (scheme VI.3). 
H
N
O
O
Ph
Baeyer-Villiger 
Oxidation
Ph
NH2
COOH
VI.15VI.18
H
N
O
O
I
VI.17
Pd(PPh3)4, PhB(OH)2, NaHCO3, DME,
H2O, 0.2 M, reflux, Ar, o.n. NaOH/H2O
H2O2 (30%)
reflux 30min.
(One pot reaction)
15 %
Scheme VI.3 One pot reaction sequence to form 5-phenyl anthranilic acid2 VI.2. 
We decided to split the reaction sequence, and focus on the Suzuki-coupling. Chen3 used similar 
conditions to Rault, albeit under microwave irradiation in order to a obtain library of 4-aryl isatins. 
When we apply the same conditions on 5-iodoisatin VI.17, we obtained a product which we cannot 
assign, (table VI.2, experiment 1). Dawei4 succeeded in preparing a series of 7-aryl substituted 
isatins from 7-iodoisatins using KF or NaHCO3 as base, when using substituted boronic acids. 
Application of these conditions for 5-iodoisatin VI.17 (experiment 2, 3) did not provide 5-phenyl 
isatin, as only starting material was recovered. 
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H
N
O
O
Ph
VI.18
H
N
O
O
I
VI.17
see table IV.2
1
2
3
4
5
6
7
Scheme VI.4 Cross-coupling alkylation attempts to form 5-phenyl isatin.  
Table VI.2 Conditions tested in cross-coupling of 5-iodoisatin and phenyl boronic acid. 
Exp Reagents Solvent T Δt Results 
1 0.1 eq Pd(PPh3)4 (5mol%), 
1.2 eq PhB(OH)2, 2 eq 
NaHCO3 
DME/H2O 
0.06 M 
Mw 
130 °C 
30 min Not assigned 
product 
2 0.06 eq Pd(OAc)2 (3mol%), 
1.5 eq PhB(OH)2, 3 eq KF 
MeOH 
0.06 M 
Reflux 
60 °C 
o.n Starting 
material  
3 0.07 eq Pd(PPh3)4, 1.2 eq 
PhB(OH)2 (5mol%), 2 eq 
NaHCO3 
DME/H2O 
0.06 M 
Reflux  
100 °C 
o.n Starting 
material 
 
V.2.1.2.2 Ortho functionalization starting from 4-amino biphenyl 
An alternative strategy to synthesize anthranilic acids involves the ortho-carboxylation of amide- 
or carbamate- protected anilines using an ortho-lithiation procedure5. Boc-protection of 4-
aminobiphenyl VI.12 proceeds easily with high yield to give VI.19, which should be a good 
substrate for ortho-lithiation and conversion to anthranilic acid derivative VI.20. 
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Ph
NHBoc
Ph
NHBoc
COOH
VI.1
Ph
NH2 1 eq Boc2O, 1eq DIPEA,
CH2Cl2 0.1 M, 0 C-r.t, o.n
 90%
VI.19 VI.20
see table VI.3
Ph
N
O
OtBu
via
VI.21
Scheme VI.5 Attempted synthesis of N-Boc-5-phenylanthranilic acid via ortho-lithiation. Different 
tested conditions are mentioned in table VI.3. 
After formation of the (yellow-orange) dianion VI.21 using tBuLi, in experiment 1, the reaction 
mixture was added to a slurry of CO2, resulting in no reaction. Alternatively, a solution of CO2 in 
THF was added during 2 hours over the generated dianion resulting in a very small amount of 
unexplained products, (experiment 2)6. Stirring the reaction for an additional 5 hours and 
increasing the temp to room temperature results in no reaction, (experiment 3)7. Increasing the 
concentration of reaction, on the other hand provides a small amount of the product (10%), next 
to 15% of Boc-deprotected 5-phenyl anthranilic acid VI.15 in addition to starting material VI.19 
as major.  
Table VI.3 Tested reaction conditions for ortho-lithiation and reaction with CO2. 
Exp Reagents Solvent T Δt Results 
1a 2.4 eq (1.7M) Tert-
Butyllithium, CO2 
THF 
0.5M 
-20 °C 2 hours Starting material 
2b 2 eq (1.7M) Tert-
Butyllithium, CO2 
THF  
0.4M 
r.t 2 hours bubbling 95%start+5%unknown 
product 
3c 3 eq (1.7M) Tert-
Butyllithium, CO2 
THF  
0.1M 
r.t 2hours bubbling 
+ 5hours stirring 
Starting material 
4c 2 eq (1.7M) Tert-
Butyllithium, CO2 
THF 
0.4M 
r.t 40 min bubbling  70% starting material +10% 
product + 15% VI.15 
a: reaction mixture was added to slurry of CO2, b: solution of CO2 in THF was added to reaction 
mixture via cannula, c: CO2 was passed over CaCl2 tube to the reaction mixture. 
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 Because of the encountered problems to provide the desired product in a sufficient yield, we 
decided at this stage to not perform further optimization experiments and therefore omit it in the 
library syntheses.  
V.2.2 Synthesis of N-Fmoc-3-amino-2-alkylpropionic acid building blocks 
The other main building blocks for our solid-phase synthesis approach are N-Fmoc-3-
aminoalkylpropionic acids VI.5 as shown in figure VI.1. To test the synthesis towards these 
building blocks, we decided to access a model building block VI.22 to demonstrate the synthetic 
steps and apply the optimized conditions to a set of further analogues. In the following sections 
the search for a general synthetic pathway for β2-(alkyl)-β-amino acid synthesis is discussed. 
                                                                
Br
COOH
FmocHN
VI.22
model compound
 
Figure VI.3: 3-(9-Fluorenylmethyloxycarbonyl)amino-2-(4-bromobenzyl)propanoic acid VI.22 
as a model compound. 
V.2.2.1 Synthesis starting from Boc-β-alanine 
Our initial attempted strategy involves the direct introduction of an alkyl group via α-alkylation of 
protected β-alanine. Previously in our laboratory, in this way β2-methyl-β-amino acid derivative 
VI.24 could be prepared, using conditions originally reported by the group of Seebach8. The 
procedure involved the deprotonation of Boc-protected methyl ester of β-alanine VI.23 using 
LDA, after which treatment with MeI as electrophile yielded the mono-methylated product VI.24 
in 58% yield, (unoptimized, additionally 26% of VI.23 could be recovered, scheme VI.6)9. 
Attempts to generalize this alkylation strategy by applying these conditions to 4-bromobenzyl 
bromide as electrophile yielded a mixture from which the desired product VI.25 could only be 
isolated with a very low yield. Reasons for this low yield can be explained by the formation of a 
complex mixture (from which the product could only be partially purified), probably arising from 
unwanted N-alkylation and over alkylation.                
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BocHN OMe
O
BocHN OMe
O
BocHN OMe
O
BocHN OMe
O
Br
b) 4 eq 4-bromobenzylbromide, THF, -78°C, 2h
VI.24
VI.23
58% yield (26 % recovered VI.23)
VI.23 VI.25
6%
a) 2 eq LDA, THF, -78°C, 20 min.
b) 4 eq MeI, THF, -78°C, 2h
a) 2 eq LDA, THF, -78°C, 20 min.
Scheme VI.6: Direct alkylation of protected β-alanine VI.23 with LDA and 4-bromobenzyl 
bromide. 
VI.2.2.2 Synthesis starting from methyl cyanoacetate 
To avoid undesired N-alkylation, the alternative alkylation of methyl cyanoacetate with alkyl 
halides was proposed (scheme VI.7). However, in the model case of 4-bromobenzyl bromide a 
major problem of double alkylation occurs, although different conditions were tested (table VI.4). 
NC
OMe
O
NC COOMe
Br
NC COOMe
Br
Br
+
VI.26 VI.27 VI.28
a) 4-bromobenzyl bromide VI.29, 
base (table VI.4)
 
Scheme VI.7: Attempted direct alkylation of methyl cyanoacetate with bromobenzyl bromide. 
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Deprotonation using K2CO3 and subsequent treatment with equimolar amounts of bromobenzyl 
bromide gave no expected product, but only a mixture of bis-benzylated VI.28 and remaining 
starting material. Use of an excess of methyl cyanoacetate (3 eq, 1 eq 4-bromobenzyl bromide) 
gave only low amounts of the mono-alkylated product, in which the major components was the bis 
alkylated species. Changing the solvent (DMF, THF) or inverse addition did not improve on the 
outcome of the reaction. 
Table VI.4. Different conditions used in the direct alkylation with an alkyl halide. 
Exp Reagents solvent T Δt  Resultsa 
VI.28/VI.27/VI.26 
1b 1 eq K2CO3 
1 eq 4-Bromobenzyl 
bromide, 
1 eq methyl cyanoacetate 
DMF 0°C 1h 63% / 0 / 37% 
2b 1 eq NaH, 
1 eq 4-Bromobenzyl 
bromide, 
3 eq methyl cyanoacetate 
DMF 0°C 3h 25% / 19% / excess 
3b 1 eq NaH, 
1 eq 4-Bromobenzyl 
bromide, 
3 eq methyl cyanoacetate 
THF 0°C 3h 28% / 14% / excess 
4c 1 eq NaH, 
1.5 eq 4-Bromobenzyl 
bromide, 
1 eq methyl cyanoacetate 
THF 0°C 3h 14% / 7% / 79% 
a Based on LCMS by comparing peak areas at 214 nm. b 4-bromobenzyl bromide was added to a 
solution of methyl cyanoacetate and base. c a solution of methyl cyanoacetate and NaH was stirred 
for 30 minutes and added dropwise to a solution of 4-bromobenzyl bromide. 
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VI.2.2.3 Knoevenagel condensation followed by reduction: 
To avoid the unwanted overalkylation problems, we searched for an alternative mono-alkylation 
route, by using a two-step sequence via a Knoevenagel-type condensation. This methodology is 
based on the initial preparation of a dehydro-cyanoacetate intermediate capable of producing only 
mono-alkylated product after double bond reduction (scheme VI.8). In this way, structural 
diversity in the final β2-amino acids would arise from employing a set of different aldehydes, rather 
than alkyl halides.  
NC
OMe
O
NC COOMe
VI.26 VI.30
i
i) 1 eq 4-Bromobenzaldehyde. 0.1 eq AcOH, 0.04 eq piperidine, dioxane, o.n., r.t
NC COOMe
Br
NC COOMe
H
VI.27 VI.31
+(see table VI.5)
Br
87%
1eq 4-Bromobenzaldehyde. 0.1 eq AcOH, 0.04 eq piperidine, 
dioxane, Pd/C 5% wt, H2 (1bar), 2 h, r.t.
"E"
Scheme VI.8: Reaction scheme to secure mono-alkylated product VI.27 via a Knoevenagel / 
reduction route. 
This methodology has been published as one pot procedure for the reaction between methyl 
cyanoacetate and unsubstituted benzaldehyde, in which the Knoevenagel reaction was allowed to 
proceed in the presence of Pd/C under an H2 (1-2 bar) atmosphere
10. However, after applying this 
procedure on 4-bromobenzaldehyde at 1 bar H2, unreacted methyl cyanoacetate was still present 
while unwanted hydro-dehalogenation of the aryl bromide occured (VI.31)11. We therefore opted 
for a two-pot procedure and as such the application of the reported Knoevenagel conditions 
(without Pd/C and H2-atmosphere) afforded the condensed product VI.30 in 87% yield. From 
LCMS and NMR spectral data it is clear that only one isomer is formed and based on literature 
evidence12, we assign the “E”-double bond geometry to the isolated product. In order to prevent 
the hydrogenolysis of the bromide, we tried to explore alternative olefin-reduction methods. 
Several reaction conditions were tested (table VI.5). 
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NC COOMe NC COOMe NC COOMe
NC COOMe
VI.32 VI.33 VI.34
VI.35
85% 88% 64%
88%
NC COOMe
VI.36
Cl MeO
O
91%
 
Figure VI.6: Yields obtained by condensation of methyl cyanoacetate and different substituted 
aldehydes. 
 
The reducing agent used should be able to reduce the intended double bond but should however, 
not be too strong in order to avoid the reduction of the nitrile or methyl ester. In experiment 1, the 
use of NaBH(OAc)3 yielded only a partial conversion while the long reflux conditions in ethanol 
yielded additionally the ethyl esters of both start and end product. Consequently a stronger 
reducing agent (NaBH4 in presence of Pd/C) was chosen (experiment 2) according to a published 
procedure in which the use of a non-polar solvent seems to be important13. 
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Table VI.5: Tested reaction conditions for the reduction of arylidene VI.30. 
Exp Reagents Solvent T Δt Results 
1 1 eq VI.30, 5 eq 
NaBH(OAc)3 
Ethanol reflux 24h product (+ethyl ester) 
+small fraction VI.30 (+ 
ethyl ester) 
2 1 eq VI.30, 2 eq AcOH, 4 
eq NaBH4, 2.5 mol% Pd/C 
Toluene r.t 18 h product + small fraction 
VI.30 + VI.31 
3 1 eq VI.30, 2 eq AcOH, 4 
eq NaBH4, 2.5 mol % Pd/C 
Toluene r.t 7h product + VI.30 
4  1 eq VI.30, 1.1 eq 
NaBH3CN, AcOH (0.4 M) 
Ethanol r.t 45 
min 
product (+ ethyl ester) 
5 1 eq VI.30, 1.1 eq 
NaBH3CN, AcOH (0.4 M) 
MeOH/CH2Cl2 
5/1 
r.t 45 
min 
product (82% yield) 
 
Reduction of both the α,β-unsaturated C-C double bonds and the carbonyl group may happen using 
these reagents, but the authors state that by increasing solvent polarity, the selectivity towards 
carbonyl reduction increases. This effect is hypothetically explained that if the reaction is carried 
out in a polar solvent, it dissolves readily NaBH4 and then reacts with the carbonyl via a 1,2-
mechanism. The poor solubility in a non-polar solvent would ensure that the NaBH4 would be 
more likely to react with acetic acid and to produce hydrogen gas that can bind to Pd/C to form a 
Pd-complex which catalyzes the hydrogenation of double bond. Under these conditions a portion 
of H-substituted product VI.31 was recovered after 18 hours reaction time, probably as a 
consequence of the above-mentioned sensitivity of the aromatic bromide. When the reaction time 
was shortened (7 hours, experiment 3), the unwanted Br-H-substitution could be avoided. 
However, insufficient conversion of the starting material VI.26 was observed.  
An article by Hutchins14 uses NaBH3CN, a reducing agent which is in terms of strength between 
NaBH(OAc)3 and NaBH4 for the reduction of double bonds conjugated with two electron-
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withdrawing groups. Through a slightly modified procedure (AcOH instead of HCl) the desired 
reduction gives complete conversion. In spite of the short reaction time, a small amount of ethyl 
ester was formed by the presence of ethanol/AcOH as the solvent. Upon changing the solvent to 
methanol, solubility problems arise, which could be solved by using a mixture of 
(MeOH/CH2Cl2)(5/1), leading to good yield (82%) of VI.27. This two-step 
Knoevenagel/reduction sequence was successfully applied to a series of derivatives (figure VI.6-
VI.7). Although available literature only describes compounds carrying electron withdrawing aryl 
substituents, we could apply the reduction procedure to electron-rich derivatives (figure VI.7).  
NC COOMe
Cl
NC COOMe
O
NC COOMe
OMe
NC COOMe
VI.37 VI.38 VI.39
VI.40
89% 96% 98%
92%
NC COOMe
VI.41
89%
Figure VI.7: Yields obtained by reduction of the corresponding alkenes with NaBH3CN/AcOH in 
CH2Cl2/MeOH 
 
Besides the use of aryl aldehydes, we also wanted access to β2-alkyl-β-amino acids. This turned 
out to be straightforward. Applying the original (one pot knoevenagel condensation/reduction) 
procedure using isobutyraldehyde (with an increase in the hydrogen pressure to 2 bar), yielded 
90% of the target product VI.42, (scheme VI.9).    
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NC COOMe
VI.42
90%
NC COOMe
VI.26
1 eq isobutyraldehyde, 0.1 eq AcOH, 0.04 eq piperidine, 
dioxane, 0.1 eq Pd/C 5%wt, 2 bar, 2h
Scheme VI.9: Knoevenagel condensation and in situ reduction to form compound VI.42.  
 
VI.2.2.4 Reduction of nitrile group 
The reduction of the nitrile function is classically carried out with H2 under high pressure using 
Pd/C as catalyst or with LiAlH4. These two methods are not applicable for us, on one hand because 
of the expected reduction of the aromatic halides and on the other hand because of the reactivity 
of the methyl ester15. The tested alternatives are shown in table VI.6. 
 
NC COOMe
Br
NC COOH
Br
COOMe
Br
HN
R +
VI.27 VI.43  R=H
VI.44  R=Boc, 94%
VI.45
(see table VI.6)
       
Scheme VI.10: Reduction of the cyano group in VI.27 to the β-aminoacid ester  
In experiment 1, the reduction according to the procedure of Baddorey16 using Raney-Nickel led 
to the formation of a small amount of the desired product VI.43, but the mixture mainly consisted 
of the starting material VI.27 and corresponding carboxylic acid; which formed due to hydrolysis 
(coming from the slurry of Raney-Nickel). 
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Table VI.6: Tested reaction conditions for the reduction of cyano group of VI.27. 
Exp Reagents Solvent T Δt Results  
1 1 eq VI.27 , Ra-Ni 
slurry (in H2O) 
0.5% NH3 in 
MeOH 
r.t 24h VI.45 + VI.27 + small 
fraction VI.43 
2 1 eq VI.27, NiCl2.6H2O 
(saturated), 7.5 eq 
BH3.THF 
Isopropanol r.t 3h Complex reaction + 
VI.27 
3 1 eq VI.27, 2 eq Boc2O, 
0.1 eq NiCl2.6H2O, 7 eq 
NaBH4  
MeOH 0°C to r.t 30 min VI.44 + alcohol + 
reduced bromide+ other 
products, (49% yield) 
amonitoring by LCMS (214 nm) 
In experiment 2, the reduction is carried out using borane in a saturated NiCl2 solution in 
isopropanol. Although described in literature for cyanohydrines17, this led to complex reaction 
mixtures containing unreacted cyanoacetate VI.27.  Better results were achieved by application of 
a procedure reported by Caddick18 (experiment 3), wherein a mixture of NaBH4/NiCl2 in MeOH 
is used. By the addition of NaBH4 to NiCl2.6H2O in methanol, hydrogen gas is formed along with 
black precipitate of Ni2B that is capable of catalyzing the further reaction between NaBH4 and 
protic solvent to form additional hydrogen gas19, which after complexation with Ni2B can reduce 
the target nitrile function.   
  8 NaBH4 + NiCl2 + 18 MeOH                                          2Ni2B + 6 B(OMe)3 + 8 NaCl + 25 H2  
  8 NaBH4 +  MeOH                                          NaB(OMe)H3 + H2
etc.
 
The formed amine after reduction of the nitrile group is protected in situ by reaction with di-tert-
butyl dicarbonate in order to avoid the inherent instability of amino esters. A disadvantage, 
however is the partial reduction (14% on LCMS) of the ester to the primary alcohol. Moreover, 
the reducing agent appears to be strong enough to reduce a fraction of the aromatic bromide (up to 
11%). This only became clear to us after the subsequent saponification step, since both products 
at this stage showed the same Rf value on TLC. Application of the same procedure on different 
acrylates shows the conversion of 10-15% of the ester to the corresponding primary alcohol. 
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Starting from isobutyl-substituted methyl cyanoacetate VI.42; we also tried reduction 
methodologies using Pd/C and LiAlH4. Both led to a complex mix of compounds in addition to 
unreduced VI.42, in contrast to the NaBH4/NiCl2 method which provides the product VI.49 in 
good yield. 
COOMe
Cl
COOMe
O
COOMe COOMe
VI.46 VI.47 VI.48 VI.49
58% 40% 57% 75%
BocHN BocHN BocHN
BocHN
Figure V.8: Yields obtained after reduction of the corresponding acryl compounds and in situ Boc 
protection. 
 
V.2.2.5 Hydrolysis of the methyl ester: 
The hydrolysis of the methyl ester in model intermediate VI.44 to the carboxylic acid proceeds 
without problems with the aid of NaOH (scheme VI.11). Dioxane has to be added as a co-solvent 
due to the poor solubility of the methyl ester in H2O/MeOH.  
           
COOMe
Br
BocHN
VI.44
COOH
Br
BocHN
VI.50
2 eq NaOH, H2O/MeOH/dioxane (2/1/1), 
o.n, r.t
65%
Scheme VI.11: Hydrolysis of the methyl ester to the corresponding carboxylic acid.  
The same procedure could be used for preparation of VI.51 and VI.52. However, to obtain VI.53 
and VI.54, the reaction at room temperature was slow (~60% conversion after 24h). Additionally, 
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heating at 50 °C for 20 minutes accomplished the hydrolysis in 80% and 95% yield respectively. 
Isolated yields of the corresponding carboxylic acids are shown in figure VI.9.    
COOH
Cl
COOH
O
COOH COOH
VI.51 VI.52 VI.53 VI.54
84% 78% 80% 95%
BocHN
BocHN BocHN BocHN
Figure VI.9: Additionally prepared N-Boc-β-aminocarboxylic acids via basic hydrolysis.  
 
VI.2.2.6 Boc-removal 
The removal of the Boc group was carried out under strongly acidic conditions (HCl), smoothly 
resulting in 99% yield of VI.55, which could be used in the next step without intermediate 
purification (scheme VI.12). 
             
COOH
Br
BocHN
VI.50
COOH
Br
HCl.H2N
VI.55
 Conc. HCl/dioxane 1/9, 7 h, r.t
99%
 
Scheme V.12: Boc-removal of the carboxylic acid using mixture of HCl/dioxane. 
 
Treatment of other Boc-protected β-amino acids, (VI.51, VI.53 and VI.54) under the same 
conditions, led to the formation of the corresponding ammonium salts in excellent yield (figure 
VI.10). However, attempted Boc-removal of furyl containing intermediate VI.52 did not yield the 
desired compound, but led to decomposition and a complex reaction mixture. Further research is 
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needed to optimize this step, possibly with another Boc-removal procedure or performing an 
alternative N-protection during nitrile reduction.  
COOH
Cl
HCl.H2N
VI.56
99%
COOH
HCl.H2N
VI.57
99%
COOH
HCl.H2N
VI.58
99%
COOH
HCl.H2N
VI.59
O
complex mixture
Figure VI.10: Yields of amine deprotection to the corresponding HCl salts.                                               
 
VI.2.2.7 Fmoc-protection  
Final protection of the obtained model crude ammonium salt VI.55 to the Fmoc-protected-β-amino 
acid VI.60 is achieved using Fmoc-OSu in the presence of Na2CO3. The protection occurs 
smoothly overnight and the final product is obtained after final purification by recrystallization, 
scheme (VI.13).          
COOH
Br
HCl.H2N
VI.55
COOH
Br
FmocHN
VI.60
1 eq Fmoc-OSu, 3 eq Na2CO3, THF/H2O,
 r.t, o.n COOH
FmocHN
VI.61
82%
(VI.60/VI.61: 89/11 ratio)
+
Scheme VI.13: Fmoc protection of the HCl salt of amino carboxylic acid VI.55.  
Further analysis, however, reveals that the product is contaminated with the corresponding benzyl 
analogue (11%) VI.61 arising from the nitrile reduction step (as mentioned above). Despite 
multiple attempts, these products turn out to be inseparable (column chromatography / HPLC / 
crystallization), so it was decided not to use this building block in the solid phase synthesis. Other 
obtained N-Fmoc -β3-alkyl-amino acids and their yields are shown in figure VI.11. 
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COOH
Cl
FmocHN
VI.62
COOH
FmocHN
VI.63
85% 92%
COOH
FmocHN
VI.64
86%
Figure VI.11: Yields of the N-Fmoc-β3-alkyl-amino acid VI.62-VI.64 after recrystallization  
 
VI.3 SOLID PHASE SYNTHESIS OF 3-SUBSTITUTED-1,5-BENZODIAZOCINE-2,6-
DIONES  
VI.3.1 Building blocks used 
A- Amino acid: 
As discussed in chapter IV, our choice of β2-amino acids for library synthesis are Fmoc-protected 
derivatives VI.62-VI.64, (figure VI.12). These building blocks will determine the nature of the 
substitution at the C-3 position of the target benzodiazocinediones. 
          
HO
O
NHFmocHO
O
NHFmoc
HO
O
NHFmoc
Cl
VI.64VI.63VI.62
 
Figure VI.12 N-Fmoc-β2-amino acids used to synthesize a library of 3-substituted 
benzodiazocinediones. 
B- Alcohols 
Introduction of diversity into the 5-position in the benzodiazocinedione skeleton is achieved by a 
Mitsunobu-Fukuyama reaction sequence. As the actual alkylation step involves a nucleophilic 
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substitution (SN2) reaction, (scheme VI.14), the rate of reaction is related to the steric and 
electronic properties of the intermediate alkoxyphosphonium salt (VI.68). Before selection of 
suitable alcohols for library construction, a series of primary alcohols were tested (table VI.7). To 
illustrate reactivity differences, these test reactions were stopped after one hour reaction times. 
Longer reaction times and / or multiple treatments could lead to better conversions if necessary. 
The Mitsunobu-Fukuyama alkylation with the aid of secondary alcohols is known to be difficult 
to happen20,21, so we prefered not to include these secondary alcohols in our libraries. The use of 
simple primary alkyl alcohols (MeOH, EtOH, pentanol, isopentanol) gives generally very good 
and fast conversion9. Similarly, methoxyethoxyethanol and 2-aminoethanol derivatives 
(experiment 2-4) gave good results; the reaction with 3-butyn-1-ol (experiment 5) on the other 
hand displayed a clear lower reaction rate, while the use of 2,2,2-trifluoroethanol did not result in 
any product formation. We suggest lowered nucleophilicity may be hampering the formation of 
the alkylating species VI.68. 
 
O
O
N
S
H
OO NO2
O
O
N
S
R
OO NO2
O
O
N
S
OO NO2
H
O
R
H
PPh3
10 eq alcohol, 5 eq Ph3P, 
5 eq DIAD, DCE, rt, 1h
VI.65
VI.66
VI.67
N NH
P
Ph Ph
Ph
O
O
O
O
OH
R
VI.69
SN2
Via:
VI.68
Scheme VI.14: Test of the Fukuyama-Mitsunobu alkylation of VI.65 with different alcohols (see 
table VI.7).  
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Electronic and structural effects also play a major role in the alkylation with (substituted) benzylic 
type alcohols. “Neutral” benzylic alcohols (experiments 7 and 8) show excellent reactivity, while 
cinnamyl alcohol (experiment 9) gives somewhat reduced levels of conversion. Electron poor 
benzylic substituents (experiments 10 and 11, -I effect of para-F and meta-OMe, respectively) are 
converted completely, while the presence of mesomerically electron donating substituents (OMe 
and OCH2Ph, experiments 12-14) in o/p- position led to zero conversion. In line of this, the 
presence of N(Me)2 in p-position would be expected to be detrimenal for reactivity, but 
surprisingly (in experiment 15) it shows excellent results. 
Table VI.7: Results for the Mitsunobu-Fukuyama alkylation with primary alcohols. 
Exp. Alcohol VI.65/VI.66(a) Purity(b) 
1 MeOH 0/100 98% 
2 O
O
OH
 
6/94 6% 
3 
NO
OH
 
4/96 92% 
 
4 
N
OH
 
1/99 94% 
5 
OH  
62/38 90% 
6 
OH
F
F
F  
100/0 94% 
7 OH
 
2/98 93% 
8 
OH  
1/99 83% 
9 
OH
 
28/73 80% 
10 OH
F  
1/99 91% 
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11 OH
OMe  
2/98 79% 
12 OH
MeO  
100/0 70% 
13 
OH
O
 
100/0 40% 
14 OH
OMeMeO  
100/0 80% 
15 
OH
N
Me
Me  
10/90 94% 
(a) Relative ratio determined from the peak areas in the HPLC chromatogram at 214 nm of the 
corresponding compounds after TFA cleavage; (b) Total HPLC purity of start and end product in the 
crude cleavage mixture TFA (214 nm). 
Based on these test results, we have chosen to include the alcohols VI.70-VI.80 in a library (figure 
VI.13). To ensure full conversion in the Mitsunobu reaction, it is decided to run the reaction three 
times (3 x 2h).  
          
MeOH
OH
O
O
OH
OH
OMe
OH
OH OH
F
EtOH
N
OH
O
O
OH
OH
VI.70 VI.71 VI.72 VI.73
VI.74 VI.75 VI.76 VI.77
VI.78 VI.79 VI.80
 
Figure VI.13 Sets of alcohols chosen for library construction.  
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C- N-Fmoc-anthranilic acids  
The different anthranilic acids for the intended library are displayed in figure VI.14 and are chosen 
for their different aromatic electron density and potential for further derivatization (Br: Suzuki-
arylation). 
  
MeO
NHFmoc
COOHBr
NHFmoc
COOH
NHFmoc
COOH
F
Me
NHFmoc
COOH
NHFmoc
COOH
VI.9VI.8
VI.10 VI.11
VI.7
Figure VI.14 Different N-Fmoc anthranilic acids used in the library.  
 
VI.3.2 Library Synthesis 
Based on the earlier results from the solid-phase synthetic strategy with ring closure in solution 
for model compound IV.34 and the above-mentioned Mitsunobu test reactions, we wanted to 
synthesize a library of 3-substituted-1,5-benzodiazocine-2,6-diones. The experimentally carried 
synthesis route with detailed reaction conditions is depicted in scheme VI.15.  
In a first step, Wang resin was loaded with the Fmoc-protected β2-amino acids. The loading values 
were determined using Fmoc UV-quantitation and were used for calculation of the overall yield of 
open-chain compounds VI.88. From these batches, the library synthesis was manually carried out 
in parallel, using custom-made glass solid-phase vessels, starting from 0.4788 mmol VI.81. 
Individual reactions were not monitored during the library synthesis, and all steps were executed 
under the optimized conditions mentioned above. 
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OH
N
H
N
O
O R2
V.1                                   VI.81                                                  VI.82                                              VI.83
VI.84                                               VI.85                                                       VI.86
VI.87                                                               VI.88
a b c
d e f
b g h
VI.1
R3
Reagents and Conditions: a)1) 2eq VI.62-VI.64, 2 eq DIC, CH2Cl2, 0.2 eq DMAP, 24h. 2) Ac2O/ DIPEA/DCM 1/1/3 , 
2x2 h. b) 20% 4-methylpiperidine in DMF 2 x 20 min. c) 5eq o-NsCl, 10eq collidine, CH2Cl2, 2x1h .d) 10eq VI.70-
VI.80, 5eq PPh3, 5eq DIAD, DCE, 3x2h. e) 2.5 eq DBU, 5eq 2-mercaptoethanol, DMF, 2x30 min. f) 10eq Fmoc-
anthranilic acid VI.7-VI.11, 5eq DIC, DCM/DMF 9/1, 24 h. g) TFA/H2O 95/5, 2x1h. h) polystyrene-bound-DCC,
DCM, 1h.
R1
O
O
NHFmoc
R1
O
O
NH2
R1
O
O
N
H
R1
o-Ns
O
O
N
R1
o-Ns
R2
O
O
NH
R1 R2
O
O
N
R1 R2
O NHFmoc
R3
O
O
N
R1 R2
O NH2
R3
HO
O
N
R1 R2
O NH2
R3
Scheme VI.15: Synthetic route with detailed reactions conditions to synthesize 3-substituted-1,5-
benzodiazocine-2,6-dione 
 
An overview of the synthesized compounds as well as a list of accompanying solid phase synthesis 
yields and cyclization yields is shown in table VI.8 and figure VI.16. A library of 13 compounds 
were thus prepared and purified using column chromatography (HPLC were needed in some 
cases).  
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Table VI.8: Solid-phase synthesis (SPS) and solution cyclization (CYC) yields of the synthesized 
library of 3-substituted-1,5-benzodiazocine-2,6-diones. 
Product  R1 R2 R3 SPS%
 [a] CYC% [b] 
VI.89 i-Bu Me H 65 67 
VI.90 i-Bu CH2CH2OCH2CH2OCH3 7-Flouro 53 55 
VI.91 i-Bu 4-Phenyl benzyl 8-Methoxy 31 30 
VI.92 i-Bu 3-Methoxybenzyl H 62 41 
VI.93 i-Bu Cinnamyl H 38 44 
VI.94 2-naphthylmethyl Me H 37 80 
VI.95 2-naphthylmethyl Ethyl 8-Bromo 63 63 
VI.96 2-naphthylmethyl 3-But-1-ynyl 8-Methoxy 35 21 
VI.97 2-naphthylmethyl 4-Fluorobenzyl 8-Methyl 62 41 
VI.98 p-chlorobenzyl Methyl 8-Methoxy 87 25 
VI.99 p-chlorobenzyl i-Pentyl H 69 39 
VI.100 p-chlorobenzyl 2-(2,5-dioxopyrrolidin-1-
yl)ethyl 
H 30 43 
VI.101 p-chlorobenzyl Benzyl 8-Bromo 50 27 
[a] Isolated yields are determined after purification and based upon the initial resin loading. [b] 
Isolated yields.  
 
SPS %         30  31  35  37  38  50  53  62  62  63  65  69  87  average=52
 
CYC %        21  25  27  30  39  41  41  43  44  55  63  67  80  average=44
median
 
 
Figure VI.16: Yields of solid-phase synthesis and cyclization. 
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VI.91
SPS : 31%
CYC: 30 %
VI.89
SPS: 65%
CYC: 67%
VI.90
SPS% 53%
CYC: 55%
VI.97
SPPS: 62%
CYC: 41%
VI.93
SPS 38%
CYC: 44%
VI.94
SPS: 37%
CYC: 80%
VI.92
SPS: 62%
CYC: 41%
VI.96
SPS 35 %
CYC: 21%
VI.95
SPPS: 63%
CYC: 63%
VI.98
SPS: 50%
CYC:27%
VI.101
SPS: 87%
CYC:25%
VI.100
SPS: 30%
CYC: 43%
VI.99
SPS: 69%
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Figure VI.17: Synthesized library of 3-substituted-1,5-benzodiazocine-2,6-diones. 
Yields of the solid-phase synthesis of α,ω-amino carboxylic acids VI.88 range between 30% and 
87% ( median: 53%, average: 52%), while cyclization yields vary from 21% to 80% (median: 
41%, average: 44%). No particular substituent effects seem to be responsible for these fluctuations.  
VI.3.3 Conclusion  
In conclusion, the earlier established conditions could be applied to a library of 3-substituted-1,5-
benzodiazocine-2,6-diones. It seems the varying yields of cyclization are a consequence of varying 
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amounts of N-acylating resin-bound side products, as the reaction mixtures are generally very 
clean. This has thus to be interpreted as resulting from an increased susceptibility to this unwanted 
N→O acyl migration reaction or could be a consequence of slower rates of cyclization. 
It may be therefore suggested to repeat those cyclizations under the alternative ClCOOMe-induced 
conditions as described for the model benzodiazocinedione IV.34 (chapter V)  
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VI.4 CONCLUSION  
Based on the proposed solid phase synthesis strategy for the 3-substituted-1,5-benzodiazocine-2,6-
diones VI.1, essential building blocks consist of N-Fmoc-anthranilic acids and N-Fmoc-2-alkyl-3-
aminopropionic acids. The former could be accessed by a one-step synthesis from corresponding 
commercially available 2-aminobenzoic acids. Fmoc protection with Fmoc-OSu delivered five N-
Fmoc-2-aminobenzoic acid derivatives VI.7-VI.11 (57-85%). 
 
COOH
NH2
COOH
NHFmoc
ii) 1 eq NaHCO3, 1 eq Fmoc-OSu, 
   THF/H2O 2/1, r.t, o.n
R R
R= H                VI.7
R=5-bromo      VI.8
R=5-methoxy   VI.9
R=5-methyl      VI.10
R=6-fluoro        VI.11
MeO
NHFmoc
COOHBr
NHFmoc
COOH
NHFmoc
COOH
F
Me
NHFmoc
COOH
NHFmoc
COOH
Fmoc-2-aminobenzoic acid2-aminobenzoicacid
VI.9VI.8
VI.10 VI.11
VI.7
R= H                
R=5-bromo      
R=5-methoxy  
R=5-methyl     
R=6-fluoro
1
2
3
4
5
6
1
2
3
4
5
6
i) 1 eq NaOH, H2O, rt, 5 min
 
Scheme VI.16 Synthesis of N-Fmoc-2-aminobenzoic acid derivatives. 
N-Fmoc-2-alkyl-3-aminopropionic acid building blocks were successfully prepared starting from 
the appropriate aldehyde and methyl cyanoacetate which were reacted via a Knoevenagel 
condensation followed by reduction using Pd/C-catalyzed hydrogenation (R=isopropyl) or 
NaCNBH3/AcOH to give compounds VI.104. Chemoselective reduction of the cyano group using 
NiCl2.6H2O/NaBH4 and in situ Boc-protection gave protected β2-amino acid intermediates VI.105. 
Hydrolysis of the ester moiety in those compounds was achieved using NaOH, while the N-
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terminus was reprotected as fluorenylmethyl carbamate to the Fmoc-protected amino acids using 
Fmoc-OSu/Na2CO3. The building blocks were obtained in good overall yields. 
O
RH
COOMeNC
R
COOMeNC COOMe
N
H
Boc
COOH
N
H
Boc COOHN
H
Fmoc
a b d
e
c
R R
R
R
VI.64: R = isopropyl            55%.
VI.63: R = 2-naphthyl          34%.
VI.62: R = 4-chlorophenyl    50%.
COOH
HCl.H2N
R
f
g
VI.102
(R=2-naphthyl or 
4-chlorophenyl
VI.103
(R= isopropyl)
VI.104 VI.105
VI.106 VI.107
overall yield
Reagents and conditions: a) methyl cyanoacetate, AcOH, piperidine, dioxane, r.t., o.n. b) NaCNBH3, AcOH, MeOH, r.t, 
1h to o.n. c) NiCl2.6H2O, NaBH4, Boc2O, MeOH, 0C to r.t., o.n. d) NaOH, H2O, MeOH, r.t to 50° C, 20 min to o.n. e)
Dioxane / concentrated HCl 9/1, r.t, 7h to o.n. f) Na2CO3, Fmoc-OSu, THF/H2O (2/1), r.t., o.n. g) methyl cyanoacetate,
AcOH, piperidine, dioxane, Pd/C 5% wt, H2 (2 bar), r.t, 2 h.
Scheme VI.17 Synthesis of N-Fmoc-2-alkyl-3-aminopropionic acid. 
 
                             
FmocHN
COOH
O
FmocHN
COOH
Br
VI.108 VI.22  
Figure VI.18 Intended compounds which could not be obtained.  
Intended compounds VI.108 and VI.22 could not be obtained successfully as bromobenzyl 
derivative VI.22 was contaminated with a substantial amount (11%) of the de-halogenated 
analogue, while for VI.108, the final N-protection sequence could not be achieved because of total 
degradation in the acidic medium used for Boc-removal.   
Alcohols VI.70-VI.80 were chosen to decorate the N-5 position in the target 3-substituted-1,5-
benzodiazocine-2,6-diones.  
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MeOH
OH
O
O
OH
OH
OMe
OH
OH OH
F
EtOH
N
OH
O
O
OH
OH
VI.70 VI.71 VI.72 VI.73
VI.74 VI.75 VI.76 VI.77
VI.78 VI.79 VI.80
 
Figure VI.19 Sets of alcohols chosen for library construction.  
The synthetic route towards 3-substituted-1,5-benzodiazocine-2,6-dione ran parallel to model 1,5-
benzodiazocine-2,6-dione, applying the N-Fmoc-β2-amino acids in the proposed synthetic route. 
The overall yields of solid-phase synthesis of ring-closing precursors are moderate to good (30-
87%, median 53%). Cyclization yields using polystyrene-bound DCC were low to moderate (21-
80%, median 41%), in agreement with expected O→N acyl migration side reactions.  
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VI.94 R1= methyl, R2= H
VI.95 R1= ethyl, R2= bromo
VI.96 R1=3-Buty-1-ynyl, R2=methoxy
VI.97 R1=4-fluorobenzyl, R2=methyl
VI.98 R1=methyl, R2=methoxy
VI.99 R1=i-pentyl, R2=H
VI.100 R1= 2-(2,5-dioxopyrolidin-1-yl)ethyl, R2=H
VI.101 R1=benzyl, R2=bromo
N
H
N
O
O R1
N
H
N
O
O R1
N
H
N
O
O R1
Cl
VI.89 R1=methyl, R2=H
VI.90 R1=2-(2-methoxyethoxy)ethyl, R2=7-fluoro
VI.91 R1=4-phenylbenzyl, R2=8-methoxy
VI.92 R1=3-methoxybenzyl, R2=H
VI.93 R1=cinnamyl, R2=H
R2 7
8
R2
R2
 
Figure VI.17: Synthesized library of 3-substituted-1,5-benzodiazocine-2,6-diones. 
 
   
 
 
 
 
 
 
 
 
 
Part 2: Results and discussion 
 
115 
 
REFRENCES 
1 Organic syntheses, Coll. Vol. 1, p.327 (1941); Vol. 5, p. 71 (1925). 
2 Gerard, A.; Lisowski, V.; Rault, S. Tetrahedron 2005, 61, 6082-6087. 
3 Liu, Y.; Ye, C.; Chen, Q.; Yang, G. Tetrahedron Lett. 2013, 54, 949-955. 
4 Dawei, M.; Qingquan, W. Tetrahedron Lett. 2001, 42, 5279-5281. 
5 Beak, P.; Snieckus, V. Acc. Chem. Res. 1982, 15 (10), 306–312. 
6 Muchowski, J. M.; Venuti, M. C. J. Org. Chem. 1980, 45, 4798-4801. 
7 Gould, S. J.; Eisenberg, R. L. J. Org. Chem. 1991, 56, 6666-6671. 
8 Seebach, D.; Wasmuth, D. Helv. Chem. Acta 1980, 63(17), 197-200. 
9 Caroen J., Ontwikkeling van een vastefasesynthesestrategie voor 1,2,3,4,5,6-hexahydro-1,5-
benzodiazocine-2,6-dionen voor toepassing in combinatorische bibliotheken, (Development of a solid-
phase synthesis strategy for 1,2,3,4,5,6-hexahydro-1,5-benzodiazocine-2,6-diones for application in 
combinatorial libraries) 2012. PhD dissertation, UGent. 
10 Kaptein, B.; Broxterman, Q.; Kierkels, J.; Gerardus, T.; Milcent, T., WO Patent 2,005,085,462: 2005. 
11 A few alternative procedure are described in literature, using Ni, PtO2 or Pd(OH)2, but we have not 
investigated these. Ni:  Ghislieri, D.; Gilmore, K.; Seeberger, H. Angew. Chem. Int. Ed. 2015, 45, 678-682; 
PtO2: Menichincheri, M.;  Bargiotti, A.; Berthelsen J.; Bertrand J. A.; Bossi R.; Ciavolella A.; Cirla A.; 
Cristiani C.; Croci V.; D’Alessio R.; Fasolini M.; Fiorentini F.; Forte B.; Isacchi A.; Martina K.; Molinari 
A.; Montagnoli A.; Orsini P.; Orzi F.; Pesenti E.; Pezzetta D.; Pillan A.; Poggesi I.; Roletto F.; Scolaro A.; 
Tatò M.; Tibolla M.; Valsasina B.; Varasi M.; Volpi D.; C. Santocanale; Vanotti E. J. Med. 
Chem., 2009, 52(2),  293–307; Pd(OH)2: Lee, J.; Gauthier D.; Rivero, R. A. J. Org. Chem., 1999, 64,  3060-
3065. And Peukert, S.; Sun, Y.; Zhang, R.; Hurley, B.; Sabio, M.; Shen, X.; Gray, C.; Dzink-Fox, J.; Toa, 
J.; Cebula, R.; Wattanasin S. Bioorg. Med. Chem. Lett. 2008, 18, 1840-1844. 
12 Hayashi, T. J. Org. Chem., 1966, 13(10), 3253-3258. 
13 Russo, A. T.; Amezcua, K. L.; Huynh, V. A.; Rousslang, Z. M.; Cordes, D. B. Tetrahedron Lett. 2011, 
52(50), 6823-6826. 
14 Hutchins, R. O.; Rotstein, D.; Natale, N.; Fanelli, J.; Dimmel, D. J. Org. Chem. 1976, 41(20), 3328-
3329. 
15 Nystrom, R. F.; Brown, W. G. J. Am. Chem. Soc. 1947, 69(5), 1197-1199. 
16 Badorrey, R.; Cativiela, C.; Dı́az-de-Villegas, M. a. D.; Gálvez, J. A.; Gil, A. Tetrahedron: Asymmetry 
2003, 14(15), 2209-2214. 
17 Lu, Y.; Miet, C.; Kunesch, N.; Poisson, J. E. Tetrahedron: Asymmetry 1993, 4(5), 893-902. 
18 Caddick, S.; Judd, D. B.; Lewis, A. K. d. K.; Reich, M. T.; Williams, M. R. Tetrahedron 2003, 59(29), 
5417-5423. 
Part 2: Results and discussion 
 
116 
 
19 Brown, C. A.; Brown, H. C. J. Am. Chem. Soc. 1963, 85(7), 1003-1005. 
20 Olsen, C. A.; Witt, M.; Hansen, S. H.; Jaroszewski, J. W.; Franzyk, H. Tetrahedron 2005, 61, 6046-
6055. The optimized conditions according to these authors are: 6 eq Ph3P, 5 eq DEAD, 5 eq alcohol (5 eq 
= 0.25M), dichloromethane / THF 1/1, r.t, 2 x 3h. 
21 Olsen, C. A.; Jorgensen, M. R.; Witt, M.; Mellor, I. R.; Usherwood, P. N. R.; Jaroszewski, J. W.; 
Franzyk, H. Eur. J. Org. Chem. 2003, 3288-3299. The optimized conditions (in solution) are as follows: 
1.5 + 1 eq Me3P, 1.5 eq 1 + 1,1 '( azodicarbonyl) dipiperidide (ADDP), 1.5 eq of alcohol (1.5 eq = 0.1 M), 
toluene / THF 8/1, rt, 22 h + 22 h. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Part 2: Results and discussion 
 
117 
 
VII SYNTHESIS OF 4-SUBSTITUTED-1,5-BENZODIAZOCINE-2,6-DIONES 
Our second target library consists of the 4-substituted-1,5-benzodiazocine-2,6-diones VII.1. To 
obtain these 8-membered bis-lactams, we expect that above-used solid-phase synthesis/solution-
phase cyclization strategy could be applied here as well. 
VII.1 RETROSYNTHESIS           
The 4-substituted-1,5-benzodiazocine-2,6-diones VII.1 are structurally similar to their 3-
substituted counterparts described in chapter VI and should therefore be accessible in a similar 
synthetic fashion (figure VII.1). The final step consists of the ring closure through lactam bond 
formation. Subsequently, the second amide bond in VII.2 can be disconnected, resulting in 
anthranilic acid building blocks VII.4 and solid-supported β3-amino acids (VII.3) which can be 
synthesized from simple coupling of N-Fmoc-3-amino-3-alkyl propionic acids VII.5 to solid 
support VII.6.  
N
H
N
O
O
NO
O O NH2
NHO
O
NHFmocHO
O
OH
R2
R2
R2
Lactam
formation
+
NHFmoc
HOOC
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+
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R3
R3
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R1 R1
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3
4
56
7
8
9
10
R3
Figure VII.1: Retrosynthetic overview of the approach towards 4-substituted-1,5-benzodiazocine-
2,6-diones VII.1. 
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VII.2 BUILDING BLOCK SYNTHESES  
VII.2.1 Synthesis of N-Fmoc-anthranilic acid derivatives 
Besides the anthranilic acids VI.7-VI.10 in chapter VI; we additionally prepared N-Fmoc-
protected 2-amino-4-trifluoromethylbenzoic acid VII.7 (yield: 62%). These five building blocks 
were used for the library synthesis. 
MeO
NHFmoc
COOHBr
NHFmoc
COOH
NHFmoc
COOH
Me
NHFmoc
COOH
NHFmoc
COOH
VI.9VI.8
V.10
VI.7
F3C
VII.7
Figure VII.2: N-Fmoc-2-aminobenzoic acid derivatives 
 
VII.2.2 Synthesis of N-Fmoc-3-alkyl-3-aminopropionic acid building blocks:  
Essential building blocks for the synthesis of 4-substituted benzodiazocinediones using our 
strategy, are N-Fmoc-3-alkyl-3-aminopropionic acids VII.5. For a first library we choose 
derivatives VII.9-VII.11, which would lead to 3-methyl-, 3-isobutyl-, and 3-benzyl-substituted 
1,5-benzodiazocine-2,6-diones. These building block were synthesized from the corresponding 
commercially available unprotected β3-amino acids VII.8, and are accessed by treatment of the 
latter with equivalent amounts of 9-fluorenylmethyl-N-succinimidyl carbonate (Fmoc-OSu) 
(scheme VII.1).  
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2 eq Na2CO3, 1 eq Fmoc-OSu, 
THF/H2O 2/1, r.t, o.n
VII.8
NH2
R
HO
O
NHFmoc
R
HO
O
NHFmocHO
O
NHFmocHO
O
NHFmocHO
O
VII.9 VII.10 VII.11
VII.5
 
Scheme VII.1: Synthesis of N-Fmoc-3-alkyl-3-aminopropionic acid derivatives.  
Table VII.1: Yields of the prepared N-Fmoc-3-amino-3-alkyl propionic acid derivatives 
Entry Compound R Yielda 
1 VII.9 Me 90 % 
2 VII.10 i-Bu 87 % 
3 VII.11 Bn 84 % 
a Yields are calculated after purification 
 
VII.3 SOLID PHASE SYNTHESIS OF 4-SUBSTITUTED-1,5-BENZODIAZOCINE-2,6-
DIONES 
After the successful synthesis of 3-substituted-1,5-benzodiazocine-2,6-diones, we followed the 
same solid-phase synthetic strategy to attempt synthesis of the 4-substituted analogues.  
VII.3.1 Coupling of Fmoc-β-amino acid on Wang resin and Fmoc removal  
In a first stage, the coupling of three racemic β3-amino acid derivatives (VII.9-VII.1) was 
performed. Wang resin was treated with DIC-activated amino acid in the presence of DMAP, 
followed by a capping procedure. The efficiency of the coupling step (table VII.2) was determined 
via a quantitative UV-based Fmoc determination method upon extensive drying of the beads. 
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NHFmoc
1. a) 2 eq Fmoc-AA-OH
        2 eq DIC
        20 min, CH2Cl2, 0°C
b) 0.2 eq DMAP
CH2Cl2, r.t,  24h
2. Ac2O/DIPEA/CH2Cl2
    (1/1/3), r.t, 2 x 1h
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O
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O
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VII.13 VII.14 VII.15
VII.6
R1
VII.12
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Scheme VII.2: Coupling of N-Fmoc-3-amino-3-alkylpropionic acid VII.9–VII.11 to Wang resin. 
 
Table VII.2: Coupling efficiency of loading amino acids to Wang resin.  
Entry Compound loadinga 
1 
2 
3 
VII.13 
VII.14 
VII.15 
0.67 mmol/g ± 0.01 
0.69 mmol/g ± 0.01 
0.64 mmol/g ± 0.01 
a determined by Fmoc-UV-quantitation 
Fmoc removal occurred with 4-methylpiperidine in DMF delivering the resin-bound primary 
amine. 
O
O
NHFmoc O
O
NH2
20% 4-methylpiperidine in DMF,
 2 x 20 min, rt
VII.12 VII.16
R1 R1
Scheme VII.3: Fmoc removal using a solution of 20% 4-methylpiperidine in DMF. 
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VII.3.2 Mitsunobu-Fukuyama reaction sequence 
To achieve N-mono alkylation, a Mitsunobu-Fukuyama alkylation sequence was performed. To 
this end, the resin-bound primary amine was initially treated with 2-nitrobenzenesulfonyl chloride 
(o-NsCl) in the presence of collidine (2,4,6-trimethylpyridine). At this stage, the actual Mitsunobu 
alkylation takes place with alcohols R2OH (10 eq) in the presence of triphenylphosphine (Ph3P, 5 
eq, 0.2 M) and diisopropyl azodicarboxylate (DIAD, 5 eq, 0.2 M). For this library, we have chosen 
to include the alcohols VII.20-VI.26 to decorate the N-5 position (figure VII.3, VII.22 was 
prepared via Cbz-protection of 4-aminobutanol). To ensure complete alkylation, this step was 
repeated two more times. Deprotection to resin-bound secondary amines VII.19 occurs with the 
aid of β-mercaptoethanol and DBU (scheme VII.4). LCMS analysis shows the unique formation 
of the expected products. 
 
O
O
NH O
O
N
R2R2
HS
OH
5 eq , 2.5 eq DBU
DMF, r.t, 2x30 min
O
O
NH2 O
O
N
S
NO2OO
H
5 eq o-Ns-Cl, 10 eq collidine
o-Ns
S
NO2OO
VII.16 VII.17
VII.18VII.19
CH2Cl2, r.t, 2x1h
10 eq R2OH,
5 eq Ph3P,
5 eq DIAD,
DCE, r.t, 3x2 h
R1 R1
R1R1
Scheme VII.4: Mitsunobu-Fukuyama alkylation three step reaction sequence, applied to resin-
bound β-amino acid.  
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MeOH
OH
CF3
OH
F
OH
VII.20
VI.24 VII.25
MeO
OH
OH
N
H
OH
VII.21 VII.22
VII.23 VII.26
O
O
VII.22
NH2
HO NHCbz
HO1 eq Et3N, 1 eq PhCH2OCOCl,
0.1 M CH2Cl2, 0C to r.t., 6 h
98%
VII.27
 
Figure VII.3 Set of alcohols chosen for library construction.  
 
VII.3.3. Coupling of Fmoc-anthranilic acid derivatives 
Due to the presence of proximal substituents in the β3-position of the resin-bound secondary amino 
acid, we can expect that steric factors could play an important role in the coupling of Fmoc-
anthranilic acid building blocks. Using VII.28 as a model substrate, we found it was indeed 
necessary to repeat the coupling step (2 x 24h) procedure as used for the resin-bound β2-substituted 
amino acids. In this way, VII.30 could be isolated in 48% yield compared to 33% yield after single 
treatment with (Fmoc-Abz)2O. As a consequence, for the rest of the library this amide forming 
step was always repeated once.   
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NHFmoc
N
O
R2
O
O
10eq VII.4 5 eq DIC, CH2Cl2/DMF 9/1,
0C to r.t. 2x24 h
VII.29
NH
R2
O
O R1 R1
R1=R2=Bn, VII.28 (model compound)
R3
NH2
N
O
Bn
HO
O Bn
VII.19
R1=R2=Bn, R3=H, VII.30, 
(model compound)
VII.31
48% from VII.15
(i) 20% 4-methylpiperidine in 
DMF, 2 x 20 min
(ii) TFA/H2O 95/5, 1 h
Scheme VII.5 Coupling of anthranilic acid anhydride to resin-bound amines VII.19. 
 
VII.3.4. Fmoc removal and cleavage from resin 
The removal of the fluorenylmethyloxycarbonyl moiety occurs smoothly by treating VII.29 with 
a solution of 20% 4-methylpiperidine in DMF 2x20 min, which is immediately followed by 
cleavage of the dipeptides VII.33 from the resin by shaking in a solution of TFA/H2O 95/5 for 1 
hour. These products were purified using column chromatography before final cyclization.  
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NHFmoc
N
O
R2
O
O
VII.29
NH2
N
O
R2
O
O
VII.32
20 % 4-methylpiperidine in DMF
2x 20 min
R1 R1
TFA/H2O 95/5
1 h
NH2
N
O
R2
HO
O
VII.33
R1
R3 R3
R341-95%
Scheme VII.6 Fmoc deprotection followed by TFA-cleavage from the resin. 
In this way, a library of 11 compounds was successfully obtained. Isolated yields varied between 
41% and 95% (calculated from VII.12, average yield: 60 %; median yield: 56%, table VII.3). 
 
VII.3.5. Cyclization using DCC-resin bound  
From the purified intermediates VII.32 , application of the ring closing conditions as described 
before (DCC-PS, 1h) readily afford the desired 4-substituted-1,5-benzodiazocine-2,6-diones VII.1 
in yields between 18% and 65% ( average yield: 40%, median yield: 45%). 
Again, the crude reaction mixtures show clean formation of the expected eight-membered final 
products without remaining starting material. The low to moderate yields are interpreted to arise 
from O→N acyl migration of the resin-bound O-acylisourea activated species, as discussed before 
for the 3-substituted analogues. 
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NH2
N
O
R2
HO
O
VII.33
R1
R3
N
H
N
O
O R2
VII.1
3 eq DCC-PS, 0.01 M DCM, 
1 h, r.t R1
R3
18-65%
         
Scheme VII.7 Cyclization of the ring closed precursor using DCC-resin.                                     
However, no obvious correlation of observed yields to the corresponding structures could be 
established, although the presence of p-bromo and p-methoxy groups on the anthranilamine moiety 
seems to lower the yields of cyclization. 
 
Table VII.3: Overview of the synthesized 4-substituted-1,5-benzodiazocine-2,6-diones.  
Product  R1 R2 R3 SPS%
 [a] Cyc% [b] 
VII.34 Me Me H 77 65 
VII.35 Me Bn H 47 45 
VII.36 Me 3-(trifluoromethyl)benzyl 8-Methoxy 57 23 
VII.37 Me 4-N(Cbz)butyl 8-Methoxy 41 18 
VII.38 Bn Me H 76 46 
VII.39 Bn Bn H 48 40 
VII.40 Bn Pentyl 8-Bromo 44 31 
VII.41 Bn 2-Methoxyethyl 9-Trifluoromethyl 56 57 
VII.42 Bn p-Fluorobenzyl 8-Bromo 56 24 
VII.43 i-Bu Me H 98 45 
VII.44 i-Bu Bn H 73 45 
[a] Isolated solid-phase synthesis yield of VII.33, measured after purification and based upon the 
initial resin loading of VII.12. [b] Isolated yields of cyclization after purification. 
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SPS %         41  44  47  48  55  56  57  70  73  76  98  average=60
 
CYC %         18  23  24  31  40  45  45  45  46  57  65  average=40
median
 
Figure VII.4: Yields of solid-phase synthesis and cyclization. 
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VII.35
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VII.38
SPS: 76%
CYC: 46%
VII.39
SPS: 48%
CYC: 40%
VII.36
SPS: 57%
CYC: 23%
VII.41
SPS: 56%
CYC: 57%
VII.42
SPS: 56%
CYC: 24%
VII.37
SPS: 41%
CYC:18%
VII.40
SPS: 44%
CYC: 31%
VII.43
SPS: 98%
CYC: 45%
VII.44
SPS: 73%
CYC: 45%
O
O
Figure VII.5 Synthesized library of 4-substituted-1,5-benzodiazocine-2,6-diones. 
 
 
 
 
 
Part 2: Results and discussion 
 
127 
 
VII.4 CONCLUSION  
Based on the proposed solid-phase synthesis strategy, essential building blocks consist of N-Fmoc-
anthranilic acids and N-Fmoc-3-amino-3-alkylpropionic acids. Both could be accessed by a one-
step synthesis from their commercially available counterparts. N-Fmoc-anthranilic acids used in 
this library are VI.7 to VI.10 in addition to VII.7 (figure VII.6). 
MeO
NHFmoc
COOHBr
NHFmoc
COOH
NHFmoc
COOH
Me
NHFmoc
COOH
NHFmoc
COOH
VI.9VI.8
V.10
VI.7
F3C
VII.7
Figure VII.6: N-Fmoc-2-aminobenzoic acid derivatives 
 
N-Fmoc-3-amino-3-alkylpropionic acid building blocks were successfully prepared by treating the 
commercially available β3-amino acids with equivalent amounts of (Fmoc-OSu) in the presence 
of Na2CO3. 
       
2 eq Na2CO3, 1 eq Fmoc-OSu, 
THF/H2O 2/1, r.t, o.n
VII.8
NH2
R
HO
O
NHFmoc
R
HO
O
NHFmocHO
O
NHFmocHO
O
NHFmocHO
O
VII.10 VII.11 VII.12
VII.9
 
Scheme VII.8: Synthesis of N-Fmoc-3-alkyl-3-aminopropionic acid derivatives. 
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Alcohols VII.20-VII26 were chosen to decorate the N-5 position in the target 4-substituted-1,5-
benzodiazocine-2,6-diones.  
         
MeOH
OH
CF3
OH
F
OH
VII.21
VI.25 VII.26
MeO
OH
OH
N
H
OH
VII.22 VII.23
VII.24 VII.27
O
O
 
Figure VII.7 Set of alcohols chosen for library construction.  
The synthetic route towards 4-substituted-1,5-benzodiazocine-2,6-dione ran parallel to 3-
substituted-1,5-benzodiazocine-2,6-dione derivatives, applying the N-Fmoc-β3-amino acids in the 
proposed synthetic route. Due to steric reasons, a double coupling procedure of N-Fmoc anthranilic 
was found to be necessary. The overall moderate to good yields (41-98%, median 56%) for the 
solid-phase synthesis of ring-closing precursors were comparable to the ones obtained for the 3-
substituted-1,5-benzodiazocine-2,6-diones. Cyclization yields using polystyrene-bound DCC 
were low to moderate (18-65%, median 45%), which are attributed with expected O→N acyl 
migration side reactions.  
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N
H
N
O
O R1
N
H
N
O
O R1
N
H
N
O
O R1
R2
R2
VII.38 R1= methyl, R2= H
VII.39 R1= benzyl, R2= H
VII.40 R1=pentyl, R2=8-bromo
VII.41 R1=2-methoxyethyl, R2=9-trifluoromethyl
VII.42 R1=p-fluorobenzyl, R2=8-bromo
VII.43 R1= methyl, R2= H
VII.44 R1= benzyl, R2= H
VII.34 R1=methyl, R2=H
VII.35 R1=benzyl, R2=H
VII.36 R1=3-(trifluoromethyl)benzyl, R2=methoxy
VII.37 R1=N(Cbz)butyl, R2=methoxy
R2
8
9
Figure VII.8 Synthesized library of 4-substituted-1,5-benzodiazocine-2,6-diones. 
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VIII. SYNTHESIS OF 3,3-DISUBSTITUTED-1,5-BENZODIAZOCINE-2,6-DIONES  
VIII.1 RETROSYNTHESIS  
Another goal of this project was to explore the potential synthesis of 3,3-disubstituted-1,5-
benzodiazocine-2,6-diones VIII.1 (figure VIII.1). Until now only model analogues with two 
methyl substituents (VIII.1, R1=R2=Me) have been synthesized at our laboratory. The purpose of 
this study is to evaluate the possible application to more diverse analogues. The synthetic 
advantage towards these analogues would be the possibility to perform the cyclization directly 
from the corresponding (Wang) resin-bound precursors, therefore avoiding the separate TFA-
cleavage and solution-phase cyclization procedure. Based on earlier work, this could lead to final 
products with high crude purity, as unwanted side products would stay resin-bound (see chapter 
VI.1).  
N
H
N
O
O
NO
O O NH2
NHO
O
NHFmocHO
O
OH
R3
R3
R3
R1
R2 R2
R2
lactam
formation
+
NHFmoc
HOOC
amide bond 
formation
2,2-amino acid 
coupling and N-
alkylation (R3OH)
+
VIII.1 VIII.2 VIII.3
VIII.4
VIII.5VIII.6
R4
R4
R4
R2
R1 R1
R1
anthranilic acids
Figure VIII.1 Retrosynthesis for 3,3-disubstituted-1,5-benzodiazocine-2,6-diones VIII.1  
As before, obviously the disconnection of the 3,3-disubstituted benzodiazocinedione VIII.1 occurs 
at the N1-C2 lactam bond, similarly to the strategies for 3- and 4-substituted 
benzodiazocinediones, (figure VIII.1). Subsequently, the second amide bond can be disconnected, 
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resulting in anthranilic acid building blocks VIII.4 and a solid-supported β2,2-amino acid (VIII.3) 
which can be synthesized from coupling of N-Fmoc-3-amino-3,3-dialkylpropionic acid VIII.5 to 
solid support VIII.6. 
VIII.2 BUILDING BLOCK SYNTHESIS  
VIII.2.1 Synthesis of N-Fmoc-2,2-dialkyl-3-aminopropionic acid building blocks 
Essential building blocks for the synthesis of 3,3-disubstituted-1,5-benzodiazocine-2,6-diones are 
N-Fmoc-2,2-dialkyl-3-aminopropionic acids. To test the synthesis of 3,3-dialkylaminopropionic 
acid, our initial choice fell on the use of model building blocks VIII.7 and VIII.8. In the following 
section our efforts to synthesis these β2,2-(dialkyl)-β-amino acids are described. 
COOH
H
N
Fmoc
VIII.7
Me
COOH
H
N
Fmoc
VIII.8
Me
 
Figure VIII.2 Model compounds β2,2-(dialkyl)-β-amino acid. 
 
VIII.2.1.1 Alkylation of methyl cyanoacetate 
Our initial experiments started from VIII.10 (which is prepared from methyl cyanoacetate, see 
chapter VI) for which the alkylation with methyl iodide towards VIII.11 was tested using different 
conditions, scheme VIII.1, table VIII.1. 
NC COOMe NC COOMe
Metable VIII.1
VIII.9
VIII.10
NC COOMe
VIII.11
1 eq isobutyraldehyde, 0.1 eq AcOH, 0.4 eq 
piperidine, dioxane, 0.1 eq Pd/C 5 wt%, 2 bar, 2 h.
 
Scheme VIII.1 Alkylation sequence to model intermediate VIII.11. 
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In experiment 1, methylation is tested in DMF using K2CO3 as a base; leading to the desired 
product VIII.11 in moderate (50%) yield. Changing the solvent to acetone, led to a low yield 
(10%). Using NaOMe as base with excess MeI or NaH as base, in MeI as solvent, provides the 
product in 40% and 22% yield respectively. A major practical problem with the isolation of product 
VIII.11 seems to be its high volatility, hampering the reproducible successful large scale synthesis. 
 
Table VIII.1 Different conditions used for methylation of VIII.10. 
Exp. Reagents Solvent T Δt Resultsa 
1 1 eq K2CO3 
1 eq MeI 
DMF 
0.1 M 
0 °C to r.t 1 h 50% product  
2 1 eq K2CO3 
1 eq MeI 
Acetone 
0.1 M 
0 °C to r.t o.n 10% product 
3 1 eq NaOMe 
2 eq MeI 
THF 
0.1 M 
0 °C to r.t o.n 40% Product  
4 1 eq NaH 
 
MeI 
0.1 M 
0 °C 1h 22% product 
a Products are obtained after purification with column chromatography 
The problem of high volatility of VIII.11 forced us to focus on the synthesis of the second model 
building blocks VIII.8. 
Alkylation of compound VIII.12 with excess methyl iodide in presence of NaOMe, indeed 
afforded the quaternary product VIII.13 in a very good yield, scheme VIII.2.              
VIII.9
NC COOMe
NC COOMe NC COOMe
Me
5 eq MeI, 2eq NaOMe, 
THF 1M, 1h.
VIII.12 VIII.13
78%
i) 1 eq isobutyraldehyde, 0.1 eq AcOH, 
  0.4 eq piperidine, dioxane, o.n, r.t.
ii) 1.1 eq NaBH3CN, 0.4 M AcOH, 
    MeOH/CH2Cl2 (5/1), r.t, 1 h
 
Scheme VIII.2 Alkylation of VIII.12 with methyl iodide in presence of NaOMe. 
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VIII.2.1.2 Reduction of the nitrile group 
The earlier mentioned successful reduction of the nitrile group in cyanoacetates (chapter VI) using 
NiCl2.6H2O and NaBH4, followed by in situ protection with di-tert-butyl dicarbonate is applied 
here to obtain the Boc-protected β2,2-amino ester VIII.14 in 60% yield. A partial reduction (20%) 
of the ester moiety to the primary alcohol VIII.15 could not be avoided (as also described in 
chapter VI). 
NC COOMe
Me
VIII.13
COOMe
H
N
Boc
Me
VIII.14
2 eq Boc2O, 0.1 eq NiCl2.6H2O,
7 eq NaBH4, 0C to r.t, o.n
60%
H
N
Boc
Me
OH
+
20%
VIII.15
Scheme VIII.3 Reduction of the cyano group in VIII.13 to the Boc-protected-β-amino acid ester 
VIII.14. 
 
VIII.2.1.3 Hydrolysis of the methyl ester: 
The hydrolysis of the methyl ester VIII.13 to the carboxylic acid proceeds without problems with 
the aid of NaOH (scheme VIII.4).  
COOMe
Me
VIII.14
COOH
H
N
Me
VIII.16
96%
H
N
Boc
Boc
4 eq NaOH, H2O/MeOH (2/1), 
50°C, 2 h.
Scheme VII.4 Hydrolysis of the methyl ester in VIII.14 to the corresponding carboxylic acid. 
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VIII.2.1.4 Boc-removal 
Treatment of the Boc protected amino acid VIII.16 with acidic conditions (HCl), smoothly 
resulted in 99% yield of VIII.17, which could be used in the next step without further intermediate 
purification (scheme VIII.5). 
COOH
H
N
Me
VIII.16
Conc. HCl/dioxane 1/9, 7 h, r.t
COOH
HCl.H2N
Me
VIII.17
Boc
99%
Scheme VIII.5 Boc-deprotection of the carboxylic acid using a mixture of HCl/dioxane. 
 
VIII.2.1.5 Fmoc-protection 
Final Fmoc protection using Fmoc-OSu in presence of Na2CO3 only afforded the Fmoc-protected-
β2,2-amino acid VIII.16 in 38% yield in addition to a mixture of compounds. An alternative 
procedure using Fmoc-Cl in presence of DIPEA and TMSCl delivered the protected product in 
better yield (44%; scheme VIII.6).    
COOH
H
N
Me
VIII.8
44%
FmocCOOH
HCl.H2N i)  2 eq TMSiCl, 1 eq DIPEA, CH2Cl2, reflux 6 h. 
ii) 2 eq DIPEA, 1 eq FmocCl,  0 C-r.t, o.n
VIII.17
Scheme VIII.6: Fmoc protection of β2,2-amino acid VIII.17.  
The rather low yield of N-protection could possibly be attributed to sterical effects. 
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VIII.3 SOLID PHASE SYNTHESIS OF A MODEL 3,3-DISUBSTITUTED-1,5-
BENZODIAZOCINE-2,6-DIONES 
In a first step, it was decided to test the synthesis route on a simple model compound. 
                                                          
N
H
N
O
O
VIII.26
 
Figure VIII.3 Model 3,3-disubstituted-1,5-benzodiazocine-2,6-dione VIII.26.  
 
VIII.3.1 Coupling of Fmoc-β2,2-amino acid on Wang resin and Fmoc removal 
Fmoc-β2,2-amino acid is coupled to Wang resin-using the same Steglich conditions (DIC/DMAP) 
of previous Fmoc-β2/β3-amino acid loading steps followed by a capping procedure. The efficiency 
of the coupling step was determined via quantitative UV-Fmoc determination after extensive 
drying of the beads. The loading was found to be 0.48 mmol.g-1 significantly lower compared to 
the usual loadings of around 0.65 mmol.g-1, indicating a steric effect of the quaternary α-
substitution pattern on the β2,2-amino acid building block. Fmoc removal is achieved by treatment 
with 4-methylpiperidine in DMF to deliver the resin VIII.19, (scheme VIII.7). 
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1. a) 2 eq Fmoc-AA-OH VIII.8, 2 eq DIC, 20 min, CH2Cl2, 0°C
2. Ac2O/DIPEA/CH2Cl2 (1/1/3), r.t, 2 x 1h
VIII.18
OH O
O
NHFmoc
VIII.6
OAc
b) 0.2 eq DMAP, CH2Cl2, r.t,  24h.
O
O
NH2
OAc
20% 4-methylpiperidine in DMF,
 2 x 20 min, rt
VIII.19
Scheme VIII.7 Coupling of Fmoc-β2,2-amino acid VIII.8 to Wang resin and Fmoc removal using 
a solution of 20% 4-methylpiperidine in DMF. 
 
 
VIII.3.2 Mitsunobu-Fukuyama alkylation sequence  
Again as before, we wished to introduce diversity at the N-5 position via a Mitsunobu- Fukuyama 
N-monoalkylation procedure. To this end, the resin-bound primary amine is treated with 2-
nitrobenzenesulfonyl chloride (5 eq) in the presence of collidine (10 eq), followed by alkylation 
with MeOH (10 eq) in the presence of triphenylphosphine (5 eq, 0.2 M) and diisopropyl 
azodicarboxylate (5 eq, 0.2 M). To ensure complete alkylation, this step was repeated two more 
times. Nosyl-removal was achieved with the aid of β-mercaptoethanol and DBU to afford resin-
bound model secondary amine VIII.22, as verified by LCMS analysis. 
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O
O
NH O
O
N
MeMe
HS
OH
5 eq , 2.5 eq DBU
DMF, r.t, 2 x 30 min
O
O
NH2 O
O
N
S
NO2OO
H
5 eq o-Ns-Cl, 10 eq collidine
o-Ns
S
NO2OO
VIII.19 VIII.20
VIII.21VIII.22
CH2Cl2, r.t, 2x1h
10 eq MeOH,
5 eq Ph3P,
5 eq DIAD,
DCE, r.t, 3x2 h
Me Me
MeMe
Scheme VII.8: Mitsnubo-Fuakayama reaction of VIII.19 with MeOH.  
 
VIII.3.3 Coupling of Fmoc-anthranilic acid derivatives and Fmoc removal 
Coupling of the Fmoc-anthranilic acid to resin-bound amine VIII.22 was achieved using the 
symmetrical anhydride method formed from N-Fmoc-anthranilic acid (10 eq) and 
diisopropylcarbodiimide (DIC 5 eq). A full conversion (monitoring via LCMS) was observed after 
double treatment. Fmoc-removal was accomplished by treatment of VIII.23 with a solution of 
20% 4-methylpiperidine in DMF 2x20 min, delivering the resin-bound dipeptide VIII.24. LCMS-
analysis shows the clean formation of the expected compound.  
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O
O
NH
MeMe
VIII.22
10eq anthranilic acid, 5 eq DIC, 
CH2Cl2/DMF 9/1, r.t, o.n.
VIII.23
O
O
N
MeMe
O NHFmoc
20 % 4-methylpiperidine in DMF
2x 20 min
VIII.24
O
O
N
MeMe
O NH2
Scheme VIII.9 Coupling of anthranilic acid to resin-bound amine VIII.22 followed by Fmoc 
removal. 
 
VIII.3.4 Attempts towards cyclization  
Previously at our laboratory, a successful cyclization/release step was observed using KOtBu in 
THF for compounds containing the β2,2-dimethyl substitution pattern. Application of these 
conditions to the resin bound amine VIII.24, however did not afford the desired cyclized product. 
No products could be detected in solution, neither at room temperature nor at 60 °C, and inspection 
of remaining resin-bound material by LCMS-analysis after TFA-cleavage, revealed mainly 
unreacted VIII.24 in the presence of a mixture of unknown impurities. Probably steric effects are 
responsible for this disappointing results. Alternatively the solution-phase cyclization was 
investigated next, in which the dipeptide VIII.25 was cleaved using TFA; purified via column 
chromatography (94% yield from VIII.18) and submitted to cyclization conditions in solution.  
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O
O
N
O NH2
N
H
N
O
O
X
TFA/H2O
95/5
i) 2 eq ClCOOMe, 4 eq DIPEA, 
0.01 M DCM, r.t, 1h
or
ii) 3 eq DCC-PS, 0.01M DCM, 
r.t, 1h
HO
O
N
O NH2
KOt-Bu, THF
VIII.24
VIII.25
VIII.26
r.t or 60 °C
94% from VIII.18
Scheme VIII.10 Cyclization attempts to form 3,5-dimethyl-3-naphthylmethyl-1,5-benzodiazocine-
2,6-dione VIII.26. 
 
Purified VIII.25 was treated initially on test scale with the earlier optimized conditions 
(ClCOOMe or polystyrene-bound DCC). The use of ClCOOMe in presence of DIPEA affords the 
cyclized VIII.26 in 29% relative purity, in addition to a mixture of compounds, while reaction 
with resin-bound DCC provided the product in 78% relative purity, along with 8% remaining 
starting material (figure VIII.4, peaks are integrated in LCMS at 214 nm).  
 
Figure VIII.4 Crude LCMS sample of the cyclized product VIII.26 using resin-bound DCC. 
Repeating the DCC-mediated reaction on bigger scale, delivered the expected 
benzodiazocinedione in 60 % yield. 
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VIII.4 CONCLUSION 
Based on the proposed solid phase synthesis strategy for the 3,3-disubstituted-1,5-benzodiazocine-
2,6-diones VIII.1, essential building blocks consist of N-Fmoc-anthranilic acids and N-Fmoc-3,3-
dialkyl-3-aminopropionic acids. A model building block of the latter was successfully prepared in 
moderate overall yield (synthetic route is depicted in scheme VIII.11). 
 
COOMeNC COOMeNC
COOMe
N
H
Boc COOH
N
H
Boc
COOH
N
H
Fmoc
a b
d e
c
COOH
HCl.H2Nf
COOMeNC
Me
Reagents and conditions: a) 1 eq 2-naphthaldehyde, 0.1 eq AcOH, 0.04 eq piperidine, dioxane, r.t., o.n. b) 1.1 eq
NaCNBH3, 0.4 M AcOH, MeOH/CH2Cl2 5/1, r.t, 1h. c) 5 eq MeI, 2 eq NaOMe, THF, 1M, 1h. d) 0.1 eq NiCl2.6H2O, 7
eq NaBH4, 2 eq Boc2O, MeOH, 0C to r.t., o.n. e) 4 eq NaOH, (H2O/MeOH 2/1), r.t to 50° C, 2h. f) Dioxane /
concentrated HCl 9/1, r.t, 7h. g)i)  2 eq TMSiCl, 1 eq DIPEA, CH2Cl2, reflux 6 h. ii) 2 eq DIPEA, 1 eq FmocCl,  0 C-r.t, 
o.n.
g
78%
60% 96% 99% 44%
Me Me Me
Me
VIII.9
VIII.27 VIII.12 VIII.13
88% 92%
VIII.14 VIII.16
VIII.17
VIII.8
NC COOMe
16% overall yield, 7 steps
Scheme VIII.11 Synthetic route to β2,2-amino acid building block VIII.16. 
 
Using this model β2,2-amino acid building block, the solid-phase synthesis of model 
benzodiazocinedione VIII.26 was investigated (detailed reaction conditions are depicted in 
scheme VIII.12). 
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OH
N
H
N
O
O Me
a b c
d e f b
g h
Reagents and Conditions: a)1) 2eq VIII.8, 2 eq DIC, CH2Cl2, 0.2 eq DMAP, 24h. 2) Ac2O/ DIPEA/CH2Cl2 1/1/3 , 2 x
2 h. b) 20% 4-methylpiperidine in DMF, 2 x 20 min. c) 5eq o-NsCl, 10eq collidine, CH2Cl2, 2 x 1 h. d) 10 eq MeOH, 5 
eq Ph3P, 5 eq DIAD, DCE, 3 x 2 h. e) 2.5 eq DBU, 5 eq 2-mercaptoethanol, DMF, 2 x 30 min. f) 10 eq Fmoc-
anthranilic acid, 5 eq DIC, CH2Cl2/DMF 9/1, 24 h. g) TFA/H2O 95/5, 2 x 1 h. h) polystyrene-bound-DCC, CH2Cl2, 1h.
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Scheme VIII.12 Solid-phase synthetic route towards VIII.26 
 
Unfortunately, the anticipated direct cyclization/release approach from precursor VIII.24 using 
KOtBu did not yield the expected benzodiazocinedione. Alternatively, the solution-phase 
cyclization using resin-bound DCC delivered the target bislactam. In conclusion, it seems the 
increased steric congestion in the cyclization precursor hampers the general application of the 
KOtBu-mediated cyclization methodology as used before for 3,3-dimethylated-1,5-
benzodiazocine-2,6-diones. 
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IX CONFORMATIONAL AND MODELING STUDY 
IX.1 INTRODUCTION 
Atropisomerism, a term coined by Kuhn in 19331, refers to stereoisomerism resulting from 
hindered rotation around a single bond such that the isolation of individual conformers is possible 
(in Greek the word atropos means without rotation). The optical activity due to axial chirality was 
first reported by Christie and Kenner in 19222, after a single enantiomer of 6,6'-dinitro-2,2'-
diphenic acid IX.1 was isolated from the racemic mixture via diastereoselective crystallization 
with a chiral resolving agent. 
                                                
NO2HOOC
NO2HOOCHOOC
HOOC NO2
NO2
IX.1  
Figure IX.1 Atropisomerism of 6,6'-dinitro-2,2'-diphenic acid IX.1 
Atropisomers are recognized as physically separable species3 when - at a given temperature - they 
have a half-life of < 1000 s. The dynamic interconversion between two isomers is influenced by 
sterical hinderance, electronic influences, temperature and solvent. To describe the atropisomers 
according to their level of interconversion at a certain temperature, half-lives were introduced 
(figure IX.2). Based on correlation of calculated energy barriers and rotational rates, atropisomers 
are categorized into three classes; class 1: compounds show no axial chirality, do not have 
atropisomers with ΔErot > ~ 20 kcal/mol, class 2: shows a noticeable interconversion over time 
ΔErot ~ 20-30 kcal/mol and may be subdivided into two subclasses, rapid interconversion / delayed 
interconversion, class 3: compounds show stability overtime, have a rotational energy barrier ΔErot 
> ~ 30 kcal/mol and can be isolated as (enantiomerically) pure compounds.  
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Figure IX.2 Classification of atropisomers based on torsion rotation energy barrier. 
This phenomenon can have a major impact on the properties of the compounds, for example in 
pharmaceutical applications4. In this respect, the ring inversion of diazepam and analogues has 
been investigated by Gilman and co-workers5. They found that the interconversion energy barrier 
increases by increasing the substitution on N1 (figure IX.3). Diazepam (IX.2, R=Me), has an 
interconversion barrier of 73.6 kJ/mol and can thus considered to be a slow interconverting mixture 
of both conformers. However, when a tert-butyl group is introduced at N1, the interconversion 
energy barrier is higher than 100.4 kJ/mol, and the mixture can be separated into stable isomers.  
                         
Cl N
N
O
R
Cl N
N
O
R
IX.2 IX.3  
Figure IX.3 Inversion of N-substituteddiazepam 
Table IX.1 Ring inversion energy barriers 
R ΔErot[kJ/mol] 
H 50.2 
Me 73.6 
iPr 88.3 
tBu <100.4 
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IX.2 CONFORMATIONAL BEHAVIOUR OF EIGHT-MEMBERED BENZO-
(BIS)LACTAM COMPOUNDS – RELEVANT LITERATURE 
The major conformation influencing moieties in the 1,5-benzodiazocine-2,6-dione skeleton 
comprise the sp2-hybridized diazocine-atoms; being the two planar amides (N1-C2 and N5-C6) 
along the C-C double bond at the annelation position, creating two possible cases of axial chirality. 
The conformational behavior of related eight-membered benzo-(bis)lactam compounds have 
already been studied in literature, so looking into these studies of reported systems might give an 
insight in the 3D structure of our scaffold.  
Because of the structural similarity in the literature the comparison of lactams is often made with 
the analogous carbocyclic parent systems (alkenes or benzo-annulated). To illustrate the influence 
of one conjugated benzene-amide moiety, it is interesting to discuss the conformation of 
benzolactams IX.4 and IX.5. An extensive conformational NMR/DFT study was recently 
performed by Witosinska6 for these structures (IX.4, IX.5, figure IX.4). It was shown that the 
amide bonds are planar and adapt the E configuration (cis), leading to a major conformer (98%) 
displaying a ground state twist-boat-chair conformation similar to the conformation of (Z,Z)-1,3-
cyclooctadiene IX.36. Because of the atropoisomerism phenomena due to the presence of the sp2-
sp2 chiral axis of the benzamide bond, the molecule can interconvert to its “flipped” mirror 
conformation, for which energy barriers of 59-66 kJmol-1 have been determined by DNMR. 
Presence of an N-methyl substituent increases the energy barriers for conformational processes; in 
fact, at room temperature, lactam IX.4b is conformationally locked and exists as a racemic mixture 
of uninterchangeable chiral conformers.  
As an illustration, the X-ray structure of IX.4a is shown in figure IX.4 (left), along the DFT-
predicted conformation (right). To have a visual insight on the possible conformational processes, 
the proposed mechanisms are shown for (Z,Z)-1,3-cyclooctadiene (figure IX.5). 
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Figure IX.4 Top: Structure of the compounds IX.4, IX.5 and their experimentally determined 
barriers for dynamic processes from DNMR. Bottom: Structure of IX.4a as determined by x-ray 
crystallographic analysis (bottom left) and computed (DFT) lowest energy conformation (bottom 
right)6.  
 
 
                                           
 
 
 
 
 
Figure IX.5 (Z,Z)-1,3-Cyclooctadiene as a carbocyclic conformational model7.  
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(Z,Z)-1,3-cyclooctadiene
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Part 2: Results and discussion 
 
146 
 
In contrast to the twist-boat chair conformations of these benzoannelated monolactam 
benzodiazocines, the introduction of an extra Л-bond (and thus extra axis of chirality) generally 
gives rise to compounds in the boat or twist-boat conformation. In principle, according to IUPAC-
rule, these 8-membered ring conformations should be addressed as “tub” conformation, but in this 
dissertation we follow the commonly used “boat” terminology. 
Again, the carbacyclic parent system may serve as a starting point to describe the expected 
conformational possibilities. It has to be kept in mind of course that accompanying energy values 
will be highly depending on the individual compounds and could thus dramatically shift equilibria 
between conformational states.  
D
D
D
D
IX.89IX.79,10
Tcoal= -98C
GkJ/mole
=26.0 Hz
Tcoal= -136C
9
Tcoal= -145C
10
GkJ/mole9
GkJ/mole10
enantiomers could be separated by chromatography 
and consequently racemized at 49-64 C, giving
GkJ/mole
IX.911
               
Figure IX.6 Structures of IX.7, IX.8, IX.9. Experimentally measured barriers (100 MHz, 
CHF2Cl/CH2CHCl 1/1 solution for IX.7 and IX.8.  
 
 
 
 
 
 
Figure IX.7 1,3,5-cyclooctatriene as a conformational model. 
As can be seen from figure IX.7, twist-boat (C7-C8 staggered) conformations are considered to be 
the ground states, which are thought to interconvert through pseudo-rotation via a boat (C7-C8 
12
3
4
5 6
7
8
IX.10
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eclipsed) transition state or through conformational ring inversion via high energetic half chair 
transition states8. 
Experimental values9,10 for these energy states and barriers have been obtained for a number of 
related systems, as summarized in figure IX.6 and figure IX.8.    
Comparing IX.7 and IX.8, the 10 kJ/mol higher barrier can be attributed to an increase in the angle 
strain in the transition state for inversion, due to the fusion of the benzene ring. During the 
transition state the three double bonds approach planarity, causing an increase of internal bond 
angles; fusion of a benzene ring will render this expansion more difficult, therefore increasing the 
barrier. 
From NMR analysis on a small series of pyrazolobenzodiazocines IX.11, Gyomore et. al.12,13 
concluded a boat-like conformational ground state and obtained x-ray crystallography data on 
IX.12 (R3=Et), showing the twisted-boat geometry (figure IX.9). 
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R3= Et, Tcoal>390 K; 
no broadening of peaks
N
NH
O
N
O
Me
Me
O
Tcoal=355 K
GkJ/mole
IX.11 IX.12 IX.13 IX.14
x-ray 
twisted-boat
Figure IX.8 Examples of studied related 8-membered ring systems. 
Here, the nature of the R3 substituents seems to be important for the level of conformational 
freedom. Where H- or Me-substituted compounds (IX.12) showed ring-interconversion (Tcoal= 268 
K, 376K, respectively), ethyl-substituted IX.12 was completely conformationally locked as no 1H 
NMR line broadening could be observed at temperature up to 390 K. Olivia-Madriol observed a 
twist-boat conformation for compound IX.14 through X-ray analysis14.  
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Figure IX.9 Structure of IX.12, as determined by x-ray crystallographic analysis. 
The boat-shaped conformation was also devised for the eight-membered homologue of diazepam 
(IX.15), a well-known benzodiazepine drug. The x-ray structure is shown in figure IX.10.   
 
 
 
 
 
 
 
 
 
Figure IX.10 Structure of IX.15 as determined by x-ray crystallographic analysis. 
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Elguero and colleagues15 studied the conformation of the, for us, strongly similar 3,4-dihydro-1,6-
benzodiazocine-2,5-dions nucleus. It was demonstrated from 1H NMR that the ground states 
involved are true boat conformations (thus C3-C4 eclipsed), confirmed by molecular modeling 
performed at our laboratory (Jan Goeman). The boat-boat interconversion process was shown to 
be influenced by the substitution pattern on the amide functionalities. For N-unsubstituted 
derivatives IX.16, a rapid interconversion was observed at room temperature, whereas mono-
methylated IX.17 showed broadening of the 1H NMR signals above 120°C, (unfortunately a full 
analysis was not possible as the compound decomposed at 140 °C). 
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Figure IX.11 Structures of compounds IX.16, IX.17, IX.18 and IX.19. 
For N,N`-dimethyl derivatives IX.18 and IX.19, broadening of the 1H NMR peaks only occurred 
at 180 °C, resulting in free energy of activation estimates over 100 kJ/mol. For trimethyl compound 
IX.19 two conformers B1 and B2 are postulated, in which the C3 methyl group is located in a 
pseudo-axial (“endo”) or pseudo-equatorial (“exo”) position, respectively. The B1/B2 ratio after N-
methylation of IX.16 (R=Me) was found to be 7/3, which equilibrated over time and temperature 
to the thermodynamic equilibrium ratio of 2/8. Own modeling experiments confirm these 
structures.                                     
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Figure IX.12 Top: Reported boat conformations of IX.19 by Elguero. Bottom: Results of our 
modelling experiment of IX.19: Left: ground state (in agreement with conformation B2); right: 
next conformer (calculated +2.17 kJ/mol), in agreement with conformer B1. From this energy 
difference, a 71/29 ratio can be expected at thermodynamic equilibrium at 298K. 
IX.3 CONFORMATIONAL ANALYSIS OF 1,5-BENZODIAZOCINE-2,6-DIONES 
IX.3.1 Modeling of 3-substituted-1,5-benzodiazocine-2,6-diones 
Four compounds were subjected to a modeling experiment (in CHCl3) using Maestro software and 
gave overall general conformational results. As illustrated in figure IX.13 for IX.20, the energetic 
ground state adopts a clear twist-boat conformation in which the C3-C4 bond is clearly present in 
the staggered rotamer (figure IX.13, left), differing from the above-discussed isomeric 1,6-
benzodiazocine-2,5-diones which seem to adopt a true boat conformation (C3-C4: eclipsed). 
Noteworthy is the presence of the C3-methyl group in the pseudo-axial position (“endo”). The next 
calculated energetic minimum (4.659 kJ mol-1) is an alternative twist-boat conformation (figure 
IX.13, right), in which the C3-methyl group assumes the pseudo-equatorial orientation (“exo”). 
These clearly arise from a ring inversion, for which a relative ratio of 87/13 can be calculated (from 
ΔG°=-RTlinK). Other calculated configurations had relative energies higher than 10 kJ.mol-1 and 
Part 2: Results and discussion 
 
151 
 
were therefore not considered. The other compounds IX.21, IX.22, IX.23 show the same 
conformational behavior (see table IX.1).  From the obtained energetic values, it seems that for 
larger substituents on C3 and N5, the calculated energy difference would lead to almost fully 
populated ground state conformations at thermodynamic equilibrium. However, being at 
thermodynamic equilibrium requires equal macroscopic rates of dynamic interconversion between 
the different conformations, which is only possible if the energy barriers for interconversion can 
be overcome at the given temperature. If barriers are too high, conformers can become 
conformationally locked and can lead to stable isomers which can eventually be isolated. Such 
behavior can have profound effects on the NMR spectra at hand, as coalescence effects will appear 
when conformational dynamics are approaching the NMR time scale. Actually, from these line-
broadening effects in 1H NMR, experimental interconversion barriers can be deduced for these 
conformational processes. 
                                                                                
N
HN
O
O
IX.20  
Figure IX.13 Two lowest energy conformers for compound IX.20. A. lowest energy conformer; 
B. conformer with relative energy: + 4.659 kJ.mol-1. 
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Table IX.1 Results of modeled 3-substituted-1,5-benzodiazocine-2,6-diones IX.20-IX.23. 
Compound ΔG° Ratio at  
298 K 
Substitution on 
C3 (Ground 
state) 
Substitution on 
C3 (Inverted 
boat) 
N
HN
O
O  
4.659 kJ.mol-1 87/13 pseudo-equatorial pseudo-axial 
N
HN
O
O  
8.807 kJ.mol-1 97/3 pseudo-equatorial pseudo-axial 
N
HN
O
O
 
9.172 kJ.mol-1 98/2 pseudo-equatorial pseudo-axial 
N
HN
O
O  
9.68 kJ.mol-1 98/2 pseudo-equatorial pseudo-axial 
 
IX.3.2 Modeling of 4-substituted-1,5-benzodiazocine-2,6-diones 
Three 4-substituted-1,5-benzodiazocine-2,6-diones were also submitted to molecular modeling (in 
CHCl3). Again, results were consistent over this series. Visualized for analogue IX.24, a twist-
boat conformation is the energetically most stable structure (figure IX.14, A; 0,0 kJ.mol-1). 
However, in contrast to the above 3-substituted derivatives, the methyl substituent at C4 is now 
occupying a pseudo-equatorial orientation (“exo”). The next energy minimum corresponds to the 
ring-inverted conformer, in which the C4-methyl group is oriented pseudo-axially (”endo”, figure 
IX.14, B; 2.605 kJ.mol-1). The other compounds IX.25 and IX.26 show the same behavior (see 
table IX.2).    
IX.21 
IX.20 
IX.22 
IX.23 
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                                                                         IX.24
N
HN
O
O
 
Figure IX.14 Two lowest energy conformers for compound IX.24. A. lowest energy conformer; 
B. conformer with relative energy: + 2.605 kJ.mol-1. 
 
Table IX.2 Results of modeled 3-substituted-1,5-benzodiazocine-2,6-diones IX.24-IX.26. 
Compound ΔG° Ratio 
at 298 
K 
Substitution on C4 
(Ground state) 
Substitution on C4 
(Inverted boat) 
N
HN
O
O  
2.605 kJ.mol-1 74/26 pseudo-axial pseudo-equatorial 
N
HN
O
O  
1.761 kJ.mol-1 67/33 pseudo-axial pseudo-equatorial 
IX.25 
IX.24 
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N
HN
O
O  
5.170 kJ.mol-1 89/11 pseudo-axial pseudo-equatorial 
 
 
IX.3.3 Experimental data on the synthesized 1,5-benzodiazocine-2,6-diones 
As we have been using racemic beta amino acids for our libraries, the final 1,5-benzodiazocine-
2,6-dione derivatives are isolated as racemates. Because of the conformational behavior discussed 
above, in case of slow ring interconversions, we can expect a mixture of possible isomers at 
ambient temperature in NMR experiments. As these are present as two diastereomeric pairs of 
enantiomers, we expect two main diastereoisomeric boat-type conformations. Depending on the 
energy barriers, higher temperatures could then lead to coalescence or even further simplification 
as the average of the conformational equilibrium will be visible. If the barriers of interconversion 
would be sufficiently high, the isolation of the isomers at room temperature would even become 
achievable. In figure IX.15 an overview on the expected conformers, along their 
enantiomeric/diastereomeric relationships. For the assignment of the (M)/(P)-helical descriptors, 
we base ourselves on existing nomenclature for the well-known 1,4-benzodiazepines, such as the 
closely related 1,4-benzodiazepine-2,5-diones 16. Assignment is thus relying on the positive (P = 
Plus, clockwise rotation) or negative (M = Minus, counterclockwise rotation) dihedral angle along 
the atom chain C2-N1-C10a-C6a. 
                
 
 
 
 
 
 
IX.26 
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Figure IX.15 Four possible conformers of 3-substituted-1,5-benzodiazodine-2,6-diones and their 
enantiomeric/diasteriomeric relationships, with assignment of (M)/(P)-helical descriptors. 
 
The presence of multiple conformational states in the synthesized 1,5-benzodiazocine-2,6-diones 
becomes immediately clear from the corresponding complex 1H NMR and 13C NMR spectra. For 
more simple-substituted benzodiazocinediones, it is generally possible to visualize two main 
conformers in differing ratios. For analogues containing larger (and thus more rotation-prone) 
substituents, additional (albeit lowly abundant, < 5%) conformers can be detected/suspected. For 
ease of discussion, these minor conformers are omitted in the following paragraphs. To avoid 
issues of impurities, compounds were intensively purified (column chromatography, followed by 
reversed phase HPLC purification). Purities were generally over 95% (LCMS analysis at 214 nm). 
In the following section, a preliminary discussion is offered. A more detailed NMR study, along 
theoretical support, on the conformational behavior could be an interesting subject of future 
research. 
In figure IX.16 an overview is given of the observed ratios of boat-type conformers, as determined 
by integration of the corresponding 1H NMR spectra. 
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Figure IX.16 Observed ratios of conformers for synthesized 1,5-benzodiazocine-2,6-diones, as determined from 1H NMR spectra.  
*could not be determined because of overlapping.
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IX.3.3.1 Analysis of 3-substituted-1,5-benzodiazocine-2,6-diones 
As an example of a “simple” 3-substituted benzodiazocine, the 1H NMR spectrum of IX.23 is 
shown in figure IX.17. Two major conformers seem to be present at room temperature, in a ratio 
of around 80/20. The observed relatively broad peaks of the isobutyl group in the minor conformer 
(0.70-0.83 ppm, as compared to the sharp peaks in the major conformer, ~0.88 ppm) are probably 
due to the less restricted rotation of this side chain, as would be expected of an isobutyl group in 
the exo-position (see figure IX.13, conformer B (exo) versus A (endo)).  
 
  
 
Figure IX.17 Details of the 1H NMR spectrum of IX.23, recorded at room temperature in acetone-
d6 (400 MHz), indicating the ratio of two conformers 8/2. 
The observed 8/2 ratio is rather different compared to the predicted 98/2 ratio, based on the 
calculated energy difference between expected conformers (9.68 kJ/mol, see table IX.1). This 
could mean that either there is an error on the calculated value (although solvent effects can 
influence these values), or that the compound is not in thermodynamic equilibrium because of 
NH 
CH3 
2 CH3 isopropyl 
N
HN
O
O
IX.23
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large conformational interconversion barriers. In an attempt to verify the latter, a heating 
experiment was conducted under microwave conditions. Heating for 30 minutes at 150 °C and 5 
minutes in 210 °C in DMSO, however, did not reveal any changes in the recorded NMR spectra. 
Although higher temperatures unfortunately led to decomposition, these results suggest the 
compound to be in thermodynamic equilibrium, when taking into account literature precedents on 
related ring systems. As such the difference in free energy between the conformers may be 
estimated to be around 3.4 kJ mol-1. The barrier for interconversion could be determined in the 
future using DNMR. 
As an example of a “more complicated” derivative, the 1H NMR spectrum of compound IX.27 
shows multiple conformations (figure IX.18). Because of the larger N-substituent, it is also 
predicted to be more conformationally restricted because of higher energy barriers.  Indeed, it is 
actually the only compound from the synthesized 3-substituted benzodiazocines for which the 
diastereomeric conformers are found to be resolved in the LCMS analysis. Unfortunately, attempts 
to separate the isomers by column chromatography or HPLC were not successful. Again, as the 
observed ~7/3 - 8/2 ratio of the major isomers is rather different from the predicted values of 
related structures (~98/2, table IX.1), a heating experiment under microwave conditions was 
conducted. To this end, the sample was heated consecutively at 150 °C, 170 °C, 190°C and 210°C 
for five minutes each, taking samples between each experiment for LCMS-analysis (integration at 
254 nm). As depicted in figure IX.20, it was found that the ratio (82/18) remained unchanged 
throughout the experiments, indicating a very high energy barrier for ring-interconversion. 
Unfortunately, further heating at 230°C caused complete decomposition of the compound. 
Alternatively, for this product a 1H NMR experiment was performed at higher temperature (130 
°C in DMSO, figure IX.19) in an attempt to visualize coalescence phenomena; however, only 
marginal broadening of the peaks could be observed which again point to considerable ring-
interconversion barriers. Because of technical reasons, recordings at higher temperatures could not 
be performed.  
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Figure IX.18: Detailed 1HNMR spectra of IX.27 in DMSO-d6 at room temperature. 
Figure IX.19: Detailed 1HNMR spectra of IX.27 in DMSO-d6 130 °C. 
DMSO-d6 at room temperature 
DMSO-d6 at 130 °C 
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Figure IX.20 Integration of two conformer peaks in LCMS at 254 nm at room temperature and 
after heating at 170 °C, 190°C, 210 °C and 230 °C for compound IX.27. 
 
 
Room temperature, MeOH, 82/18 
170 °C, mw, 5 min, DMSO, 83/17 
190 °C, mw, 5 min, DMSO, 83/17 
210 °C, mw, 5 min, DMSO, 83/17 
230 °C, mw, 5 min, DMSO, decomposed 
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IX.3.3.2 Analysis of 4-substituted-1,5-benzodiazocine-2,6-diones 
The main conformers of 4-substituted-1,5-benzodiazocine-2,6-diones were integrated in the 1H 
NMR spectra showing conformer ratios between 50/50 and 87/13 (figure IX.16). A detailed NMR 
analysis for the simple derivative IX.24 is illustrated in figure IX.21.  
 
 
 
 
Figure IX.21 1HNMR spectrum of IX.24 in acetone-d6 at room temperature.   
For this compound, two conformers are observed in approximately 6/4 ratio. After a detailed 
analysis of observed coupling constants, we assign the (P)-helical descriptor to the major 
conformer, while the minor conformer involves the inverted (M)-structure. The corresponding 
Newman projections are depicted in figure IX.22 (for the R-enantiomer). These results are 
consistent with the predicted conformations, shown in figure IX.14.  
NH 
N
H
N
O
O
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Figure IX.22 Newman projection of the major and minor conformers of compound IX.24. 
Again, the observed ratio (~6/4) is somewhat differing from the calculated 74/26 (table IX.2), so 
we wished to verify if the observed conformers are actually in thermodynamic equilibrium. 
Thus, again a heating experiment under microwave irradiation was conducted. A room temperature 
1H NMR spectrum was recorded after heating at 150 °C and 210 °C in DMSO, but no change in 
Φ[degree] 90 0 
J H
-H
 H
z 
Karplus Equation 
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the conformation ratio was observed. Unfortunately the compound decomposed at higher 
temperature.  
Next, an NMR study was performed by recording 1H NMR spectra at various temperatures (from 
298 K till 398 K, figure IX.23). From the observed coalescence phenomena, the activation energy 
can be estimated17 using the following equation; 
ΔG≠ = aTc [9.972 + log 
𝑇𝑐
∆𝜈
] 
Tc: The coalescence temperature 
a= 1.914 x 10-2 for units kJ/mol 
 Δν: difference in chemical shift (in Hz) between distinguished signals 
 
Figure IX.23 1HNMR spectra at different temperatures for compound IX.24 (DMSO-d6-500 
MHz). Left: N-H signals; Middel: N5-CH3 signals (the migrating large singlet is attributable to 
water in the sample).  
Potential errors on the estimation of this values arise from the (sometimes difficult) determination 
of Tc and Δν. Often the isotropic chemical shifts of the exchanging species are temperature 
dependent, so Δν changes with temperature and error in ΔG≠ can become large. Examination of 
the 1H NMR experiment at different temperatures revealed that the coalescence temperature ranges 
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from 363 K to 388 K, depending on the signals of interest (see figure IX.23). Calculation of 
activation energy at coalescence for the different peaks through the above equation gives an 
average value of ΔG≠ = 77.6 kJ/mol, indicating a rapid interconversion between the conformers at 
room temperature and verifying that they are in thermodynamic equilibrium. 
 
IX.4 CONCLUSION 
A conformational analysis of representative members for the two synthesized libraries (3-
substituted and 4-substituted 1,5-benzodiazocine-2,6-dione) was performed via a computational 
modeling experiment which clearly show two ring-inverted twist-boat conformations (differing 
from the literature-discussed isomeric 1,6-benzodiazocine-2,5-diones which  adopt true boat 
conformations). For the 3-substituted 1,5-benzodiazocine-2,6-dione; the C3-substituent is present 
in the pseudo axial position (“endo”) in the ground state, while for the 4-substituted 1,5-
benzodiazocine-2,6-dione the C4-substituent adopts a pseudo equatorial orientation (“exo”). The 
“endo” and “exo” conformers form a pair of  “ring-flipped” conformational states with calculated 
energy differences of 1-10 kJ.mol-1 depending on the specific structure. The presence of these 
conformational states in the synthesized 1,5-benzodiazocine-2,6-diones was clear from the 
corresponding complex 1H NMR and 13C NMR spectra showing ratios varying between ~ 50/50 
to 90/10. 
From the observed coalescence phenomena in a series of 1H NMR experiments at temperatures 
from 298 K to 398 K of 4,5-dimethyl-1,5-benzodiazocine-2,6-dione IX.24, a conformational 
energy barrier of 77.6 kJ.mol-1 was estimated. 
However, more complexly substituted library members only display marginal line broadening 
effects in 1H NMR spectra at high temperature (130 °C), therefore revealing a significantly higher 
rotational barrier. For these compounds, 1H NMR spectra were recorded after heating the samples 
up to 210 °C. However, no changes in conformer ratios were observed. In this case, peak ratios 
were also found to be unchanged after heating the sample to temperatures up to 210 °C. As a result, 
thermodynamic equilibrium between the two boat conformers can be suggested. Interestingly, in 
one compound IX.27 diastereomeric conformers were visible in LCMS as two peaks which 
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suggest that this compound exists as two stable atropisomers. Preparative separation, however, 
was not successful.   
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X. GENERAL CONCLUSION AND FUTURE PERSPECTIVES 
The overall goal of this work was to synthesize parallel combinatorial libraries of compounds 
based on the potentially interesting 1,5-benzodiazocine-2,6-dione scaffold, namely 3-substituted-
1,5-benzodiazocine-2,6-diones X.1, 4-substituted-1,5-benzodiazocine-2,6-diones X.2 and 3,3-
disubstituted-1,5-benzodiazocine-2,6-diones X.3 (figure X.1) using commercially available or 
easily accessible building blocks, allowing a fast and efficient diversification of the target 
molecules.       
             
N
H
N
O
O
R1
R2
X.1
R3
N
H
N
O
O R2
X.2
R3
R1 N
H
N
O
O R3
X.3
R4
R1
R2
  
Figure X.1 Target compounds. 
Our choice of methodology fell on the development of a solid-phase synthesis route. Although a 
solid-phase approach has some inherent disadvantages (such as a long initial synthesis 
development time and scale up problems), this strategy is still very useful in early stage drug 
discovery and development phases, as an available general synthesis would allow the fast 
generation of a large diversity of analogues around the skeleton of interest. As we choose the 
benzodiazocine framework with privileged-structure-like properties, we expect that the developed 
synthesis route can be applied in a broad range of different drug discovery programs targeting a 
large diversity of therapeutic biochemical targets.  
The development and optimization time of the solid-phase synthesis is relatively slow as it 
involves careful consideration of the polymeric support and linker choice in order to be compatible 
with the synthesis strategy. Moreover, reaction monitoring is more time consuming as classical 
solution techniques are not possible to apply on solid-phase chemistry. Instead intermediates are 
typically destructively cleaved off from the resin to submit for conventional analytical techniques. 
However, after settlement of the carefully optimized synthetic multistep strategy, a fast access to 
a multitude of libraries is possible as intermediate purifications are limited to simple filtration and 
washing steps, which are amenable for automation.   
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In an answer to our initial goal (goal 1, section IV), we have thoroughly investigated the synthesis 
of a model compound X.4, which was achieved through the solid-phase synthesis of an open-chain 
precursor, which was cyclized in solution phase using solid-supported DCC in good yield.   
                                                                  
N
H
N
O
O Bn
X.4  
Figure X.2 Model compound 5-benzyl-3,4-dihydro-1,5-benzodiazocine-2(1H),6(5H)-dione. 
Using the developed synthetic procedure for the model compound, the synthetic route towards 3-
substituted-1,5-benzodiazocine-2,6-diones was explored. Essential building blocks in this 
synthesis consist of N-Fmoc-anthranilic acid and N-Fmoc-β2-amino acid derivatives and 
commercially available alcohols. A synthetic route towards the β2-amino acid building blocks was 
developed starting from commercially available methyl cyanoacetate and appropriate aldehyde. In 
this way three N-Fmoc-β2-amino acids building blocks were synthesized, and applied in a library 
of 13 3-substituted-1,5-benzodiazocine-2,6-dione diversified on three positions with moderate to 
good overall yield for solid phase synthesis and low to moderate cyclization yields.  
Our next goal consisted of 4-substituted-1,5-benzodiazocine-2,6-diones X.2. A set of three 
commercially available β3-amino acids was used as building blocks in an essentially similar route. 
However, a double coupling procedure of N-Fmoc anthranilic acid was found to be necessary due 
to steric reasons. In this way, a library of 11 4-substituted-1,5-benzodiazocine-2,6-dione 
diversified on 3 positions was synthesized with moderate to good overall yield for solid phase 
synthesis and low to moderate cyclization yields comparable to the 3-substituted-1,5-
benzodiazocine-2,6-diones. 
The last challenging compound that was tackled consisted of the 3,3-disubstituted-1,5-
benzodiazocine-2,6-dione. An essential model β2,2-amino acid building block was synthesized 
with difficulty starting from methyl cyanoacetate and appropriate aldehyde. Unfortunately the 
anticipated direct cyclization/release approach using KOtBu did not yield the expected 
benzodiazocinedione. Alternatively, the solution-phase cyclization using resin-bound DCC 
delivered the target bislactam in moderate yield. The direct cyclization/release methodology using 
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KOtBu seems to be only applicable to more simple quaternary β2,2-amino acid building blocks, as 
demonstrated before in our laboratory for 3,3-dimethyl-1,5-benzodiazocine-2,6-diones. 
Although the synthesis is expected to be applied to the synthesis of homochiral libraries, all 
compounds in this study were prepared from racemic β2-, β3- and β2,2-amino acids, delivering the 
corresponding racemic benzodiazocinediones. This is justifiable as this is an initial library 
synthesis demonstration and the racemic compounds can be screened as such in high-throughput 
screening platforms.  
For the subsequent and more specific drug discovery programs, the synthesis of optically pure 
compounds will be desirable. This would require the use of optically active β-amino acids, which 
are only very limitedly commercially available, but for which synthetic strategies are becoming 
valuable in literature. As such β3-amino acids could be obtained from the corresponding α-amino 
acids, and β2-amino acids can be accessed from linear or cyclic β-alanine derivatives that can be 
alkylated. 
Computational modeling experiments show two ring-inverted twist-boat conformations for 
representatives of both of the synthesized two libraries (3-substituted and 4-substituted-1,5-
benzodiazocine-2,6-diones). The presence of these two conformational states was clear from the 
corresponding complex 1H NMR and 13C NMR spectra. Because of the importance of 
atropisomerism in pharmaceutical applications, a further study was conducted. For simple 
compound X.6 a series of 1H NMR experiments at different temperatures show coalescence effects 
from which an estimated interconversion energy barrier of 77.6 kJ.mol-1 was obtained. For more 
complex structures only marginal broadening of peaks in the 1H NMR spectra could be obtained 
up to 130 °C, indicative for significantly higher barriers between conformers; heating experiments 
up to 210 °C did not reveal any change in the observed ratio of conformers. Interestingly, both 
conformers of compound X.5 (as the only example from the synthesized libraries) were observed 
as separate peaks during LCMS analyses, suggesting that this structure consists of two co-existing 
stable atropoisomers.  
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Figure X.3 Selected compounds showing high and low energy barriers as determined by 1H NMR 
heating experiments and LCMS analyses. 
Further research is clearly necessary to gain more detailed insight in the conformational behavior 
of these potentially pharmaceutically interesting structures. In this regard, further investigation of 
N1-alkylated analogues and influences of cis/trans-C3,C4-disubstitution patterns could be useful. 
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XI ENGLISH SUMMARY  
XI.1 INTRODUCTION  
A perceptive analysis of modern drug research highlights the importance of so called “privileged 
structures”. Before, new active compounds were typically sought in natural resources (plants, 
animals, microorganisms) or were obtained after random screening of individually synthesized 
“synthetic” compounds. The privileged structures term, was introduced to represent substructures 
that confer activity to two or more different receptors1. Molecules based upon these (sub)structures 
have been shown to yield a higher success rate in the discovery of new drug candidates that comply 
to Lipiniski’s rule2. An important class of privileged structures consist of a family of compounds 
built around the popular 1,4-benzodiazepine motif. For example, the 1,4-benzodiazepine-2,5-dione 
skeleton is considered to be of a special interest as established drug-like scaffold in recent 
medicinal chemistry, as illustrated in figure XI.1. Besides the important seven-membered 
benzodiazepine privileged structures, the corresponding eight membered homologue could be 
potentially interesting for drug discovery purposes. Examples of these biologically active 
benzodiazocines are known (see figure XI.1), but are clearly underrepresented, probably as a 
consequence of the known difficulties to synthesize such challenging medium-ring skeletons.      
N
N
H O
O
(+)-CGP 48506
N
HN
O
muscle relaxant
N
H
N
O
O
MeO
HO
HO
(RK-1441B) antibiotic
N
H
N
O
O
I
HDM2 antagonist
COOH
Cl
Cl
XI.1 XI.2 XI.3 XI.4
Figure XI.1 Examples of bio-active compounds built around a central privileged structure. Left: 
1,4-benzodiazepine-2,5-dione derivative XI.1 and XI.2. Right: 1,5-benzodiazocine derivative XI.3 
and XI.4. 
To be able to maximally exploit a given privileged structure in diverse drug discovery programs, 
a general and straightforward synthesis methodology to the skeleton would be advantageous, in 
which a high structural side chain diversity could be introduced. To this end, a solid phase synthesis 
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approach considered to be a useful tool (combinatorial chemistry), which could potentially 
synthesize a broad range of analogues using sets of modular building blocks, and has shorten the 
cost and time.  
XI.2. AIM AND OBJECTIVES 
The aim of this PhD thesis is to synthesize libraries of structurally diverse compounds on the basis 
of a 1,5-benzodiazocine-2,6-dione skeleton (figure XI.2, general structure of derivatives: XI.5), 
through a solid-phase chemistry-based approach. These compounds have only limitedly been 
reported in literature. 
                                                   XI.5
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10c
R5
 
Figure XI.2 Representative structure for the 1,5-benzodiazocine-2,6-dione skeleton 
The specific aim of this project are 1) an initial optimization of a previously explored synthetic 
route, 2) validation of the synthetic route to 3- and 4-substituted analogues and 3) the synthesis of 
more challenging 3,3-disubstituted-1,5-benzodiazocine-2,6-diones. Moreover, the required 
building blocks (β-amino acids) will have to be synthesized in-house as they are generally not 
commercially available.  
 
XI.3. RESULTS AND DISCUSSION 
XI.3.1. General synthesis strategy 
Retrosynthesis of the intended 1,5-benzodiazocine-2,6-dione skeleton results in two basic building 
blocks: anthranilic acid derivatives XI.8 and β-amino acids XI.9; which can be connected via two 
amide bonds.  
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Scheme XI.1 Retrosynthesis for target benzodiazocinedione XI.5. 
XI.3.2 Solid phase synthesis of a model 1,5-benzodiazocine-2,6-dione 
In order to verify and optimize the earlier developed methodology3, 5-benzyl-3,4-dihydro-1,5-
benzodiazocine-2(1H),6(5H)-dione XI.11 has been chosen as model target compound. The 
synthesis involved Wang resin-loading of Fmoc β-alanine XI.13 (scheme XI.2) followed by 
removal of the fluorenylmethoxycarbonyl moiety using 4-methylpiperidine in DMF, N-mono-
benzylation through a Mitsunobu-Fukayama alkylation sequence, coupling with the symmetrical 
anhydride of N-Fmoc-anthranilic acid and Fmoc-removal to form resin-bound dipeptide XI.18. 
Previous trials to cyclize the aminoester using acid-, base-, or nucleophilic catalysts failed, while 
the use of strong bases (KOtBu, NaH) caused the formation of an elimination product arising from 
acidic α-protons3. Therefore, cleavage of the dipeptide X.19 from the resin was performed with 
TFA a range of cyclization conditions was tried. Among the tested conditions, cyclization could 
be achieved in solution using ClCOOMe or by reaction with solid-support-bound DCC-coupling 
reagent (75% isolated yield for both). In the latter case, the formation of 2 % of 16-membered ring 
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next to 8-membered ring was obseved in addition to the occurrence of an O→N acyl migration of 
the DCC resin-activated carboxylic acid. However, the easier work up of the DCC resin 
(filteration) convinced us to apply these conditions in the next libraries 
OH
N
H
N
O
O Bn
a
b
c, d, e
f
g
XI.11
a) 1) 2 eq XI.13, 2 eq DIC, CH2Cl2, 0.2 eq DMAP, 24h. 2) Ac2O/ DIPEA/DCM 1/1/3, 2 x 2 h. b) 20% 4-
methylpiperidine in DMF 2 x 20 min. c) 5 eq o-NsCl, 10 eq collidine, CH2Cl2, 2 x 1 h. d) 10 BnOH, 5 eq PPh3, 5 eq 
DIAD, DCE, 3 x 2 h. e) 2.5 eq DBU, 5 eq 2-mercaptoethanol, DMF, 2 x 30 min. f) 10 eq Fmoc-anthranilic acid, 5
eq DIC, DCM/DMF 9/1, 24 h. g) TFA/H2O 95/5, 2 x 1 h. h) polystyrene-bound-DCC, DCM, 1h.
O
O
NHR O
O
NH
Bn
O
O
N
Bn
O NHR
HO
O
N
Bn
O NH2
R= Fmoc XI.14
R= H        XI.15
b
R= Fmoc XI.17
R= H        XI.18
h
HOOC
NHFmoc+
XI.13XI.12
XI.16
XI.19
75%
88% from XI.14
Scheme XI.2 Synthesis of 5-benzyl-3,4-dihydro-1,5-benzodiazocine-2(1H),6(5H)-dione XI.11. 
XI.3.3 Synthesis of 3-substituted-1,5-benzodiazocine-2,6-diones 
XI.3.3.1 Synthesis of N-Fmoc-anthranilic acid building blocks  
Fmoc protection of commercially available 2-aminobenzoic acids with Fmoc-OSu delivered six 
N-Fmoc-2-aminobenzoic acid derivatives XI.21-XI.25 (scheme XI.3). Attempts to the synthesis 
of 5-phenyl anthranilic acid turned out to be less straightforward. Neither Suzuki cross-coupling 
reaction of 5-iodoisatine with phenylboronic acid and subsequent Baeyer-Villiger oxidation, nor 
ortho-lithiation of N-Boc-4-phenylaniline acid provided the desired product in appropriate yield.  
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R= H                       XI.21
R=5-bromo             XI.22
R=5-methoxy          XI.23
R=5-methyl             XI.24
R=6-fluoro               XI.25
R=4-trifluoromethyl XI.26  
Scheme XI.3 Synthesis of N-Fmoc-2-aminobenzoic acid derivatives. 
 
XI.3.3.2 Synthesis of N-Fmoc-3-amino-2-alkylpropionic acid building blocks 
Although in this PhD project we used racemic β2-amino acids, optically pure derivatives could 
also be applied. However, general methods for their preparation are limited, but are reported from 
linear or cyclic β-alanine derivatives4,5 or by homochiral aminomethylation of 2-alkylacetic acid 
enolates6.  
N-Fmoc-2-alkyl-3-aminopropionic acid building blocks were successfully prepared (as depicted 
in scheme XI.4) starting from the appropriate aldehydes and methyl cyanoacetate which were 
reacted via a Knoevenagel condensation followed by reduction using Pd/C-catalyzed 
hydrogenation (R=isopropyl) or NaCNBH3/AcOH to give compounds XI.29. Chemoselective 
reduction of the cyano group using NiCl2.6H2O/NaBH4 and in situ Boc-protection gave protected 
β2-amino acid intermediates XI.30. Hydrolysis of the ester moiety in those compounds was 
accomplished using NaOH, while the N-terminus was reprotected as fluorenylmethyl carbamate 
to the Fmoc-protected amino acids using Fmoc-OSu/Na2CO3. The building blocks were obtained 
in good overall yields. 
Intended compounds XI.36 and XI.37 (figure XI.3) could not be obtained successfully as 
bromobenzyl derivative XI.37 was contaminated with a considerable amount (11%) of the de-
halogenated analogue, while for XI.36, the final N-protection sequence could not be achieved 
because of total decomposition in the acidic medium used for Boc-removal.   
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XI.33: R = isopropyl            55%.
XI.34: R = 2-naphthyl          34%.
XI.35: R = 4-chlorophenyl    50%.
COOH
HCl.H2N
R
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XI.27
(R=2-naphthyl or 
4-chlorophenyl
XI.28
(R= isopropyl)
XI.29 XI.30
XI.31 XI.32
overall yield
a) 1 eq methyl cyanoacetate, 0.1 eq AcOH, 0.04 eq piperidine, dioxane, r.t., o.n. b) 1.1 eq NaCNBH3, 0.4 M AcOH,
MeOH, r.t, 1h to o.n. c) 0.1 eq NiCl2.6H2O, 7 eq NaBH4, 2 eq Boc2O, MeOH, 0C to r.t., o.n. d) 4 eq NaOH
(H2O/MeOH 2/1), r.t to 50° C, 20 min to o.n. e) Dioxane / concentrated HCl 9/1, r.t, 7h to o.n. f ) 3 eq Na2CO3,1 eq
Fmoc-OSu, THF/H2O (2/1), r.t., o.n. g) 1 eq methyl cyanoacetate, 0.1 eq AcOH, 0.04 eq piperidine, dioxane, Pd/C 5% 
wt, H2 (2 bar), r.t, 2 h.
R
Scheme XI.4 Synthesis of N-Fmoc-2-alkyl-3-aminopropionic acid. 
 
                             
FmocHN
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COOH
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XI.36 XI.37  
Figure XI.3 Intended compounds which could not be obtained.  
XI.3.3.3 Alcohols  
A series of primary alcohols were tested during the optimization of model compound, and a set of 
successful alcohols was chosen to decorate the N-5 position in the target 3-substituted-1,5-
benzodiazocine-2,6-diones.  
XI.3.3.4 Library Synthesis 
The synthetic route towards 3-substituted-1,5-benzodiazocine-2,6-diones could be performed 
using the procedure developed for the model 1,5-benzodiazocine-2,6-dione.  
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a) 1) 2 eq XI.33-XI.35, 2 eq DIC, CH2Cl2, 0.2 eq DMAP, 24h. 2) Ac2O/ DIPEA/DCM 1/1/3, 2 x 2 h. b) 20% 4-
methylpiperidine in DMF 2 x 20 min. c) 5 eq o-NsCl, 10 eq collidine, CH2Cl2, 2 x 1 h .d) 10 eq alcohol, 5 eq PPh3, 5 
eq DIAD, DCE, 3 x 2 h. e) 2.5 eq DBU, 5 eq 2-mercaptoethanol, DMF, 2 x 30 min. f) 10 eq Fmoc-anthranilic acid
XI.21-XI.26, 5 eq DIC, DCM/DMF 9/1, 24 h. g) TFA/H2O 95/5, 2x1h. h) polystyrene-bound-DCC, DCM, 1h.
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Scheme XI.5 Synthetic route towards 3-substituted-1,5-benzodiazocine-2,6-diones XI.44. 
The overall yields of solid-phase synthesis of ring-closing precursors are moderate to good (figure 
XI.4). Cyclization yields using polystyrene-bound DCC were low to moderate, in agreement with 
expected O→N acyl migration side reactions.  
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Figure XI.4 Synthesized library of 3-substituted-1,5-benzodiazocine-2,6-diones. 
 
XI.3.4 SYNTHESIS OF 4-SUBSTITUTED-1,5-BENZODIAZOCINE-2,6-DIONES  
Based on the proposed solid-phase synthesis strategy, essential building blocks consist of N-Fmoc-
anthranilic acids and N-Fmoc-3-amino-3-alkylpropionic acids.  
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XI.3.4.1 N-Fmoc-anthranilic acid building blocks  
The different N-Fmoc-anthranilic acids were prepared (scheme XI.3). 
XI.3.4.2 Synthesis of N-Fmoc-3-amino-3-alkylpropionic acid building blocks 
In this study, only racemic β-amino acid building blocks were used. However, enantiopure β3-
amino acids are available by preparation from α-amino acids using Arndt-Eistert homologation7, 
but because of security risks associated with diazomethane needed in the reaction; an alternative 
method via nucleophilic substitution with CN- 8 may be preferred to use it in a large scale 
production.    
N-Fmoc-3-amino-3-alkylpropionic acid building blocks were successfully prepared by treating the 
commercially available β3-amino acids XI.58 with equivalent amounts of Fmoc-OSu in the 
presence of Na2CO3. 
               
2 eq Na2CO3, 1 eq Fmoc-OSu,
XI.58
NH2
R
HO
O
NHFmoc
R
HO
O
XI.59       R= Me, yield=90%     
XI.60       R=i-Bu, yield=87%   
XI.61       R=Bn, yield=84%
THF/H2O 2/1, r.t, o.n
 
Scheme XI.6: Synthesis of N-Fmoc-3-alkyl-3-aminopropionic acid derivatives. 
XI.3.4.3 Library Synthesis 
The synthetic route towards 4-substituted-1,5-benzodiazocine-2,6-dione ran parallel to 3-
substituted-1,5-benzodiazocine-2,6-dione derivatives, applying the N-Fmoc-β3-amino acids in the 
proposed synthetic route. Due to steric reasons, a double coupling procedure of N-Fmoc anthranilic 
acids was found to be necessary. The overall moderate to good yields (depicted in figure XI.5) for 
the solid-phase synthesis of ring-closing precursors were comparable to the ones obtained for the 
3-substituted-1,5-benzodiazocine-2,6-diones. Cyclization yields using polystyrene-bound DCC 
were low to moderate, which are attributed to O→N acyl migration side reactions.  
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Figure X.5 Synthesized library of 4-substituted-1,5-benzodiazocine-2,6-diones. 
XI.3.5 Synthesis of 3,3-disubstituted-1,5-benzodiazocine-2,6-diones  
Based on the proposed solid phase synthesis strategy, essential building blocks consist of N-Fmoc-
anthranilic acids and N-Fmoc-3,3-dialkyl-3-aminopropionic acids. The synthesis of 3,3-dimethyl-
1,5-benzodiazocine-2,6-diones was previously demonstrated at our laboratory; using simple N-
Fmoc-3,3-dimethyl-3-aminopropionic acid building block. To further validate this synthetic 
strategy a more complex model building block XI.73 was successfully prepared in moderate 
overall yield (synthetic route is depicted in scheme XI.7). 
Using this model β2,2-amino acid building block XI.73, the solid-phase synthesis of model 
benzodiazocinedione XI.87 was investigated (detailed reaction conditions is depicted in scheme 
XI.8). 
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a) 1 eq methyl cyanoacetate, 0.1 eq AcOH, 0.04 eq piperidine, dioxane, r.t., o.n. b) 1.1 eq NaCNBH3, 0.4 M AcOH,
MeOH/CH2Cl2 5/1, r.t, 1h. c) 5 eq MeI, 2 eq NaOMe, THF, 1M, 1h. d) 0.1 eq NiCl2.6H2O, 7 eq NaBH4, 2 eq Boc2O,
MeOH, 0C to r.t., o.n. e) 4 eq NaOH, (H2O/MeOH 2/1), r.t to 50° C, 2h. f) Dioxane / concentrated HCl 9/1, r.t, 7h. g)i) 
 2 eq TMSiCl, 1 eq DIPEA, CH2Cl2, reflux 6 h. ii) 2 eq DIPEA, 1 eq FmocCl,  0 C-r.t, o.n.
g
78%
60% 96% 99% 44%
Me Me Me
Me
XI.74 XI.75 XI.76 XI.77
88% 92%
XI.78 XI.79 XI.80
XI.73
16% overall yield, 7 steps
O
H
Scheme XI.7 Synthetic route to β2,2-amino acid building block XI.73. 
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a) 1) 2 eq XI.73, 2 eq DIC, CH2Cl2, 0.2 eq DMAP, 24h. 2) Ac2O/ DIPEA/CH2Cl2 1/1/3 , 2x2 h. b) 20% 4-
methylpiperidine in DMF, 2 x 20 min. c) 5 eq o-NsCl, 10 eq collidine, CH2Cl2, 2 x 1 h. d) 10 eq MeOH, 5 eq Ph3P, 5
eq DIAD, DCE, 3 x 2 h. e) 2.5 eq DBU, 5 eq 2-mercaptoethanol, DMF, 2 x 30 min. f)  10 eq Fmoc-anthranilic acid, 5 
eq DIC, CH2Cl2/DMF 9/1, 24 h. g) TFA/H2O 95/5, 2 x 1 h. h) polystyrene-bound-DCC, CH2Cl2, 1h.
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Scheme XI.8 Solid-phase synthetic route towards XI.87. 
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Unfortunately, the anticipated direct cyclization/release approach from precursor XI.85 using 
KOtBu did not yield the expected benzodiazocinedione. Alternatively, the solution-phase 
cyclization using resin-bound DCC delivered the target bislactam. In conclusion, it seems the 
increased steric congestion in the cyclization precursor hampers the general application of the 
KOtBu-mediated cyclization methodology as used before for 3,3-dimethylated-1,5-
benzodiazocine-2,6-diones.  
XI.3.5 Conformational and Modeling study 
A modeling experiment clearly show a ground state twist-boat conformation for both of the 
synthesized two libraries (3-substituted and 4-substituted-1,5-benzodiazocine-2,6-diones). The 
presence of two conformational states in the synthesized 1,5-benzodiazocine-2,6-diones was clear 
from the corresponding complex 1H NMR and 13C NMR spectra. Higher temperature 1H NMR 
experiment was performed for selected members of the two libraries revealed that for presence of 
an N-5 substituent increases the energy barriers for conformational processes; at room temperature, 
compound XI.74 is conformationally locked and exists as a mixture of uninterchangeable chiral 
conformers (as the only compound clearly seen in LCMS as two separable peaks) indicating a very 
high energy barrier for ring-interconversion. Unlike compound XI.75 high temperature 1H NMR 
experiment shows coalescence in peaks that leads to calculation of energy barrier at coalescence. 
Thermodynamic equilibrium present between two conformers can be concluded 
                                        
N
H
N
O
OF
O
O
XI.74
N
H
N
O
O
XI.75  
XI.4 CONCLUSION AND FUTURE PERESPECTIVE 
The initial objectives of this project have been reached: the initially chosen model compound could 
be synthesized after optimization of the proposed solid-phase synthetic route and small libraries 
of 3-and 4-substituted-1,5-benzodiazocine-2,6-diones were synthesized in good to moderate 
yields. The more challenging quaternary carbon on the position 3 of the ring system could be 
introduced, albeit not via the proposed cyclization/release strategy.  
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The established solid-phase buildup and solution-phase cyclization methodologies can be applied 
in the future for the construction of further libraries of pharmaceutically relevant analogues. In this 
regard, further investigation on the possibilities of C3,C4-disubstitution could be useful. 
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XII NEDERLANDSE SAMENVATTING 
 
In dit doctoraatswerk werd de vastefasesynthese van structureel diverse 1,5-benzodiazocine-2,6-
dionen beoogd. Dit relatief onverkende skelet is potentieel interessant vanuit farmaceutisch 
perspectief, aangezien het een duidelijke verwantschap vertoont met de populaire benzodiazepine 
bevoorrechte structuren, en daardoor een bruikbare scaffold kan betekenen voor de ontwikkeling 
van nieuwe geneesmiddelen inwerkend op een brede waaier aan diverse biochemische 
doelwitstructuren. 
Om een zo algemeen mogelijke vlotte toegangsweg te ontwikkelen tot een breed gamma aan 
gesubstitueerde analogen, werd een vastefasesynthesemethodologie vooropgesteld, aangezien dit 
door het gebruik van modulaire bouwstenen en de eenvoudige intermediaire opzuiveringsstappen 
de mogelijkheid biedt tot automatisering. 
 
Schema XII.1 Algemene syntheseroute tot de beoogde 1,5-benzodiazocine-2,6-dionen. 
 
De syntheseroute (schema XII.1) houdt in het algemeen de opeenvolgende koppeling van een beta-
aminozuurbouwsteen op Wanghars in, waarna de ontschermde primaire aminegroep wordt mono-
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gealkyleerd in een zogenaamde Mitsunobu-Fukuyama sequentie met behulp van commercieel 
verkrijgbare alcoholen. Koppeling van Fmoc-anthranilzuurbouwstenen met daaropvolgende N-
ontscherming levert de ringsluitingsprecursoren die na harsafsplitsing gecycliseerd worden met 
behulp van een harsgebonden carbodiimidereagens. 
 
In een eerste deel werd deze reeds vroeger aan ons laboratorium verkende vastesyntheseroute 
toegepast en geoptimaliseerd voor een modelverbinding (XII.8, R1=R2=R4=H, R3=Bn), leidend 
tot de bepaling van algemeen bruikbare reactiecondities om toe te passen voor verdere 
bibliotheeksynthesen. 
In een tweede deel werden deze reactie-omstandigheden gebruikt voor de synthese van 3-
gesubstitueerde benzodiazocines, door gebruik te maken van een set geschikte β2-
aminozuurbouwstenen. Deze bouwstenen werden gesynthetiseerd uitgaande van 
methylcyanoacetaat en verschillende aldehyden, via initiële Knoevenaegel condensatie. 
Toepassing van de achtstapsvastefasesynthese leverde een bibliotheek van 13 
cyclisatieprecursoren XII.7 in matig tot goede rendementen (30-87%) die werden gecycliseerd tot 
de overeenkomstige 1,5-benzodiazocine-2,6-dionen XII.8 (21-80%). 
Vervolgens werd de methodologie eveneens toegepast op de synthese van een serie 4-
gesubstitueerde benzodiazocines. Hierbij werd gebruik gemaakt van commercieel verkrijgbare β3-
aminozuurbouwstenen, die beschermd werden als fluorenylmethylcarbamaat. De 
hogerontwikkelde omstandigheden leidden op deze manier tot een bibliotheek van 11 
cyclisatieprecursoren XII.7 (41-98% rendement) die succesvol konden worden gecycliseerd tot de 
bedoelde 1,5-benzodiazocine-2,6-dionen XII.18 (18-65% rendement). 
In een laatste doelstelling werden eveneens verbindingen met een 3,3-disubstitutiepatroon beoogd. 
Vroeger onderzoek aan ons laboratorium had aangetoond dat de synthese van 3,3-
dimethylanalogen moglijk is via directe cyclisatie van de harsgebonden precursoren na 
behandeling met KOtBu. Hiertoe werd een model β2,2-aminozuurbouwsteen gesynthetiseerd, die 
werd omgezet via de vastefasesynthesestrategie tot het cruciale harsgebonden intermediair XII.9 
(schema XII.2). Pogingen om de directe cyclisatie met gelijktijdige  afsplitsing van het gewenste 
achtringskelet XII.11 te bewerkstelligen, leverden echter geen product op, zodat de cyclisatie 
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diende te worden uitgevoerd met harsgebonden carbodiimidereagens na afsplitsing van de 
precursor XII.10 in oplossing. 
 
Schema XII.2 Synthese van 3,3-digesubstitueerde modelverbinding XII.11. 
 
De complexe NMR spectra van de gesynthetiseerde 1,5-benzodiazocine-2,6-dionen tonen de 
aanwezigheid aan van atropoisomerie, een potentieel belangrijk fenomeen in farmaceutische 
toepassingen. Ondersteunende modelling experimenten en vergelijking met literatuurvoorbeelden 
leert dat de verbindingen twee geïnverteerde boot-type conformaties aannemen, die kunnen 
interconverteren via een relatief hoge energiebarrière. Voor 4,5-dimethyl-1,5-benzodiazocine-2,6-
dion XII.12 (figuur XII.1) kon uit een serie 1H NMR-experimenten bij verschillende temperaturen 
op basis van waargenomen coalescentieverschijnselen (Tcoal~100°C) een barrière ΔG≠ van 77.6 
kJ/mol geschat worden, wat wijst op een vlotte boot/boot-interconversie bij kamertemperatuur. Bij 
analogen met complexere substituenten kan in de NMR spectra geen piekverbreding meer worden 
waargenomen (T=130°C), wat wijst op hogere interconversiebarrières. Voor verbinding XII.13 
konden bovendien (als enige in de aangemaakte bibliotheken) in LCMS-analysen beide 
conformeren als gescheiden pieken worden waargenomen, wat er op wijst dat deze molecule als 
twee stabiele atropoïsomeren voorkomt. 
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Figuur XII.1 Structuur van verbindingen XII.12 en XII.13, gebruikt voor een conformationele 
studie. 
 
In elk geval is verder onderzoek wenselijk om een meer gedetailleerd inzicht te verkrijgen in het 
conformationeel gedrag van deze potentieel farmaceutisch interessante structuren. 
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XIII.1 INSTRUMENTATION AND METHODS  
XIII.1.1 Solvents and reagents  
All commercial solvents and reagents were used as received, unless otherwise noted. Reactions in 
solution were performed with freshly distilled solvents, reactions on solid phase were performed 
with freshly distilled solvents or HPLC quality. Washing of resins was performed with solvents of 
HPLC grade. Dichloromethane, 1,2-dichloroethane, triethylamine and diisopropylethylamine 
were dried on calcium chloride. THF was dried on sodium and benzophenone.  
XIII.1.2 Purification  
Column chromatography was performed standard with Grace Division LC 60Å silica (60-200 μm) 
or (in case of difficult separation) with Rocc silica 60Å (40-60 μm). The eluent consisted of 
technical solvents for large scale purification and of HPLC solvents for small scale purifications.  
Preparative HPLC-purifications of more than 10 mg crude product were performed on a 
Phenomenex Luna C18 column (5μm, 250 x 21,20 mm), making use of a Kontron 422 type HPLC-
pump and a MELZ lcd 312 RI-detector. For purifications of less than 10 mg product, an adjusted 
Phenomenex Luna C18 column (5μm, 250 x 10,00 mm) was applied on the same system.  
XIII.1.3 Characterization  
Reactions in solution were monitored using Thin Layer Chromatography (TLC). The Rf values 
were determined on Machery-Nagel SIL-G25 U254 TLC-plates, by using UV-light (254 nm) or 
by developing them with a suitable staining reagent (a KMnO4 solution in water, cerium 
molybdate/Hanessian's staining or ninhydrine solution).  
Reactions on solid phase were monitored by LC-MS after cleaving off a small amount of product 
from the solid support by treatment with an appropriate cleavage reagent (TFA/H2O 9/1). The 
analyses were performed on a VL type Agilent 1100 LC/MS system, charged with a Phenomenex 
Luna C18 column (methods A and B) or with a Kinetex C18 column (methods C and D). Reported 
retention times are obtained by method A, unless specified otherwise. A 5mM solution of NH4OAc 
in water (solvent A) and acetonitrile (solvent B) were used as eluents on this system. The gradients 
are mentioned below. 
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Method A 
Time Solvent A Solvent B 
0 min 100 0 
2 min 100 0 
17 min 0 100 
22 min 0 100 
22.5 min 100 0 
30 100 0 
 
Method B 
Time Solvent A Solvent B 
0 min 80 0 
2 min 80 0 
32 min 0 80 
37 min 0 80 
37.5 min 80 0 
40 80 0 
 
Method C 
Time Solvent A Solvent B 
0 min 80 20 
2 min 80 20 
32 min 20 80 
37 min 20 80 
37.5 min 80 20 
40 80 20 
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Method D 
Time Solvent A Solvent B 
0 min 100 50 
2 min 100 50 
32 min 50 100 
37 min 50 100 
37.5 min 100 50 
40 100 50 
 
Method E 
Time Solvent A Solvent B 
0 min 80 50 
2 min 80 50 
32 min 50 80 
37 min 50 80 
37.5 min 80 50 
40 80 50 
 
UV spectra were recorded using a Hitachi U-2010 UV-VIS Spectrophotometer or Varian Cary 3E 
UV-VIS Spectrophotometer. NMR analyses were performed on a Bruker Avance 300, 400 or a 
Bruker DRX500. 1H NMR measurements were performed at 300, 400 or 500 MHz; 13C NMR 
measurements at 75, 100 or 125 MHz on the above-mentioned spectrometers. Chemical shifts are 
reported in ppm, using the residual solvent signal as reference value (CDCl3: 7.26 ppm/77.00 ppm, 
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DMSO-d6: 2.50 ppm/39.51 ppm), acetone-d6: 2.05/29.84 ppm and D2O: 4.79 ppm). Melting points 
were recorded on a Kofler melting apparatus.  
XIII.1.4 Equipment  
Small scale solid phase reactions (< 50 mg resin) were performed in small glass vials using a 
Selecta Vibromatic whristshaker. Larger scale reactions were performed in homemade screw-
capped glass tubes equipped with a glass fritted filter and filtration system for the vacuum pump. 
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XIII.2 SYNTHESIS OF FMOC-PROTECTED ANTHRANILIC ACID DERIVATIVES 
XIII.2.1 General procedure    
          
NH2
COOH
NHFmoc
COOH
i) 1eq NaOH, H2O, r.t, 5 min
ii) 1eq NaHCO3, 1eq Fmoc-OSu
    THF/H2O 2/1, r.t, o.nx x
 
To a solution of anthranilic acid (72.9 mmol, 1 eq) in 1M NaOH (72.9 mmol, 1 eq) is added THF 
(73 ml) and Fmoc-OSu (72.9 mmol, 1 eq). After 5 min, THF (72 ml) and NaHCO3 (72.9 mmol, 1 
eq) is added and the resulting mixture is stirred overnight at room temperature. The reaction 
mixture is acidified using 12 M HCl until pH=1-2 and after adding (100 ml) H2O, the aqueous 
phase is extracted three times with ethyl acetate. The combined organic layers are dried with 
anhydrous magnesium sulfate, the drying agent filtered and the volatiles removed under reduced 
pressure. The crude solid is purified by recrystallization. 
XIII.2.2   N-(9-FLUORENYLMETHOXYCARBONYL)-2-AMINOBENZOIC ACID VI.7 
Recrystallization solvent: EtOAc  
Yield: 87%; white fluffy powder, 22.8 g from 10 g anthranilic acid 
M.P.: 226 °C 
Molecular Formula: C22H17NO4 
Molecular weight: 359.37 g mol-1 
LC-MS: Peak at 4.9 min; ES-MS negative mode [m/z (fragment, intensity)]: 358.1 (M-H+, 61), 
162.0 (O=C=N-Ph-COO-, 100), 136.0 (H2N-Ph-COO
-, 47). 
1H NMR: (500 MHz, DMSO-d6): δ 10.83 (s, 1H), 8.16 (br. d, J = 7.9 Hz, 1H), 7.98 (d, J = 7.9 Hz, 
1H), 7.93 (d, J = 7.5 Hz, 2H), 7.70 (d, J = 7.5 Hz, 2H), 7.58 (t, J = 7.9 Hz, 1H), 7.44 (t, J = 7.4 Hz, 
2H), 7.35 (J = 7.4 Hz, 2H), 7.12 (t, J = 7.6 Hz, 1H), 4.50 (d, J = 6.7 Hz, 2H), 4.37 (t, J = 6.0 Hz, 
1H) ppm. 
H
N
O
O
COOH
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13C NMR: (125 MHz, DMSO-d6): δ 170.3 (C), 153.2 (C), 144.2 (C), 141.4 (C), 141.3 (C), 134.8 
(CH), 131.8 (CH), 128.3 (CH), 127.7 (CH), 125.5 (CH), 122.6 (CH), 120.8 (CH), 118.9 (CH), 
116.3 (C), 66.8 (CH2), 47.0 (CH) ppm. 
IR (HATR): 3320 (m, sharp), 2500-3300 (m, broad), 3066 (w), 2988 (w), 2948 (w), 1740 (s), 1665 
(s), 1602 (m), 1586 (s), 1535 (m), 1523 (s), 1468 (m), 1452 (m), 1399 (m), 1327 (w), 1300 (m), 
1258 (s), 1212 (s), 1166 (m), 1152 (w), 1096 (m), 1068 (w), 1052 (s), 1043 (w), 1002 (w), 953 
(w), 935 (w), 897 (m), 862 (w), 794 (w), 766 (s), 744 (m), 726 (w), 683 (m), 668 (w), 650 (w), 
622 (w), 588 (w), 553 (w), 538 (m) cm-1. 
TLC: Rf = 0.38 (Dichloromethane/MeOH 70/30).  
 
XIII.2.3   N-(9-FLUORENYLMETHOXYCARBONYL)-2-AMINO-5-BROMOBENZOIC ACID 
VI.8 
 Recrystallization solvent: EtOAc 
Yield: 85 % (white powder), 5.1 g from 3 g 2-amino-5-
bromobenzoic acid 
M.P.: 256 °C 
Molecular Formula: C22H16BrNO4 
Molecular weight: 438.27 g mol-1 
LC-MS: Peak at 5.3 min; ES-MS negative mode [m/z (fragment, intensity)]: 438.0 (M(81Br)-H+, 
100), 436.0 (M(79Br)-H+, 100).  
HR-MS (ESI): C22H17
81BrNO4
+ [M+H+]: Calculated 438.0341 Found 438.0352. 
1H NMR: (300 MHz, DMSO-d6): δ 10.69 (s, 1H), 8.09 (d, J = 9.0 Hz, 1H), 8.02 (d, J = 2.0 Hz, 
1H), 7.90 (d, J = 7.5 Hz, 2H), 7.73 (br d, J = 8.8 Hz, 1H), 7.67 (d, J = 7.3 Hz, 2H), 7.42 (t, J = 7.5 
Hz, 2H), 7.33 (t, J = 7.4 Hz, 2H), 4.49 (d, J = 6.6 Hz, 2H), 4.34 (t, J = 6.4 Hz, 1H) ppm. 
13C NMR: (75 MHz, DMSO-d6): δ 168.3 (C), 152.5 (C), 143.5 (C), 140.8 (C), 140.0 (C), 136.6 
(CH), 133.2 (CH), 127.7 (CH), 127.1 (CH), 125.0 (CH), 120.7 (CH), 120.2 (CH), 118.0 (C), 113.4 
(C), 66.4 (CH2), 46.4 (CH) ppm.  
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IR (HATR): 3429 (w), 3333 (vw), 3042 (vw), 1733 (m), 1672 (m), 1595 (w), 1578 (m), 1517 (m), 
1461 (w), 1447 (w), 1409 (w), 1387 (m), 1310 (w), 1287 (vw), 1242 (s), 1215 (s), 1189 (m), 1158 
(w), 1100 (w), 1092 (w) , 1076 (w), 1040 (m), 1009 (vw), 975 (vw), 939 (vw), 893 (vw), 866 (vw), 
837 (w), 814 (vw), 790 (w), 767 (vw) 756 (w), 733 (m), 722 (w), 699 (m), 675 (w), 645 (w) cm-1. 
TLC: Rf = 0.32 (Dichloromethane/MeOH 70/30).  
 
XIII.2.4  N-(9-FLUORENYLMETHOXYCARBONYL)-2-AMINO-5-METHOXYBENZOIC ACID 
VI.9 
 Recrystallization solvent: aqueous MeOH. 
Yield: 63 %; (off-white cotton powder), 4.0 g from 2.5 g 2-
amino-5-methoxybenzoic acid. 
M.P.: 240 °C 
Molecular Formula: C23H19NO5 
Molecular weight: 389.41 g mol-1. 
LC-MS: Peak at 4.8 min; ES-MS negative mode [m/z (fragment, intensity)]: 388.0 (M-H+, 60), 
192.0 (M-fluorenylmethanol-H+, 100), 166.1(M-dibenzofulvene-CO2, 58).  
HR-MS (ESI): C23H20NO5
+ [M+H+]: calculated 390.1341, found 390.1330. 
1H NMR: (300 MHz, DMSO-d6): δ 13.69 (br s, 1H), 10.40 (s, 1H), 8.16 (d, J = 8.0 Hz, 1H), 7.90 
(d, J = 7.4 Hz, 2H), 7.67 (d, J = 7.2 Hz, 2H), 7.43 (d, J = 3.2 Hz, 1H), 7.41 (d, J = 7.4 Hz, 2H), 
7.33 (dt, J = 7.4 Hz/1.0 Hz, 2H), 7.18 (dd, J = 9.1 Hz/3.0 Hz, 1H), 4.45 (d, J = 6.8 Hz, 2H), 4.33 
(t, J = 6.8 Hz, 1H), 3.75 (s, 3H) ppm. 
13C NMR: (125 MHz, DMSO-d6): δ 169.2 (C), 153.8 (C), 152.9 (C), 143.7 (C), 140.8 (C), 134.0 
(C), 127.7 (CH), 127.1 (CH), 125.0 (CH), 120.4 (CH), 120.2 (CH), 117.6 (C), 114.7 (CH), 66.1 
(CH2), 55.4 (CH3), 46.5 (CH) ppm. 
IR (HATR):  3332 (vw), 2933 (vw), 1725 (s), 1673 (m), 1611 (w), 1591 (w), 1531 (m), 1476 (w), 
1441 (w), 1424 (w), 1402 (w), 1315 (vw), 1279 (m), 1246 (s), 1208 (s), 1183 (s), 1154 (w), 1104 
H
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(w), 1090 (m), 1050 (m), 1032 (m) , 981 (w), 907 (w), 890 (w), 827 (w), 790 (w), 753 (m), 737 
(s), 673 (m), 654 (w) cm-1. 
TLC: Rf = 0.27 (Dichloromethane/MeOH 70/30). 
 
XIII.2.5   N-(9-FLUORENYLMETHOXYCARBONYL)-2-AMINO-5-METHYLBENZOIC ACID 
VI.10 
Recrystallization solvent: aqueous MeOH 
Yield: 60 % (white powder), 4.5 g from 3 g 2-amino-5-
methylbenzoic acid 
M.p.: 228 °C 
Molecular Formula: C23H19NO4 
Molecular weight: 373.41 g mol. -1 
LC-MS: Peak at 5.1 min; ES-MS negative mode [m/z (fragment, intensity)]: 372.1 (M-H+, 100). 
1H NMR: (500 MHz, DMSO-d6): δ 10.64 (s, 1H), 8.03 (br. d, J = 8.1 Hz, 1H), 7.92 (d, J = 7.5 Hz, 
2H), 7.78 (d, J = 2.0 Hz, 1H), 7.69 (d, J = 7.5 Hz, 2H), 7.43 (t, J = 7.4 Hz, 2H), 7.39 (dd, J = 8.1 
Hz/2.0 Hz, 1H), 7.35 (t, J = 7.4 Hz, 2H), 4.48 (d, J = 6.8 Hz, 2H), 4.35 (t, J = 6.8 Hz, 1H), 2.29 (s, 
3H) ppm. 
13C NMR: (125 MHz, DMSO-d6): δ 169.6 (C), 152.6 (C), 143.6 (C), 140.7 (C), 138.4 (C), 134.7 
(CH), 131.1 (CH), 131.0 (C), 127.6 (CH), 127.0 (CH), 124.9 (CH), 120.1 (CH), 118.4 (CH), 115.7 
(C), 66.1 (CH2), 46.4 (CH), 20.0 (CH3) ppm.  
IR(HATR): 3318 (w), 2946 (w), 1729 (m), 1668 (s), 1590 (m), 1580 (m), 1524 (s), 1475 (m), 1448 
(m),1415 (m), 1401 (m), 1316 (w), 1295 (w), 1252 (s), 1224 (s), 1207 (s), 1154 (m), 1100 (m), 
1085 (vw), 1067 (m), 1036 (m), 962 (vw), 939 (vw), 899 (w), 932 (w), 791 (w), 757 (m), 738 (s), 
697 (w), 670 w), 649 (w) cm-1. 
TLC: Rf = 0.54 (Dichloromethane/MeOH 70/30). 
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XIII.2.6   N-(9-FLUORENYLMETHOXYCARBONYL)-2-AMINO-6-FLUOROBENZOIC ACID 
VI.11 
 Recrystallization solvent: EtOAc. 
Yield: 55 % (beige powder), 4.0 g from 3 g 2-amino-6-fluorobenzoic 
acid. 
M.P.: 181.5 °C 
Molecular Formula: C22H16FNO4 
Molecular weight: 377.36 g mol-1 
LC-MS: Peak at 4.8 min; ES-MS negative mode [m/z (fragment, intensity)]: 376.0 (M-H+, 100), 
179.9 (M-fluorenylmethanol-H+, 100).  
1H NMR: (300 MHz, DMSO-d6): δ 10.01 (s, 1H), 7.89 (d, J = 7.3 Hz, 1H), 7.89 (d, J = 7.3 Hz, 
1H), 7.69 (d, J = 7.3 Hz, 2H), 7.20-7.60 (m, 6H), 7.01 (t, J = 9.5 Hz, 1H), 4.43 (d, J = 6.8 Hz, 2H), 
4.31 (t, J = 6.6 Hz, 1H) ppm. 
13C NMR: (75 MHz, DMSO-d6): δ 166.1 (C), 160.7 (d, J = 252.5 Hz, C), 153.2 (C), 143.6 (C), 
140.8 (C), 139.4 (d, J = 4.9 Hz, C), 133.0 (d, J = 11.0 Hz, CH), 127.7 (CH), 127.1 (CH), 125.1 
(CH), 120.2 (CH), 117.2 (d, J = 2.7 Hz, CH), 111.7 (d, J = 15.4 Hz, C), 110.9 (d, J = 23.0 Hz, 
CH), 66.3 (CH2), 46.5 (CH) ppm. 
IR (HATR): 3064 (w), 1700 (s), 1683 (s), 1611 (m), 1577 (m), 1527 (s), 1473 (m), 1463 (m), 1438 
(m), 1398 (m), 1368 (m), 1326 (w), 1287 (m), 1256 (s), 1227 (s), 1211 (s), 1171 (m), 1113 (m), 
1031 (w), 983 (m), 969 (m), 941 (w), 887 (vw), 831 (w), 809 (m), 794 (m), 780 (m), 768 (m), 757 
(m), 739 (m), 731 (s), 718 (m), 689 (m), 649 (m) cm-1. 
TLC: Rf = 0.30 (Dichloromethane/MeOH 70/30). 
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XIII.2.7 N-(9-FLUORENYLMETHOXYCARBONYL)-2-AMINO-4-
TRIFLUOROMETHYLBENZOIC ACID VII.7 
Recrystallization solvent: aqueous MeOH. 
Yield: 62 % (white needles), 3.7 g from 3 g 2-amino-4-
trifluoromethylbenzoic acid. 
M.P.: 218 °C 
Molecular Formula: C23H16F3NO4 
Molecular weight: 427.37 g mol-1. 
LC-MS: Peak at 5.5 min; ES-MS negative mode [m/z (fragment, intensity)]: 426.1 (M-H+, 100).  
HR-MS (ESI): Not detectable by mass spectrometer (positive and negative mode). 
1H NMR: (400 MHz, Acetone-d6): δ 8.84 (s, 1H), 8.31 (d, J=8.3 Hz, 1H), 7.89 (d, J=7.6 Hz, 2H), 
7.73 (d, J =7.5 Hz, 2H), 7.49 -7.21 (m, 5H), 4.53 (d, J=7.1 Hz, 2H), 4.37 (t, J= 8.2 Hz, 1H) ppm.  
13C NMR: (100 MHz, Acetone-d6): major conformer: δ 169.8 (C), 154.4 (C), 145.2 (C), 142.6 (C), 
136.2 (q, J= 32.6 Hz, C), 133.9 (CH), 129.1 (CH), 128.5 (CH), 128.4 (CH), 125.1 (q, J=272.3 Hz, 
C), 126.5 (CH), 121.4 (CH), 119.1 (q, J=3.3 Hz, CH), 116.3 (q, J=3.8 Hz, CH), 68.4 (CH2), 48.2 
(CH) ppm. 
IR (HATR): 3204 (w), 2949 (w), 1713 (m), 1697 (m), 1622 (w), 1588 (m), 1534 (m), 1473 (m), 
1436 (m), 1378 (m), 1329 (m), 1309 (m), 1297 (w), 1274 (m), 1251 (m), 1224 (m), 1197 (m), 1173 
(s), 1135 (s), 1126 (s), 1098 (m), 1049 (s), 1000 (m), 921 (m), 891 (w), 844 (vw), 796 (m), 784 
(m), 753 (m), 737 (s), 723 (s), 667 (m), 731 (m), 720 (vw) cm-1. 
TLC: Rf = 0.16 (Dichloromethane/MeOH 70/30). 
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XIII.3 SYNTHESIS OF N-FMOC-3-AMINO-2-ALKYLPROPIONIC ACIDS 
XIII.3.1 Synthesis of methyl 3-aryl-2-cyanoacrylates  
XIII.3.1.1 General procedure 
           
COOMeNC
1 eq aldehyde, 0.1 eq AcOH
NC COOMe
0.04 eq piperidine, dioxane, r.t, o.n
R
  
To a mixture of methyl cyanoacetate (124 mmol, 1 eq) and aldehyde (124 mmol, 1 eq) in dioxane 
(30 ml) is added acetic acid (12.4 mmol, 0.1 eq) and piperidine (5 mmol, 0.04 eq). The mixture is 
stirred overnight at room temperature. The reaction mixture was evaporated under reduced 
pressure, the residue was dissolved in 300 ml CH2Cl2 and washed with 300 ml water and 300 ml 
brine. The organic layer is concentrated under reduced pressure and the residue recrystallized from 
ethylacetate or purified by column chromatography (F.C.). 
XIII.3.1.2 METHYL 3-(4-BROMOPHENYL)-2-CYANOACRYLATE VI.30 
F.C.: Hexane/EtOAc 80/20 
Yield: 87% 
Molecular Formula: C11H8BrNO2  
Molecular weight: 266.09 g mol-1  
LC-MS: Peak at 6.4 min, not detectable by mass spectrometer (positive and negative modes) 
HRMS (ESI): not detectable by mass spectrometer (positive and negative modes). 
1H NMR: (300 MHz, CDCl3): δ 8.21 (s, 1H), 7.87 (d, J = 8.7 Hz, 2H), 7.67 (d, J = 8.7 Hz, 2H), 
3.96 (s, 3H) ppm.  
13C NMR: (75 MHz, CDCl3): δ 162.8 (C), 153.8 (CH), 132.7 (CH), 132.3 (CH), 130.2 (C), 128.4 
(C), 115.2 (C), 103.2 (C), 53.5 (CH3) ppm.  
CNMeOOC
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IR (HATR): 3099 (w), 3076 (w), 3032 (w), 2223 (m), 1720 (s), 1607 (s), 1580 (s), 1490 (m), 1427 
(m), 1409 (m), 1370 (w), 1312 (w), 1272 (s), 1202 (s), 1009 (m), 986 (w), 967 (m), 840 (m), 821 
(m), 792 (m), 762 (m), 706 (m) cm-1. 
TLC: Rf = 0.31  (hexane/EtOAc 80/20).  
XIII.3.1.3 METHYL 3-(4-CHLOROPHENYL)-2-CYANOACRYLATE VI.32 
Yield: 85 % (White powder)  
Molecular Formula: C11H8ClNO2  
Molecular Weight: 221.6 g.mol-1 
LC-MS: Peak at 6.4 min, not detectable by mass spectrometer (positive and negative modes) 
HRMS (ESI): Not detectable by mass spectrometer (positive and negative mode). 
1H NMR: (500 MHz, CDCl3): δ 8.21 (s, 1H), 7.94 (d, J=8.5, 2H) 7.49 (d, J=8.5, 2H), 3.94 (s, 3H) 
ppm. 
13C NMR: (125 MHz, CDCl3): δ 162.8 (C), 153.7 (CH), 139.7 (C), 132.2 (CH), 129.8 (C), 129.7 
(CH), 115.2 (C), 103.0 (C), 53.5 (CH3) ppm.  
IR (HATR):  3079 (w), 3030 (w), 2960 (w), 1722 (s), 1606 (s), 1585 (s), 1562 (m), 1493 (m), 1452 
(m), 1414 (m), 1370 (w), 1312 (m), 1271 (s), 1203 (s), 1112 (m), 1088 (s), 1048 (m), 1013 (m) , 
966 (m), 837 (m), 817 (m), 794 (m), 761 (m), 709 (m), 670 (w) cm-1.  
TLC: Rf = 0.33 (hexane/EtOAc 80/20).  
 
XIII.3.1.4 METHYL 2-CYANO-3-(FURAN-2-YL)ACRYLATE VI.33 
F.C.: hexane/Acetone 90/10 
Yield: 88% (orange solid) 
Molecular Formula: C9H7NO3  
Molecular weight: 177.16 g mol-1  
CNMeOOC
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LC-MS: Peak at 5.3 min; ES-MS positive mode [m/z (fragment, intensity)]: 178.0 (M+H+, 100), 
146.0 (M-MeO-, 35). 
1H NMR: (500 MHz, CDCl3): δ 8.04 (s, 1H), 7.77 (d, J =1.5 Hz, 1H), 7.41 (d, J =3.5 Hz, 1H), 6.68 
(dd, J =3.7 Hz / 1.7 Hz, 1H), 3.92 (s, 3H) ppm.  
13C NMR: (125 MHz, CDCl3): δ 163.1 (C), 148.7 (C), 148.4 (CH), 139.7 (CH), 122.0 (CH), 115.3 
(C), 114.0 (CH), 98.2 (C), 53.3 (CH3) ppm.  
IR (HATR): 3128 (w), 3044 (m), 2958 (w), 2226 (m), 1913 (vw), 1726 (s), 1690 (vw), 1613 (s), 
1540 (w), 1520 (vw), 1464 (w), 1450 (vw), 1428 (m), 1337 (vw), 1286 (w), 1250 (s), 1209 (s), 
1154 (w), 1093 (s), 1066 (w), 1015 (s), 976 (m), 960 (w), 926 (w), 882 (w), 846 (w), 818 (w), 765 
(vw), 752 (s), 705 (s), 674 (vw) cm-1.  
TLC: Rf = 0.58 (dichloromethane/acetone 97/3). 
 
XIII.3.1.5 METHYL 2-CYANO-3-(4-METHOXYPHENYL)ACRYLATE VI.34 
Yield: 64% (white powder) 
Molecular Formula: C12H11NO3  
Molecular weight: 217.22 g mol-1  
LC-MS: Peak at 6.0 min; ES-MS positive mode [m/z (fragment, intensity)]: 218.1 (M+H+, 100), 
186.1 (M+MeO-, 25).  
1H NMR: (300 MHz, CDCl3): δ 8.18 (s, 1H), 8.01 (d, J=8.8 Hz, 2H), 7.00 (d, J=8.8 Hz, 2H), 3.92 
(s, 3H), 3.90 (s, 3H) ppm.  
13C NMR: (75 MHz, CDCl3): δ 163.9 (C), 163.6 (C), 154.6 (CH), 133.7 (CH), 124.3 (C), 116.2 
(CN), 114.8 (CH), 98.8 (C), 55.6 (CH3), 53.2 (CH3) ppm.  
IR (HATR): 3011 (w), 2961 (w), 2215 (m), 1723 (s), 1610 (w), 1583 (s), 1559 (s), 1514 (s), 1428 
(m), 1263 (s), 1212 (s), 1182 (s), 1129 (m), 1089 (m), 1027 (m), 1012 (w), 970 (m), 948 (w), 833 
(s), 806 (m), 757 (m), 747 (w), 726 (w), 627 (m) cm-1.  
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XIII.3.1.6 METHYL 3-(2-NAPHTHYL)-2-CYANOACRYLATE VI.35  
Yield: 99 % (Yellow powder) 
M.p.: 156.5 °C 
Molecular Formula: C15H11NO2 
Molecular weight: 237.07 g mol-1 
LC-MS: Peak at 6.6 min; ES-MS positive mode [m/z (fragment, intensity)]: 255.1 (M+NH4, 18), 
238.0 (M+H+, 100)  
HRMS (ESI): C15H12NO2
+ [M+H+]: calculated 238.0868, found 238.0864. 
1H NMR: (300 MHz, CDCl3): δ 8.36 (d, J=7.7 Hz, 2H) 8.16 (d, J=8.7 Hz, 1H), 7.98-7.48 (m, 5H), 
3.85 (s, 3H) ppm.  
13C NMR: (75 MHz, CDCl3): δ 163.1 (C), 155.2 (CH), 135.4 (C), 134.2 (CH), 132.7 (C), 129.3 
(CH), 129.1 (CH), 128.9 (C), 127.8 (CH), 127.2 (CH), 125.2 (CH), 125.1 (CH), 115.7 (C), 102.1 
(C), 53.4 (CH3) ppm. 
IR (HATR):  3026 (w), 2948 (w), 2921 (w), 2220 (s), 1725 (s, sharp), 1598 (s, sharp), 1571 (m), 
1469 (w), 1457 (w), 1432 (m), 1378 (w), 1342 (w), 1277 (m), 1245 (s), 1220 (s), 1183 (m), 1161 
(w), 1127 (w) , 1091 (m), 1022 (w), 979 (m), 963 (w), 911 (w), 894 (w), 869 (w), 860 (w), 813 
(s), 759 (m), 748 (s), 719 (m), 643 (w)  cm-1. 
TLC: Rf = 0.20 (hexane/EtOAc 90/10). 
XIII.3.1.7 METHYL 3-PHENYL-2-CYANOACRYLATE VI.36  
F.C.: hexane/EtOAc 90/10 
Yield: 91 % (white powder) 
Molecular Formula: C11H9NO2 
Molecular weight: 187.19 g mol-1 
LC-MS: Peak at 5.9 min; ES-MS positive mode [m/z (fragment, intensity)]: 205.1 (M+NH4, 35), 
188.1 (M+H+, 100).  
CNMeOOC
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1H NMR: (300 MHz, CDCl3): δ 8.26 (s, 1H, 8.05-7.95 (m, 2H), 7.63-7.45 (m, 2H), 3.94 (s, 3H) 
ppm.  
13C NMR: (75 MHz, CDCl3): δ 162.9 (C), 155.3 (CH), 133.4 (CH), 131.3 (C), 131.1 (CH), 129.2 
(CH), 115.4 (C), 102.5 (C), 53.3 (CH3) ppm. 
TLC: Rf = 0.21 (hexane/EtOAc 90/10). 
 
XIII.3.2 Synthesis of 3-substituted methyl 2-cyanopropionates 
XIII.3.2.1 Synthesis of methyl 2-cyano-4-methylpentanoate VI.42  
            
NC COOMe COOMeNC
1 eq isobutyraldehyde, 0.1 eq AcOH
0.04 eq piperidine, dioxane, 
Pd/C 5wt%, 2h, r.tVI.46 VI.42
 
To a mixture of methyl cyanoacetate (15 g, 150.5 mmol) and isobuteraldehyde (13.6 g, 150 mmol) 
in dioxane (45 ml) is added acetic acid (870 µl, 15 mmol), piperidine (600 µl, 15 mmol) and (300 
mg, Pd/C 10 wt % (300 mg).The mixture is stirred under a hydrogen atmosphere (2 barr) at room 
temperature for 2 hours; then filtered on celite and the filterate concentrated under reduced 
pressure. The residue is dissolved in 60 ml ethyl acetate and washed with water and brine. The 
organic layer is concentrated under reduced pressure and the residue is purified by flash 
chromatography (F.C.) (Silica gel, Hexane/ EtOAc, 95/5).  
Yield: 82% (Colorless liquid)  
Molecular Formula: C8H13NO2 
Molecular weight: 155.19 g.mol-1 
LC-MS: Peak at 5.7 min; ES-MS negative mode [m/z (fragment, intensity)]: 154.2 (M-H+, 90).  
HRMS (ESI): C8H12NO2
- [M-H+]: calculated 154.0868, found 154.0880. 
1H NMR: (500 MHz, CDCl3): δ 3.80 (s, 3H), 3.53 (dd, J= 5.8/5.0Hz, 1H), 1.74-1.90 (m, 3H), 
0.97 (dd, J= 6.2/6.3 Hz, 6H) cm-1. 
COOMeNC
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13C NMR: (125 MHz, CDCl3): δ 166.9 (C), 116.5 (C), 53.4 (CH3), 38.4 (CH2), 35.7 (CH), 26.1 
(CH), 22.3 (CH3), 21.2 (CH3) ppm.   
IR (HATR): 3390 (w),  2959 (w), 2250 (vw), 1746.4 (s, sharp), 1469 (w), 1436 (m), 1389 (w), 
1371 (w), 1335 (w), 1308 (w), 1268 (m), 1248 (m), 1219 (m), 1200 (m), 1172 (m), 1135 (w), 1114 
(w), 1008 (m), 960 (vw), 935 (vw), 910 (vw), 832.7 (vw), 763 (vw), 641 (vw), 617 (vw) cm-1. 
TLC: Rf = 0.16 (Hexane/EtOAc 95/5).  
XIII.3.2.2 Synthesis of methyl 3-aryl-2-cyanopropionates 
XIII.3.2.2.1 General procedure 
             
NC COOMe
AcOH 0.4 M, 1.1 eq NaBH3CN
MeOH/CH2Cl2 (5/1), 40 min, r.t
R
NC COOMe
R
 
To a solution of the acrylate (22.3 mmol, 1 eq) in MeOH/ CH2Cl2 (5/1, 300 ml) is added NaBH3CN 
(25 mmol, 1 eq), and a small amount of p-bromocresol “green”. The mixture is acidified with 
AcOH (50 mmol, 2 eq), turning the color to yellow. The reaction is stirred overnight at room 
temperature, after which water is added and the product extracted using CH2Cl2 (3x 250 ml). The 
combined organic layers are concentrated under reduced pressure, the residue is purified by flash 
chromatography (F.C.) 
 
XIII.3.2.2.2 METHYL 3-(4-CHLOROPHENYL)-2-CYANOPROPIONATE VI.37 
F.C.: hexane/EtOAc 90/10 
Yield: 89% (yellow oil)  
Molecular Formula: C11H10ClNO2 
Molecular Weight: 223.6 g mol-1 
LC-MS: Peak at 6.0 min; ES-MS negative mode [m/z (fragment, intensity)]: 224.0 (M(37Cl)-H+, 
33), 222.0 (M(35Cl)-H+, 100).  
COOMeNC
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HRMS (ESI): C11H9
35ClO2
-
 [M-H
+]: calculated 222.0322, found: 222.0332. 
1H NMR: (300 MHz, CDCl3): δ 7.32 (dt, J=8.7/2.5 Hz, 2H), 7.20 (dt, J=8.7/2.3 Hz, 2H), 3.81 (s, 
3H), 3.73 (dd, J = 8.1 Hz / 5.8 Hz, 1H), 3.25 (dd, J=13.9/6.2 Hz, 1H), 3.18 (dd, J=13.9/8.4 Hz, 
1H) ppm.  
13C NMR: (75 MHz, CDCl3): δ 165.7 (C), 133.8 (C), 133.6 (C), 130.4 (CH), 129.0 (CH), 115.8 
(CN), 53.6 (CH3), 39.3 (CH), 35.0 (CH2) ppm.  
IR (HATR): 3078 (w), 3029 (w), 2959 (w), 2919 (w), 2846 (vw), 2223 (m), 1723 (s, sharp), 1606 
(m), 1585 (m), 1562 (m), 1493 (m), 1413 (m), 1370 (w), 1312 (w), 1272 (s), 1203 (s), 1191 (s), 
1112 (m), 1088 (s), 1013 (w), 967 (m), 836 (m), 819 (m), 794 (m), 761 (m), 709 (w), 670 (w), 626 
(w) cm-1. 
TLC: Rf =0.23 (hexane/ EtOAc 80/20).  
 
XIII.3.2.2.3 METHYL 3-(4-BROMOPHENYL)-2-CYANOPROPANOATE VI.27 
F.C.: Hexane/EtOAc 80/20 
Yield: 81% (Colorless oil) 
Molecular Formula: C11H10BrNO2  
Molecular weight: 268.11 g mol-1  
LC-MS: Peak at 6.1 min; ES-MS negative mode: [m/z (fragment, intensity)] 268.0 (M(81Br) -
H+,100), 266.0 (M(79Br) -H+,100).  
HRMS (ESI): C11H9
79BrNO2
- [M-H+]: calculated 265.9817, found 265.9829. 
1H NMR: (300 MHz, CDCl3): δ 7.44-7.37 (m, 2H), 7.12-7.05 (m, 2H), 3.73 (s, 3H), 3.65 (dd, J= 
8.1/5.8 Hz, 1H), 3.22-3.04 (m, 2H) ppm. 
13C NMR: (75 MHz, CDCl3): δ 165.7 (C), 134.1 (C), 132.1 (CH), 130.8 (CH), 122.0 (C), 115.7 
(CN), 53.7 (CH3), 39.2 (CH), 35.0 (CH2) ppm. 
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IR(HATR): 3026 (w), 2954 (w), 2251 (w), 1744 (s), 1593 (w), 1488 (m), 1436 (m), 1406 (w), 
1345 (w), 1264 (m), 1212 (m), 1180 (w), 1162 (w), 1105 (w), 1072 (m), 1012 (m), 963 (vw), 916 
(vw), 894 (w), 845 (vw), 826 (w), 803 (m), 781 (w), 714 (m), 642 (vw), 619 (w) cm-1. 
TLC: Rf = 0.19 (hexane/EtOAc 80/20). 
 
XIII.3.2.2.4 METHYL 2-CYANO-3-(FUR-2-YL)PROPANOATE VI.38 
Yield: 96%, (brown oil) 
Molecular Formula: C9H9NO3  
Molecular weight: 179.17 g mol-1  
LC-MS: Peak at 5.2 min; ES-MS negative mode [m/z (fragment, intensity)]: 178.0 (M-H+,100), 
118.1 (12).  
1H NMR: (300 MHz, CDCl3): δ 7.39-7.36 (m, 1H), 6.36-6.32 (m, 1H), 6.28-6.25 (m, 1H), 3.89-
3.82 (m, 1H),  3.83 (s, 3H), 3.40-3.23 (m, 2H) ppm. 
13C NMR: (75 MHz, CDCl3): δ 165.6 (C), 148.8 (C), 142.6 (CH), 115.7 (C), 110.6 (CH), 108.4 
(CH), 53.7 (CH3), 36.9 (CH), 28.5 (CH2) ppm. 
IR(HATR): 3128 (w), 3044 (m), 2958 (w), 2226 (m), 1726 (s), 1690 (vw), 1613 (s), 1540 (m), 
1520 (vw), 1464 (w), 1450 (vw), 1428 (m), 1337 (w), 1286 (w), 1250 (s), 1209 (s), 1154 (w), 1093 
(s), 1066 (w), 1015 (s), 976 (w), 160 (w), 926 (m), 882 (m), 846 (w), 818 (m), 752 (s), 705 (s), 
674 (vw) cm-1. 
TLC: Rf = 0.20 (hexane/EtOAc 80/20). 
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XIII.3.2.2.5 METHYL 2-CYANO-3-(4-METHOXYPHENYL)PROPIONATE VI.39 
Molecular Formula: C12H13NO3 
Molecular Weight: 219.23 g mol-1 
1H NMR: (300 MHz, CDCl3): δ 7.18-7.13 (m, 2H), 6.88-6.81 (m, 2H), 3.74 
(s, 3H), 3.73 (s, 3H), 3.70 (dd, J = 8.1/5.8 Hz, 1H), 3.21-3.06 (m, 2H). 
TLC: Rf = 0.15 (hexane/EtOAc 80/20). 
 
 XIII.3.2.2.6 METHYL 2-CYANO-3-(NAPHTH-2-YL)PROPIONATE VI.40 
F.C.: Hexane/ EtOAc 90/10 
Yield 97% (White powder) 
M.p. 82 °C 
Molecular Formula: C15H13NO2 
Molecular Weight: 239.26 g mol-1 
LC-MS: Peak at 6.2 min, ES-MS negative mode [m/z (fragment, intensity)]: 238.1 (M-1, 100), 
239.0 (M, 18). 
HRMS (ESI): C15H12NO2
-
 [M-H
+]: calculated 238.0946, found: 238.0883. 
1H NMR: (300 MHz, CDCl3): δ 7.88-7.79 (m, 3H), 7.76 (br.s, 1H), 7.55-7.43 (m, 2H), 7.38 (dd, 
J= 8.5/1.9 Hz, 1H), 3.85 (dd, J= 8.3/5.7 Hz, 1H), 3.80 (s, 3H), 3.49 (dd, J= 13.8/5.7, 1H), 3.38 
(dd, J= 13.8/8.5 Hz, 1H) ppm.  
13C NMR: (75 MHz, CDCl3): δ 166.0 (C), 133.4 (C), 132.7 (C), 132.6 (C), 128.7 (CH), 128.1 
(CH), 127.8 (CH), 127.7 (CH), 126.6 (CH), 126.4 (CH), 126.2 (CH), 116.03 (CN), 53.6 (CH), 39.5 
(CH3), 35.9 (CH2) ppm.  
IR(HATR):  3053 (w), 3023 (w), 2969 (w), 2925 (w), 2251 (w), 1757 (s), 1738 (s, sharp), 1631 
(w), 1599 (w), 1508 (w), 1429 (m), 1367 (w), 1322 (m), 1267 (s), 1251 (s), 1227 (s), 1213 (s), 
1185 (m), 1147 (m), 1164 (m), 1123 (m), 1072 (m), 1028 (m), 1015 (m), 979 (m), 951 (m), 903 
COOMeNC
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(m), 882 (w), 863.8 (m), 839 (w), 814 (s, sharp), 791 (w), 740 (s), 716 (w), 655 (m), 624 (w) cm-
1.  
TLC: Rf = 0.24 (hexane/EtOAc 80/20). 
 
XIII.3.2.2.7 METHYL 2-CYANO-3-PHENYLPROPIONATE VI.41 
F.C.: Hexane/EtOAc 90/10 
Yield: 89% (colorless liquid) 
Molecular Formula: C11H11NO2 
Molecular Weight: 189.21 g mol-1 
LC-MS: Peak at 5.7 min; ES-MS negative mode [m/z (fragment, intensity)]: 188.1 (M-1, 100). 
1H NMR: (300 MHz, CDCl3): δ 7.39-7.35 (m, 1H), 7.34-7.31 (m, 2H), 7.30-7.25 (m, 2H), 3.80 (s, 
3H), 3.78-3.73 (m, 1H), 3.33-3.16 (m, 2H) ppm.  
13C NMR: (75 MHz, CDCl3): δ 166.0 (C), 135.2 (C), 129.1 (CH), 128.9 (CH), 128.7 (CH), 127.8 
(CH), 127.6 (CH), 116.1 (CN), 53.5 (CH3), 39.5 (CH), 35.7 (CH2) ppm.  
TLC: Rf = 0.24 (hexane/EtOAc 90/10). 
 
XIII.3.3 Synthesis of methyl 3-(tert-butoxycarbonyl)amino-2-alkylpropionates 
XIII.3.3.1 General procedure  
           
R
COOMeNC
0.1 eq NiCl2.6H2O, 7 eq NaBH4
R
COOMe
HN
Boc
2 eq Boc2O, 0.2 M MeOH, 0 to r.t
 
To a cooled (0 °C) solution of the nitrile (122 mmol, 1 eq) in MeOH (610 ml) is added Boc2O (244 
mmol, 2 eq) and NiCl2.6H2O (12 mmol, 0.1 eq). Afterwards NaBH4 (855 mmol, 7 eq) is added 
protionwise (0.22 eq every 10 min). After the addition, the reaction is stirred overnight under N2 
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gas. The reaction mixture was concentrated under reduced pressure and the residue is dissolved in 
ethylacetate. After washing with a saturated aqeous solution of NaHCO3, the organic layer is dried 
over magnesium sulfate. After filtering the drying agent, the solvent is removed under reduced 
pressure and the residue is purified by flash chromatography (F.C.). 
 
XIII.3.3.2 METHYL 3-(TERT-BUTOXYCARBONYL)AMINO-2-(4-BROMOBENZYL)-
PROPIONATE VI.44 
F.C.: Hexane/EtOAc 80/20 
Yield: 49% (colourless oil) 
Molecular Formula: C16H22BrNO4  
Molecular weight: 372.25 g mol-1  
LC-MS: Peak at 6.8 min; ES-MS positive mode: [m/z (fragment, intensity)]: 318.0 (M(81Br)-
isobutene+H+, 5), 316.0 (M(79Br)-isobutene+H+, 5), 286.0 (6), 284.0 (6), 274.0 (M(81Br)-
isobutene-CO2+2H
+, 100), 272.0 (M(79Br)-isobutene-CO2+2H
+, 100), 242.0 (10), 240.0 (10). 
HRMS (ESI): C11H15
79BrNO2
+ [M- isobutene-CO2+2H
+]: calculated: 272.0286, found 272.0281. 
1H NMR: (500 MHz, CDCl3): δ 7.33 (d, J = 8.2 Hz, 2H), 6.97 (d, J = 8.2 Hz, 2H), 4.73 (br.s, NH), 
3.57 (s, 3H), 3.40-3.10 (m, 2H), 2.90-2.76 (m, 2H), 2.75-2.60 (m, 1H), 1.36 (s, 9H) ppm. 
13C NMR: (125 MHz, CDCl3): δ 174.4 (C), 155.8 (C), 137.3 (C), 131.6 (CH), 130.6 (CH), 120.5 
(C), 79.5 (C), 51.9 (CH3), 47.2 (CH), 41.5 (CH2), 35.2 (CH2), 28.3 (CH3) ppm. 
IR(HATR): 3285 (vw), 2976 (vw), 2951 (vw), 1730 (m), 1690 (w), 1621 (s), 1530 (w), 1483 (w), 
1417 (m), 1366 (m), 1249 (w), 1206 (vw), 1163 (m), 1072 (vw), 1012 (m), 954 (vw), 849 (w), 815 
(vw) cm-1. 
TLC: Rf = 0.11 (hexane/EtOAc 90/10). 
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XIII.3.3.3 METHYL 3-(TERT-BUTOXYCARBONYL)AMINO-2-(4-CHLOROBENZYL)-
PROPIONATE VI.46 
F.C.: Hexane/Acetone 95/5  
Yield: 58 % White powder 
Molecular Formula: C16H22ClNO4 
Molecular Weight: 327.8 g mol-1 
LC-MS: Peak at 6.651 min, ES-MS positive mode [m/z (fragment, intensity)]: 240.1 (6), 230.1 
(M(37Cl)-isobutene-CO2+H
+, 33), 228.1 (M(35Cl)-isobutene-CO2+H
+, 100), 198 (M(35Cl)-
isobutene-CO2-OMe
-, 12), 196 (M(37Cl)-isobutene-CO2-OMe
-, 5).  
HRMS (ESI): Peak for C11H15
35ClNO2
+
 [M-isobutene-CO2+2H
+]: calculated 228.0791, found: 
228.086. 
1HNMR: (300 MHz, CDCl3): δ 7.36-7.21 (m, 2H), 7.13 (dt, J= 8.3/2.5 Hz, 2H), 4.89 (br.s, NH), 
3.64 (s, 3H), 3.42-2.74 (m, 5H), 1.42 (s, 9H) ppm. 
13CNMR: (75 MHz, CDCl3): δ 174.3 (C), 155.7 (C), 136.7 (C), 132.4 (C), 130.1 (CH), 128.6 (CH), 
128.5 (CH), 126.5 (CH), 79.4 (C), 51.8 (CH3), 47.2 (CH), 41.4 (CH2), 35.1 (CH2), 28.2 (CH3) 
ppm. 
IR (HATR): 3405 (vw), 3079 (w), 3030 (w), 2960 (w), 1721 (s), 1606 (m), 1585 (s), 1563 (m), 
1493 (m), 1425 (m), 1414 (m), 1370 (w), 1312 (m), 1270 (s), 1203 (s), 1112 (m), 1087 (s), 1013 
(m), 966 (m), 903 (w), 837 (s), 817 (m), 784 (m), 761 (m), 709 (m), 670 (w), 626 (w) cm-1. 
TLC: Rf = 0.11(hexane/ EtOAc 90/10). 
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XIII.3.3.4 METHYL 3-(TERT-BUTOXYCARBONYL)AMINO-2-(FUR-2-
YLMETHYL)PROPIONATE VI.47 
F.C.: hexane/EtOAc 90/10 to 60/40 
Yield: 40% (brown oil) 
Molecular Formula: C14H21NO5  
Molecular weight: 283.32 g mol-1  
LC-MS: Peak at 6.0 min; ES-MS positive mode [m/z (fragment, intensity)]: 184.1 (M-isobutene-
CO2+2H
+, 100), 166.1 (7), 152.0 (18), 123.0 (7). 
1H NMR: (300 MHz, CDCl3): δ 7.26-7.15 (m, 1H), 6.22-6.17(m, 1H), 5.99 (d, J= 3.4 Hz, 1H), 
4.82 (br s, 1H), 3.62 (s, 3H), 3.40-3.10 (m, 2H), 3.00-2.70 (m, 3H), 1.36 (s, 9H) ppm. 
13C NMR: (75 MHz, CDCl3): δ 174.2 (C), 155.8 (C), 152.1 (C), 141.6 (CH), 110.3 (CH), 106.8 
(CH), 79.4 (C), 52.0 (CH3), 44.7 (CH), 41.2 (CH2), 28.3 (CH3), 28.0 (CH2) ppm. 
IR(HATR): 3357 (br.m), 2976 (w), 2930 (w), 1706 (s), 1506 (s), 1467 (m), 1390 (w), 13650 (m), 
1161 (s), 1097 (w), 1076 (w), 1047 (w), 1008 (m), 971 (w), 928 (m), 885 (w), 857 (w), 836 (w), 
804 (w), 782 (w), 733 (m) cm-1. 
TLC: Rf = 0.79 (dichloromethane/MeOH 90/10). 
 
XIII.3.3.5 METHYL 3-(TERT-BUTOXYCARBONYL)AMINO-2-(NAPHTH-2-YLMETHYL) 
PROPANOATE VI.48 
 F.C.: Hexane/EtOAc 90/10 
Yield: 57% (White powder)  
M.p.: 92.5 °C 
Molecular Formula: C20H25NO4 
Molecular Weight: 343.41 g mol-1 
COOMe
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LC-MS: Peak at 6.8 min; ES-MS positive mode [m/z (fragment, intensity)]: 329.2 (10), 288.2 (M-
isobutene+H+, 100), 244.2 (M-isobutene-CO2+H
+, 95). 
HRMS (ESI): C20H25NO4Na
+
 [M+Na
+]: calculated 366.1681, Found: 366.1667. 
1H NMR: (500 MHz, CDCl3): δ 7.82-7.77 (m, 3H), 7.62 (s, 1H), 7.48-7.42 (m, 2H), 7.32-7.30 (dd, 
J=8.4/1.6 Hz, 1H), 4.90 (br.s, NH), 3.65 (s, 3H), 3.45-3.30 (m, 2H), 3.15-3.11(m, 1H), 3.07-2.97 
(m, 2H), 1.44 (s, 9H) ppm. 
13C NMR: (125 MHz, CDCl3): δ 174.6 (C), 155.8 (C), 135.8 (C), 133.5 (C), 132.3 (C), 128.2 (CH), 
127.6 (CH), 127.6 (CH), 127.4 (CH), 127.1(CH), 126.1 (CH), 125.5(CH), 79.5 (C), 51.9 (CH3), 
47.4 (CH), 41.7 (CH2), 36.1 (CH2), 28.4 (CH3) ppm. 
IR (HATR) :  3382 (w), 3052 (w), 2975 (w), 2926 (w), 1711 (s), 1632 (w), 1600 (w), 1507 (m), 
1436 (m), 1390 (w), 1365 (w), 1249 (m), 1199 (m), 1162 (s), 1094 (m), 1051 (m), 1018 (m), 975 
(w), 895 (w), 856 (w), 816 (m), 781 (w), 747 (m), 650 (w) cm-1. 
TLC: Rf = 0.12 (hexane/EtOAc 90/10). 
 
XIII.3.3.5 METHYL 3-(TERT-BUTOXYCARBONYL)AMINO-2-ISOBUTYL-PROPIONATE VI.49 
F.C.: (Pentane/EtOAc 96/4 to 90/10) 
Yield: 74% (Colorless liquid)  
Molecular Formula: C13H25NO4 
Molecular weight: 259.34 g.mol-1 
LC-MS Peak at 6.4 min; ES-MS positive mode [m/z (fragment, intensity)]: 172.1 (25), 160.1 (M-
isobutene-OMe+H+, 100), 128.1 (M-isobutene-CO2-OMe, 34), 99.1 (M-isobutene-CO2-
COOMe+H+, 18).  
HRMS (ESI): not detectable by mass spectrometer (positive and negative modes). 
1H NMR (300 MHz, CDCl3): δ 4.85 (br.s, NH), 3.69 (s, 3H), 3.38-3.17 (m, 2H), 2.73-2.64 (m, 
1H), 1.68-1.50 (m, 2H), 1.43 (s, 9H), 1.35-1.22 (m, 1H), 0.90 (d, J =6.4 Hz, 6H) ppm.  
COOMe
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13C NMR (125 MHz, CDCl3): δ 175.8 (C), 155.8 (C), 79.3 (C), 51.7 (CH3), 43.7 (CH), 41.9 (CH2), 
38.7 (CH2), 28.3 (3 CH3), 25.85 (CH), 22.53 (CH3), 22.38 (CH3) ppm.  
IR (HATR) 3377 (w), 2955 (m), 2930 (m), 2870 (w), 1715 (s), 1700 (s), 1509 (m), 1466 (w), 1453 
(w), 1432 (w), 1389 (w), 1365 (m), 1338 (w), 1268 (m), 1247 (m), 1149 (m), 1164 (s), 1072 (w), 
1041 (w), 1025 (w), 967 (w), 768 (w), 759 (vw), 861 (w), 833 (w), 780 (w), 775 (w), 730 (vw), 
725 (vw), 680 (w), 650 (w), 614 (w), 601 (w) cm-1. 
TLC Rf = 0.16 (hexane/EtOAc 95/5).  
 
XIII.3.4 Synthesis of 3-(tert-butoxycarbonyl)amino-2-alkylpropionic acids 
XIII.3.4.1 General procedure 
R
COOMe
HN
Boc A: 2 eq NaOH, H2O/MeOH (2/1), 50°C, 20 min
R
COOH
HN
Boc
B: 2 eq NaOH, H2O/MeOH/dioxane (2/1/1),r.t, o.n
       
A: The methyl ester (23 mmol, 1 eq) is dissolved in a mixture of H2O and MeOH (2/1) (500 ml) 
then NaOH (69.4 mmol, 3 eq) is added. The reaction is refluxed at 50° C for 20 min. The reaction 
mixture is concentrated under reduced pressure, after which the residue is purified by column 
chromatography.  
B: To a solution of methyl ester (20.53 mmol, 1 eq) in H2O/MeOH/dioxane (2/1/1) (100 ml), is 
added NaOH (41.06 mmol, 2 eq). The reaction mixture is stirred overnight at room temperature, 
after which it is acidified with a 1 M aqueous KHSO4 solution to pH 2. The product is extracted 
with ethyl acetate (600 ml) and filtered over silica.  
 
 
 
 
Part 3: Experimental Procedures 
 
213 
 
XIII.3.4.2 2-(4-BROMOBENZYL)-3(TERT-BUTOXYCARBONYL)AMINOPROPIONIC ACID 
VI.50 
Procedure: B 
F.C.: hexane/EtOAc/AcOH 90/10/1 
Yield: 65% (white powder) 
Molecular Formula: C15H20BrNO4  
Molecular weight: 358.23 g mol-1  
LC-MS: Peak at 4.6 min; ES-MS negative mode: [m/z (fragment, intensity)]: 358.0 (M(81Br)-H+, 
100), 356.0 (M(79Br)-H+, 100), 283.9 (M(81Br)-tBuOH-H+, 40), 281.9 (M(79Br)-tBuOH-H+, 40). 
HRMS (ESI): C10H13
79BrNO2
+ [M-isobutene-CO2+2H
+]: calculated 258.0130, found 258.0123. 
1H NMR: (300 MHz, CDCl3): δ 7.34 (d, J = 8.3 Hz, 2H), 7.00 (d, J = 8.3 Hz, 2H), 6.46 (2x br.s, 
NH), 3.4-2.5 (m, 5H), 1.37 (s, 9H) ppm. 
13C NMR: (75 MHz, CDCl3): δ 178.7 (C), 157.9 (C), 137.0 (C), 134.1 (C), 131.7 (CH), 130.6 
(CH), 74.3 (C), 47.4 (CH), 42.1 (CH2), 35.0 (CH2), 28.3 (CH3) ppm. 
TLC: Rf = 0.08 (hexane/EtOAc/AcOH 80/20/1). 
 
XIII.3.4.3 3-(TERT-BUTOXYCARBONYL)AMINO-2-(4-CHLOROBENZYL)PROPIONIC ACID 
VI.51 
Procedure: B 
F.C.: hexane/EtOAc/AcOH 70/30/1 
Yield: 99% (White powder) 
Molecular Formula: C15H20ClNO4 
Molecular Weight: 313.77 g mol-1 
HN
COOH
Br
O O
HN
COOH
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LC-MS: Peak at 4.5 min; ES-MS negative mode [m/z (fragment, intensity)]: 627.1 
(M(37Cl)+M(35Cl)-H+, 20), 625.1 (M(35Cl)+M(35Cl)-H+, 25), 314.1 (M(37Cl)-H+, 31), 313.1 (20), 
312.0 (M(35Cl)-H+, 100), 238.0 (M(35Cl)-tBuOH-H+,40), 239.0 (5), 240.0 (M(37Cl)-t-BuOH-H+, 
10).  
HRMS (ESI): C15H19
35ClNO4
-
 [M-H
+]: calculated 312.1003, found: 312.1007. 
1H NMR: (300 MHz, CDCl3): δ 7.32-7.18 (m, 2H), 7.16-7.08 (m, 2H), 6.53 and 4.97 (2x br.s, NH), 
3.48-2.60 (m, 5H), 1.42 (s, 9H) ppm.  
13C NMR: (75 MHz, CDCl3): δ 178.6 (C), 155.9 (C), 136.5 (C), 132.5 (C), 130.2 (CH), 128.1 
(CH), 79.8 (C), 47.1 (CH), 41.2 (CH2), 34.9 (CH2), 28.3 (CH3) ppm. 
IR(HATR): 3317 (m), 3070 (w), 2983 (m), 2933 (w), 2899 (w), 1703 (s, sharp), 1637 (s), 1560 
(w), 1493 (m), 1478 (m), 1462 (m), 1452 (m), 1435 (m), 1409 (s), 1364 (m), 1340 (m), 1296 (m), 
1283 (s), 1256 (m), 1228 (m), 1202 (m), 1160 (m), 1141 (m), 1089 (m), 1068 (m), 1026 (m), 1013 
(m), 969 (m), 969 (w), 853 (w), 842 (m), 812 (w), 793 (m), 773 (m), 701 (m), 679 (m) cm-1.  
TLC: Rf =0.17 (hexane/EtOAc/AcOH 70/30/1).  
 
XIII.3.4.4 3-(TERT-BUTOXYCARBONYL)AMINO-2-(FUR-2-YLMETHYL)PROPIONIC ACID 
VI.52 
Procedure: B 
Yield: 78% (yellow powder) 
Molecular Formula: C13H19NO5  
Molecular weight: 269.29 g mol-1  
LC-MS: Peak at 4.0 min; ES-MS positive mode: [m/z (fragment, intensity)]: 268.1 (M-H+, 93), 
194.0 (M-tBuOH-H+, 100). 
HRMS (ESI): Peak for C13H18NO5
- [M-H+]: calculated 268.1185, found 268.1188. 
1HNMR: (300 MHz, CDCl3): δ 7.31-7.29 (m, 1H), 6.46 and 4.99 (2x br.s, NH), 6.27-6.26 (m, 1H), 
6.05-6.11 (m, 1H), 3.48-2.71 (m, 5H), 1.42 (s, 9H) ppm. 
HN
COOH
O O
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13CNMR: (75 MHz, CDCl3): δ 178.5 (C), 156.0 (C), 152.0 (C), 141.6 (CH), 110.3 (CH), 107.0 
(CH), 81.3 (C), 45.0 (CH), 42.2 (CH2), 28.3 (CH3), 27.9 (CH2) ppm. 
IR(HATR): 3380 (m), 2982 (w), 2940 (w), 1681 (s), 1599 (w), 1520 (s), 1437 (m), 1391 (m), 1367 
(m), 1327 (w), 1270 (w), 1249 (s), 1195 (vw), 1181 (vw), 1157 (s), 1081 (w), 1056 (m), 1010 (m), 
939 (s), 899 (m), 884 (w), 856 (w), 839 (w), 798 (w), 783 (w), 734 (s), 676 (w) cm-1. 
TLC: Rf = 0.09 (hexane/EtOAc/AcOH 80/20/1). 
 
XIII.3.4.5 3-(TERT-BUTOXYCARBONYL)AMINO-2-(NAPHTH-2-YLMETHYL) PROPIONIC 
ACID VI.53  
Procedure: A 
F.C.: hexane/EtOAc/AcOH 85/15/10 to 80/20/10  
Yield 98% (White powder)  
M.P. 124 °C 
Molecular Formula: C19H23NO4 
Molecular Weight: 329.39 g mol-1 
LC-MS: Peak at 4.6 min; ES-MS negative mode [m/z (fragment, intensity)]: 328.1 (M-H+, 100).  
HRMS (ESI): C15H12NO2
-
 [M-H
+]: calculated 328.1548, Found: 328.1552. 
1H NMR: (500 MHz, Acetone-d6): δ 7.86-7.82 (m, 3H), 7.75 (s, 1H), 7.49-7.42 (m, 3H), 6.08 (br.s, 
NH), 3.36-3.35 (m, 2H), 3.12-3.01 (m, 3H), 1.40 (s, 9H) ppm.  
13C NMR: (125 MHz, Acetone-d6): δ 175.3 (C), 138.0 (C), 134.7 (C), 133.4 (C), 128.8 (CH), 128.5 
(CH), 128.5 (CH), 128.3 (CH), 126.9 (CH), 126.3 (CH), 78.8 (C), 48.2 (CH), 42.9 (CH2), 36.6 
(CH2), 28.6 (CH3) ppm.  
IR (HATR): 3399 (m), 3054 (w), 2976 (m), 2942 (w), 2897 (w), 1688 (s, sharp), 1601 (w), 1514 
(m), 1443 (m), 1392 (m), 1365 (m), 1309 (w), 1271 (m), 1256 (m), 1241 (m), 1168 (s), 1097 (w), 
1055 (w), 963 (w), 909 (w), 896 (w), 876 (w), 862 (w), 813 (m), 771 (w), 751 (m), 657 (w) cm-1. 
COOH
HN
O O
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TLC: Rf = 0.11 (hexane/EtOAc/AcOH 85/15/1). 
 
XIII.3.4.6  2-(TERT-BUTOXYCARBONYL)AMINOMETHYL-4-METHYLPENTANOIC ACID 
VI.54 
Procedure: A 
F.C.: hexane/EtOAc/AcOH 70/30/1 
Yield: 97% (White powder) 
M.p.: 114 °C 
Molecular Formula: C12H23NO4 
Molecular weight: 245.31 
LC-MS: Peak at 4.8 min; ES-MS negative mode [m/z (fragment, intensity)]: 170.1 (M-tBuOH-H+, 
90), 244.1 (M-H+, 100), 245.1 (M, 18).  
HRMS (ESI): C12H22NO4
- [M-H+] calculated: 244.1548, found: 244.1557. 
1H NMR (500 MHz, Acetone-d6): δ 5.97 (br.s, 1H), 3.15-3.28 (m, 2H), 2.78-2.65 (m, 1H), 1.68-
1.66 (m, 1H), 1.53-1.50 (m, 1H), 1.39 (s, 9H), 1.33-1.29 (m, 1H), 0.91 (d, J=6.3 Hz, 6H) ppm. 
13C NMR (125 MHz, Acetone-d6): δ 156.7 (C), 78.8 (C), 44.1 (CH), 43.4 (CH2), 39.7 (CH2), 28.7 
(CH3), 26.8 (CH), 23.3 (CH3), 22.6 (CH3) ppm. 
IR (HATR): 3377 (w), 2956 (m), 2932 (m), 2871 (m), 1710 (s), 1650 (vw), 1510 (m), 1455 (m), 
1391 (m), 1336 (m), 1351 (m), 1270 (m), 1251 (m), 1168 (s), 1120 (s), 1102 (s), 1068 (s), 984 
(vw), 967 (w), 934 (w), 915 (vw), 889 (w), 865 (m), 843 (vw), 807 (w), 776 (vw), 743 (vw), 635 
(vw), 620 (vw) cm-1.  
TLC: Rf = 0.36 (hexane/EtOAc/AcOH 70/30/1). 
 
 
 
COOH
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XIII.3.5 Synthesis of HCl salts of 3-amino-2-alkylpropionic acids 
XIII.3.5.1 General procedure  
                   
R
COOH
HN
Boc
R
COOH
HCl.H2N
Dioxane/conc. HCl 9/1
r.t , 7 h
 
To a solution of Boc-amino acid (13.5 mmol, 1 eq), in dioxane (120 ml) is added 13.5 ml 
concentrated HCl and the obtained colorless solution is stirred for 7 h at room temperature. The 
reaction mixture is concentrated under reduced pressure to give the product as a white solid. The 
products are used as such in the next step.      
 
XIII.3.6 Synthesis of 3-(9-Fluorenylmethyloxycarbonyl)amino-2-alkylpropionic acids 
XIII.3.6.1 General procedure  
      
R
COOH
HCl.H2N
R
COOH
HN
Fmoc1 eq FmocOSu, 1 eq NaHCO3
THF/H2O 2/1
 
To a solution of crude amino acid hydrochloride (8.9 mmol, 1 eq) in water (30 ml), is added sodium 
bicarbonate (8.93 mmol, 1 eq). After 5 minutes THF (60) ml and Fmoc-OSu (8.93 mmol, 1 eq) are 
added and the reaction mixture is stirred overnight at room temperature. The resulting white 
suspension is acidified using 1 M HCl to pH 1 and the resulting clear solution is extracted with 
EtOAc (3 x 100 ml). The combined organic phases are washed with 1 M HCl (4x100 ml) to remove 
HOSu and concentrated under reduced pressure. The obtained residue is further purified by 
recrystallization in EtOAc. 
 
 
 
Part 3: Experimental Procedures 
 
218 
 
XIII.3.6.2 3-(9-FLUORENYLMETHYLOXYCARBONYL)AMINO-2-(4-
BROMOBENZYL)PROPIONIC ACID VI.60 
Yield 82% (white powder) 
Formula: C25H22BrNO4 
Molecular Weight: 480.35 g mol-1 
LC-MS: Peak at 5.4 min; ES-MS positive mode [m/z (fragment, 
intensity)]: 482.0 (M(81Br)+H+, 25), 480.0 M(79Br)+H+, 25), 304.0 (M(81Br)-
fluorenylmethyl+2H+, 20), 302.0 (M(79Br)-fluorenylmethyl+2H+, 20), 258.0 (M(81Br)-
dibenzofulvene-CO2+H
+, 20), 256.0 (M(79Br)-dibenzofulvene-CO2+H
+, 20), 179.1 (fluorenyl 
methyl cation, 100).   
1H NMR: (500 MHz, DMSO-d6): δ 12.33 (br.s, 1H), 7.89 (d, J = 7.6 Hz, 2H), 7.70 (d, J = 7.22 
Hz, 2H), 7.51 (t, J = 5.3 Hz, 1H), 7.47 (d, J = 8.2 Hz, 2H), 7.42 (t, J = 7.4 Hz, 1H), 7.36-7.25 (m, 
2H), 7.23-7.02 (m, 2H), 4.39-4.19 (m, 2H), 3.28-3.09 (m, 2H), 2.83-2.57 (m, 2H) ppm. 
13C NMR: (500 MHz, DMSO-d6): δ 174.9 (C), 156.6 (C), 144.3 (C), 144.2 (C),  141.2 (C), 139.1 
(C), 131.6 (CH), 129.2 (CH), 128.7 (CH), 128.6 (CH), 128.1 (CH), 128.05 (CH), 127.5 (CH), 
127.2 (CH), 126.6 (CH), 125.6 (CH), 125.8 (CH), 120.6 (CH), 119.8 (C), 65.9 (CH2), 47.4 (CH), 
47.2 (CH), 42.4 (CH2), 34.8 (CH2) ppm. 
TLC: Rf =0.42 (dichloromethane/MeOH 90/10). 
 
XIII.3.6.3 3-(9-FLUORENYLMETHYLOXYCARBONYL)AMINO-2-(4-
CHLOROBENZYL)PROPIONIC ACID VI.62 
Yield 92% (white powder) 
Molecular Formula: C25H22ClNO4 
Molecular Weight: 435.89 g mol-1 
LC-MS: Peak at 5.2 min; ES-MS positive mode [m/z (fragment, 
intensity)]: 460.0 (M(37Cl)+Na+, 11), 458.0 (M(35Cl)+Na+, 33), 438.1 (M(37Cl)+H+, 13), 436.1 
Cl
COOH
HN
O O
HN
COOH
Br
O O
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(M(35Cl)+H+, 38), 260.0 (M(37Cl)-dibenzofulvene+H+, 9), 258.0 (M(37Cl)- dibenzofulvene+H+ 
,27), 242.0 (M(37Cl)-dibenzofulvene-H2O+H
+, 12), 240.0 ((M(35Cl)-dibenzofulvene-H2O+H
+, 36), 
216.0 (M(37Cl)-dibenzofulvene-CO2+H
+, 7), 214.1 ((M(35Cl)-dibenzofulvene-CO2+H
+, 20), 196.0 
(9), 180.1 (18), 179.1 (fluorenylmethyl cation, 100).  
HRMS (ESI): C25H23
35ClNO4
+
 [M+H
+]: calculated 436.1316, found: 436.1305. 
1H NMR: (300 MHz, DMSO-d6): δ 12.30 (br s, 1H), 7.87 (d, J = 7.5 Hz, 2H), 7.68 (d, J = 7.3 Hz, 
2H), 7.49 (t, J = 5.7, 1H), 7.40 (t, J = 7.3 Hz, 2H), 7.36-7.28 (m, 4H), 7.20 (d, J = 8.3 Hz, 1H), 
7.18 (br.s, 1H), 4.37-4.17 (m, 3H), 3.30-2.60 (m, 5H) ppm.  
13C NMR: (75 MHz, DMSO-d6): δ 174.4 (C), 156.1 (C), 143.8 (C), 140.7 (C), 138.1 (C), 130.8 
(C), 130.6 (CH), 128.1 (CH), 127.6 (CH), 127.0 (CH), 125.2 (CH), 120.1 (CH), 65.35 (CH2), 46.9 
(CH), 46.7 (CH), 41.9 (CH2), 34.3 (CH2) ppm. 
IR(HATR): 3323 (m), 3070 (vw), 3013 (vw), 2982 (w), 2956 (vw), 2930 (w), 1692 (s), 1637 (m), 
1584 (vw), 1556 (m), 1492 (m), 1463 (vw), 1450 (w), 1408 (m), 1370 (m), 1326 (w), 1268 (s), 
1217 (vw), 1204 (vw), 1180 (w), 1160 (m), 1110 (w), 1089 (m), 1014 (w), 983 (w), 870 (w), 845 
(m), 795 (m), 756 (w), 738 (w), 729 (vw), 646 (m) cm-1.  
TLC: Rf =0.51 (dichloromethane/MeOH 90/10). 
 
XIII.3.6.4 3-(9-FLUORENYLMETHYLOXYCARBONYL)AMINO-2-(NAPHTH-2-YLMETHYL) 
PROPIONIC ACID VI.63 
Yield: 87% (white powder) 
M.p 192 °C  
Molecular Formula: C29H25NO4 
Molecular Weight: 451.51 g mol-1 
LC-MS: Peak at 5.4 min; ES-MS positive mode [m/z (fragment, intensity)]: 452.2 (M+H+, 90), 
274.1, ([M-dibenzofulvene+H+, 10). 
HRMS (ESI): C29H26NO4
+ [M+H+]: calculated 452.1861, found 452.1844.  
COOH
HN
O O
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1H NMR: (500 MHz, Acetone-d6): δ 7.88-7.78 (m, 5H), 7.76 (s, 1H), 7.70-7.68 (d, J=7.4, 2H), 
7.50-7.35 (m, 5H), 7.31 (t, J= 7.2 Hz, 2H), 6.6 (br.s., NH), 4.33 (d, J=7.2 Hz, 2H), 4.22 (t, J= 7.2 
Hz, 1H), 3.53-3.40 (m, 2H), 3.19-2.93 (m, 3H) ppm.  
13C NMR: (125 MHz, Acetone-d6): δ 178.9 (C), 174.2 (C), 156.3 (C), 144.3 (C), 144.2 (C), 141.2 
(C), 136.9 (C), 133.7 (C), 132.4 (C), 127.9 (CH), 127.6 (CH), 127.5 (CH), 127.5 (CH), 127.3 (CH), 
127.0 (CH), 125.9 (CH), 125.4 (CH), 125.2 (CH), 119.9 (CH), 66.1 (CH2), 47.3 (CH), 47.2 (CH), 
42.2 (CH2), 35.6(CH2) ppm. 
IR(HATR): 3338 (m), 3042.9 (w), 2966 (w), 2930 (w), 1686 (s), 1615 (m), 1559 (s), 1449 (m), 
1379 (w), 1361 (w), 1323 (w), 1265 (m), 1213 (w), 1290 (w), 1162 (m), 1129 (w), 1102 (w), 1083 
(vw), 1021 (w), 986 (w), 960 (w), 948 (w), 895 (w), 858 (w), 812 (w), 758 (m), 740 (s),701 (vw), 
645 (m) cm-1. 
TLC: Rf = 0.22 (hexane/EtOAc/AcOH 70/30/1). 
 
XIII.3.6.5 2-(9-FLUORENYLMETHYLOXYCARBONYL)AMINOMETHYL-4-METHYL 
PENTANOIC ACID VI.64 
Yield: 84% (White fluffy powder)  
M.p. 178 °C  
Molecular Formula: C22H25NO4 
Molecular weight: 367.43 g mol-1 
LC-MS: Peak at 5.0 min; ES-MS positive mode [m/z (fragment, intensity)]: 368.2 (M+H+, 100), 
190.1 ([M-t-butyl]+2H+, 5).  
HRMS (ESI): C22H26NO4
+ [M+H+]: calculated: 368.1861, found: 368.1862. 
1H NMR (300 MHz, DMSO-d6): δ 7.88 (d, J=7.5 Hz, 2H), 7.69 (d, J=7.4, 2H), 7.50-7.25 (m, 4H), 
4.35-4.15 (m, 3H), 3.25-3.00 (m, 2H), 2.60-2.46 (m, 1H), 1.63-1.14 (m, 3H), 0.87 (d, J=1.7 Hz, 
3H), 0.84 (d, J=1.7 Hz, 3H) ppm. 
COOH
HN
OO
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13C NMR (75 MHz, DMSO-d6): δ 176.0 (C), 156.2 (C), 143.9 (C), 143.9 (C), 140.7 (C), 128.9 
(CH), 127.6 (CH), 127.3 (CH), 127.1 (CH), 125.2 (CH), 125.0 (CH), 121.4 (CH), 120.1 (CH), 50.4 
(CH2), 46.7 (CH), 43.7 (CH), 42.8 (CH2), 37.4 (CH2) 25.7 (CH), 23.0 (CH3), 21.9 (CH3) ppm.  
IR (HATR): 3287 (m), 2959 (m), 2942 (m), 2919 (m), 2908 (m), 2866 (m), 1689 (s, sharp), 1556 
(m), 1465 (w), 1447 (m), 1384 (w), 1365 (w), 1330 (w), 1297 (s), 1265 (m), 1254 (m), 1234 (m), 
1220 (m),  1219 (vw), 1161 (m), 1128 (w), 1108 (w), 1084 (w), 1043 (vw), 1009.5 (w), 995 (w), 
938 (m), 884 (w), 813 (w), 782 (w), 756 (m), 739 (s, sharp), 672 (m), 639 (m) cm -1. 
TLC: Rf = 0.30 (hexane/EtOAc/AcOH 70/30/1). 
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XIII.4 SYNTHESIS OF 3-SUBSTITUTED-1,5-BENZODIAZOCINE-2,6-DIONES  
XIII.4.1 β2-Amino acid coupling on Wang resin 
OH
1. Fmoc-AA-OH, 2 eq DIC, 0.2 eq DMAP, 
     CH2Cl2, r.t, 24 h
2. Ac2O/DIPEA/CH2Cl2  (1/1/3), r.t, 2x1 hr
NH2
O
O
R1
3. 20% 4-methylpiperidine in DMF, 2x20 min
VI.6 VI.82
 
General procedure: Preactivation: To a cooled (0°C) solution of N-Fmoc-β2-amino acid VI.62-
VI.64 (1 mmol, 2 eq) in CH2Cl2 (5ml), (1 mmol, 2 eq) DIC is added. The reaction mixture is stirred 
for 20 minutes at 0 °C.  
Coupling: The crude preactivation mixture is transferred to a solid-phase reaction vessel 
containing Wang resin (0.5 mmol, 1 eq, calculated from manufacturer’s loading 1.9 mmol/g), 
washed and preswollen with CH2Cl2) after which DMAP is added (0.1 mmol, 0.2 eq). The 
suspension is shaken for 24 hours at room temperature after which the resin is filtered and washed 
consecutively with CH2Cl2 (3x), DMF (3x), MeOH (3x), and CH2Cl2 (3x).  
Capping: The resin is suspended in Ac2O/DIPEA/CH2Cl2 (1/1/3, 10 ml) and shaken for 1 h. The 
resin is filtered and washed with CH2Cl2. This capping procedure is repeated once). The resin is 
filtered and consecutively washed with CH2Cl2 (3x), DMF (3x), MeOH (3x) and CH2Cl2 (3x) and 
dried under reduced pressure.  
Loading: The loading of the resulting resins was determined by Fmoc UV quantification: 
(R1=isobutyl: 0.6626 mmol/g, R1=naphtha-2-ylmethyl: 0.4785 mmol/g, R1=chlorobenzyl: 0.3137 
mmol/g). Yields of final products were calculated in reference to these loading values. An amount 
of resin-bound Fmoc-amino acid is suspended in a 20% 4-methylpiperidine solution in DMF. The 
absorbance of the dibenzofulvene/4-methylpiperidine adduct at 300 nm is correlated to its 
concentration using a calibration line. 
Deprotection: The resin is washed with DMF (3x) and treated with a solution of 20% 4-
methylpiperidine in DMF for 20 min. The resin is filtered and washed with DMF (3x). The 4-
methylpiperidine treatment is repeated once, then the resin is subsequently filtered and washed 
with DMF (3x), MeOH (3x), CH2Cl2 (3x) and DMF (3x). 
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-Amount of resin. For synthesis of the individual library members we used 0.4788 mmol of the 
above-prepared Fmoc-β-amino acid-loaded Wang resins. 
 
XIII.4.2 Nosyl coupling 
VI.82
NH2
O
O
R1
N
H
O
O
R1
S
NO2OO5 eq o-Ns-Cl, 10 eq collidine,
CH2Cl2, r.t, 2x1h
VI.83
 
General procedure: To a suspension of resin VI.82 (0.800 g, 0.478 mmol, 1 eq) in dry DCE (11.3 
ml) is added 2,4,6-collidine (633 μl, 4.788 mmol, 10 eq) and 2-nitrobenzenesulfonyl chloride (531 
mg, 2.394 mmol, 5 eq). After 1 hour shaking, the resin is filtered and washed with DMF (3x15 
ml), MeOH (3x15 ml) and CH2Cl2 (3x15 ml). This procedure is repeated once, delivering the nosyl 
protected resin bound amino acid VI.83. 
This reaction was optimized for compounds VI.83, with R1=2-naphthyl or isobutyl. LC-MS 
analysis after cleavage of a small amount of resin-bound material confirmed the identity of the 
expected products.  
 
Molecular Formula: C20H18N2O6S 
Molecular Weight: 414.43 g mol-1. 
LC-MS: Peak at 4.8 min, ES-MS negative mode [m/z (fragment, 
intensity)]: 827.0 (2M-H+, 10), 413.0 (M-H+, 100). 
Molecular Formula: C13H18N2O6S 
Molecular Weight: 330.35 g mol-1. 
LC-MS: Peak at 4.4 min, ES-MS negative mode [m/z (fragment, 
intensity)]: 329.1 (M-H+, 100), 201.2 (NO2-Ph-SO2NH
-, 5). 
 
N
H
O
HO
S
OO NO2
N
H
O
HO
S
OO NO2
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XIII.4.3 Mitsunobu alkylation 
N
H
O
O
S
OO NO2
N
O
O
S
OO NO2
10 eq VI.70-VI.80, 5 eq Ph3P, 
5 eq DIAD, DCE, r.t, 3x2h
R2R1 R1
VI.83 VI.84
 
General procedure: the resin was suspended in DCE (12 ml) and triphenylphosphine (628 mg, 
2.394 mmol, 5 eq), alcohol VI.70-VI.80 (4.788.mmol, 10 eq) and DIAD (471 μl, 2.394 mmol, 5 
eq) were sequentially added. The reaction mixture is shaken for 2 h at room temperature after 
which the resin is drained and washed with dry CH2Cl2 and dry DCE. This Mitsunobu procedure 
was repeated twice, the resin was filtered and washed with DMF (3x15 ml), MeOH (3x15 ml) and 
CH2Cl2 (3x15 ml).  
This reaction was optimized for compounds VI.84, with R1=2-naphthyl, R2=Me and R1=isobutyl, 
R2=Me. LC-MS analysis after cleavage of a small amount of resin-bound material confirmed the 
identity of the expected products.   
 
Molecular Formula: C21H20N2O6S 
Molecular Weight: 428.45 g mol-1. 
LC-MS: Peak at 5.0 min, ES-MS negative mode [m/z (fragment, 
intensity)]: 855.1 (2M-H+, 100), 427.1 (M-H+, 100). 
 
Molecular Formula: C14H20N2O6S 
Molecular Weight: 344.38 g mol-1. 
LC-MS: Peak at 4.5 min, ES-MS negative mode [m/z (fragment, 
intensity)]: 687.1 (2M-H+, 38), 343.1 (M-H+, 80), 215.1 (NO2-Ph-
SO2NMe
-, 28). 
 
N
O
HO
S
OO NO2
Me
N
O
HO
S
OO NO2
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XIII.4.4 Nosyl removal  
N
O
O
S
OO NO2
Me
NH
O
O
Me
2.5 eq DBU, 5 eq HSCH2CH2OH
 DMF, r.t, 2x30min
R1 R1
VI.84 VI.85
 
General procedure: The resin is suspended in DMF (12 ml) and DBU (179 μl, 1.197 mmol, 2.5 
eq) and 2-mercaptoethanol (168 μl, 2.394 mmol, 5 eq) were added. The resulting suspension was 
shaken for 30 min after which the resin was drained and washed with DMF (3x15 ml), MeOH 
(3x15 ml) and CH2Cl2 (3x15 ml). This procedure is repeated once, after which the resin was 
drained and washed with DMF (3x15 ml). 
This reaction was optimized for compounds VI.85, with R1=2-naphthyl, R2=Me and R1=isobutyl, 
R2=Me. LC-MS analysis after cleavage of a small amount of resin-bound material confirmed the 
identity of the expected products.  
Molecular Formula: C15H17NO2 
Molecular Weight: 243.30 g mol-1. 
LC-MS: Peak at 4.1 min, ES-MS positive mode [m/z (fragment, 
intensity)]: 244.1 (M+H+, 100). 
 
Molecular Formula: C8H17NO2 
Molecular Weight: 159.22 g mol-1. 
LC-MS: Peak at 3.1 min, ES-MS negative mode [m/z (fragment, intensity)]: 
158.2 (M-H+, 100). 
 
 
 
 
NH
O
HO
Me
NH
O
HO
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XIII.4.5 Coupling of Fmoc-anthranilic acids 
NH
O
O
R2
N
O
O
R2
O NHFmoc
10 eq VI.7-VI.11, 5 eq DIC
CH2Cl2/DMF 9/1, r.t, 24 hR1 R1
R3VI.85 VI.86
 
General procedure: Preactivation: To a cooled solution (0°C) of the appropriate N-Fmoc-
protected anthranilic acid derivative VI.7-VI.11 (4.788 mmol, 10 eq) in CH2Cl2/DMF (9/1) (11.3 
ml), was added DIC (252 μl, 2.394 mmol, 5 eq) and the reaction mixture was stirred for 30 min at 
0 °C.  
Coupling: The crude preactivation mixture was transferred to the appropriate resin VI.85, 
preswollen in CH2Cl2/DMF 9/1, and the resulting suspension is shaken for 24 h. The resin was 
drained and washed consecutively with DMF (3x15 ml), MeOH (3x15 ml) and CH2Cl2 (3x15 ml).  
This reaction was optimized for compounds VI.86, with R1=2-naphthyl, R2=Me, R3=H and R1=2-
naphthyl, R2=Me, R3=H. LC-MS analysis after cleavage of a small amount of resin-bound material 
confirmed the identity of the expected products.  
 
Molecular Formula: C37H32N2O5 
Molecular Weight: 584.66 g mol-1. 
LC-MS: Peak at 5.6 min, ES-MS positive mode [m/z 
(fragment, intensity)]: 585.2 (M+H+, 100).    
 
Molecular Formula: C30H32N2O5 
Molecular Weight: 500.58 g mol-1. 
LC-MS Peak at 5.6 min, ES-MS positive mode [m/z (fragment, 
intensity)]: 501.2 (M+H+, 100), 160.2 (HOOC-CH(iBu)-CH2-NHMe+H
+, 28). 
N
O
HO
Me
O NHFmoc
N
O
HO
Me
O NHFmoc
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X.4.6 Fmoc removal 
N
O
O
R2
O NHFmoc
R1
R3
20 % 4-methylpiperidine in DMF
r.t, 2x20min
N
O
O
R2
O NH2
R1
R3VI.86 VI.87
 
Removal of the Fmoc protecting group, See section X.4.1 
 
X.4.7 Cleavage from the resin 
N
O
O
R2
O NH2
R1
R3
N
O
HO
R2
O NH2
R1
R3
TFA/H2O 9/1, 1 h.
VI.87 VI.88
 
General procedure: resin VI.87 is suspended in a mixture of trifluoroacetic acid/water 95/5 (15 
ml) and shaken for 1 hour at room temperature. The resin is filtered and washed extensively with 
dichloromethane. The filtrate is concentrated under reduced pressure and the obtained residue is 
further purified by flash chromatography (F.C) or preparative reversed-phase HPLC. 
 
XIII.4.7.1  4-METHYL-2-(METHYL-(N-ANTHRANOYL-N-METHYL)PENTANOIC ACID XIII.1 
F.C.: hexane/EtOAc/AcOH 60/40/1  
SPS yield: 88% (colorless glass), 46 mg from 119 mg resin VI.82 
Molecular Formula: C15H22N2O3 
Molecular weight: 278.34 g mol-1. 
LC-MS: Peak at 3.7 min; ES-MS positive mode [m/z (fragment, intensity)]: 579.2 (2M+Na+, 8), 
279.1 (M+H+, 100), 261.1 (M-OH-, 10).  
HRMS (ESI): Not detectable by mass spectrometer (positive and negative mode). 
NH2
N
O
HO
O
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1H NMR: (300 MHz, CD3OD): presence of two amide rotamers on NMR-time scale (ratio cannot 
be determined): δ 7.11 (td, J= 1.3/7.6 Hz, 1H), 7.01 (d, J=6.9 Hz ,1H), 6.74 (d, J=8.1 Hz, 1H), 
6.65 (t, J= 7.4 Hz, 1H), 3.61 (br.s, 2H), 2.98 (s, 3H), 2.89-2.51 (m, 1H), 1.79-1.09 (m, 3H), 0.89 
(br. s, 6H) ppm.  
13C NMR: (125 MHz, CD3OD): no multiple conformers observed: δ 146.1 (C), 131.7 (CH), 128.7 
(CH), 122.1 (C), 118.3 (CH), 117.5 (CH), 50.0 (CH2), 44.1 (CH), 40.6 (CH2), 37.1 (CH3), 27.5 
(CH), 23.6 (CH3), 22.5 (CH3) ppm. 
IR (HATR): 3380 (m), 3345 (m), 3166 (w), 3070 (w), 2953 (m), 2926 (m), 1711 (m), 1614 (s), 
1584 (s), 1538 (s), 1491 (m), 1465 (m), 1450 (m), 1383 (w), 1366 (w), 1353 (w), 1315 (m), 1301 
(m), 1261 (m), 1197 (s), 1158 (m), 1123 (m), 1081 (w), 1031 (w), 998 (w), 942 (vw), 893 (w), 852 
(vw), 816 (w), 792 (w), 745 (s), 699 (w), 660 (w), 622 (w) cm-1.  
TLC: Rf = 0.41 (hexane/EtOAc/AcOH 40/60/1). 
 
XIII.4.7.2 2-(N(2-AMINO-6-FLUOROBENZOYL),N(METHOXYETHOXY-2-
ETHYL)AMINOMETHYL)PENTANOIC ACID XIII.2 
F.C.: hexane/EtOAc/AcOH 60/40/10 
SPS yield: 53% (brown glass), 93 mg from 800 mg resin VI.82 
Molecular Formula: C19H29FN2O5 
Molecular weight: 384.44 g mol-1. 
LC-MS: Peak at 4.1 min; ES-MS positive mode [m/z (fragment, intensity)]: 385.1 (M+H+, 100). 
HRMS (ESI): C19H30FN2O5
+ [M+H+] calculated: 385.2138, found: 385.2142. 
1H NMR: (300 MHz, CDCl3): presence of two amide rotamers on NMR-time scale (ratio cannot 
be determined): δ 7.13-6.95 (m, 1H), 6.57-6.26 (m, 4H), 4.21-2.51 (m, 14H), 1.73-0.96 (m, 3H), 
0.91 (d, J= 6.4 Hz, 3.74H), 0.81 (d, J= 6.2 Hz, 0.66H), 0.79 (d, J= 6.2 Hz, 0.66H), 0.72 (d, J= 6.2 
Hz, 0.74H), 0.60 (d, J= 6.2 Hz, 0.47H) ppm.  
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13C NMR: (75 MHz, CDCl3): presence of two amide rotamers on NMR-time scale (ratio cannot 
be determined): major conformer δ 179.5 (d, J= 21.0 Hz, C), 178.4 (CO), 166.9 (CO), 158.5 (d, 
J= 244.3 Hz, C), 145.7 (d, J= 22.2 Hz, C), 131.1 (d, J= 22.0 Hz, CH), 111.6 (CH), 104.0 (CH), 
71.6 (CH2), 70.1 (CH2), 68.6 (CH2), 58.8 (CH3), 49.8 (CH2), 44.5 (CH2), 42.2 (CH), 39.1 (CH2), 
25.9 (CH), 22.9 (CH3), 22.0 (CH3) ppm. 
IR (HATR): 3443 (vw), 3355 (w), 2953 (w), 2869 (w), 1715 (m), 1621 (s), 1614 (s), 1463 (s), 
1434 (m), 1385 (w), 1367 (w), 1352 (w), 1327 (w), 1245 (m), 1196 (s), 1113 (s), 1095 (s), 1050 
(m), 1029 (w), 993 (m), 923 (w), 842 (w), 789 (m), 767 (w), 753 (m), 720 (m), 641 (w) cm-1. 
TLC: Rf = 0.05 (hexane/EtOAc/AcOH 60/40/1). 
 
XIII.4.7.3 4-METHYL-2-(N-(4-PHENYLBENZYL),N(2-AMINO-5-
METHOXYBENZOYL)AMINOMETHYL)PENTANOIC ACID XIII.3 
F.C.: hexane/EtOAc/AcOH 60/40/1 
SPS yield: 31% (brown powder), 127 mg from 800 mg resin VI.82 
Molecular Formula: C28H32N2O4 
Molecular weight: 460.56 g mol-1. 
LC-MS: Peak at 5.3 min; ES-MS positive mode [m/z (fragment, 
intensity)]: 921.4 (2M+H+, 30), 461.2 (M+H+, 100).  
HRMS (ESI): C28H33N2O4
+ [M+H+] calculated: 461.2440, found: 461.2462. 
1H NMR: (300 MHz, CDCl3): (two amide rotamers ratio 80/20) δ 7.57 (d, J=7.5 Hz, 2H), 7.47-
7.42 (t, J=7.0 Hz, 2H), 7.39-7.33 (tt, J=1.3/7.4 Hz, 2H), 7.25-7.11 (m, 4H), 6.74 (d, J=11.4 Hz, 
2H), 5.12 (br.s, 0.2H), 4.59 (br.s, 0.8H), 3.91-3.82 (m, 1H), 3.58 (s, 3H), 3.39-3.30 (m, 1H), 3.02-
2.70 (m, 1H), 1.64-1.08 (m, 3H), 0.87-0.58 (br.s, 6H) ppm. 
13C NMR: (75 MHz, CDCl3): no multiple conformers observed: δ 179.0 (CO), 171.4 (CO), 162.7 
(C), 140.7 (C), 140.4 (C), 135.2 (C), 128.8 (CH), 127.7 (CH), 127.6 (CH), 127.5 (CH), 127.4 (CH), 
127.3 (CH), 126.9 (CH), 122.7 (C), 119.4 (CH), 119.5 (CH), 118.3 (C), 117.3 (CH), 117.2 (CH), 
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111.9 (CH), 55.5 (CH3), 52.9 (CH2), 47.7 (CH2), 42.0 (CH), 39.0 (CH2), 25.9 (CH), 22.7 (CH3), 
22.0 (CH3) ppm. 
IR (HATR): 3447 (vw), 3559 (vw), 2952 (w), 1697 (m), 1633 (m), 1591 (m), 1499 (m), 1485 (m), 
1465 (m), 1426 (m), 1364 (w), 1281 (m), 1200 (s), 1135 (s), 1075 (w), 1037 (m), 1007 (w), 928 
(vw), 816 (w), 797 (w), 759 (m), 739 (w), 721 (m), 696 (m) cm-1.  
TLC: Rf = 0.29 (hexane/EtOAc/AcOH 60/40/1). 
 
XIII.4.7.4 4-METHYL-2-(N-ANTHRANOYL,N-(3-
METHOXYBENZYL)AMINOMETHYL)PENTANOIC ACID XIII.4 
F.C.: hexane/EtOAc/AcOH 80/20/1 
SPS yield: 62% (pale brown), 109 mg from 800 mg resin VI.82 
Molecular Formula: C22H28N2O4 
Molecular weight: 384.46 g mol-1. 
LC-MS: Peak at 4.6 min; ES-MS positive mode [m/z (fragment, intensity)]: 769.3 (2M+H+, 10), 
385.1 (M+H+).  
HRMS (ESI): C22H29N2O4
+ [M+H+] calculated: 385.2127, found: 385.2118. 
1H NMR: (300 MHz, CDCl3): presence of two amide rotamers on NMR-time scale (ratio cannot 
be determined): δ 7.26-7.08 (m, 3H), 6.85-6.60 (m, 7H), 4.62-4.44 (m, 2H), 3.78 (s, 3H), 3.70-
3.34 (m, 2H), 3.08-2.80 (m, 1H), 1.62-1.40 (m, 2H), 1.23-1.03 (m, 1H), 0.87 (br. s, 6H) ppm. 
13C NMR: (75 MHz, CDCl3): no multiple conformers observed: δ 179.3 (CO), 172.1 (CO), 160.0 
(C), 144.2 (C), 138.0 (C), 130.6 (CH), 129.7 (CH), 127.6 (CH), 120.3 (C), 119.7 (CH), 117.9 (CH), 
116.6 (CH), 113.2 (CH), 112.9 (CH), 55.2 (CH3), 53.8 (CH2), 47.7 (CH2), 42.1 (CH), 39.1 (CH2), 
25.9 (CH), 22.7 (CH3), 22.03 (CH3) ppm.  
IR (HATR): 3596 (vw), 3357 (vw), 2952 (w), 1718 (m), 1597 (s), 1585 (s), 1490 (s), 1465 (s), 
1421 (s), 1382 (vw), 1367 (w), 1287 (m), 1260 (s), 1191 (s), 1191 (s), 1149 (s), 1116 (m), 1047 
(m), 1036 (m), 994 (w), 971 (w), 873 (vw), 775 (m), 748 (s), 691 (w), 623 (vw) cm-1. 
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TLC: Rf = 0.18 (hexane/EtOAc/AcOH 60/40/1).  
 
XIII.4.7.5 4-METHYL-2-(METHYL-(N-ANTHRANOYL,N-(1-PHENYLPROP-1-EN-3-
YL)AMINOMETHYL)PENTANOIC ACID XIII.5 
F.C.: hexane/EtOAc/AcOH 80/20/1 to 70/30/1 
SPS yield: 38% (brown glass), 66 mg from 800 mg resin VI.82 
Molecular Formula: C23H28N2O3 
Molecular weight: 380.48 g mol-1. 
LC-MS: Peak at 4.9 min; ES-MS positive mode [m/z (fragment, intensity)]: 761.3 (2M+H+, 24), 
381.3 (M+H+, 100). 
HRMS (ESI): C23H29N2O3
+ [M+H+] calculated: 381.2178, found: 381.2175. 
1H NMR: (300 MHz, CDCl3): presence of two amide rotamers on NMR-time scale (ratio cannot 
be determined): δ 7.30-7.01 (m, 7H), 6.68-6.53 (m, 4H), 6.35 (d, J =14.1 Hz, 1H), 5.95 (d, J=12.6 
Hz, 1H), 4.10-3.86 (m, 2H), 3.69-3.40 (m, 2H), 3.03-2.82 (m, 1H), 1.69-1.29 (m, 2H), 1.23-1.07 
(m, 1H), 0.70-1.01 (m, 6H) ppm.  
13C NMR: (75 MHz, CDCl3): no multiple conformers observed: δ 179.1 (CO), 171.9 (CO), 143.9 
(C), 136.1 (C), 133.1 (CH), 130.5 (CH), 128.7 (CH), 128.5 (CH), 128.1 (CH), 127.8 (CH), 127.3 
(CH), 126.4 (CH), 124.2 (CH), 120.6 (C),117.7 (CH), 116.5 (CH), 52.1 (CH2), 48.0 (CH2), 42.3 
(CH), 39.1 (CH2), 25.9 (CH), 22.8 (CH3), 22.0 (CH3) ppm. 
IR (HATR): 3447 (vw), 3348 (vw), 2951 (w), 2868 (w), 1718 (m), 1613 (s), 1586 (s), 1465 (s), 
1444 (m), 1366 (m), 1238 (m), 1193 (s), 1157 (m), 1116 (w), 1051 (w), 1029 (w), 962 (m), 801 
(vw), 748 (s), 691 (m), 638 (w) cm-1. 
TLC: Rf = 0.21 (hexane/EtOAc/AcOH 60/40/1). 
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XIII.4.7.6 3-(N-ANTHRANOYL-N-METHYL)AMINO-2-(NAPHTH-2-YLMETHYL)PROPIONIC 
ACID XIII.6 
 F.C.: hexane/EtOAc/AcOH 40/60/1 
HPLC: method A, tret = 11.7 
SPS yield 37% (colorless glass) 60 mg from 800 mg resin VI.82 
Molecular Formula: C22H22N2O3 
Molecular weight: 362.42 g mol-1. 
LC-MS: Peak at 4.2 min; ES-MS positive mode [m/z (fragment, intensity)]: 725.2 (2M+H+, 10), 
363.1 (M+H+, 100).  
HRMS (ESI): C22H23N2O3
+ [M+H+] calculated: 363.1708, found: 363.1695. 
1H NMR: (300 MHz, CDCl3): presence of two amide rotamers on NMR-time scale (ratio cannot 
be determined): δ 7.84-7.68 (m, 3H), 7.67-7.59 (m, 1H), 7.49-7.39 (m, 2H), 7.30-7.17 (m, 1H), 
7.15-6.92 (m, 2H), 6.71-6.51 (m, 2H), 5.3 (br.s, 2H), 4.01 (br.s, 1H), 3.46 (dd, J= 3.6/13.5 Hz, 
1H), 3.28-3.15 (m, 2H), 2.80-3.03 (m, 4H) ppm. 
13C NMR: (75 MHz, CDCl3): no multiple conformers observed: δ 177.1 (CO), 171.8 (CO), 144.2 
(C), 135.6 (C), 133.4 (C), 132.2 (C), 131.1 (CH), 130.6 (CH), 128.2 (CH), 127.5 (CH), 127.3 (CH), 
127.0 (CH), 126.0 (CH), 125.5 (CH), 120.3 (C), 117.7 (CH), 116.8 (CH), 116.7 (CH), 49.1 (CH2), 
45.5 (CH), 36.1 (CH2), 35.8 (CH3) ppm.  
IR (HATR): 3462 (w), 3369 (w), 3229 (w), 3033 (m), 2937 (m), 1723 (m), 1710 (m), 1692 (m), 
1679 (w), 1611 (s), 1586 (s), 1529 (vw), 1493 (w), 1484 (w), 1462 (w), 1449 (w), 1431 (w), 1402 
(m), 1367 (w), 1346 (w), 1310 (w), 1289 (w), 1269 (w), 1201 (w), 1170 (w),  1075 (m), 1031 (vw), 
948 (vw), 855 (w), 818 (m), 749 (s), 708 (vw), 630 (vw) cm-1. 
TLC: Rf = 0.24 (hexane/EtOAc/AcOH 40/60/1).  
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XIII.4.7.7 3-(N-(2-AMINO-5-BROMOBENZOYL),N-ETHYL)AMINO-2-(NAPHTH-2-YL) 
PROPIONIC ACID XIII.7 
F.C.: hexane/EtOAc/AcOH 80/20/1 to 70/30/1 
SPS yield: 63% (beige glass), 138 mg from 800 mg resin VI.82  
Molecular Formula: C23H23BrN2O3 
Molecular weight: 455.34 g mol-1. 
LC-MS: Peak at 4.7 min; ES-MS negative mode [m/z (fragment, intensity)]: 909.0 (2M(Br79/Br81)-
H+, 100). 456.0 (M(Br81)-H+, 20)  
HRMS (ESI): C23H22
79BrN2O3
- [M-H+] calculated: 453.0813, found: 453.0825. 
1H NMR: (300 MHz, CDCl3): presence of two amide rotamers on NMR-time scale (ratio cannot 
be determined): δ 7.86-7.72 (m, 3H), 7.64 (s, 1H), 7.51-7.40 (m, 2H), 7.38-7.24 (m, 1H), 7.18-
7.08 (m, 2H), 6.38 (d, J=8.4 Hz, 1H), 6.22 (br.s, 2H), 3.86 (br.s, 1H), 3.48 (br.s, 1H), 3.29-3.06 
(m, 4H), 2.89 (br.s, 1H), 0.93 (br.s, 3H) ppm.  
13C NMR: (75 MHz, CDCl3): no multiple conformers observed: δ 177.5 (CO), 170.2 (CO), 142.7 
(C), 135.4 (C), 133.4 (C), 133.0 (CH), 132.2 (C), 129.4 (CH), 128.2 (CH), 127.9 (CH), 127.6 (CH), 
127.5 (CH), 127.3 (CH), 126.9 (CH), 126.1 (CH), 122.4 (C), 118.1 (CH), 109.2 (C), 48.1 (CH2), 
46.9 (CH2), 45.5 (CH), 36.1 (CH2), 13.6 (CH3) ppm. 
IR (HATR): 3360 (w), 3054 (vw), 2970 (w), 2928 (w), 1713 (m), 1600 (s), 1581 (s), 1504 (w), 
1483 (s), 1454 (m), 1434 (m), 1401 (m),  1382 (w), 1360 (w), 1279 (s), 1254 (s), 1170 (m), 1150 
(m), 1100 (m), 1079 (m), 1014 (w), 980 (w), 953 (w), 889 (w), 854 (w), 801 (s), 746 (s), 638 (vw), 
618 (w) cm-1. 
TLC: Rf = 0.15 (hexane/EtOAc/AcOH 60/40/1). 
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XIII.4.7.8 3-(N-(4-BUT-1-YNYL),N-(2-AMINO-5-METHOXBENZOYL))AMINO-2-(NAPHTH-2-
YL)PROPIONIC ACID XIII.8 
F.C.: hexane/EtOAc/AcOH 70/30/1 
SPS yield: 35% (brown glass), 74 mg from 800 mg resin VI.82  
Molecular Formula: C26H26N2O4 
Molecular weight: 430.49 g mol-1. 
LC-MS: Peak at 4.5 min; ES-MS positive mode [m/z (fragment, intensity)]: 861.3 (2M+H+, 25), 
431.2 (M+H+, 100). 
HRMS (ESI): C26H27N2O4
+ [M+H+] calculated: 431.1970, found: 431.1966. 
1H NMR: (300 MHz, CD3OD): presence of two amide rotamers on NMR-time scale (ratio cannot 
be determined): δ 7.78-7.56 (m, 4H), 7.45-7.30 (m, 3H), 6.93-6.46 (m, 3H), 3.79-3.40 (m, 7H), 
3.23-2.66 (m, 3H), 2.47-2.22 (m, 3H) ppm. 
13C NMR: (75 MHz, CD3OD): no multiple conformers observed: δ 177.8 (CO), 173.5 (CO), 153.4 
(C), 138.7 (C), 137.4 (C), 135.0 (C), 133.8 (C), 129.2 (CH), 128.7 (CH), 128.5 (CH), 128.4 (CH), 
128.2 (CH), 127.1 (CH), 126.6 (CH), 123.1 (C), 119.2 (CH), 118.4 (CH), 113.4 (CH), 71.9 (CH), 
56.3 (CH3), 56.1 (CH2), 47.0 (CH2), 37.6 (CH), 36.7 (CH2), 17.3 (CH2) ppm. 
TLC: Rf = 0.08 (hexane/EtOAc/AcOH 60/40/1). 
 
XIII.4.7.9 2-(NAPHTH-2-YL)-3-(N-(4-FLUOROBENZYL),N-(2-AMINO-5-
METHYLBENZOYL))AMINOPROPIONIC ACID XIII.9 
F.C.: hexane/EtOAc/AcOH 80/20/1 to 60/40/1 
SPS yield: 74% (pale brown glass), 88 mg from 800 mg resin 
VI.82  
Molecular Formula: C29H27FN2O3 
Molecular weight: 470.53 g mol-1. 
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LC-MS: Peak at 5.2 min; ES-MS positive mode [m/z (fragment, intensity)]: 941.3 (2M+H+, 10), 
471.3 (M+H+, 100). 
HRMS (ESI): C29H28FN2O3
+ [M+H+] calculated: 471.2084, found: 471.2076. 
1H NMR: (300 MHz, CDCl3): presence of two amide rotamers on NMR-time scale (ratio cannot 
be determined): δ 7.91-7.75 (m, 3H), 7.63 (s, 1H), 7.54-7.40 (s, 2H), 7.35-6.97 (m, 5H), 6.90 (dd, 
J= 8.2/1.4 Hz, 1H), 6.79 (s, 1H), 6.64 (d, J = 8.1 Hz, 1H), 4.49 (br.s, 2H), 3.61 (br.s, 1H), 3.41-
3.31 (m, 2H), 3.16 (br.s, 1H), 2.88-2.73 (m, 1H), 2.09 (s, 3H) ppm.  
13C NMR: (75 MHz, CDCl3): no multiple conformers observed: δ 175.1 (CO), 170.7 (CO), 162. 
(d, J =243 Hz, C), 142.6 (C), 136.4 (C), 132.9 (C), 131.7 (C), 130.6 (CH), 129.5 (CH), 129.4 (CH), 
129.4 (CH), 129.4 (CH), 127.7 (CH), 127.4 (d, J=9 Hz, CH), 127.3 (CH), 126.8 (CH), 126.0 (CH), 
125.4 (CH), 124.3 (C), 120.0 (C), 115.7 (CH), 115.3 (d, J=21.4 Hz, CH), 51.2 (CH2), 46.1 (CH2), 
44.9 (CH), 35.6 (CH2), 19.8 (CH3) ppm. 
IR (HATR): 3434 (w), 3358 (w), 2926 (w), 1737 (s), 1713 (m), 1584 (s), 1540 (s), 1505 (s), 1480 
(m), 1440 (m), 1415 (m), 1347 (w), 1287 (m), 1224 (s), 1206 (s), 1170 (m), 1154 (m), 1097 (m), 
1026 (m), 971 (w), 945 (w), 929 (w), 889 (vw), 852 (m), 827 (s), 810 (s), 767 (w), 748 (m), 715 
(vw), 632 (w), 658 (vw) cm-1. 
TLC: Rf = 0.17 (hexane/EtOAc/AcOH 60/40/1). 
 
XIII.4.7.10 2-(4-CHLOROPHENYL)-3-(N-(2-AMINO-5-METHOXYBENNOYL),N-
METHYL)AMINOPROPIONIC ACID XIII.10 
F.C.: hexane/EtOAc/AcOH 40/60/1 
HPLC: method B, tret = 17.2 
SPS yield: 35% (white glass), 42 mg from 1 gm resin VI.82  
Molecular Formula: C19H21ClN2O4 
Molecular weight: 376.83 g mol-1. 
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LC-MS: Peak at 4.1 min; ES-MS positive mode [m/z (fragment, intensity)]: 419.0 
(M(35Cl)+CH3CN+H
+, 7), 379.0 (M(37Cl)+H+, 40), 377.0 (M(35Cl)+H+, 100). 
HRMS (ESI): C19H22
35ClN2O4
+ [M+H+] calculated: 377.1268, found: 377.1263. 
1H NMR: (500 MHz, CDCl3): presence of two amide rotamers on NMR-time scale (ratio ~ 60/40): 
δ 7.22-6.99 (m, 4H), 6.79 (d, J=6.3 Hz, 1.27H), 6.75-6.66 (m, 0.73H), 6.71-6.52 (m, 2H), 5.12 
(br.s, 2H), 3.96-3.77 (m, 1H), 3.72 (s, 3H), 3.47-3.38 (m, 2H), 3.17-2.99 (m, 2H), 2.94 (s, 3H) 
ppm.  
13C NMR: (75 MHz, CDCl3): no multiple conformers observed: δ 175.7 (CO), 172.0 (CO), 141.2 
(C), 132.7 (C), 132.4 (C), 130.17 (CH), 130.15 (CH), 130.09 (CH), 129.7 (CH), 128.6 (CH), 128.5 
(C), 127.1 (C), 117.5 (CH), 112.4 (CH), 57.1 (CH3), 55.7 (CH), 50.5 (CH), 38.0 (CH3), 35.2 (CH2) 
ppm. 
TLC: Rf = 0.08 (hexane/EtOAc/AcOH 60/40/1). 
 
XIII.4.7.11 2-(4-CHLOROPHENYL)-3-(N-(2-AMINO-5-BROMOBENZOYL),N-
BENZYL)AMINOPROPIONIC ACID XIII.11 
F.C.: hexane/EtOAc/AcOH 80/20/1 
HPLC: method C, tret = 18.5 
SPS yield: 50% (white glass), 65 mg from 1 gm resin VI.82  
Molecular Formula: C24H22BrClN2O3 
Molecular weight: 501.81 g mol-1. 
LC-MS: Peak at 5.1; ES-MS min positive mode [m/z (fragment, intensity)]: 505.0 
(M(79Br)(37Cl)+H+, 28), 502.9 (M(79Br)(35Cl)+H+, 100).  
HRMS (ESI): C24H23
79Br35ClN2O3
+ [M+H+] calculated: 501.0580, found: 501.0581. 
1H NMR: (500 MHz, CDCl3): presence of two amide rotamers on NMR-time scale (ratio ~ 70/30): 
δ 7.97-7.49 (m, 11H), 6.57 (d, J= 8.5 Hz, 0.72H), 6.65 (d, J= 8.3 Hz, 0.28H), 4.67-4.46 (m, 2H), 
3.71-3.43 (m, 2H), 3.34-3.11 (m, 1H), 2.98-2.68 (m, 2H) ppm.  
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13C NMR: (125 MHz, CDCl3): no multiple conformers observed: δ 177.2 (CO), 170.7 (CO), 143.3 
(C), 133.5 (CH), 132.5 (C), 130.1 (CH), 128.9 (CH), 128.7 (CH), 128.0 (CH), 127.6 (CH), 121.8 
(C), 118.2 (CH), 109.3 (C), 48.0 (CH2), 47.5 (CH2), 45.4 (CH), 35.2 (CH2) ppm. 
TLC: Rf = 0.19 (hexane/EtOAc/AcOH 70/30/1). 
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XIII.4.8 Cyclization in solution 
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DCC-PS, CH2Cl2, 1h, 
r.t
VI.88 VI.1
 
To a solution of purified α,ω-β-amino carboxylic acids (0.197 mmol, 1 eq) in CH2Cl2 (19.7 ml) is 
added polystyrene-bound DCC (loading 2.3 mmol/g, 0.568 mmol, 2.9 eq). The obtained 
suspension is shaken for 1 h at room temperature after which the resin was filtered and washed 
with CH2Cl2. The filtrate was concentrated under reduced pressure. The obtained crude 
compounds are purified by flash chromatography (F.C) or preparative reversed-phase HPLC. 
 
XIII.4.8.1 3,4-DIHYDRO-3-ISOBUTYL-5-METHYLBENZO[g][1,5]DIAZCOCINE-2(1H),6(5H)-
DIONE VI.89 
F.C.: Hexane/EtOAc/AcOH 40/60/10 
CYC yield: 67% (colorless glass), 18 from 23 mg XIII.1 
Molecular Formula: C15H20N2O2 
Molecular weight: 260.33 g mol-1. 
LC-MS: Peak at 4.9 min; ES-MS positive mode [m/z (fragment, intensity)]: 521.2 (2M+H+, 100), 
261.1 (M+H+, 38).  
1HNMR: (300 MHz, Acetone-d6): presence of two inversed boat-type conformers (ratio 80/20 
individual assignments not possible): δ 8.70-8.30 (br.m, NH), 7.55-7.30 (m, 3H), 7.24 (d, J =7.7 
Hz, 1H), 3.75-3.50 (m, 0.25H), 3.45-3.13 (m, 2.45H), 3.09 (s, ~2.35H), 3.02 (br.s, ~0.65H), 2.70-
2.59 (m, 0.25H), 1.70-1.56 (m, 1H), 1.37-1.25 (m, 1H), 1.13-1.03 (m, 1H), 0.88 (d, J= 1.3 Hz, 
~2.4H), 0.87 (d, J= 1.7 Hz, ~2.5H), 0.80 (br.d, J= 6.2 Hz, ~0.7H), 0.73 (br.d, J= 5.6 Hz, ~0.5H) 
ppm. 
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13CNMR: (75 MHz, Acetone-d6): no multiple conformations observed: δ 173.8 (CO), 131.8 (CH), 
128.9 (CH), 128.8 (CH), 128.0 (CH), 54.2 (CH2), 47.4 (CH3), 33.5 (CH), 29.8 (CH2), 26.9 (CH), 
23.6 (CH3), 23.0 (CH3) ppm. 
TLC: Rf = 0.15 (Hexane/EtOAc/AcOH 40/60/10).  
 
XIII.4.8.2 3,4-DIHYDRO-7-FLUORO-3-ISOBUTYL-5-(2-METHOXYETHOXY-2-
ETHYL)BENZO [g][1,5]DIAZOCINE-2(1H),6(5H)-DIONE VI.90 
F.C.: hexane/EtOAc/AcOH 70/30/10 
CYC yield: 55% (white glass), 40 mg from 76 mg XIII.2  
HPLC: method C, tret = 17.9 min and 18.9 min, mixture of 
diastereomeric atropisomers 
Molecular Formula: C19H27FN2O4 
Molecular weight: 366.42 g mol-1. 
LC-MS: Two peaks at 5.2 min and 5.3 min diastereomeric atropisomers, ratio 82/18; ES-MS 
positive mode [m/z (fragment, intensity)]: 367.1 (M+H+, 100).  
HRMS (ESI): Peak for C19H28FN2O4
+ [M+H+]: calculated 367.2033, found 367.2028. 
1H NMR: (500 MHz, Acetone-d6): presence of two inversed boat-type conformers (ratio 82/18, 
individual assignment not possible): δ 8.78-8.62 (2x br.s, NH, ratio 2/8), 7.55-7.49 (m, 1H), 7.23-
7.16 (m, 1H), 7.14-7.09 (m,1H), 3.83-3.46 (m, 9H), 3.28-3.18 (m, 5H), 1.67-150 (m, 1H), 1.31-
1.21 (m, 1H), 1.15-1.01 (m, 1H), 0.88 (d, J= 6.7 Hz, ~2.5H), 0.86 (d, J= 6.9 Hz, ~2.4H), 0.79 (d, 
J= 6.7 Hz, ~0.6H), 0.72 (d, J= 6.0 Hz, ~0.6H)  ppm. 
13C NMR: (125 MHz, Acetone-d6): two conformers are present: major conformer: δ 173.5 (CO), 
164.3 (CO), 159.6 (d, J=248.9 Hz, C), 136.2 (C), 132.0 (d, J= 9.1 Hz, CH), 123.2 (d, J= 3.6 Hz, 
CH), 115.3 (d, J= 21.8 Hz, CH), 72.5 (CH2), 70.9 (CH2), 70.1 (CH2), 53.1 (CH2), 47.7 (CH3), 46.2 
(CH2), 40.6 (CH2), 26.3 (CH), 23.0 (CH3), 22.4 (CH3) ppm. 
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IR (HATR): 3462 (w), 2953 (m), 2924 (m), 2870 (m), 1649 (s), 1613 (s), 1578 (w), 1470 (m), 
1450 (w), 1420 (m), 1420 (m), 1394 (w), 1367 (w), 1338 (w), 1308 (w), 1274 (w), 1232 (w), 1198 
(w), 1098 (s), 1058 (m), 1045 (m), 993 (w), 879 (vw), 824 (w), 760 (m), 715 (w), 677 (w), 613 
(vw), 575 (vw) cm-1. 
TLC: Rf = 0.09 (Hexane/EtOAc/AcOH 1/1/1). 
 
XIII.4.8.3 3,4-DIHYDRO-3-ISOBUTYL-8-METHOXY-5-(4-
PHENYLBENZYL)BENZO[g][1,5]DIAZOCINE-2(1H),6(5H)-DIONE VI.91 
F.C.: dichloromethane/MeOH 99/1. 
CYC yield: 30% (yellow glass), 22 mg from 80 mg XIII.3  
Molecular Formula: C28H30N2O3 
Molecular weight: 442.54 g mol-1. 
LC-MS: peak at 6.9 min positive mode; ES-MS [m/z 
(fragment, intensity)]: 885.3 (2M+H+, 100), 443.2 (M+H+, 40).  
HRMS (ESI): Peak for C28H31N2O3
+ [M+H+]: calculated 443.2334, found 443.2338. 
1H NMR: (500 MHz, Acetone-d6): presence of two inversed boat-type conformers (ratio 80/20, 
individual assignment not possible): δ 8.50 and 8.35 (2x br.s, ratio 2/8, NH), 7.67-7.64 (m, 4H), 
7.51-7.45 (m, 4H), 7.37-7.34 (m, 1H), 7.21 (d, J=8.7 Hz, 1H), 7.08-7.01 (m, 2H), 5.32 (d, J=14.8, 
~0.8H), 5.30 (d, J=14.8, ~0.2H), 4.29 (d, J=14.8 Hz, ~0.8 H), 4.09 (d, J=15.0 Hz, ~0.2 H), 3.86 
(s, 3H), 3.56 (dd, J=9.7/14.7 Hz, ~0.2H), 3.32 (dd, J=13.8/6.9 Hz, ~0.8H), 3.16-2.90 (m, 2H), 
1.63-1.49 (m, 1H), 1.31 (ddd, J=14.0/8.6/6.0 Hz, 1H), 1.05 (ddd, J=14.0/8.1/6.3 Hz, 1H) 0.85 (d, 
J= 6.3 Hz, ~2.4H), 0.84 (d, J= 6.4 Hz, ~2.5H), 0.78 (br.d, J= 6.6 Hz, ~0.6H), 0.72 (br.d, J= 6.7 
Hz, ~0.6H) ppm. 
13C NMR: (125 MHz, Acetone-d6): two conformers are present: major conformer: δ 173.7 (CO), 
169.6 (CO), 159.8 (C), 141.6 (C), 141.1 (C), 137.9 (C), 137.6 (C), 129.8 (CH), 129.8 (CH), 129.3 
(CH), 128.3 (CH), 128.0 (CH), 127.8 (CH), 127.3 (C), 117.1 (CH), 113.2 (CH), 56.1 (CH3), 50.8 
(CH2), 48.5 (CH2), 46.6 (CH), 40.6 (CH2), 26.4 (CH), 23.1 (CH3), 22.6 (CH3) ppm. 
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IR (HATR): 3452 (w), 3028 (m), 2953 (m), 2869 (w), 1643 (s), 1487 (s), 1470 (s), 1434 (m), 1407 
(m), 1366 (w), 1319 (w), 1292 (m), 1219 (s), 1176 (w), 1118 (vw), 1097 (w), 1033 (w), 1007 (w) 
, 928 (vw), 857 (vw), 822 (vw), 760 (m), 739 (w), 696 (m), 638 (vw), 623 (m)  cm-1. 
TLC: Rf = 0.28 (Dichloromethane/MeOH 97/3). 
 
XIII.4.8.4 3,4-DIHYDRO-3-ISOBUTYL-5-(3-METHOXYBENZYL)BENZO[g][1,5]DIAZOCINE-
2(1H),6(5H)-DIONE VI.92 
F.C.: Dichloromethane/MeOH 99/1 
HPLC: method A, tret = 13.2 
CYC yield: 41% (brown glass), 30 mg from 79 mg XIII.4  
Molecular Formula: C22H26N2O3 
Molecular weight: 366.45 g mol-1. 
LC-MS: peak at 6.1 min; ES-MS positive mode [m/z (fragment, intensity)]: 733.3 (2M+H+, 100), 
367.1 (M+H+, 40).  
HRMS (ESI): Peak for C22H27N2O3
+ [M+H+]: calculated 367.2021, found 367.2011. 
1H NMR: (500 MHz, Acetone-d6): presence of two inversed boat-type conformers (ratio 80/20, 
individual assignment not possible): δ 8.72 and 8.53 (2x br.s, NH, ratio 2/8), 7.53-7.40 (m, 3H), 
7.26 (t, J= 7.1 Hz, 2H), 6.97-6.94 (m, 2H), 6.86-6.84 (m, 1H), 5.20 (d, J=14.8 Hz, ~0.8H), 5.14 
(d, J=15.3 Hz, ~0.2H), 4.32 (d, J=14.8 Hz, ~0.8H), 4.15 (d, J=14.5 Hz, ~0.2H), 3.80 (s, 3H), 3.60-
3.24 (m, 1H), 3.11-2.60 (m, 2H), 1.90-1.00 (m, 3H), 0.83 (d, J= 6.0 Hz, ~2.3H), 0.81 (d, J= 6.1 
Hz, ~2.6H), 0.76 (d, J= 6.3 Hz, ~0.6H), 0.69 (d, J= 6.1 Hz, ~0.6H) ppm. 
13C NMR: (125 MHz, Acetone-d6): no multiple conformers observed: δ 173.6 (CO), 169.8 (CO), 
161.1 (C), 139.9 (C), 136.5 (C), 134.7 (C), 131.6 (CH), 130.5 (CH), 128.7 (CH), 128.4 (CH), 127.6 
(CH), 121.2 (CH), 114.5 (CH), 114.0 (CH), 55.5 (CH3), 50.9 (CH2), 48.9 (CH2), 46.8 (CH), 40.7 
(CH2), 26.3 (CH), 23.0 (CH3), 22.5 (CH3) ppm. 
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IR (HATR): 3469 (vw), 3057 (w), 2954 (w), 1641 (s), 1600 (s), 1487 (m), 1470 (m), 1434 (m), 
1418 (m), 1365 (m), 1342 (m), 1305 (m), 1279 (m), 1258 (m), 1222 (m), 1163 (w), 1037 (w), 1004 
(w), 953 (vw), 914 (vw), 873 (w), 779 (m), 761 (m), 747 (m), 725 (m), 693 (m), 678 (w), 634 (w) 
cm-1.  
TLC: Rf = 0.31 (Dichloromethane/MeOH 95/5).  
 
XIII.4.8.5 5-CINNAMYL-3,4-DIHYDRO-3-ISOBUTYLBENZO[g][1,5]DIAZOCINE-
2(1H),6(5H)-DIONE VI.93 
F.C.: dichloromethane/MeOH 99/1 
HPLC: method B, tret = 30.5 
CYC yield: 44% (yellow glass), 20 mg from 47 mg XIII.5  
Molecular Formula: C23H26N2O2 
Molecular weight: 362.46 g mol-1. 
LC-MS: Peak at 6.3 min; ES-MS positive mode [m/z (fragment, intensity)]: 725.3 (2M+H+, 100), 
363.3 (M+H+, 25).  
HRMS (ESI): Peak for C23H27N2O2
+ [M+H+]: calculated 363.2072, found 363.2066. 
1H NMR: (500 MHz, Acetone-d6): presence of two inversed boat-type conformers (ratio 70/30, 
individual assignment not possible): δ 8.75-8.40 (m, NH), 7.60-7.20 (m, 9H), 6.74-6.62 (m, 1H), 
6.35-6.24 (m, ~0.7H), 5.80-5.70 (m, ~0.3H), 4.68-4.20 (m, 2H), 3.60-2.50 (m, 3H), 1.66-1.50 (m, 
1H), 1.35-1.22 (m, 1H), 1.10-0.98 (m, 1H), 0.90-0.61 (m, 6H) ppm. 
13C NMR: (125 MHz, Acetone-d6): two conformers are present: major conformer: δ 173.8 (CO), 
169.2 (CO), 137.9 (C), 136.8 (C), 134.5 (C), 134.1 (CH), 131.5 (CH), 129.8 (CH), 129.5 (CH), 
128.7 (CH), 128.5 (CH), 128.4 (CH), 127.6 (CH), 127.5 (CH), 126.0 (CH), 51.5 (CH2), 48.1 (CH2), 
47.8 (CH), 40.8 (CH2), 26.4 (CH), 23.0 (CH3), 22.5 (CH3) ppm. 
TLC: Rf =0.36 (Dichloromethane/MeOH 95/5). 
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XIII.4.8.5 3,4-DIHYDRO-3-(NAPHTH-2-YL)METHYL-5-METHYLBENZO[g][1,5]DIAZOCINE-
2(1H),6(5H)-DIONE VI.94 
F.C.: hexane/EtOAc/AcOH 1/1/1 
HPLC: method A, tret = 14.9 
CYC yield 80% (colorless glass), 41 mg from 118.2 mg XIII.6  
Molecular Formula: C22H20N2O2 
Molecular weight: 344.40 g mol-1. 
LC-MS: peak at 5.5 min; ES-MS positive mode [m/z (fragment, intensity)]: 689.2 (2M+H+, 100), 
345.1 (M+H+, 64).  
HRMS (ESI): Peak for C22H21N2O2
+ [M+H+]: calculated 345.1603, found 345.1593. 
1H NMR: (400 MHz, Acetone-d6): presence of two inversed boat-type conformers (ratio 75/25, 
individual assignment not possible): δ 8.70-8.40 (br.m, NH), 7.90-7.60 (m, 4H), 7.50-7.26 (m, 
6H), 7.20-7.05 (m, 1H), 3.75-3.40 (m, 2H), 3.35-3.16 (m, 1H), 3.13-3.03 (m, 3H), 3.00-2.80 (m, 
2H) ppm. 
13C NMR: (100 MHz, Acetone-d6): no multiple conformers observed: δ 172.5 (CO), 136.5 (C), 
136.1 (C), 134.5 (C), 133.4 (C), 131.1 (CH), 128.9 (CH), 128.4 (CH), 128.4 (CH), 128.3 (CH), 
128.2 (CH), 128.1 (CH), 127.3 (CH), 126.9 (CH), 126.4 (CH), 52.9 (CH2), 50.1 (CH), 37.8 (CH2), 
32.9 (CH3) ppm. 
IR (HATR): 3453 (vw), 3049 (w), 2920 (w), 1645 (s), 1632 (s), 1602 (s), 1575 (m), 1505 (w), 
1478 (m), 1441 (m), 1401 (s), 1357 (w), 1326 (w), 1271 (w), 1248 (w), 1228 (w), 1192 (vw), 1125 
(vw), 1106 (w), 1070 (w), 1037 (w), 1008 (w), 953 (vw), 915 (vw), 898 (vw), 860 (w), 821 (w), 
780 (m), 756 (m), 676 (w), 640 (w), 620 (w) cm-1. 
TLC: Rf = 0.17 (Hexane/EtOAc/AcOH 40/60/10). 
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XIII.4.8.6 8-BROMO-3,4-DIHYDRO-5-ETHYL-3-(NAPHTH-2-
YL)METHYLBENZO[g][1,5]DIAZOCINE-2(1H),6(5H)-DIONE VI.95 
F.C.: hexane/EtOAc/AcOH 60/40/10 
HPLC: method E, tret = 13.0 
CYC yield: 63% (brown glass), 48 mg from 80 mg XIII.7  
Molecular Formula: C23H21BrN2O2 
Molecular weight: 437.32 g mol-1. 
LC-MS: Peak at 6.2 min; ES-MS positive mode [m/z (fragment, intensity)]: 879 (2M(81Br)+H+, 
10), 875.0 (2M(79Br)+H+, 75), 440.0 (M (81Br)+H+, 25), 439.0 (M(81Br), 100), 438.0 (M (79Br)+H+, 
25). 
HRMS (ESI): Peak for C23H22
79BrN2O2
+ [M+H+]: calculated 437.0864, found 437.0876. 
1H NMR: (400 MHz, Acetone-d6): presence of two inversed boat-type conformers (ratio ~ 80/20, 
individual assignment not possible): δ 8.63 and 8.53 (2x br.s, NH, ratio 3/7), 7.90-7.05 (m, 9H), 
6.97 (d, J=8.2 Hz, 1H), 3.79-3.35 (m, 5H), 3.25-2.90 (m, 2H), 1.17 (t, J= 7.2 Hz, ~2.8H), 1.11 (t, 
J= 6.9 Hz, ~0.2H) ppm. 
13C NMR: (100 MHz, Acetone-d6): no multiple conformers observed: δ 172.7 (CO), 169.6 (CO), 
138.3 (C), 136.5 (C), 134.6 (C), 134.0 (CH), 133.7 (C), 133.5 (C), 131.3 (CH), 129.8 (CH), 129.3 
(CH), 129.0 (CH), 128.5 (CH), 128.4 (CH), 127.0 (CH), 126.5 (CH), 126.3 (CH), 120.7 (C), 51.3 
(CH2), 51.1 (CH), 41.5 (CH2), 37.8 (CH2), 13.4 (CH3) ppm. 
IR (HATR): 3401 (vw), 3187 (w), 3048 (w), 2975 (w), 1641 (s), 1631 (s), 1506 (w), 1470 (m), 
1433 (m), 1383 (m), 1349 (m), 1312 (m), 1279 (m), 1248 (w), 1219 (w), 1189 (w), 1156 (vw), 
1122 (w), 1078 (w), 1016 (w), 991 (w), 953 (vw), 899 (w), 863 (w), 818 (m), 744 (m), 697 (vw), 
647 (w), 619 (vw) cm-1.  
TLC: Rf = 0.10 (Hexane/EtOAc/AcOH 60/40/10). 
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XIII.4.8.7 5-(BUT-1-YN-4-YLE)-3,4-DIHYDRO-8-METHOXY-3-(NAPHTH-2-
YL)METHYLBENZO[g][1,5]DIAZOCINE-2(1H),6(5H)-DIONE VI.96 
F.C.: hexane/EtOAc/AcOH 60/40/10 
HPLC: method D, tret = 10.4 
CYC yield: 21% (brown glass), 23 mg from 74 mg XIII.8  
Molecular Formula: C26H24N2O3 
Molecular weight: 412.48 g mol-1. 
LC-MS: Peak at 6.0 min, ES-MS positive mode [m/z (fragment, intensity)]: 825.3 (2M+H+, 100), 
413.0 (M+H+, 90).  
HRMS (ESI): Peak for C26H25N2O3
+ [M+H+]: calculated 413.1865, found 413.1861. 
1H NMR: (500 MHz, CDCl3): presence of two inversed boat-type conformers (ratio 70/30, 
individual assignment not possible): δ 7.81-7.38 (m, 6H), 7.24-6.68 (m, 5H), 3.95-3.81 (m, 1H), 
3.80 (s, 3H), 3.70-3.25 (m, 4H), 3.30-2.78 (m, 2H), 2.67-2.42 (m, 2H), 1.95 (t, J= 2.5Hz, ~0.3H) 
1.87 (t, J = 2.5 Hz, ~0.7H)  ppm. 
13C NMR: (125 MHz, CDCl3): two conformers are present: major conformer: δ 172.9 (CO), 168.7 
(CO), 159.1 (C), 135.6 (C), 134.4 (C), 133.4 (C), 132.4 (C), 128.5 (CH), 127.8 (CH), 127.6 (CH), 
127.4 (CH), 126.9 (CH), 126.3 (CH), 125.8 (CH), 124.7 (C), 116.7 (CH), 112.3 (CH), 80.1 (C), 
70.1 (CH), 55.7 (CH3), 51.3 (CH2), 48.8 (CH), 45.1 (CH2), 37.2 (CH2), 17.8 (CH2) ppm. 
IR (HATR): 3434 (vw), 3054 (w), 2964 (w), 1637 (s), 1493 (m), 1476 (m), 1432 (m), 1397 (m), 
1356 (m), 1317 (m), 1289 (m), 1218 (m), 1180 (w), 1146 (w), 1124 (w), 1108 (w), 1076 (w), 1031 
(m), 963 (vw), 909 (w), 860 (w), 817 (m), 727 (m), 643 (m), 622 (m) cm-1.   
TLC: Rf = 0.12 (Hexane/EtOAc/AcOH 60/40/10). 
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XIII.4.8.8 3,4-DIHYDRO-5-(4-FLUOROBENZYL)-8-METHYL-3-(NAPHTH-2-
YL)METHYLBENZO[g][1,5]DIZAOCINE-2(1H),6(5H)-DIONE VI.97 
F.C.: dichloromethane/MeOH 99/1 
HPLC: method D, tret = 16.6 
CYC yield: 41% (colorless glass), 29 mg from 80 mg XIII.9  
Molecular Formula: C29H25FN2O2 
Molecular weight: 452.51 g mol-1. 
LC-MS: Peak at 6.7 min; ES-MS positive mode [m/z (fragment, intensity)]: 905.7 (2M+1H+, 70), 
493.9 (M+CH3CN+H
+, 10), 452.8 (M, 100).  
HRMS (ESI): Peak for C29H26FN2O2
+ [M+H+]: calculated 453.1978, found 453.1983. 
1H NMR: (400 MHz, CDCl3): presence of two inversed boat-type conformers (ratio ~ 75/25, 
individual assignment not possible): δ 7.84-6.70 (m, 15H), 5.31 (d, J=14 Hz, ~0.25H), 5.13 (d, 
J=14.7 Hz, ~0.75H), 4.24 (d, J=14.7 Hz, ~0.75H), 4.15 (d, J=14.9 Hz, ~0.25H), 3.43-3.25 (m, 
2H), 3.10-2.90 (m, 2H), 2.83-2.65 (m, 1H), 2.37 and 2.35 (2x br.s, 3H) ppm. 
13C NMR: (100 MHz, CDCl3): two conformers are present: major conformer: δ 172.7 (CO), 169.2 
(CO), 162.4 (d, J=246.5 Hz, C), 138.4 (C), 134.4 (C), 133.9 (C), 133.4 (C), 132.4 (C), 132.1 (d, 
J=2.9 Hz, C), 131.6 (CH), 130.1 (d, J= 8.1 Hz, CH), 129.7 (C), 128.5 (d, J= 7.3 Hz, CH), 127.6 
(CH), 127.4 (CH), 126.8 (CH), 126.2 (d, J= 16.1 Hz, CH), 125.8 (CH), 115.6 (d, J= 21.3 Hz, CH), 
49.0 (CH2), 48.4 (CH), 47.9 (CH2), 37.2 (CH2), 20.9 (CH3) ppm. 
IR (HATR): 3405 (vw), 3194 (w), 3048 (w), 2923 (w), 1637 (s), 1507 (m), 1473 (m), 1437 (m), 
1413 (m), 1388 (m), 1352 (m), 1312 (m), 1248 (w), 1219 (m), 1155 (m), 1094 (w), 1033 (w), 1016 
(vw), 954 (vw), 925 (vw), 891 (vw), 853 (w), 817 (s), 790 (m), 748 (m), 655 (vw), 627 (vw) cm-1.   
TLC: Rf = 0.07 (Dichloromethane/MeOH 99/1). 
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XIII.4.8.9 3-(4-CHLOROBENZYL)-3,4-DIHYDRO-8-METHOXY-5-
METHYLBENZO[g][1,5]DIAZOCINE-2(1H),6(5H)-DIONE VI.98 
F.C.: hexane/EtOAc/AcOH 80/20/10 
HPLC: method A, tret = 16.8 
CYC yield: 25% (yellow glass), 13 mg from 43mg XIII.10  
Molecular Formula: C19H19ClN2O3 
Molecular weight: 358.81 g mol-1. 
LC-MS: Peak at 5.4 min; ES-MS positive mode [m/z (fragment, intensity)]: 721.2 (2M(35Cl)+H+, 
15), 717.1 (2M(35Cl)+H+,90), 400.1 (M(37Cl)+CH3CN, 15), 361.0 (M (
37Cl)+H+, 35), 359.0 (M 
(35Cl)+H+, 100). 
HRMS (ESI): Peak for C19H20
35ClN2O3
+ [M+H+]: calculated 359.1162, found 359.1146. 
1H NMR: (400 MHz, Acetone-d6): presence of two inversed boat-type conformers (ratio 70/30, 
individual assignment not possible): δ 8.19 and 8.12 (2x br.s, NH, ratio 3/7), 7.17-6.93 (m, 5H), 
6.90-6.83 (m, 1H), 6.80-6.71 (m, 1H), 3.72 and 3.3.71 (2x s, 3H), 3.60-3.02 (m, 3H), 2.92 (s, 3H), 
2.64-2.52 (m, 2H) ppm. 
13C NMR: (100 MHz, Acetone-d6): no multiple conformers observed: δ 178.6 (CO), 169.6 (CO), 
159.7 (C), 138.1 (C), 132.1 (C), 131.7 (CH), 130.8 (C), 129.3 (CH), 129.1 (CH), 128.0 (C), 116.8 
(CH), 112.9 (CH), 56.1 (CH3), 52.9 (CH2), 50.0 (CH), 36.8 (CH2), 33.0 (CH3) ppm. 
IR (HATR): 3399 (br. m), 3059 (vw), 2921 (s), 2851 (m), 1659 (m), 1650 (m), 1641 (m), 1632 
(m), 1547 (vw), 1492 (m), 1441 (m), 1429 (s), 1410 (s), 1317 (s), 1259 (m), 1232 (m), 1159 (m), 
1091 (s), 1058 (s), 1033 (s), 1013 (s), 896 (vw), 872 (w), 820 (m), 799 (m), 767 (w), 718 (w), 703 
(vw), 661 (w), 610 (w) cm-1.  
TLC: Rf = 0.08 (Hexane/EtOAc/AcOH 60/40/10). 
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XIII.4.8.10 3-(4-CHLOROBENZYL)-3,4-DIHYDRO-5-
ISOPENTYLBENZO[g][1,5]DIAZOCINE-2(1H),6(5H)-DIONE VI.99 
F.C.: hexane/EtOAc/AcOH 80/20/10 
Chemical Formula: C22H25ClN2O2 
Molecular Weight: 384.89 g mol-1. 
LC-MS: Peak at 6.4 min; ES-MS positive mode [m/z (fragment, 
intensity)]: 773.3 (2M(37Cl)/(37Cl), 20), 769.3 (2M(35Cl)/(35Cl), 100), 
388.2 (M(37Cl)/(37Cl), 20), 385.2 (M (35Cl)+H+, 65). 
HRMS (ESI): Peak for C22H26
35ClN2O2
+ [M+H+]: calculated 385.1682, found 385.1689. 
1H NMR: (300 MHz, CDCl3): presence of two inversed boat-type conformers (ratio cannot be 
determined, individual assignment is not possible): δ 7.75 (br.s, NH), 7.55-7.30 (m, 3H), 7.24-6.64 
(m, 5H), 3.75-3.20 (m, 4H), 3.15-2.55 (m, 3H), 1.70-1.35 (m, 3H), 1.05-0.65 (m, 6H) ppm. 
13C NMR: (75 MHz, CDCl3): two conformers are present: major conformer δ 172.6 (CO), 168.4 
(CO), 135.4 (C), 134.8 (C), 132.8 (C), 132.1 (C), 130.8 (CH), 130.1 (CH), 128.8 (CH), 128.2 (CH), 
128.0 (CH), 126.0 (CH), 50.4 (CH2), 49.3 (CH), 44.8 (CH2), 36.5 (CH2), 36.4 (CH2), 26.2 (CH), 
22.4 (CH3) ppm. 
IR (HATR): 3295 (w), 3055 (w), 2955 (m), 2923 (m), 1637 (s), 1604 (m), 1575 (m), 1488 (m), 
1473 (m), 1443 (m), 1420 (m), 1395 (m), 1365 (m), 1317 (m), 1282 (w), 1248 (w), 1230 (w), 1196 
(w), 1153 (w), 1116 (w), 1091 (m), 1013 (m), 950 (vw), 914 (vw), 895 (w), 869 (w), 842 (m), 812 
(w), 779 (m), 759 (m), 722 (m), 660 (w), 634 (w), 568 (w) cm-1.  
TLC: Rf = 0.53 (Dichloromethane/MeOH 95/5). 
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XIII.4.8.11 8-BROMO-3-(4-CHLOROBENZYL)-3,4-DIHYDRO-5-(2-(2,5-DIOXOPYRROLIDIN-
1-YL)ETHYL)BENZO[g][1,5]DIAZOCINE-2(1H),6(5H)-DIONE VI.100 
F.C.: hexane/EtOAc/AcOH 80/20/10 
Chemical Formula: C23H21BrClN3O4 
Molecular Weight: 518.78 g mol-1. 
LC-MS: Peak at 5.7 min, ES-MS positive mode [m/z (fragment, 
intensity)]: 522.0 (M (81Br, 37Cl), 27), 521.0 (M (79Br, 37Cl)+H+, 
24), 520.0 (M (81Br, 35Cl), 100), 519.9 (M(79Br, 35Cl)+H+, 18), 
518.0 (M(79Br, 35Cl), 80). 
HRMS (ESI): Peak for C23H22
79Br35ClN3O4
+ [M+H+]: calculated 518.0482, found 518.0476. 
1H NMR: (300 MHz, CDCl3): presence of two inversed boat-type conformers (ratio cannot be 
determined, individual assignment not possible): δ 7.65-7.30 (m, 3H), 7.22 (d, J=8.3 Hz, 2H), 
7.10-6.90 (m, 2H), 6.77 (d, J=8.5 Hz, 1H), 4.35-4.05 (m, 1H), 3.95-3.75 (m, 1H), 3.68-3.57 (m, 
1H), 3.40-2.93 (m, 4H), 2.88-2.55 (m, 6H) ppm. 
13C NMR: (75 MHz, CDCl3): two conformers are present: major conformer δ 178.2 (CO), 178.0 
(CO), 172.9 (CO), 172.4 (CO), 168.6 (C), 135.4 (CH), 134.5 (C), 133.5 (CH), 131.5 (C), 131.3 
(CH), 130.6 (C), 129.3 (C), 129.1 (C), 128.9 (C), 128.0 (C), 122.2 (CH), 51.3 (CH2), 50.1 (CH2), 
48.9 (CH), 48.1 (CH2), 44.1 (CH2), 36.7 (CH2), 28.7 (CH2) ppm. 
IR (HATR): 3493 (vw), 1772 (w), 1697 (s), 1643 (s), 1594 (w), 1472 (m), 1428 (m), 1400 (m), 
1354 (m), 1330 (m), 1298 (w), 1251 (w), 1227 (w), 1153 (s), 1119 (m), 1089 (w), 1014 (w), 941 
(w), 911 (w), 882 (w), 816 (m), 795 (w), 771 (w), 729 (w), 700 (w), 665 (m), 613 (w), 596 (w) cm-
1
. 
TLC: Rf= 0.36 (Dichloromethane/MeOH 95/5). 
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XIII.4.8.12 5-BENZYL-8-BROMO-3-(4-CHLOROBENZYL)-3,4-
DIHYDROBENZO[g][1,5]DIAZOCINE-2(1H),6(5H)-DIONE VI.101 
F.C.: hexane/EtOAc/AcOH 80/20/10 
HPLC: method A, tret = 18.2 
CYC yield: 27% (yellow glass), 22 mg from 70 mg XIII.11  
Molecular Formula: C24H20BrClN2O2 
Molecular weight: 483.78 g mol-1. 
LC-MS: Peak at 6.7 min; ES-MS positive mode [m/z (fragment, intensity)]: 971.0 (2M(79Br, 
37Cl)+H+, 30), 967.0 (2M(79Br, 35Cl)+H+, 100), 527.1 (M (79Br, 37Cl)+CH3CN+H
+, 10), 488.0 (M 
(81Br, 37Cl)+ H+, 5), 486.0 (M (79Br, 37Cl)+ H+, 35), 485.0 (M (81Br, 35Cl), 90) . 
HRMS (ESI): Peak for C24H21
79Br35ClN2O2
+ [M+H+]: calculated 483.0474, found 483.0472. 
1H NMR: (400 MHz, CDCl3): presence of two inversed boat-type conformers (ratio cannot be 
determined, individual assignment not possible): δ 9.2 (br.s, 1H), 7.71-7.49 (m, 2H), 7.41-7.16 (m, 
7H), 7.06-6.78 (m, 3H), 5.34 (d, J=14.8 Hz, 0.3H), 5.23 (d, J =14.6 Hz, 0.7H), 4.26 (d, J = 14.8 
Hz, 0.7H), 4.14 (d, J = 15.1 Hz, 0.3H), 3.45-2.45 (m, 5H) ppm. 
13C NMR: (100 MHz, CDCl3): two conformers are present: major conformer: δ 172.0 (CO), 167.3 
(CO), 135.8 (C), 135.8 (C), 135.0 (C), 134.0 (CH), 133.0 (C), 132.5 (C), 131.2 (CH), 130.2 (CH), 
128.9 (CH), 128.9 (CH), 128.4 (CH), 128.1 (CH), 127.6 (CH), 121.8 (C), 49.1 (CH2), 48.6 (CH2), 
48.3 (CH), 36.2 (CH2) ppm. 
IR (HATR): 3259 (vw), 3059 (w), 3030 (w), 2965 (w),  2916 (w), 1643 (s), 1491 (m), 1470 (m), 
1441 (m), 1397 (m), 1355 (m), 1329 (w), 1261 (w), 1202 (w), 1182 (w), 1152 (w), 1091 (m), 1077 
(m), 1014 (m), 957 (w), 935 (w), 910 (w), 885 (vw), 812 (m), 799 (m), 762 (w), 731 (m), 698 (m), 
664 (w), 639 (vw), 634 (vw), 617 (w) cm-1.  
TLC: Rf = 0.47 (Hexane/EtOAc/AcOH 60/40/10). 
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XIII.5 SYNTHESIS OF N-FMOC-3-AMINO-3-ALKYLPROPIONIC ACIDS 
XIII.5.1 General procedure    
          
2 eq Na2CO3, 1 eq Fmoc-OSu,
VII.8
NH2
R
HO
O
NHFmoc
R
HO
O
VII.5
THF/H2O 2/1, r.t, o.n
 
To a solution of β-amino acid VII.8 (11.2 mmol, 1 eq) in a mixture of THF/H2O (112 ml) is added 
Na2CO3 (22.3 mmol, 2 eq). After 5 min, Fmoc-OSu (11.2 mmol, 1 eq) is added and the resulting 
mixture is stirred overnight at room temperature. The reaction mixture is acidified using 6 M HCl 
until pH=1-2 and after adding (20 ml) H2O, the aqueous phase is extracted three times with ethyl 
acetate. The combined organic layers are dried with anhydrous magnesium sulfate, the drying 
agent filtered and the volatiles removed under reduced pressure. The crude solid is purified by 
flash chromatography (F.C.). 
 
XIII.5.2 3-(N-(9-FLUORENYLMETHYLOXYCARBONYL)AMINO)BUTANOIC ACID VII.9 
F.C.: Dichloromethane/MeOH 98/2 to 85/15  
Yield: 83%; white fluffy powder, 13 g from 5 g XIII.12 
Molecular Formula: C19H19NO4 
Molecular weight: 325.34 g mol-1 
LC-MS: Peak at 5.0 min; ES-MS positive mode [m/z (fragment, intensity)]: 326.0 (M+H+, 100). 
HR-MS (ESI): C19H20NO4
+ [M+H+]: calculated 326.1392, found 326.1383. 
1H NMR: (300 MHz, DMSO-d6): presence of two carbamate rotamers on NMR-time scale (ratio 
cannot be determined): δ 7.89 (d, J = 7.5 Hz, 2H), 7.68 (d, J = 7.4 Hz, 2H), 7.51-7.20 (m , 4H), 
4.45-4.15 (m, 3H), 3.94-3.75 (m, 1H), 2.43 (dd, J= 7.0/15.6 Hz, 1H), 2.26 (dd, J= 7.2/15.1 Hz, 
1H), 1.08 (d, J= 6.4 Hz, 3H) ppm. 
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IR (HATR): 3317 (m), 3046 (w), 2922 (w), 1686 (s), 1532 (s), 1476 (w), 1448 (m), 1411 (w), 1374 
(w), 1349 (w), 1272 (m), 1256 (s), 1214 (s), 1164 (w), 1094 (m), 1052 (m), 994 (w), 938 (w), 925 
(w), 830 (w), 794 (w), 776 (w), 758 (m), 739 (s), 683 (w), 646 (w), 650 (w), 621 (w) cm-1. 
TLC: Rf = 0.44 (Dichloromethane/MeOH 90/10). 
 
XIII.5.3 3-(N-(9-FLUORENYLMETHYLOXYCARBONYL)AMINO)-4-PHENYLBUTANOIC 
ACID VII.11 
F.C.: Dichloromethane/MeOH 99/1 to 97/3  
Yield: 90%; white fluffy powder, 4 g from 2 g XIII.13  
Molecular Formula: C25H23NO4 
Molecular weight: 401.45g mol-1 
LC-MS: Peak at 5.6 min; ES-MS positive mode [m/z (fragment, 
intensity)]: 402.1 (M+H+, 100). 
1H NMR: (400 MHz, CDCl3): presence of two carbamate rotamers on NMR-time scale (ratio ~ 
90/10): δ 6.85 (d, J= 7.4 Hz, 2H), 7.64 (d, J = 7.4 Hz, 2H), 7.40 (dd, J=7.5 Hz, 2H), 7.32-7.10 (m, 
3H), 3.94-3.75 (m, 7H), 6.51 and 5.99 (2x br.s, NH, 9/1 ratio), 4.40-4.05 (m, 4H), 2.93 (d, J= 6.9 
Hz, 2H), 2.58 (d, J= 6.6 Hz, 1.81H), 2.44 (br.s, 0.22H) ppm. 
13C NMR: (100 MHz, CDCl3): two carbamate rotamers are present: major rotamer δ 172.8 (C), 
156.4 (C), 145.2 (C), 142.2 (C), 139.6 (C), 130.3 (CH), 129.2 (CH), 128.5 (CH), 128.0 (CH), 127.2 
(CH), 126.2 (CH), 120.8 (CH), 66.8 (CH2), 50.9 (CH), 49.2 (CH), 41.0 (CH2), 39.0 (CH2),  ppm.  
IR (HATR): 3312 (m), 3064 (w), 3031 (w), 2948 (w), 2920 (w), 1668.4 (s), 1620 (m), 1539 (m), 
1497 (m), 1475 (w), 1433 (m), 1416 (m), 1317 (m), 1298 (m), 1270 (m), 1214 (s), 1134 (m), 1099 
(m), 1081 (m), 1040 (m), 997 (w), 974 (w), 919 (w), 864 (w), 842 (vw), 816 (w), 780 (w), 758 
(w), 733 (m), 718 (w), 699 (m), 656 (m), 620 (w) cm-1. 
TLC: Rf = 0.46 (Dichloromethane/MeOH 90/10). 
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XIII.5.4 3-(N-(9-FLUORENYLMETHYLOXYCARBONYL)AMINO)-5-METHYLHEXANOIC 
ACID VII.10 
F.C.: Dichloromethane/MeOH 99/1 to 96/4  
Yield: 86%; white fluffy powder, 3.4 g from 2 g XIII.14  
Molecular Formula: C22H25NO4 
Molecular weight: 367.44 g mol-1 
LC-MS: Peak at 4.5 min; ES-MS positive mode [m/z (fragment, 
intensity)]: 368.2 (M+H+, 100). 
HR-MS (ESI): C22H26NO4
+ [M+H+]: calculated 328.1861, found 328.1858. 
1H NMR: (300 MHz, Acetone-d6): presence of two carbamate rotamers on NMR-time scale (ratio 
95/5): δ 7.85 (d, J=7.5 Hz, 2H), 7.80-7.63 (m, 1.95H), 7.62-7.54 (m, 0.05H), 7.46-7.05 (m, 4H), 
6.36 and 5.83 (2x br.s, NH, ratio 95/5). 4.33 (d, J=6.8 Hz, 1.84 H), 4.48-4.83 (m, 0.16H), 4.27-
4.18 (m, 1H), 4.15-3.99 (m, 1H), 2.59 (d, J=6.4 Hz, 0.22H), 2.54 (d, J= 6.4 Hz, 0.78H), 2.50 (d, 
J=6.7 Hz, 0.78H), 2.45 (d, J=6.6 Hz, 0.22H), 1.79-1.09 (m, 3H), 0.92 (dd, J= 5.5 Hz, 5.91H), 0.71 
(dd, J= 5.3 Hz, 0.09H) ppm. 
13C NMR: (75 MHz, Acetone-d6): two carbamate rotamers are present on NMR-time scale: major 
rotamer δ 173.3 (CO), 157.1 (C), 145.7 (C), 142.6 (C), 129 (CH), 128.4 (CH), 129.4 (CH), 126.6 
(CH), 121.2 (CH), 67.1 (CH2), 48.7 (CH), 47.9 (CH), 45.1 (CH2), 41.2 (CH2), 26.0 (CH), 24.1 
(CH3), 22.6 (CH3)  ppm.  
IR (HATR): 3331 (w), 3054 (w), 2957 (w), 1688 (s), 1530 (vw), 1532 (m), 1465 (w), 1447 (m), 
1420 (w), 1388 (w), 1365 (w), 1349 (w), 1297 (m), 1262 (m), 1231 (m), 1196 (m), 1155 (w), 1115 
(m), 1085 (m), 1039 (m), 994 (w), 972 (w), 936 (w), 851 (w), 799 (vw), 777 (w), 758 (m), 736 (s), 
683 (w), 645 (w), 640 (w), 622 (w) cm-1. 
TLC: Rf = 0.41 (Dichloromethane/MeOH 90/10). 
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XIII.6 SYNTHESIS OF N-CBZ-4-AMINOBUTAN-1-OL 
          
NH2
HO NHCbz
HO1 eq Et3N, 1 eq PhCH2OCOCl,
VII.27 VII.22
0.1 M CH2Cl2, 0C to r.t., 6 h
 
To a solution of 4-aminobutan-1-ol VII.27 (11.2 mmol, 1 eq) in CH2Cl2 (15 ml) is added Et3N 
(12.3 mmol, 1.1 eq) and benzyl chloroformate (12.3 mmol, 1.1 eq) at 0 °C. The resulting mixture 
is stirred for 6 hours at room temperature. The reaction mixture is diluted with saturated NH4Cl 
(50ml) at 0C. The organic layer washed with brine (50 ml). The combined organic layers are dried 
with anhydrous magnesium sulfate, the drying agent filtered and the volatiles removed under 
reduced pressure. The crude liquid is purified by flash chromatography (F.C.). 
XIII.6.1 4-N-(CARBOXYBENZYL)BUTAN-1-OL VII.22 
F.C.: Dichloromethane/MeOH 99/1 to 96/4  
Yield: 98%; white powder, 2.4 g from 1 g VII.27 
Molecular Formula: C12H17NO3 
Molecular weight: 223.27 g mol-1 
LC-MS: Peak at 4.8 min; ES-MS positive mode [m/z (fragment, intensity)]: 224.2 (M+H+, 100). 
HR-MS (ESI): C12H18NO3
+ [M+H+]: calculated 224.1286, found 224.1277. 
1H NMR: (300 MHz, CDCl3): δ 7.39-7.28 (m, 5H), 5.11 (br.s, 2 H), 3.66 (t, J= 5.8 Hz, 2H), 3.23 
(t, J=6.6 Hz, 2H), 1.70-1.52 (m, 4H) ppm. 
13C NMR: (75 MHz, Acetone-d6): δ 156.5 (CO), 136.6 (C), 129.5 (CH), 128.1 (CH), 128.1 (CH), 
66.6 (CH2), 62.3 (CH2), 40.9 (CH2), 29.6 (CH2), 26.5 (CH2) ppm.  
IR (HATR): 3366 (m), 3324 (m), 3040 (w), 2948 (w), 1682 (m), 1586 (w), 1529 (m), 1488 (w), 
1365 (w), 1336 (m), 1267 (m), 1233 (m), 1137 (w), 1103 (w), 1054 (m), 1030 (w), 1010 (m), 961 
(w), 908 (w), 843 (w), 781 (w), 749 (w), 727 (m), 696 (w), 638 (w) cm-1. 
TLC: Rf = 0.2 (Dichloromethane/MeOH 90/10). 
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XIII.7 SYNTHESIS OF 4-SUBSTITUTED-1,5-BENZODIAZOCINE-2,6-DIONES 
XIII.7.1 β3-Amino acid coupling on Wang resin 
OH
1. 2 eq Fmoc-AA-OH, 2 eq DIC, 0.2 eq DMAP, 
     CH2Cl2, r.t, 24 h
2. Ac2O/DIPEA/CH2Cl2  (1/1/3), r.t, 2x1 h
NH2
O
O
3. 20% 4-methylpiperidine in DMF, 2x20 min
R1
VII.6 VII.16
 
General procedure: Preactivation: To a cooled (0°C) solution of N-Fmoc-β3-amino acid VII.9-
VII.11 (2 eq) in CH2Cl2 (5 ml), DIC (5.449 mmol, 2 eq) is added. The reaction mixture is stirred 
for 20 minutes at 0 °C.  
Coupling: The crude preactivation mixture is transferred to a solid-phase reaction vessel 
containing Wang resin (0.5 mmol, 1 eq, calculated from manufacturer’s loading 1.9 mmol/g), 
washed and preswollen with CH2Cl2) after which DMAP is added (0.5449 mmol, 0.2 eq). The 
suspension is shaken for 24 hours at room temperature after which the resin is filtered and washed 
consecutively with CH2Cl2 (3x), DMF (3x), MeOH (3x), and CH2Cl2 (3x).  
Capping: The resin is suspended in Ac2O/DIPEA/CH2Cl2 (1/1/3, 10 ml) and shaken for 1 h. The 
resin is filtered and washed with CH2Cl2. This capping procedure is repeated once. The resin is 
filtered and consecutively washed with CH2Cl2 (3x), DMF (3x), MeOH (3x) and CH2Cl2 (3x) and 
dried under reduced pressure.  
Loading: The loading of the resulting resins was determined by Fmoc UV quantification: Fmoc-
β-Homoala-Wang: 0.6690 mmol/g, Fmoc-β-Homoleu-Wang: 0.6894 mmol/g, Fmoc-Homophe-
Wang: 0.6429 mmol/g.Yields of final products were calculated in reference to these loading 
values. An amount of resin-bound Fmoc-amino acid is suspended in a 20% 4-methylpiperidine 
solution in DMF. The absorbance of the dibenzofulvene/4-methylpiperidine adduct at 300 nm is 
correlated to its concentration using a calibration line. 
Deprotection: The resin is washed with DMF (3x) and treated with a solution of 20% 4-
methylpiperidine in DMF for 20 min. The resin is filtered and washed with DMF (3x). The 4-
methylpiperidine treatment is repeated once. The resin is subsequently filtered and washed with 
DMF (3x), MeOH (3x), CH2Cl2 (3x) and DMF (3x). 
Part 3: Experimental Procedures 
 
256 
 
-Amount of resin. For synthesis of the individual library members we used 0.2427 mmol of the 
above-prepared Fmoc-β-amino acid-loaded Wang resins. 
 
XIII.7.2 Nosyl coupling 
NHFmoc
O
O N
H
O
O
S
OO NO2
 5 eq o-Ns-Cl, 10 eq collidine,
CH2Cl2, r.t, 2 x 1 h
R1 R1
VII.16 VII.17
 
General procedure: to a suspension of resin VII.16 (0.428 g, 0.243 mmol, 1 eq) in dry DCE (6 
ml) is added 2,4,6-collidine (321 μl, 2.427 mmol, 10 eq) and 2-nitrobenzenesulfonyl chloride (269 
mg, 1.213 mmol, 5 eq). After 1 hour shaking, the resin is filtered and washed with DMF (3x15 
ml), MeOH (3x15 ml) and CH2Cl2 (3x15 ml). This procedure is repeated once, delivering the nosyl 
protected resin bound amino acid VII.17.  
This reaction was optimized for compounds VII.16, with R1=methyl or benzyl. LC-MS analysis 
after cleavage of a small amount of resin-bound material confirmed the identity of the expected 
products. 
Molecular Formula: C10H12N2O6S 
Molecular Weight: 288.27 g mol-1. 
LC-MS: Peak at 3.5 min; ES-MS negative mode [m/z (fragment, 
intensity)]: 287.0 (M-H+, 100). 
Molecular Formula: C16H16N2O6S 
Molecular Weight: 364.37 g mol-1. 
LC-MS: Peak at 4.5 min; ES-MS positive mode [m/z (fragment, 
intensity)]: 382.0 (M+ NH4
+, 100), 365.0 (M+H+, 18). 
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XIII.7.3 Mitsunobu alkylation 
N
H
O
O
S
OO NO2
N
O
O
S
OO NO2
10 eq VII.20-VII.26, 5 eq Ph3P, 
5 eq DIAD, DCE, r.t, 3x2h
R2
R1 R1
VII.17 VII.18
 
General procedure: the resin was suspended in DCE (9.2 ml) and triphenylphosphine (319 mg, 
1.214 mmol, 5. eq), alcohol VII.20-VII.26 (2.427 mmol, 10 eq) and DIAD (318 ml, 1.214 mmol, 
5 eq) were sequentially added. The reaction mixture is shaken for 2 h at room temperature after 
which the resin is drained and washed with dry dichloromethane and dry DCE. This Mitsunobu 
procedure was repeated twice, the resin was filtered and washed with DMF (3x15 ml), MeOH 
(3x15 ml) and CH2Cl2 (3x15 ml).  
This reaction was optimized for compounds VII.18, with (R1=methyl, R2=methyl), (R1=methyl, 
R2=benzyl), (R1=benzyl, R2=methyl) or (R1=benzyl, R2=benzyl). LC-MS analysis after cleavage 
of a small amount of resin-bound material confirmed the identity of the expected products. 
Molecular Formula: C11H14N2O6S 
Molecular Weight: 302.3 g mol-1. 
LC-MS Peak at 3.7 min; ES-MS positive mode [m/z (fragment, 
intensity)]: 320.0 (M+NH4
+, 100), 303.1 (M+H+, 35). 
Molecular Formula: C17H18N2O6S 
Molecular Weight: 378.39 g mol-1. 
LC-MS: Peak at 4.8 min; ES-MS positive mode [m/z (fragment, 
intensity)]: 396.1 (M+NH4
+, 58), 379.1 (M+H+, 100). 
Molecular Formula: C17H18N2O6S 
Molecular Weight: 378.39 g mol-1 
LC-MS: Peak at 4.7 min; ES-MS positive mode [m/z (fragment, 
intensity)]: 396.1 (M+H2O, 100), 379.0 (M+H
+, 20). 
N
O
HO
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Molecular Formula: C23H22N2O6S 
Molecular Weight: 454.49 g mol-1 
LC-MS: Peak at 5.5 min; ES-MS positive mode [m/z (fragment, 
intensity)]: 472.1 (M+H2O, 100), 455.0 (M+H
+, 100). 
 
 
XIII.7.4 Nosyl removal 
N
O
O
S
OO NO2
Me
NH
O
O
R2
2.5 eq DBU, 5 eq HSCH2CH2OH
DMF, r.t, 2x30min
R1 R1
VII.18 VII.19
 
General procedure: the resin is suspended in DMF (4.8 ml) and DBU (90.7 μl, 0.6067 mmol, 2.5 
eq) and 2-mercaptoethanol (85.1 μl, 1.214 mmol, 5 eq) were added. The resulting suspension was 
shaken for 30 min after which the resin was drained and washed with DMF (3x15 ml), MeOH 
(3x15 ml) and CH2Cl2 (3x15 ml). This procedure is repeated once, after which the resin was 
drained and washed with DMF (3x15ml). 
This reaction was optimized for compounds VII.19, with R1=benzyl, R2=benzyl. LC-MS analysis 
after cleavage of a small amount of resin-bound material confirmed the identity of the expected 
products. 
Molecular Formula: C17H19NO2 
Molecular Weight: 269.33 g mol-1. 
LC-MS: Peak at 4.3 min; ES-MS positive mode [m/z (fragment, intensity)]: 
270.1 (M+H+, 100). 
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XIII.6.5 Coupling of Fmoc-anthranilic acids 
NH
O
O
R2
N
O
O
R2
O NHFmoc
10 eq VI.7-VI.10 and VII.7 , 5 eq DIC
CH2Cl2/DMF 9/1, r.t, 24 h
R3
R1 R1
VII.19 VII.28
 
General procedure: Preactivation: To a cooled solution (0°C) of the appropriate N-Fmoc-
protected anthranilic acid derivative VI.7-VI.10 and VII.7 (2.427 mmol, 10 eq) in CH2Cl2/DMF 
(9/1) (6 ml), is added DIC (127.6 μl, 1.214 mmol, 5 eq) and the reaction mixture was stirred for 
30 min at 0 °C.  
Coupling: The crude preactivation mixture was transferred to the appropriate resin VII.19, 
preswollen in CH2Cl2/DMF 9/1, and the resulting suspension is shaken for 24 h. The resin was 
drained and washed consecutively with DMF (3x15 ml), MeOH (3x15 ml) and CH2Cl2 (3x15 ml).  
This reaction was optimized for compounds VII.28, with R1=benzyl, R2=methyl. LC-MS analysis 
after cleavage of a small amount of resin-bound material confirmed the identity of the expected 
products. 
Molecular Formula: C33H30N2O5 
Molecular Weight: 534.60 g mol-1. 
LC-MS: Peak at 6.4 min; ES-MS positive mode [m/z (fragment, 
intensity)]: 535.2 (M+H+, 100). 
 
XIII.7.6 Fmoc removal 
N
O
O
R2
O NHFmoc
R3
20 % 4-methylpiperidine in DMF
r.t, 2x20min
N
O
O
R2
O NH2
R3
R1 R1
VII.28 VII.31
 
Removal of the Fmoc protecting group, see section XIII.6.1 
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XIII.7.7 Cleavage from the resin 
N
O
O
R2
O NH2
R3
N
O
HO
R2
O NH2
R3
TFA/H2O 9/1, 1 h.
R1 R1
VII.31 VII.32
 
General procedure: resin VII.31 is suspended in a mixture of trifluoroacetic acid/water 95/5 (10 
ml) and shaken for 1 hour at room temperature. The resin is filtered and washed extensively with 
dichloromethane. The filtrate is concentrated under reduced pressure and the obtained residue is 
further purified by flash chromatography (F.C.) or preparative reversed-phase HPLC. 
 
XIII.7.7.1  3-(N-ANTHRANOYL,N-METHYL)BUTANOIC ACID XIII.15  
F.C.: dichloromethane/MeOH 99/1 to 97/3 
SPS yield: 77% (colorless foam), 63 mg from 700 mg resin VII.16 
Molecular Formula: C12H16N2O3 
Molecular weight: 236.26 g mol-1. 
LC-MS: Peak at 3.411 min; ES-MS positive mode [m/z (fragment, intensity)]: 237.1 (M+H+, 100).  
HRMS (ESI): Peak for C12H17N2O3
+ [M+H+] calculated: 237.1239, found: 237.1236. 
1H NMR: (300 MHz, CDCl3): presence of two amide rotamers on NMR-time scale (two rotamers 
ratio 55/45): δ 7.15 (t, J = 7.6 Hz, 1H), 7.10-6.95 (m, 3H), 6.74 (br.s, 2H), 5.30-4.71 (m, ~0.55H), 
4.70-4.03 (m, ~0.45H), 2.85 (br.s, 3H), 2.70-2.22 (m, 2H), 1.26 (d, J =6.6 Hz, 3H) ppm.  
13C NMR: (75 MHz, CDCl3): no multiple conformers observed: δ 171.9 (CO), 130.5 (CH), 127.5 
(CH), 127.4 (CH), 127.2 (CH), 118.3 (C), 117.1 (C), 52.1 (CH), 38.04 (CH2), 31.6 (CH3), 18.0 
(CH3) ppm. 
IR (HATR): 3448 (w), 3360 (w), 2969 (w), 1715 (m), 1608 (s), 1578 (s), 1494 (m), 1483 (m), 1453 
(m), 1400 (m), 1356 (m), 1304 (m), 1255 (m), 1197 (m), 1159 (m), 1135 (m), 1064 (m), 1032 (m), 
938 (w), 888 (w), 860 (w), 837 (vw), 797 (w), 749 (s), 721 (w), 667 (vw), 640 (w) cm-1. 
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TLC: Rf = 0.15 (dichloromethane /MeOH 97/3). 
 
XIII.7.7.2  3-(N-ANTHRANOYL,N-BENZYL)BUTANOIC ACID XIII.16  
F.C.: Hexane/EtOAc/AcOH 55/45/1 
SPS yield: 46% (colorless glass), 66 mg from 700 mg resin VII.16  
Molecular Formula: C18H20N2O3 
Molecular weight: 312.36 g mol-1. 
LC-MS: Peak at 4.340 min; ES-MS positive mode [m/z (fragment, intensity)]: 313.1 (M+H+, 100).  
HRMS (ESI): Peak for C18H21N2O3
+ [M+H+] calculated: 313.1552, found: 313.1548. 
1H NMR: (400 MHz, CDCl3): presence of two amide rotamers on NMR-time scale (ratio ~50/50): 
δ 7.50-6.50 (m, 11H), 4.49 (br.s, 2H), 3.80-3.55 (m, ~0.48H), 3.28-2.95 (m, ~0.52H) 2.86-2.29 
(m, 2H), 1.22 (d, J = 6.5 Hz, 3H) ppm.  
13C NMR: (100 MHz, CDCl3): two amide rotamers are present on NMR-time scale: major rotamer 
δ 174.2 (CO), 171.0 (C), 137.6 (C), 131.4 (CH), 128.7 (CH), 127.0 (broad, CH), 124.5 (CH), 60.9 
(CH2), 52.7 (CH), 38.2 (CH2), 19.7 (CH3) ppm. 
IR (HATR): 3457 (vw), 3338 (vw), 3028 (w), 2938 (w), 2934 (w), 1704 (m), 1665 (m), 1614 (m), 
1589 (m), 1495 (m), 1441 (m), 1421 (m), 1383 (w), 1349 (m), 1298 (w), 1186 (s), 1133 (s), 1087 
(m), 1078 (m), 1018 (m), 975 (w), 911 (vw), 855 (vw), 836 (w), 797 (w), 781 (w), 749 (m), 721 
(m), 698 (m), 632 (w) cm-1. 
TLC: Rf = 0.05 (dichloromethane /MeOH 97/3). 
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XIII.7.7.3 3-(N-(-2-AMINO-5-METHOXYBENZOYL),N-(3-
TRIFLUOROMETHYLBENZYL))BUTANOIC ACID XIII.17  
F.C.: dichloromethane /MeOH 98/2 
SPS yield 57% (brown glass), 110 mg from 192 mg resin VII.16 
Molecular Formula: C20H21F3N2O4 
Molecular weight: 410.38 mol.g-1. 
LC-MS: Peak at 4.5 min; ES-MS positive mode [m/z (fragment, intensity)]: 411.1 (M+H+, 100).  
HRMS (ESI): Peak for C20H22F3N2O4
+ [M+H+] calculated: 411.1531, found: 411.1531. 
1H NMR (300 MHz, CDCl3): presence of two amide rotamers on NMR-time scale (ratio 75/25): δ 
8.79 (s, 2H), 7.58-7.31 (m, 5H), 6.98-6.55 (m, 2H), 5.00 (d, J =15.2 Hz, 1H), 4.50 (br.s, 1H), 4.28 
(d, J =15 Hz, 1H,), 3.81 (br.s, ~2.3H), 3.46 (br.s, ~0.7H), 2.77-2.30 (m, 2H), 1.35-1.18 (m, 3H) 
ppm.  
13C NMR (100 MHz, CDCl3): no multiple conformers observed: δ 170.5 (CO), 158.8 (C), 138.8 
(C), 130.7 (C), 130.5 (CH), 129.2 (CH), 126.5 (CH), 125.8 (C), 124.1 (CH), 123.7 (CH), 122.8 
(C), 115.2 (CH), 113.3 (CH), 55.7 (CH3), 52.8 (CH), 43.6 (CH2), 38.2 (CH2), 19.8 (CH3) ppm. 
IR (HATR): 3418 (w), 2974 (w), 2936 (w), 2841 (w), 1668 (m), 1632 (m), 1598 (s), 1503 (m), 
1455 (m), 1437 (m), 1421 (m), 1326 (s), 1290 (m), 1265 (m), 1191 (s), 1163 (s), 1120 (s), 1096 
(m), 1073 (m), 1029 (m), 987 (w), 943 (vw), 914 (w), 877 (w), 831 (w), 797 (m), 751 (w), 721 
(m), 701 (m), 656 (w), 632 (vw) cm-1. 
TLC: Rf = 0.47 (dichloromethane /MeOH 95/5). 
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XIII.7.7.4 3-(N-(-2-AMINO-5-METHOXYBENZOYL),N-(CARBOXYBENZYLAMINOBUT-4-
YL))BUTANOIC ACID XIII.18  
F.C.: dichloromethane /MeOH 99/1 to 98/2 
SPS yield 41% (pale brown glass), 89 mg from 700 mg resin VII.16 
Molecular Formula: C24H31N3O6 
Molecular weight: 457.51 mol.g-1. 
LC-MS: Peak at 4.3 min; ES-MS positive mode [m/z (fragment, 
intensity)]: 458.2 (M+H+, 100).  
HRMS (ESI): Peak for C24H32N3O6
+ [M+H+] calculated: 458.2291, 
found: 458.2289. 
1H NMR (300 MHz, CDCl3): presence of two amide rotamers on NMR-time scale (ratio cannot 
be determined): δ 9.08 (br.s, 2H), 7.62-6.69 (m, 8H), 5.07 (br.s 2H), 4.55-4.21 (m, 1H), 3.77 (br.s, 
3H), 3.55-2.20 (m, 6H), 1.75-1.07 (m, 7H) ppm. 
13C NMR (100 MHz, CDCl3): no multiple conformers observed: δ 156.7 (C), 136.6 (C), 129.3 (C), 
128.5 (CH), 128.0 (CH), 128.0 (CH), 117.8 (C), 115.5 (CH), 112.8 (CH), 66.5 (CH2), 55.6 (CH3), 
52.1 (CH), 40.7 (CH2), 40.2 (CH2), 38.4 (CH2), 30.9 (CH3), 27.4 (CH2), 25.6 (CH2) ppm.    
IR (HATR): 3333 (w), 2939 (w), 2874 (w), 1673 (s), 1622 (m), 1593 (m), 1503 (s), 1455 (m), 1430 
(m), 1382 (m), 1354 (m), 1326 (m), 1288 (m), 1259 (m), 1197 (s), 1181 (s), 1132 (s), 1086 (m), 
1028 (m), 912 (w), 879 (w), 833 (w), 798 (m), 776 (m), 737 (m), 720 (m), 697 (m), 640 (w) cm-1. 
TLC: Rf = 0.04 (dichloromethane /MeOH 95/5). 
 
XIII.7.7.5  3-(N-ANTHRANOYL,N-METHYL)-4-PHENYLBUTANOIC ACID XIII.19 
F.C.: dichloromethane /MeOH 97/3 
SPS yield: 76% (yellow glass) 130 mg from 442 mg resin VII.16  
Molecular Formula: C18H20N2O3 
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Molecular weight: 312.36 mol.g-1. 
LC-MS: Peak at 4.2 min; ES-MS positive mode [m/z (fragment, intensity)]: 625.2 (2M+H+, 5), 
313.1 (M+H+, 100).  
HRMS (ESI): Peak for C18H21N2O3
+ [M+H+] calculated: 313.1552, found: 313.1558. 
1H NMR (400 MHz, CDCl3): presence of two amide rotamers on NMR-time scale (ratio ~ 55/45): 
δ 7.58 (br.s, 2H), 7.37-6.80 (m, 7H), 6.77-6.30 (m, 2H), 5.33-5.10 (m, ~0.54H), 4.50-4.15 (m, 
~0.46H), 3.10-2.29 (s, 7H) ppm.  
13C NMR (100 MHz, CDCl3): two amide rotamers are present on NMR time scale: major rotamer: 
δ 174.5 (CO), 171.8 (CO), 141.3 (C), 137.2 (C), 130.5 (CH), 129.2 (CH), 129.0 (CH), 128.6 (CH), 
127.2 (CH), 122.3(C), 119.3 (CH), 117.6 (CH), 57.8 (CH), 38.2 (CH2), 36.2 (CH2), 27.3 (CH3) 
ppm. 
IR (HATR): 3455 (vw), 3362 (w), 3059 (w), 3026 (w), 2926 (w), 1708 (s), 1611 (s), 1582 (s), 1494 
(m), 1453 (m), 1401 (m), 1309 (m), 1263 (m), 1193 (s), 1135 (s), 1062 (m), 1030 (m), 982 (vw), 
965 (w), 909 (w), 832 (w), 737 (w), 749 (s), 731 (s), 722 (s), 699 (s), 642 (m) cm-1. 
TLC: Rf = 0.05 (dichloromethane /MeOH 97/3). 
 
XIII.7.7.6   3-(N-ANTHRANOYL,N-BENZYL)-4-PHENYLBUTANOIC ACID XIII.20 
F.C.: dichloromethane /MeOH 99/1 
HPLC: method A, tret = 12.3 
SPS yield 48% (yellow glass), 72 mg from 822 mg resin VII.16  
Molecular Formula: C24H24N2O3 
Molecular weight: 388.45 mol.g-1 
LC-MS: Peak at 5.0 min; ES-MS positive mode [m/z (fragment, intensity)]: 389.2 (M+H+, 100).  
HRMS (ESI): Peak for C24H25N2O3
+ [M+H+] calculated: 389.1865, found: 389.1866. 
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1H NMR (400 MHz, CDCl3): presence of two amide rotamers on NMR-time scale (ratio cannot 
be determined): δ 7.59-6.61 (m, 14 H), 5.18-4.10 (m, 2H), 3.80-2.25 (m, 5H) ppm. 
13C NMR (100 MHz, CDCl3): two amide rotamers are present on NMR-time scale: major rotamer 
δ 138.3 (C), 129.3 (C), 129.1 (C), 128.7 (CH), 128.7 (CH), 128.5 (CH), 126.8 (CH), 54.5 (CH2), 
42.9 (CH), 42.5 (CH2) 34.5 (CH2) ppm. 
IR (HATR): 3447 (w), 3363 (w), 3060 (w), 3026 (w), 2926 (w), 1713 (m), 1612 (s), 1587 (s), 1494 
(m), 1453 (m), 1412 (m), 1365 (m), 1305 (m), 1246 (m), 1216 (m), 1155 (m), 1108 (w), 1077 (w), 
1027 (m), 978 (w), 959 (w), 908 (w), 873 (w), 854 (w), 809 (vw), 749 (s), 698 (s), 652 (w), 632 
(vw) cm-1. 
TLC: Rf = 0.15 (dichloromethane /MeOH 97/3). 
 
XIII.7.7.7 3-(N-(2-AMINO-5-BROMOBENZOYL),N-(PENT-1-YL))-4-PHENYL BUTANOIC 
ACID XIII.21  
F.C.: dichloromethane /MeOH 99/1 
SPS yield 44% (beige glass), 101 mg from 800 mg resin VII.16  
Molecular Formula: C22H27BrN2O3 
Molecular weight: 447.36 mol.g-1. 
LC-MS: Peak at 5.1 min; ES-MS positive mode [m/z (fragment, 
intensity)]: 450.1 (M(81Br)+H+, 20), 449.0 (M(79Br)+H+, 100), 448.1 (M(81Br), 20), 447.1 
(M(79Br), 95).  
HRMS (ESI): Peak for C22H28
79BrN2O3
+ [M+H+] calculated: 447.1283, found: 477.1275. 
1H NMR (400 MHz, CDCl3): presence of two amide rotamers on NMR-time scale (ratio cannot 
be determined): δ 7.41-6.45 (m, 10H), 4.37 (br.s, 1H), 3.73-2.42 (m, 6H), 1.84-0.77 (m, 9H) ppm. 
13C NMR (100 MHz, CDCl3): no multiple conformers observed: δ 170.4 (CO), 138.4 (C), 132.9 
(CH), 129.5 (CH), 129.3 (CH), 129.2 (CH), 128.7 (CH), 128.5 (CH), 127.1 (CH), 126.8 (CH), 60.8 
(CH2), 42.9 (CH), 42.5 (CH2), 39.8 (CH2), 36.9 (CH2), 28.5 (CH2), 21.9 (CH2), 13.8 (CH3) ppm. 
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IR (HATR): 3446 (w), 3362 (w), 3065 (w), 3026 (w), 2954 (m), 2929 (m), 2869 (w), 1711 (s), 
1605 (s), 1580 (s), 1485 (s), 1454 (s), 1401 (m), 1361 (m), 1280 (m), 1255 (m), 1200 (s), 1144 (s), 
1104 (m), 1080 (w), 1029 (m), 885 (w), 816 (m), 749 (m), 722 (w), 699 (s), 668 (w), 621 (w) cm-
1. 
TLC: Rf = 0.23 (dichloromethane /MeOH 9/1). 
 
XIII.7.7.8 3-(N-(2-AMINO-4-TRIFLUOROMETHYLBENZOYL),N-(2-METHOXYETHYL))-4-
PHENYLBUTANOIC ACID XIII.22  
F.C.: dichloromethane /MeOH 98/2  
HPLC: method A, tret = 12.3 
SPS yield 56% (yellow glass), 130 mg from 800 mg resin VII.16 
Molecular Formula: C21H23F3N2O4 
Molecular weight: 424.41 mol.g-1. 
LC-MS: Peak at 4.7 min, ES-MS positive mode [m/z (fragment, intensity)]: 425.0 (M+H+, 100).  
HRMS (ESI): Peak for C21H24F3N2O4
+ [M+H+] calculated: 425.1688, found: 425.1697. 
1H NMR (400 MHz, CDCl3): presence of two amide rotamers on NMR-time scale (ratio cannot 
be determined): δ 7.55-6.90 (m, 8H), 6.8 (br.s, 2H), 4.38 (br.s, 1H), 4.10-2.85 (m, 11H) ppm.  
13C NMR (100 MHz, CDCl3): no multiple conformers observed: δ 171.3 (CO), 132.3 (d, J= 31.5 
Hz, C), 130.7 (CH), 129.9 (CH), 129.9 (CH), 127.8 (CH), 125.1 (d, J= 271.5 Hz, C), 113.4 (CH), 
112.9 (q, J= 4.4 Hz, CH), 71.1 (CH2), 59.1 (CH3), 43.1 (CH2), 39.3 (CH2), 30.7 (CH2), 30.6 (CH) 
ppm. 
IR (HATR): 3461 (w), 3362 (w), 3059 (w), 3027 (w), 2930 (w), 2891 (w), 1713 (m), 1624 (m), 
1594 (m), 1544 (w), 1510 (w), 1495 (w), 1436 (m), 1334 (s), 1287 (w), 1253 (m), 1202 (w), 1163 
(m), 1116 (s), 1089 (s), 1030 (w), 1015 (w), 924 (w), 870 (w), 817 (m), 777 (w), 747 (w), 700 (m), 
670 (w), 652 (vw) cm-1. 
TLC: Rf = 0.5 (dichloromethane /MeOH 95/5). 
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XIII.7.7.9 3-(N-(2-AMINO-5-BROMOBENZOYL),N-(4-FLUOROBENZYL))-4-
PHENYLBUTANOIC ACID XIII.23  
F.C.: dichloromethane /MeOH 98/2  
HPLC: method A, tret = 12.8 
SPS yield: 56% (colorless glass), 140 mg from 800 mg resin VII.16  
Molecular Formula: C24H22BrFN2O3 
Molecular weight: 485.35 mol.g-1. 
LC-MS: Peak at 5.1 min; ES-MS positive mode [m/z (fragment, intensity)]: 488.0 (M(Br81)+H+, 
25), 486.1 (M(Br79)+H+, 25).  
HRMS (ESI): Peak for C24H23
79BrFN2O3
+ [M+H+] calculated: 485.0876, found: 485.0862. 
1H NMR (400 MHz, acetone-d6): presence of two amide rotamers on NMR-time scale (ratio cannot 
be determined): δ 7.59-6.45 (m, 12H), 5.85-4.21 (m, 3H), 3.09-2.53 (m, 4H) ppm. 
13C NMR (100 MHz, aceone-d6): two amide rotamers are present on NMR-time scale: individual 
signals cannot be assigned; all signals are listed: δ 139.7 (C), 133.9 (C), 133.4 (CH), 133.3 (CH), 
131.6 (CH), 131.6 (CH), 131.5 (CH), 131.5 (CH), 131.2 (CH), 130.8 (CH), 130.6 (CH), 130.5 
(CH), 129.9 (CH), 129.9 (CH), 129.8 (CH), 129.8 (CH), 128.1 (CH), 128.0 (CH), 127.9 (CH), 
122.3 (CH), 119.1 (CH), 116.6 (CH), 116.4 (CH), 116.1 (CH), 108.5 (C) 59.8 (CH), 44.8 (CH2), 
42.7 (CH2), 40.9 (CH2), 38.8 (CH2) ppm. 
IR (HATR): 3449 (w), 3365 (w), 3059 (w), 3026 (w), 2932 (w), 1714 (s), 1661 (s), 1608 (s), 1583 
(s), 1508 (s), 1486 (m), 1453 (m), 1437 (m), 1413 (m), 1368 (m), 1295 (m), 1221 (s), 1201 (s), 
1155 (s), 1142 (s), 1097 (m), 1029 (w), 1014 (w), 985 (w), 961 (w), 890 (w), 817 (m), 749 (m), 
721 (w), 700 (m), 661 (w), 620 (w) cm-1. 
TLC: Rf = 0.11 (dichloromethane /MeOH 95/5). 
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XIII.7.7.10  3-(N-ANTHRANOYL,N-METHYL-)-5-METHYLHEXANOIC ACID XIII.24 
F.C.: dichloromethane /MeOH 98/2 to 97/3 
SPS yield: 99% (beige glass), 133 mg from 428 mg resin VII.16  
Molecular Formula: C15H22N2O3 
Molecular weight: 278.34 mol.g-1. 
LC-MS: Peak at 4.0 min; ES-MS positive mode [m/z (fragment, intensity)]: 557.2 (2M+H+, 15), 
279.1 (M+H+, 100).  
HRMS (ESI): Peak for C15H23N2O3
+ [M+H+] calculated: 279.1708, found: 279.1695. 
1H NMR (400 MHz, CDCl3): presence of two amide rotamers on NMR-time scale (ratio ~ 60/40): 
δ 8.70-7.01 (m, 4H), 6.8 (br.s, 2H), 5.18 (br.s, ~0.6H), 4.09 (br.s, 0.4H), 2.86 and 2.78 (2x br.s, 
3H), 2.65-2.29 (m, 2H), 1.71-1.20 (m, 3H), 1.03-0.60 (m, 6H) ppm.  
13C NMR (100 MHz, CDCl3): two amide rotamers are present on NMR-time scale: major rotamer 
δ 174.7 (CO) 130.0 (CH), 127.7 (CH), 125.8 (CH), 123.8 (CH), 49.0 (CH), 41.0 (CH2), 30.8 (CH3), 
29.6 (CH2), 24.9 (CH), 23.1 (CH3), 21.9 (CH3) ppm. 
IR (HATR): 3452 (w), 3362 (w), 2956 (m), 2928 (w), 2870 (w), 1711 (m), 1671 (m), 1612 (s), 
1583 (s), 1496 (m), 1453 (m), 1402 (m), 1368 (m), 1337 (m), 1266 (m), 1239 (m), 1185 (s), 1134 
(s), 1062 (m), 1032 (m), 955 (w), 921 (w), 901 (w), 873 (w), 834 (w), 797 (w), 749 (m), 720 (m), 
642 (w) cm-1. 
TLC: Rf = 0.18 (dichloromethane /MeOH 95/5). 
 
XIII.7.7.11  3-(N-ANTHRANOYL,N-BENZYL)-5-METHYLHEXANOIC ACID XIII.25  
F.C.: dichloromethane /MeOH 98/2 
SPS yield: 73% (brown glass), 125 mg from 428 mg VII.16  
Molecular Formula: C21H26N2O3 
Molecular weight: 354.44 mol.g-1. 
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LC-MS: Peak at 4.7 min, ES-MS positive mode [m/z (fragment, intensity)]: 355.1 (M+H+, 100).  
HRMS (ESI): Peak for C21H27N2O3
+ [M+H+] calculated: 355.2021, found: 355.2020. 
1H NMR (400 MHz, Acetone-d6): presence of two amide rotamers on NMR-time scale (ratio 
cannot be determined): δ 7.52-6.50 (m, 11H), 4.85-4.30 (m, 3H), 2.88-2.48 (m, 2H), 1.64-1.42 (m, 
2H), 0.95-0.55 (m, 6H) ppm. 
13C NMR (100 MHz, Acetone-d6): two amide rotamers are present on NMR-time scale: individual 
signals cannot be assigned; all signals are listed: δ  173.5 (CO), 170.7 (CO), 140.8 (C), 138.8 (C), 
131.9 (C), 131.2 (CH), 130.8 (CH), 129.6 (CH), 129.5 (CH), 128.9 (CH), 128.7 (CH), 126.7 (CH), 
122.9 (CH), 118.1 (CH), 55.7 (CH), 45.2 (CH2), 43.4 (CH2), 38.4 (CH2), 25.4 (CH), 23.2 (CH3), 
23.1 (CH3) ppm. 
IR (HATR): 3449 (w), 3362 (w), 3061 (w), 3029 (w), 2956 (m), 2868 (w), 1713 (m), 1681 (m), 
1614 (s), 1586 (s), 1494 (m), 1449 (m), 1437 (m), 1420 (m), 1366 (m), 1351 (m), 1304 (m), 1281 
(m), 1262 (m), 1203 (m), 1181 (s), 1150 (s), 1110 (m), 1077 (w), 1029 (w), 1002 (w), 977 (w), 
961 (w), 916 (w), 839 (w), 819 (vw), 798 (w), 782 (w), 751 (m), 735 (m), 722 (m), 698 (m), 673 
(vw), 646 (w), 616 (vw) cm-1. 
TLC: Rf = 0.23 (DCM/MeOH 95/5). 
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XIII.7.8 Cyclization in solution 
     
N
O
HO
R2
O NH2
R3
N
H
N
O
O R2
R3
DCC-PS, CH2Cl2, 
0.01M, 1h, r.t
R1
R1
VII.32
VII.1
 
General procedure: To a solution of purified α,ω-aminocarboxylic acids (0.048 mmol, 1eq) in  
CH2Cl2 (4.8 ml) is added polystyrene-bound DCC (loading 2.3 mmol/g, 0.141 mmol, 2.9 eq). The 
obtained suspension is shaken for 1 h at room temperature after which the resin was filtered and 
washed with CH2Cl2. The filtrate was concentrated under reduced pressure. The obtained crude 
compounds are purified by flash chromatography (F.C.) or preparative reversed-phase HPLC. 
XIII.7.8.1 3,4-DIHYDRO-4,5-DIMETHYLBENZO[g][1,5]DIAZOCINE-2(1H),6(5H)-DIONE 
VII.34 
F.C.: dichloromethane/MeOH 98/2 
CYC yield: 65% (white glass), 12 mg from 20 mg XIII.15  
Molecular Formula: C12H14N2O2 
Molecular weight: 218.25 g mol-1. 
LC-MS: Peak at 3.8 min; ES-MS positive mode [m/z (fragment, intensity)]: 437.2 (2M+H+, 100), 
260.2 (M+CH3CN+H
+, 30), 219.1 (M+H+, 45).  
HRMS (ESI): Peak for C28H33N2O4
+ [M+H+] calculated: 219.1133, found: 219.1137. 
1H NMR (300 MHz, Acetone-d6): presence of two inversed boat-type conformers (ratio 60/40): 
major conformer: (P)-(R)-IX.24: δ 8.50 (br.s, NH), 7.41-7.30 (m, 3H), 7.22 (d, J= 8.9 Hz, 1H), 
4.09 (ddq, J= 6.4/(3x)6.4/12.4 Hz, 1H),  2.96 (s, 1.8H), 2.83 (br.dd, J=16.3/5.8 Hz, 1H), 2.63 (dd, 
J=16.5/12.1Hz, 1H), 1.20 (d, J=6.7Hz, 3H). Minor conformer (M)-(R)-IX.24: 8.78 (br.s, NH), 
7.50-7.43 (m, 3H), 7.16 (d, J= 8.3 Hz, 1H), 3.86 (ddq, J=11.2/8.5/(x3)6.6 Hz, 1H), 3.06 (s, 3H), 
2.40 (dd, J=12.5/8.5 Hz, 1H), 2.25 (dd, J=12.5/11.3Hz, 1H), 1.15 (d, J=6.6 Hz, 3H) ppm. 
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13C NMR (75 MHz, Acetone-d6): two inverted boat-type conformers are present on NMR-time 
scale: individual signals cannot be assigned ; all signals are listed: δ 138.9 (C), 137.0 (C), 135.4 
(C), 131.6 (CH), 131.5 (CH), 131.3 (CH), 128.8 (CH), 128.6 (CH), 128.3 (CH), 127.7 (CH), 126.6 
(CH), 56.0 (CH2), 51.7 (CH2), 44.6 (CH2), 41.8 (CH2), 37.8 (CH3), 26.5 (CH3), 21.1 (CH3), 19.9 
(CH3) ppm. 
IR (HATR): 3226 (w), 3085 (w), 2989 (w), 2943 (w), 1659 (m), 1651 (m), 1614 (s), 1591 (s), 1574 
(m), 1494 (w), 1471 (m), 1443 (m), 1427 (m), 1402 (m), 1357 (s), 1343 (m), 1291 (w), 1251 (w), 
1233 (m), 1186 (w), 1169 (w), 1119 (w), 1106 (w), 1093 (w), 1066 (w), 1038 (w), 1021 (w),1010 
(w), 949 (w), 884 (w), 876 (w), 778 (w), 760 (s), 712 (m), 702 (m), 672 (w), 656 (w), 628 (w) cm-
1.  
TLC: Rf = 0.14 (Dichloromethane/MeOH 98/2). 
 
XIII.7.8.2 5-BENZYL-3,4-DIHYDRO-4-METHYLBENZO[g][1,5]DIAZOCINE-2(1H),6(5H)-
DIONE VII.35 
F.C.: hexane/EtOAc/AcOH 50/50/1 
CYC yield: 45% (white glass), 28 mg from 66 mg XIII.16  
Molecular Formula: C18H18N2O2  
Molecular weight: 294.34 g mol-1. 
LC-MS: Peak at 4.9 min; ES-MS positive mode [m/z (fragment, intensity)]: 0-100 % acetonitrile 
in 6 min. 589.2 (2M+H+, 65), 336.1 (M+CH3CN+H
+, 10), 295.1 (M+H+, 100).  
HRMS (ESI): Peak for C18H19N2O2
+ [M+H+] calculated: 295.1446, found: 295.1452. 
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1H NMR (400 MHz, CDCl3): presence of two inversed boat-type conformers: (ratio 60/40, 
individual assignment not possible): δ 8.00 and 7.84 (2x br.s, NH, ratio 6/4), 7.61 (dd, J=1.4/7.1 
Hz, 0.6H), 7.57 (dd, J= 1.6/7.0 Hz, 0.4H), 7.50-7.21 (m, 7H), 7.17 (br.d, J= 7.1Hz, 0.4H), 7.10 (d, 
J= 7.5 Hz, 0.6H), 4.99 (d, J= 15.2 Hz, 0.4H), 4.83 (d, J= 14.5 Hz, 0.6H), 4.71 (d, J= 14.5 Hz, 
0.6H), 4.58 (d, J= 15.6 Hz, 0.4H), 4.25-4.10 (m, 0.4H), 4.00-3.82 (m, 0.6H), 2.80-2.20 (m, 2H), 
1.07 (d, J= 6.7 Hz, 1H), 0.99 (d, J= 6.6Hz, 2H) ppm. 
13C NMR (100 MHz, CDCl3): two inverted boat-type conformers are present on NMR-time scale: 
individual signals cannot be assigned ; all signals are listed: δ 172.1 (C), 169.8 (C), 168.8 (C), 
138.4 (C), 137.0 (C), 136.8 (C), 134.9 (C), 134.0 (C), 132.7 (C), 130.8 (CH), 129.9 (CH), 128.9 
(CH), 128.6 (CH), 128.3 (CH), 128.1 (CH), 127.9 (CH), 127.7 (CH), 127.2 (CH), 127.2 (CH), 
127.0 (CH), 126.1 (CH), 125.4 (CH), 52.9 (CH2), 52.1 (CH), 52.3 (CH), 44.4 (CH2), 44.1 (CH2), 
40.8 (CH2), 21.4 (CH3), 20.3 (CH3) ppm.   
IR (HATR): 3395 (w), 3061 (w), 2971 (w), 2934 (w), 1668 (s), 1600 (s), 1540 (w), 1494 (m), 1477 
(m), 1449 (m), 1417 (m), 1374 (m), 1347 (m), 1207 (m), 1295 (w), 1252 (w), 1237 (w), 1201 (m), 
1167 (m), 1105 (m), 1079 (m), 1022 (s), 977 (w), 925 (w), 917 (w), 876 (vw), 848 (vw), 779 (m), 
760 (m), 725 (m), 697 (m), 676 (w), 632 (w), 610 (w) cm-1.  
TLC: Rf = 0.07 (hexane/EtOAc/AcOH 85/15/1) 
 
XIII.7.8.3 3,4-DIHYDRO-8-METHOXY-4-METHYL-5-(3-
(TRIFLUOROMETHYL)BENZYL)BENZO[g][1,5]DIAZOCINE-2(1H),6(5H)-DIONE VII.36 
F.C.: Hexane/EtOAc/AcOH 50/50/1 
CYC yield: 23% (yellow glass), 4.5 mg from 20 mg XIII.17  
Molecular Formula: C20H19F3N2O3 
Molecular weight: 392.37 g mol-1. 
LC-MS: Peak at 5.6 min; ES-MS positive mode [m/z (fragment, 
intensity)]: 785.2 (2M+H+, 70), 393.1 (M+H+, 100).  
HRMS (ESI): Peak for C20H20F3N2O3
+ [M+H+] calculated: 393.1426, found: 393.1430. 
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1H NMR (300 MHz, CDCl3): presence of two inversed boat-type conformers: (ratio 60/40, 
individual assignment not possible): δ 7.66-7.44 (m, 5H), 7.18-6.94 (m, 3H), 5.03 (d, J= 15.6 Hz, 
0.40H), 4.99 (d, J= 14.9 Hz, 0.60H), 4.61 (d, J= 14.7 Hz, 0.60H), 4.58 (d, J= 16.0 Hz, 0.40H), 
4.30-4.10 (m, 0.40H), 3.89 (s, 1.2H), 3.87 (s, 1.8H), 2.94-2.80 (m, 0.6H), 2.85-2.25 (m, 2H), 1.08 
(d, J=6.5 Hz, 1.2 H), 1.08 (d, J=6.6 Hz, 1.8H) ppm. 
13C NMR (75 MHz, CDCl3): two inverted boat-type conformers are present: major conformer: δ 
172.7 (CO), 171.1 (CO), 159.3 (C), 139.3 (C), 137.7 (C), 131.8 (CH), 129.2 (CH), 127.0 (CH), 
125.3 (d, J=3.9 Hz, CH), 124.7 (d, J=3.8 Hz, CH), 117.5 (CH), 113.9 (CH), 55.8 (CH3), 52.8 (CH), 
52.7 (CH2), 40.4 (CH2), 21.6 (CH3) ppm. 
IR (HATR): 3191 (w), 3064 (w), 2926 (w), 1653 (m), 1637 (s), 1617 (m), 1540 (w), 1493 (m), 
1473 (w), 1448 (m), 1436 (w), 1417 (w), 1405 (w), 1382 (w), 1340 (m), 1325 (s), 1287 (m), 1274 
(m), 1223 (m), 1194 (m), 1157 (m), 1116 (s), 1075 (s), 1037 (m), 1022 (m), 940 (w), 923 (w), 890 
(w), 811 (m), 799 (m), 770 (w), 749 (w), 744 (w), 701 (w). 659 (w), 643 (w), 620 (w) cm-1.   
TLC: Rf = 0.40 (hexane/EtOAc/AcOH 50/50/1). 
 
XIII.7.8.4 5-(CARBOXYBENZYLAMINOBUT-4-YL)-3,4-DIHYDRO-8-METHOXY-4-
METHYLBENZO[g][1,5]DIAZOCINE-2(1H),6(5H)-DIONE VII.37 
F.C.: Dichloromethane/MeOH 99/1 to 98/2 
CYC yield: 17% (yellow oil), 5 mg from 30 mg XIII.18  
Molecular Formula: C24H29N3O5 
Molecular weight: 439.51 g mol-1. 
LC-MS: Peak at 5.3 min; ES-MS positive mode [m/z (fragment, 
intensity)]: 440.2 (M+H+, 100).  
HRMS (ESI): Peak for C24H30N3O5
+ [M+H+] calculated: 440.2185, found: 440.2191. 
1H NMR (400 MHz, CDCl3): presence of two inversed boat-type conformers: (ratio ~ 67/33, 
individual assignment not possible): δ 7.44 (br.s, 0.67NH), 7.40-7.28 (m, 5H), 7.18 (br.s, 0.33NH), 
7.07 (d, J=8.4 Hz, 0.35H), 7.03-6.88 (m, 2.67H), 5.39 (br.s, 0.67NH), 5.25 (br.s, 0.33H), 5.19-
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5.05 (m, 2H), 4.23-4.11 (m, 0.67H), 4.10-3.98 (m, 0.33H), 3.84 (s, 3H), 3.87-3.74 (m, 0.67H), 
3.69-3.58 (m, 0.33H), 3.45-3.10 (m, 0.33H), 2.98-2.85 (m, 0.67H), 1.67-1.48 (m, 4H), 1.21 (d, J= 
7.1 Hz, 1.00H), 1.17 (d, J = 6.7 Hz, 2.00H) ppm. 
13C NMR (100 MHz, CDCl3): two inverted boat-type conformers are present: individual signals 
cannot be assigned; all signals are listed: δ 168.1 (CO), 159.2 (C), 138.5 (C), 136.9 (C), 128.4 
(CH), 128.0 (CH), 128.0 (CH), 128.0 (CH), 127.0 (CH), 126.6 (C), 125.0 (C), 117.6 (CH), 116.5 
(CH), 113.5 (CH), 66.4 (CH2), 55.7 (CH3), 52.9 (CH), 48.4 (CH2), 40.7 (CH2), 27.4 (CH2), 26.8 
(CH2), 25.1 (CH2), 21.5 (CH3) ppm. 
IR (HATR): 3312 (w), 3245 (w), 3064 (w), 2920 (m), 2868 (w),  
1715 (s), 1697 (s), 1669 (s), 1651 (s), 1622 (s), 1615 (s), 1555 (m), 1540 (m), 1522 (m), 1496 (s), 
1473 (s), 1454 (s), 1436 (m), 1374 (m), 1338 (m), 1320 (m), 1289 (m), 1233 (s), 1173 (m), 1132 
(m), 1088 (w), 1027 (m), 915 (vw), 871 (vw), 855 (w), 814 (w). 775 (w), 736 (w), 698 (w), 664 
(w), 654 (w), 600 (w) cm-1.     
TLC: Rf = 0.16 (Dichloromethane/MeOH 95/5). 
 
XIII.7.8.5 4-BENZYL-3,4-DIHYDRO-5-METHYLBENZO[g][1,5]DIAZOCINE-2(1H),6(5H)-
DIONE VII.38 
F.C.: dichloromethane/MeOH 99/1 
CYC yield: 46% (colorless glass), 5 mg from 10 mg XIII.19  
Molecular Formula: C18H18N2O2 
Molecular weight: 294.34 g mol-1. 
LCMS: Peak at 5.2 min, ES-MS positive mode [m/z (fragment, intensity)]: 589.3 (2M+H+, 100), 
336.1 (M+CH3CN+H
+, 10), 295.1 (M+H+, 100).  
HR-MS (ESI): Peak for C18H19N2O2
+ [M+H+] calculated: 295.1446, found: 295.1437. 
1H NMR (400 MHz, CDCl3): presence of two inversed boat-type conformers: (ratio ~ 50/50, 
individual assignment not possible): δ 7.55-6.90 (m, 9H), 4.34-4.25 (m, 0.47H), 4.10-3.90 (m, 
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0.53H), 3.3 (s, 1.47H), 2.95 (s, 1.53H), 2.93-2.74 (m, 1.59H), 2.67 (dd, J= 6.8/13.4 Hz, 1.41H) 
2.43 (d, J= 9.9 Hz, 1H) ppm. 
13C NMR (100 MHz, CDCl3): two inverted boat-type conformers are present: individual signals 
cannot be assigned; all signals are listed: δ 172.0 (CO), 170.3 (CO), 169.1 (CO), 168.4 (CO), 137.0 
(C), 136.3 (C), 136.3 (C), 135.0 (C), 133.7 (C), 132.7 (C), 130.9 (CH), 130.8 (CH), 130.1 (CH), 
129.1 (CH),  128.9 (CH),  128.8 (CH), 128.6 (CH), 128.2 (CH), 128.2 (CH), 127.6 (CH),  127.2 
(CH), 127.1 (CH), 126.3 (CH), 125.3 (CH), 61.0 (CH), 55.4 (CH), 41.7 (CH2), 41.3 (CH2), 39.4 
(CH2), 39.0 (CH3), 38.7 (CH2), 26.6 (CH3) ppm. 
 IR (HATR): 3201 (w), 3074 (w), 2940 (w), 2873 (w), 1664 (m), 1635 (m), 1620 (m), 1602 (s), 
1496 (w), 1480 (m), 1457 (w), 1431 (w), 1401 (m),1374 (w), 1207 (m), 1153 (s), 1108 (m), 1072 
(m), 1057 (m), 1028 (m), 1002 (m), 811 (w), 778 (w), 754 (m), 700 (m), 667 (w), 625 (w), 615 
(vw) cm-1.  
TLC: Rf = 0.12 (Dichloromethane/MeOH 97/3). 
 
XIII.7.8.6 4,5-DIBENZYL-3,4-DIHYDROBENZO[g][1,5]DIAZOCINE-2(1H),6(5H)-DIONE 
VII.39 
F.C.: hexane/EtOAc/AcOH 50/50/1 
CYC yield: 48% (colorless glass), 14 mg from 35 mg XIII.20  
Molecular Formula: C24H22N2O2 
Molecular weight: 370.44 g mol-1. 
LC-MS: Peak at 5.8 min; ES-MS positive mode [m/z (fragment, intensity)]: 
741.3 (2M+H+, 20), 371.2 (M+H+, 100).  
HRMS (ESI): Peak for C24H23N2O2
+ [M+H+] calculated: 371.1759, found:.371.1750 
1H NMR (400 MHz, CDCl3): presence of two inversed boat-type conformers: (ratio 80/20, 
individual assignment not possible): δ 7.61-7.31 (m, 8H), 7.26-7.09 (m, 4H), 6.86 (d, J=7.3Hz, 
2H), 4.92 (d, J= 14.4Hz, ~0.8H), 4.80(s, ~0.4H), 4.49-4.34 (m, ~0.2H), 4.28 (d, J= 14.4 Hz, 
~0.8H), 4.08-3.95 (m, ~0.8H), 2.74-2.18 (m, 4H) ppm. 
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13C NMR (100 MHz, CDCl3): two inverted boat-type conformers are present: major conformer: δ 
171.9 (CO), 137.0 (C), 136.5 (C), 136.4 (C), 133.8 (C), 131.0 (CH), 130.1 (CH), 129.0 (CH), 129.0 
(CH), 128.8 (CH), 128.7 (CH), 128.2 (CH), 127.9 (CH), 127.1 (CH), 125.4 (CH), 57.4 (CH), 53.4 
(CH2), 42.5 (CH2), 38.8 (CH2) ppm 
IR (HATR): 3317 (vw), 3060 (w), 3027 (w), 3002 (w), 2922 (w), 2852 (w), 1667 (s), 1626 (s), 
1600 (m), 1491 (w), 1473 (m), 1450 (m), 1415 (w), 1383 (m), 1361 (w), 1340 (w), 1315 (m), 1291 
(w), 1256 (w), 1238 (w), 1199 (w), 1161 (w), 1149 (w), 1105 (w), 1077 (w), 1043 (w), 1027 (w), 
1003 (w), 974 (w), 951 (w), 935 (vw), 811 (w), 869 (vw), 845 (vw), 779 (m), 756 (m), 735 (s), 
703 (m), 696 (m), 645 (w), 634 (w), 616 (w) cm-1.  
TLC: Rf = 0.33 (hexane/EtOAc/AcOH 50/50/1). 
 
XIII.7.8.7 4-BENZYL-8-BROMO-3,4-DIHYDRO-5-PENTYLBENZO[g][1,5]DIAZOCINE-
2(1H),6(5H)-DIONE VII.40 
F.C.: Dichloromethane/MeOH 99/1 to 98/2 
CYC yield: 31% (white powder), 9 mg from 30 mg XIII.21  
Molecular Formula: C22H25BrN2O2 
Molecular weight: 429.35 g mol-1. 
LC-MS: Peak at 6.4 min; ES-MS positive mode [m/z (fragment, 
intensity)]: 859.0 (2M(79Br)+H+, 50), 432.1(M(81Br)+H+, 30), 431.1 (M(81Br), 30), 430.0 
(M(79Br)+H+, 24), 429.1 (M(79Br), 100)   
HRMS (ESI): Peak for C22H26
79BrN2O2
+ [M+H+] calculated: 429.1177, found: 429.1172. 
1H NMR (400 MHz, CDCl3): presence of two inversed boat-type conformers: (ratio 84/16, 
individual assignment not possible): δ 7.59-7.20 (m, 6H), 7.08-6.86 (m, 3H), 4.33-4.22 (m, 0.16H), 
4.10-3.90 (m, 1.68H), 3.67-3.54 (m, 0.16H), 3.33-3.21 (m, 0.16H), 2.99 (dd, J=14.0/7.8 Hz, 
0.16H), 2.86-265 (m, 2H), 2.63-2.52 (m, 0.84H), 2.51-2.35 (m, 1.68H), 1.60-1.15 (m, 6H), 0.93 
(t, J=7.0 Hz, 0.48H), 0.88 (t, J = 7.1 Hz, 2.52H) ppm. 
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13C NMR (100 MHz, CDCl3): two inverted boat-type conformers are present: major conformer: δ 
171.8 (CO), 166.4 (C), 138.8 (C), 135.7 (C), 133.5 (CH), 132.7 (CH), 132.6 (C), 129.4 (CH), 128.9 
(CH), 127.4 (CH), 126.5 (CH), 121.4 (C), 58.6 (CH), 50.3 (CH2), 41.8 (CH2), 38.5 (CH2), 29.0 
(CH2), 27.0 (CH2), 22.3 (CH2), 14.0 (CH3) ppm. 
IR (HATR): 3200 (w), 3064 (w), 3028 (w), 2956 (w), 2928 (w), 1676 (s), 1616 (s), 1474 (s), 1452 
(m), 1363 (m), 1312 (m), 1232 (w), 1178 (w), 1146 (w), 1121 (w), 1101 (w), 1079 (w), 1049 (vw), 
1028 (vw), 933 (vw), 915 (vw), 882 (w), 818 (w), 754 (w), 726 (w), 702 (m), 646 (vw), 618 (vw) 
cm-1. 
TLC: Rf = 0.50 (Dichloromethane/MeOH 95/5). 
 
XIII.7.8.8 4-BENZYL-3,4-DIHYDRO-5-(2-METHOXYETHYL)-9-
(TRIFLUOROMETHYL)BENZO[g][1,5]DIAZOCINE-2(1H),6(5H)-DIONE VII.41 
F.C.: Dichloromethane/MeOH 98/2 
CYC yield: 56.7% (white glass), 18 mg from 30 mg XIII.22  
Molecular Formula: C21H21F3N2O3 
Molecular weight: 406.39 g mol-1. 
LCMS: Peak at 5.7 min; ES-MS positive mode [m/z (fragment, intensity)]: 407.2 (M+H+, 100).  
HR-MS (ESI): Peak for C21H22F3N2O3
+ [M+H+] calculated: 407.1582, found: 407.1581. 
1H NMR (400 MHz, CDCl3): presence of two inversed boat-type conformers: (ratio 80/20, 
individual assignment not possible): δ 7.99 and 7.81 (2x br.s, NH, ratio 8/2), 7.68-7.50 (m, 2H), 
7.42-7.18 (m, 4H), 7.07-6.92 (m, 2H), 4.34-4.00 (m, 2H), 3.65-3.45 (m, 2H), 3.38 (s, 0.66H), 3.33 
(s, 2.34H), 3.10-2.30 (m, 5H) ppm. 
13C NMR (100 MHz, CDCl3): no multiple conformations observed: δ 171.8 (CO), 167.2 (C), 140.2 
(C), 136.6 (C), 134.4 (C), 132.7 (q, J= 33.0 Hz, C) 130.6 (CH), 129.2 (CH), 128.9 (CH), 127.3 
(CH), 124.7 (q, J= 3.7 Hz, CH), 123.0 (q, J= 272.9 Hz, C), 122.3 (q, J= 3.7 Hz, CH), 70.6 (CH2), 
59.3 (CH3), 55.9 (CH), 50.2 (CH2), 42.1 (CH2), 38.8 (CH2) ppm. 
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IR (HATR): 3198 (w), 3121 (w), 3059 (w), 2981 (w), 2926 (w), 1688 (m), 1651 (w), 1605 (s), 
1578 (w), 1513 (w), 1470 (w), 1453 (w), 1390 (w), 1371 (w), 1330 (s), 1299 (m), 1212 (w), 1173 
(m), 1117 (s), 1080 (m), 1069 (m), 1016 (w), 997 (w), 959 (w), 921 (w), 892 (w), 876 (w), 838 
(w), 813 (w), 778 (w), 755 (w), 735 (w), 717 (w), 701 (m), 670 (w), 642 (w) cm-1.     
TLC: Rf = 0.22 (Dichloromethane/MeOH 98/2). 
 
XIII.7.8.9 4-BENZYL-8-BROMO-3,4-DIHYDRO-5-(4-
FLUOROBENZYL)BENZO[g][1,5]DIAZOCINE-2(1H),6(5H)-DIONE VII.42 
F.C.: Dichloromethane/MeOH 98/2 
CYC yield: 23.9% (white powder), 7 mg from 30 mg XIII.23  
Molecular Formula: C24H20BrFN2O2 
Molecular weight: 467.33 g mol-1. 
LC-MS: Peak at 6.3 min; ES-MS positive mode [m/z (fragment, 
intensity)]: 937.0 (2M(81Br)+H+, 12), 935.0 (2M(79Br)+H+, 23), 470.0 (M(81Br)+H+, 28), 469.1 
(M(81Br), 100), 468.1 (M (79Br)+H+, 28), 467.0 (M (79Br), 100).  
HRMS (ESI): Peak for C24H21
79BrFN2O2
+ [M+H+] calculated: 467.0770, found: 467.0774. 
1H NMR (400 MHz, CDCl3): presence of two inversed boat-type conformers: (ratio 87/13, 
individual assignment not possible): δ 7.70 (d, J=2.3 Hz, 0.13H), 7.62 (br.s, NH), 7.58 (dd, 
J=2.3/8.3 Hz, 0.13H), 7.53 (dd, J=2.3/8.4 Hz, 0.87H), 7.70 (d, J=2.2 Hz, 0.87H), 7.40-7.16 (m, 
5H), 7.06-6.83 (m, 5H), 5.02 (d, J =14.5 Hz, 0.87H), 4.79 (d, J=15.5 Hz, 0.13H), 4.68 (d, J=15.6 
Hz, 0.13H), 4.49-4.28 (m, 0.13H), 4.08 (d, J = 14.6 Hz, 1H,), 4.09-3.98 (m, 0.87H), 2.84 (dd, 
J=6.8 Hz, 0.13H), 2.75-2.61 (m, 2.13H), 4.45 (dd, J=12.7/11.6 Hz, 0.87H), 2.30 (br.dd, J=12.6/8.3 
Hz, 0.87H) ppm. 
13C NMR (100 MHz, CDCl3): two inverted boat-like conformers are present: major conformer: δ 
171.6 (CO), 167.3 (CO), 162.4 (d, J= 246.5 Hz, C), 138.0 (C), 135.6 (C), 133.9 (CH), 133.0 (CH), 
132.7 (C), 132.0 (d, J= 2.9 Hz, C), 130.5 (d, J= 8.1 Hz, CH), 129.3 (CH), 128.9 (CH), 127.5 (CH), 
N
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126.5 (CH), 121.5 (C), 115.6 (d, J=21.3 Hz, CH), 57.7 (CH), 52.7 (CH2), 41.8 (CH2), 38.3 (CH2) 
ppm. 
IR (HATR): 3198 (w), 3062 (w), 3028 (w), 2922 (w), 1676 (s), 1615 (s), 1605 (s), 1508 (s), 1471 
(s), 1453 (m), 1415 (m), 1364 (m), 1343 (m), 1307 (m), 1261 (w), 1219 (s), 1179 (w), 1155 (m), 
1109 (w), 1095 (w), 1080 (w), 1049 (w), 1028 (w), 1015 (w), 970 (w), 933 (vw), 884 (w), 849 (w), 
821 (m), 777 (w), 754 (m), 731 (w), 702 (s), 656 (w), 647 (w), 614 (vw) cm-1.   
TLC: Rf = 0.19 (Dichloromethane/MeOH 98/2). 
 
XIII.7.8.10 3,4-DIHYDRO-4-ISOBUTYL-5-METHYLBENZO[g][1,5]DIAZOCINE-2(1H),6(5H)-
DIONE VII.43 
F.C.: Dichloromethane/MeOH 99/1 to 98/2 
CYC yield: 45% (colorless glass), 13 mg from 30 mg XIII.24  
Molecular Formula: C15H20N2O2 
Molecular weight: 260.33 g mol-1. 
LC-MS: Peak at 4.8 min, ES-MS positive mode [m/z (fragment, intensity)]: 521.2 (2M+H+, 100), 
302 (M+ CH3CN+H
+, 10), 261.1 (M+H+, 40).  
HRMS (ESI): Peak for C15H21N2O2
+ [M+H+] calculated: 261.1603, found: 261.1610. 
1H NMR (400 MHz, CDCl3): presence of two inversed boat-type conformers: (ratio 75/25, 
individual assignment not possible): δ 7.64 (br.s, NH), 7.54-7.37 (m, 3H), 7.17 (br.dd, J= 1/7.8 
Hz, 0.75H), 7.10 (br.dd, J= 1.2/7.9 Hz, 0.25H), 3.95 (dq, 4.5/9.4 Hz, 0.75H), 3.85-3.70 (m, 0.25H), 
3.18 (s, 0.77H), 3.00 (s, 2.23H), 2.71 (d, J=9.0 Hz, 1.46H), 2.52 (dd, J=12.4/9.0 Hz, 0.27H), 2.22 
(dd, J=12.3/10.7 Hz, 0.25H), 1.65-0.96 (m, 3H), 0.88 (d, J=6.4 Hz, 0.8H), 0.88 (d, J=6.4 Hz, 
0.88H), 0.85 (d, J=6.7 Hz, 2.2 Hz), 0.65 (d, J= 6.5 Hz, 2.2H) ppm. 
13C NMR (100 MHz, CDCl3): two inverted boat-like conformers are present: major conformer: δ 
170.5 (C), 169.4 (C), 135.0 (C), 132.8 (C), 130.8 (CH), 128.3 (CH), 127.5 (CH), 126.2 (CH), 52.6 
(CH), 45.3 (CH2), 41.9 (CH2), 26.2 (CH), 24.5 (CH3), 23.0 (CH3), 21.3 (CH3) ppm.  
N
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IR (HATR): 3483 (w) 3063 (w), 2954 (w), 2923 (w), 2869 (w), 1623 (br.s), 1602 (s), 1540 (w), 
1468 (m), 1454 (m), 1426 (m), 1401 (m), 1365 (s), 1287 (w), 1265 (w), 1234 (m), 1177 (w), 1116 
(w), 1070 (w), 1031 (w), 990 (vw), 953 (w), 926 (vw), 892 (vw), 847 (vw), 779 (w), 758 (m), 711 
(w), 660 (w), 628 (w), 614 (w) cm-1. 
TLC: Rf = 0.27 (Dichloromethane/MeOH 95/5). 
 
XIII.7.8.11 5-BENZYL-3,4-DIHYDRO-4-ISOBUTYLBENZO[g][1,5]DIAZOCINE-2(1H),6(5H)-
DIONE VII.44 
F.C.: Dichloromethane/MeOH 99/1 to 98/2 
CYC yield: 45% (colorless glass), 13 mg from 30 mg XIII.25  
Molecular Formula: C21H24N2O2 
Molecular weight: 336.42 g mol-1. 
LC-MS: Peak at 5.8 min; ES-MS positive mode [m/z (fragment, intensity)]: 
673.3 (2M+H+, 80), 337.1 (M+H+, 100).  
HRMS (ESI): Peak for C21H25N2O2
+ [M+H+] calculated: 337.1916, found: 337.1926. 
1H NMR (400 MHz, CDCl3): presence of two inversed boat-type conformers: (ratio ~ 65/35, 
individual assignment not possible): δ 7.69 (br.s, NH), 7.62-7.21 (m, 8H), 7.16 (dd, J= 1.7/7.8 Hz, 
0.4H), 7.09 (dd, J=1.5/7.8 Hz, 0.6H), 4.89 (d, J=14.2 Hz, 0.65H), 4.80 (d, J=15.1 Hz, 0.35H), 4.66 
(d, J=15.1 Hz, 0.35H), 4.61 (d, J=14.4 Hz, 0.65H), 4.15-4.01 (m, 0.35H), 3.85-3.72 (m, 0.65H), 
2.66-2.10 (m, 2H), 1.64-0.96 (m, 3H), 0.72 (d, J=6.4 Hz, 2H), 0.69 (d, J=6.3 Hz, 2H), 0.58 (d, 
J=6.3 Hz, 1H), 0.56 (d, J=6.4 Hz, 0.1H) ppm. 
13C NMR (100 MHz, CDCl3): two inverted boat-like conformers are present: major conformer: δ 
172.3 (CO), 170.3 (CO), 168.9 (C), 137.2 (C), 136.6 (C), 133.9 (C), 130.8 (CH), 129.0 (CH), 128.6 
(CH), 128.2 (CH), 128.1 (CH), 127.8 (CH), 125.4 (CH), 54.0 (CH), 53.2 (CH2), 45.8 (CH2), 39.1 
(CH2), 24.5 (CH), 23.4 (CH3), 20.9 (CH3) ppm; minor conformer: δ 170.4 (CO), 138.3 (C), 135.0 
(C), 132.7 (C), 127.5 (CH), 127.5 (CH), 126.1 (CH), 53.8 (CH), 44.5 (CH2), 42.7 (CH2), 42.1 
(CH2), 24.3 (CH), 22.3 (CH3), 21.4 (CH3) ppm. 
N
H
N
O
O
Part 3: Experimental Procedures 
 
281 
 
IR (HATR): 3197 (w), 3061 (w), 2954 (w), 2919 (w), 2868 (w), 1672 (s), 1620 (s), 1600 (s), 1494 
(m), 1477 (m), 1470 (m), 1452 (m), 1416 (m), 1370 (s), 1351 (m), 1323 (m), 1301 (m), 1287 (w), 
1248 (m), 1203 (w), 1184 (w), 1161 (m), 1104 (w), 1077 (w), 1028 (w), 1001 (w), 977 (w), 950 
(w), 918 (w), 882 (vw), 847 (w), 816 (w), 779 (m), 760 (s), 723 (m), 697 (s), 632 (w), 627 (w), 
614 (vw) cm-1.  
TLC: Rf = 0.34 (Dichloromethane/MeOH 95/5). 
XIII.8 SYNTHESIS OF N-FMOC-3-AMINO-2,2-DIALKYLPROPIONIC ACID  
XIII.8.1 Synthesis of METHYL 2-CYANO-2,5-(DIMETHYL)METHYL PENTANOATE VIII.11 
            
NC COOMe NC COOMe
Me1 eq K2CO3, 1 eq MeI, 0.1 M DMF, 1 hr
VIII.10 VIII.11
 
To a cooled (0 °C) solution of nitrile VIII.10 (0.99 mmol, 1 eq) in THF (10 ml) is added K2CO3 
(0.99 mmol, 1 eq). After 30 min, MeI (0.99 mmol, 1 eq) is added dropwise, and the reaction 
mixture is stirred for 1 hour. Ammonium chloride is added and the reaction mixture is extracted 
using ethylacetate (3x). The combined organic layers are concentrated under reduced pressure after 
which the residue is purified by flash chromatography in (hexane/ethylacetate 95/5). 
F.C.: hexane/EtOAc 95/5. 
Yield: 50% (colorless oil)  
Molecular Formula: C9H15NO2 
Molecular Weight: 169.22 g mol-1 
LC-MS: no ionization 
GC-MS: Peak at 9.9 min, ES-MS negative mode [m/z (fragment, intensity)]: 168 (M-H+), 154 (M-
Me-H+), 127 (M-Me -CN-H+).  
NC COOMe
Me
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1H NMR: (300 MHz, CDCl3): δ 3.82 (s, 3H), 1.94-1.66 (m, 3H), 1.61 (s, 3H), 1.02 (d, J= 6.6 Hz, 
3H), 0.91 (d, J= 6.4 Hz, 3H) ppm.  
13C NMR: (75 MHz, CDCl3): δ 170.4 (CO), 120.1 (CN), 53.4 (CH3), 46.5 (CH2), 42.9 (C), 26.1 
(CH), 25.1 (CH3), 23.3 (CH3), 22.3 (CH3) ppm.  
IR (HATR): 2959 (w), 2876 (vw), 2243 (vw), 1743 (s), 1626 (w), 1457 (m), 1436 (w), 1390 (w), 
1306 (w), 1284 (w), 1237 (s), 1185 (m), 1150 (m), 1084 (w), 986 (w), 980 (w), 929 (w), 850 (w), 
820 (w), 802 (w), 765 (w), 647 (vw), cm-1. 
TLC: Rf =0.19 (hexane/ EtOAc 95/5)  
 
XIII.8.1 Synthesis of METHYL 2-CYANO-2-(NAPHTH-2-YL)METHYL)PROPIONATE VIII.13 
        
NC COOMe NC COOMe
Me
5 eq MeI, 2eq NaOMe, THF 1M, 1h.
VIII.12 VIII.13
 
To a cooled (0 °C) solution of nitrile VIII.12 (4.18 mmol, 1eq) in THF (100 ml) is added NaOMe 
(8.38 mmol, 2 eq). After 30 min, MeI (20.9 mmol, 5 eq) is added dropwise, and the reaction 
mixture is stirred for 35 min. Water is added and the reaction mixture is extracted using 
ethylacetate (3x). The combined organic layers are concentrated under reduced pressure after 
which the residue is purified by flash chromatography in (hexane/ethylacetate 95/5). 
F.C.: hexane/EtOAc 95/5. 
Yield: 78% (yellow oil)  
Molecular Formula: C16H15NO2 
Molecular Weight: 253.29 g mol-1 
LC-MS: Peak at 6.4 min, ES-MS negative mode [m/z (fragment, intensity)]: 252.2 (M-H+, 5), 
329.2 (M, 20).  
NC COOMe
Me
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HRMS (ESI): C16H19N2O2
+
 [M+NH4
+]: calculated 271.1446; Found: 271.1444. 
1H NMR: (300 MHz, CDCl3): δ 7.86-7.82 (m, 3H), 7.75 (br.s, 1H), 7.53-7.47 (m, 2H), 7.41 (dd, 
1H, J=8.5/1.9 Hz), 3.75 (s, 3H), 3.42 (d, J = 13.4 Hz, 1H), 3.23 (d, J= 13.4 Hz, 1H), 1.69 (s, 3H) 
ppm.  
13C NMR: (75 MHz, CDCl3): δ 169.5 (CO), 133.2 (C), 132.8 (C), 131.6 (C), 129.0 (CH), 128.3 
(CH), 127.8 (CH), 127.6 (CH), 126.3 (CH), 126.1 (CH), 119.6 (CN), 53.4 (CH3), 45.3 (C), 43.8 
(CH2), 23.2 (CH3) ppm.  
IR (HATR): 3054 (w), 2987 (w), 2964 (w), 2953 (w), 1741 (s, sharp), 1633 (w), 1699 (w), 1508 
(w), 1453 (m), 1434 (m), 1379 (w), 1322 (w), 1283 (m), 1253 (s), 1232 (s), 1202 (m), 1156 (m), 
1115 (m), 1090 (w), 1017 (w), 984 (w), 897 (w), 859 (m), 822 (m), 783 (m), 748 (s), 663 (w), 634 
(vw), 623 (w) cm-1. 
TLC: Rf =0.16 (hexane/ EtOAc 95/5)  
 
XIII.8.2 Synthesis of METHYL 2-METHYL-3-(NAPHTH-2-YLMETHYL)-3-(TERT-
BUTOXYCARBONYL)AMINOPROPIONATE VIII.14 
COOMeNC
0.1 eq NiCl2.6H2O, 7 eq NaBH4, 2 eq Boc2O, 
0.2 M MeOH, 0 to r.t
COOMe
HN
Boc
VIII.13 VIII.14
 
To a cooled (0 °C) solution of the nitrile (10.06 mmol, 1 eq) in MeOH (82 ml) is added Boc2O 
(20.12 mmol, 2 eq) and NiCl2.6H2O (0.12 mmol, 0.1 eq). Afterwards NaBH4 (70.42 mmol, 7 eq) 
is added protionwise (0.22 eq every 10 min). After the addition, the reaction mixture is stirred 
overnight under N2 atmosphere, after which it is concentrated under reduced pressure. The residue 
is dissolved in ethyl acetate. After washing with a saturated aqueous solution of NaHCO3, the 
organic layer is dried over magnesium sulfate. The drying agent is filtered, the solvent is removed 
under reduced pressure and the residue is purified by flash chromatography. 
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F.C.: hexane/EtOAc 95/5 to 9/1. 
Yield: 60% (yellow oil)  
Molecular Formula: C21H27NO4 
Molecular Weight: 357.44 g mol-1 
LC-MS: Peak at 6.1 min; ES-MS positive mode [m/z (fragment, intensity)]: 258.1 (M M-
isobutene-CO2+H
+, 100), 226.1 (M-isobutene-CO2-OMe
-, 18), 197.1 (18).   
HRMS (ESI): C16H20NO2
+ [M-isobutene-CO2+H
+]: calculated 258.1494; Found: 258.1501. 
1H NMR: (300 MHz, CDCl3): δ 7.84-7.72 (m, 3H), 7.57 (br.s, 1H), 7.50-7.41 (m, 2H), 7.22 (dd, 
J=8.4/1.7 Hz, 1H), 4.97 (br.s, NH), 3.69 (s, 3H), 3.45-3.30 (m, 2H), 3.08 (d, J= 13.6 Hz, 1H), 3.00 
(d, J= 13.4 Hz, 1H), 1.46 (s, 9H), 1.24 (s, 3H) ppm.  
13C NMR: (75 MHz, CDCl3): δ 176.4 (CO), 156.1 (CO), 134.1 (C), 133.2 (C), 132.3 (C), 128.6 
(CH), 128.2 (CH), 127.7 (CH), 127.6 (CH), 127.6 (CH), 126.0 (CH), 125.5 (CH), 79.2 (C), 51.9 
(CH3), 48.7 (CH2), 47.0 (C), 43.3 (CH2), 28.3 (3XCH3) 20.3 (CH3) ppm.  
IR (HATR): 3372 (w), 3052 (w), 2975 (w), 1713 (s, sharp), 1633 (vw), 1600 (w), 1505 (m), 1454 
(m), 1391 (w), 1364 (m), 1332 (w), 1253 (m), 1245 (m), 1165 (s), 1042 (w), 1016 (w), 989 (vw), 
952 (w), 915 (w), 897 (w), 856 (m), 823 (m), 802 (m), 779 (w), 654 (w), 634 (w), 621 (w), 609 
(w) cm-1. 
TLC: Rf =0.10 (hexane/ EtOAc 9/1). 
 
 
 
 
 
 
 
COOMe
HN
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XIII.8.3 Synthesis of 2-METHYL-2-(NAPHTH-2-YLMETHYL)-2-(TERT-
BUTOXYCARBONYL)AMINOPROPIONIC ACID VIII.16 
COOMe
HN
Boc 4 eq NaOH, H2O/MeOH (2/1), 50°C, 2 h
COOH
HN
Boc
VIII.14 VIII.16
To a solution of methyl ester (8.3 mmol, 1 eq) in H2O/MeOH (2/1) (83 ml), is added NaOH (16.6 
mmol, 2 eq). The reaction mixture is refluxed at 50° C for 2 h, after which it is acidified with a 1 
M aqueous KHSO4 solution to pH 2. The product is extracted with ethyl acetate (600 ml) and 
filtered over silica, the residue is purified by column chromatography 
F.C (hexane/EtOAc/AcOH 97/3/1) 
Yield: 97% (yellow oil)  
Molecular Formula: C20H25NO4 
Molecular Weight: 343.41 g mol-1 
LC-MS: Peak at 4.9 min; ES-MS negative mode [m/z (fragment, intensity)]: 342.1 (M-H+, 100), 
268.1 (M-isobutene-H2O-H
+, 25).   
HRMS (ESI): C20H24NO4
- [M-H+]: calculated 342.1705; Found: 342.1710. 
1H NMR: (300 MHz, CDCl3): presence of two carbamate rotamers on NMR-time scale: (ratio ~ 
40/60): δ 7.82-7.73 (m, 3H), 7.63 (br.s, 1H), 7.49-7.42 (m, 2H), 7.30 (dd, 1H, J = 1.6/8.5 Hz), 6.28 
and 5.03 (2x br.s, NH, ratio 40/60), 3.78-3.55 (m, 0.37H), 3.41-3.35 (m, 0.63H), 3.10 (br.s, 2H), 
1.45 (s, 9H), 1.26 (s, 3H) ppm.  
13C NMR: (75 MHz, CDCl3): presence of two carbamate rotamers on NMR-time scale: δ 177.7 
(CO), 177.8 (CO), 157.8 (CO), 155.9 (CO), 135.7 (C), 135.6 (C), 133.5 (C), 132.3 (C), 128.3 (CH), 
127.6 (CH), 127.5 (CH), 127.5 (CH), 127.4 (CH), 127.3 (CH), 127.3 (CH) 127.1 (CH), 127.0 
(CH), 126.1 (CH), 125.5 (CH), 81.2 (C), 79.7 (C), 47.4 (CH3), 47.1 (CH3), 42.2 (CH2), 41.4 (C), 
35.9 (CH2), 28.3 (CH3), 28.2 (CH3), 28.2 (CH3) ppm.  
COOH
H
NO
O
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IR (HATR): 3457 (vw), 3323 (vw), 3052 (w), 2975 (w), 2929 (w), 2915 (w), 1697 (s, sharp), 1600 
(w), 1507 (m), 1454 (m), 1421 (m), 1392 (m), 1365 (m), 1332 (w), 1270 (m), 1248 (m), 1163 (s), 
1041 (w), 1016 (m), 950 (w), 910 (w), 895 (w), 856 (m), 821 (m), 776 (m), 746 (m), 734 (w), 650 
(w), 621 (w) cm-1. 
TLC: Rf = 0.34 (hexane/ EtOAc/AcOH 7/3/1). 
 
XIII.8.4 Synthesis of HCl salt of 2-METHYL-2-(NAPHTH-2-
YLMETHYL)AMINOHYDROCHLORIDEPROPIONIC ACID VIII.17 
          
COOH
HN
Boc
COOH
HCl.H2N
VIII.16 VIII.17
Dioxane/conc. HCl 9/1, r.t , 7 h.
  
To a solution of Boc-amino acid (3.211 mmol, 1 eq), in dioxane (32 ml) is added concentrated HCl 
4 ml. The obtained colorless solution is stirred for 7 h at room temperature, after which it is 
concentrated under reduced pressure to give the product as a white solid. The product is used as 
such in the next step.      
XIII.8.5 Synthesis of 3-(9-FLUORENYLMETHYLOXYCARBONYL)AMINO-2-METHYL-2-
(NAPHTH-2-YLMETHYL)PROPIONIC ACID VIII.8 
COOH
H
N
Me
VIII.8
44%
FmocCOOH
HCl.H2N i)  2 eq TMSiCl, 1 eq DIPEA, CH2Cl2, reflux 6 h. 
ii) 2 eq DIPEA, 1 eq FmocCl,  0 C-r.t, o.n
VIII.17
To a mixture of crude amino acid hydrochloride (3.211 mmol, 1 eq) in dichloromethane (32 ml), 
is added DIPEA (3.211 mmol, 1 eq) and TMSCl (6.432 mmol, 2 eq). The mixture is refluxed for 
6 hours then it is allowed to cool down to 0°C followed by addition of DIPEA (6.433 mmol, 2 eq) 
and FmocCl (3.211 mmol, 1eq). The reaction mixture is stirred overnight at room temperature. 
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The resulting white suspension is acidified using 6 M HCl to pH 1 and the resulting clear solution 
is extracted with EtOAc (3 x 50 ml). The combined organic phases are concentrated under reduced 
pressure. The obtained residue is further purified by flash chromatography. 
F.C.: Petroleum ether/Acetone 99/1 to 8/2. 
Yield: 44% (white powder) 
Molecular Formula: C30H27NO4 
Molecular Weight: 465.54 g mol-1 
LC-MS: Peak at 5.7 min; ES-MS positive mode [m/z (fragment, intensity)]: 931.2 (2M+H+, 40), 
243.1 ([M-dibenzofluvene-CO2+H
+], 100). 
HRMS (ESI): C30H28NO4
+ [M+H+]: calculated 466.2018, found: 466.2019. 
1H NMR: (300 MHz, Acetone-d6): δ 7.87-7.79 (m, 5H), 7.76 (s, 1H), 7.71 (d, J=7.5 Hz, 2H), 7.50-
7.38 (m, 5H), 7.34-7.29 (td, J =7.3/0.9 Hz, 2H), 6.4 (br.s., NH), 4.35 (d, J=6.9 Hz, 2H), 4.23 (t, J= 
6.9 Hz, 1H), 3.49 (br.s, 2H), 3.23 (d, J= 13.3 Hz, 1H), 3.01 (d, J= 13.2 Hz, 1H), 1.20 (2x br.s, 3H) 
ppm.  
13C NMR: (75 MHz, Acetone-d6): δ 177.4 (CO), 158.1 (C), 145.6 (C), 142.6 (C), 136.5 (C), 134.9 
(C), 133.8 (C), 130.1 (CH), 130.1 (CH), 129.0 (CH), 129.0 (CH), 128.9 (CH), 128.7 (CH), 128.4 
(CH), 127.2 (CH), 126.8 (CH), 126.6 (CH), 121.3 (CH), 67.5 (CH2), 49.7 (CH2), 49.0 (C), 48.6 
(CH), 43.8 (CH2), 20.9 (CH3) ppm. 
IR(HATR): 3421 (w), 3320 (w), 3052 (w), 3023 (w), 2923 (m), 2853 (w), 2581 (w), 1953 (vw), 
1697 (s, sharp), 1611 (w), 1600 (w), 1518 (m), 1507 (m), 1476 (w), 1462 (m), 1449 (m), 1415 (w), 
1385 (w), 1359 (w), 1324 (w), 1224 (br.m), 1153 (m), 1140 (m), 1023 (w), 987 (w), 962 (w), 950 
(w), 916 (w), 895 (w), 857 (w), 822 (m), 758 (m), 735 (s), 702 (w), 666 (w), 620 (w) cm-1. 
TLC: Rf = 0.11 (Petroleum ether/Acetone 8/2). 
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XIII.9 SYNTHESIS OF 3,3-DISUBSTITUTED-1,5-BENZODIAZOCINE-2,6-DIONES  
XIII.9.1 β2,2-Amino acid coupling on Wang resin 
OH
1. 2 eq Fmoc-AA-OH  VIII.8, 2 eq DIC, 
    0.2 eq DMAP, CH2Cl2, r.t, 24 h
2. Ac2O/DIPEA/CH2Cl2  (1/1/3), r.t, 2x1 h
3. 20% 4-methylpiperidine in DMF, 2x20 min
VIII.6
O
O
NH2
OAc
VIII.19
 
Preactivation: To a cooled (0°C) solution of N-Fmoc-β2,2-amino acid VIII.8 (2 eq) in CH2Cl2 (3 
ml), DIC (0.970 mmol, 2 eq) is added. The reaction mixture is stirred for 20 minutes at 0 °C.  
Coupling: The crude preactivation mixture is transferred to a solid-phase reaction vessel 
containing Wang resin (0.5 mmol, 1 eq, calculated from manufacturer’s loading 1.9 mmol/g), 
washed and preswollen with CH2Cl2) after which DMAP is added (0.0970 mmol, 0.2 eq). The 
suspension is shaken for 24 hours at room temperature after which the resin is filtered and washed 
consecutively with CH2Cl2 (3x), DMF (3x), MeOH (3x), and CH2Cl2 (3x).  
Capping: The resin is suspended in Ac2O/DIPEA/CH2Cl2 (1/1/3, 10 ml) and shaken for 1 h. The 
resin is filtered and washed with CH2Cl2. This capping procedure is repeated once. The resin is 
filtered and consecutively washed with CH2Cl2 (3x), DMF (3x), MeOH (3x) and CH2Cl2 (3x) and 
dried under reduced pressure.  
Loading: The loading of the resulting resins was determined by Fmoc UV quantification: 0.4836 
mmol/g. Yield of final product was calculated in reference to this loading values. Amount of resin 
for the following synthesis we used 0.0484 mmol of the prepared Fmoc-β2,2-amino acid-loaded 
Wang resin. 
Deprotection: The resin is washed with DMF (3x) and treated with a solution of 20% 4-
methylpiperidine in DMF for 20 min. The resin is filtered and washed with DMF (3x). The 4-
methylpiperidine treatment is repeated once. The resin is subsequently filtered and washed with 
DMF (3x), MeOH (3x), CH2Cl2 (3x) and DMF (3x). 
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XIII.9.2 Nosyl coupling 
     
O
O
NH2
OAc
VIII.19
 5 eq o-Ns-Cl, 10 eq collidine,
CH2Cl2, r.t, 2 x 1 h
O
O
N
H
OAc
VIII.20
S
OO NO2
 
To a suspension of resin VIII.19 (0.1 g, 0.0484 mmol, 1 eq) in dry DCE (1.2 ml) is added 2,4,6-
collidine (64 μl, 0.464 mmol, 10 eq) and 2-nitrobenzenesulfonyl chloride (54 mg, 0.2418 mmol, 5 
eq). After 1 hour shaking, the resin is filtered and washed with DMF (3x10 ml), MeOH (3x10 ml) 
and CH2Cl2 (3x10 ml). This procedure is repeated once, delivering the nosyl protected resin bound 
amino acid VIII.20.  
XIII.9.3 Mitsunobu-Fukuyama alkylation  
O
O
N
H
OAc
VIII.20
S
OO NO2
O
O
N
OAc
VIII.21
S
OO NO2
10 eq MeOH, 5 eq Ph3P, 5 eq DIAD, 
DCE, r.t, 3x2h
 
The resin was suspended in DCE (1.2 ml) and triphenylphosphine (64 mg, 0.242 mmol, 5 eq), 
MeOH (0.484 mmol, 10 eq) and DIAD (48 μl, 0.242 mmol, 5 eq) were sequentially added. The 
reaction mixture is shaken for 2 h at room temperature after which the resin is drained and washed 
with dry dichloromethane and dry DCE. This Mitsunobu procedure was repeated twice, the resin 
was filtered and washed with DMF (3x10 ml), MeOH (3x10 ml) and CH2Cl2 (3x10 ml).  
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Molecular Formula: C22H22N2O6S 
Molecular Weight: 442.48 g mol-1. 
LCMS Peak at 5.1 min, ES-MS negative mode [m/z (fragment, 
intensity)]: 441.0 (M-H+, 100). 
 
XIII.9.4 Nosyl removal  
O
O
N
OAc
VIII.21
S
OO NO2
2.5 eq DBU, 5 eq HSCH2CH2OH
DMF, r.t, 2x30min
VIII.22
O
O
NH
OAc
 
The resin is suspended in DMF (1 ml) and DBU (18 μl, 0.121 mmol, 2.5 eq) and 2-mercaptoethanol 
(17 μl, 0.242 mmol, 5 eq) were added. The resulting suspension was shaken for 30 min after which 
the resin was drained and washed with DMF (3x10 ml), MeOH (3x10 ml) and CH2Cl2 (3x10 ml). 
This procedure is repeated once, after which the resin was drained and washed with DMF 
(3x10ml). 
XIII.9.5 Coupling of Fmoc-anthranilic acid 
O
O
N
OAc
NHFmoc
VIII.22
O
O
NH
OAc
10 eq anthranilic acid, 5 eq DIC
CH2Cl2/DMF 9/1, r.t, 24 h
VIII.23
O
 
NO2
S
N
OO
Me
O
HO
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Preactivation: To a cooled solution (0°C) of the appropriate N-Fmoc-anthranilic acid (0.484 
mmol, 10 eq) in CH2Cl2/DMF (9/1) (1.2 ml), is added DIC (26 μl, 0.242 mmol, 5 eq) and the 
reaction mixture was stirred for 30 min at 0 °C.  
Coupling: The crude preactivation mixture was transferred to the appropriate resin VIII.22, 
preswollen in CH2Cl2/DMF 9/1, and the resulting suspension is shaken for 24 h. The resin was 
drained and washed consecutively with DMF (3x10 ml), MeOH (3x10 ml) and CH2Cl2 (3x10 ml).  
 
XIII.9.6 Fmoc removal 
O
O
N
OAc
NHFmoc
VIII.23
O
20 % 4-methylpiperidine in DMF
r.t, 2x20min
VIII.24
O
O
N
OAc
NH2O
 
The resin is washed with DMF (3x) and treated with a solution of 20% 4-methylpiperidine in DMF 
for 20 min. The resin is filtered and washed with DMF (3x). The 4-methylpiperidine treatment is 
repeated once. The resin is subsequently filtered and washed with DMF (3x), MeOH (3x), CH2Cl2 
(3x) and DMF (3x). 
XIII.9.7 Cleavage from the resin 
VIII.24
O
O
N
OAc
NH2O
TFA/H2O 9/1, 1 h.
VIII.25
HO
O
N
NH2O
 
Part 3: Experimental Procedures 
 
292 
 
Resin VIII.24 is suspended in a mixture of trifluoroacetic acid/water 95/5 (5 ml) and shaken for 1 
hour at room temperature. The resin is filtered and washed extensively with dichloromethane. The 
filtrate is concentrated under reduced pressure and the obtained residue is further purified by flash 
chromatography (F.C.) in dichloromethane/MeOH 99/1 to 95/5. 
XIII.9.7.1 3-(N-ANTHRANOYL,N-METHYL)-2-METHYL-2-(NAPHTH-2-
YLMETHYL)PROPIONIC ACID VIII.25 
SPS yield 94% (white foam)  
Molecular Formula: C23H24N2O3 
Molecular Weight: 376.45 g mol-1. 
LCMS Peak at 4.6 min, ES-MS positive mode [m/z (fragment, 
intensity)]: 377.2 (M+H+, 100). 
1H NMR: (300 MHz, CDCl3): δ 7.85-7.61 (m, 4H), 7.50-7.38 (m, 2H), 7.29 (br.s, 1H), 7.25-7.01 
(m, 2H), 6.77-6.58 (m, 2H), 5.86 (br.s, 2H), 4.05-3.82 (m, 2H), 3.51-3.37 (m, 1H), 2.99 (s, 3H), 
2.95-2.77 (m, 1H) 1.22 (br.s, 3H) ppm.  
13C NMR: (75 MHz, CDCl3): δ 133.3 (C), 132.3 (C), 130.7 (CH), 129.1 (CH), 128.6 (CH), 127.9 
(CH), 127.7 (CH), 127.7 (CH), 127.5 (CH), 125.9 (CH), 125.6 (CH), 117.7 (CH), 116.6 (CH), 56.5 
(CH2), 51.5 (CH3), 48.6 (CH2), 37.5 (CH3) ppm. 
TLC: Rf = 0.3 (DCM/MeOH 9/1). 
XIII.9.8 Cyclization in solution  
NH2
N
Me
O
HO
O
N
H
N
O
O
DCC-PS, CH2Cl2, 
0.01M, 1h, r.t
VIII.25 VIII.26
 
NH2
N
Me
O
HO
O
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To a solution of purified α,ω-aminocarboxylic acid (0.048 mmol, 1eq) in CH2Cl2 (4.8 ml) is added 
polystyrene-bound DCC (loading 2.3 mmol/g, 0.06 mmol, 2.9 eq). The obtained suspension is 
shaken for 1 h at room temperature after which the resin was filtered and washed with CH2Cl2. 
The filtrate was concentrated under reduced pressure. The obtained crude compound is purified by 
flash chromatography (F.C.) in dichloromethane/methanol 99/1. 
XIII.9.8.1 3,4-DIHYDRO-3,5-DIMETHYL-3-(NAPHTH-2-
YLMETHYL)BENZO[g][1,5]DIAZOCINE-2(1H),6(5H)-DIONE VIII.26 
 CYC yield: 60% 
Molecular Formula: C23H22N2O2 
Molecular Weight: 358.43 g mol-1. 
LCMS Peak at 5.8 min, ES-MS positive mode [m/z (fragment, 
intensity)]: 717.2 (2M+H+, 100), 359.2 (M+H+, 65). 
1H NMR: (300 MHz, Acetone-d6): presence of two conformers (ratio 86/14, individual assignment 
not possible): 8.53 (br.s, NH), 7.92-7.74 (m, 3H), 7.63 (br.s, 1H), 7.51-7.43 (m, 2H), 7.44-7.23 (m, 
4H), 7.20-7.12 (m, 1H), 3.90 (d, J=15.7 Hz, 1H), 3.22 (d, J=15.7 Hz, 1H), 3.20 (s, 0.42 H), 3.16 
(s, 2.58 H), 2.93 (d, J=13.4 Hz, 1H), 2.76 (d, J=13.4 Hz, 1H), 1.37 (s, 3H) ppm.  
13C NMR: (300 MHz, Acetone-d6): no multiple conformations observed: δ 174.7 (CO), 169.8 
(CO), 136.1 (C), 135.8 (C), 135.1 (C), 134.3 (C), 133.4 (C), 131.2 (CH), 129.6 (CH), 129.4 (CH), 
128.7 (CH), 128.4 (CH), 128.4 (CH), 128.3 (CH), 127.9 (CH), 127.1 (CH), 126.8 (CH), 126.4 
(CH), 60.7 (CH2), 50.8 (C), 44.6 (CH2), 35.9 (CH3), 25.8 (CH3), ppm.  
TLC: Rf = 0.25 (DCM/MeOH 9/1). 
N
H
N
O
O
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
